[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fF_a_57jKYMpRqjnIrawbIgmUH1OtFGJF9a34j3yaC18":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":84,"rows":91},"Yale University",[4],1733,false,382,83,3770769,188,996,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Schizophrenia",47,{"name":18,"count":19},"Obesity",46,{"name":21,"count":22},"Depression",38,{"name":24,"count":25},"Nicotine Dependence",35,{"name":27,"count":28},"Alcohol Use Disorder",31,{"name":30,"count":31},"Opioid Use Disorder",30,{"name":33,"count":31},"Smoking",{"name":35,"count":36},"HIV",29,[38,43,48,53,58,63,67,71,75,79],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02407808","Cannabinoids, Learning, and Memory","2018-08-10","THC",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03554174","Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder","2021-07-08","Low Dose Psilocybin",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04699123","The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer","2025-06-30","NC318 800 mg",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05553938","Effects of Acute and Chronic Empagliflozin Heart Failure","2025-11","Empagliflozin 10 mg",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03670056","Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy","2025-12","Combination immunotherapy with Ipilimumab and Nivolumab",{"nctId":64,"briefTitle":65,"date":61,"intervention":66},"NCT06498713","Patient Controlled Administration of Liquid Acetaminophen","Acetaminophen 650 mg Oral",{"nctId":68,"briefTitle":69,"date":61,"intervention":70},"NCT06027840","Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use","Varenicline",{"nctId":72,"briefTitle":73,"date":74,"intervention":42},"NCT05641766","Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks","2025-12-01",{"nctId":76,"briefTitle":77,"date":74,"intervention":78},"NCT03746535","Cardiovascular Disease Risk in Women With Endometriosis","Elagolix",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04599478","Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)","2025-12-12","Naltrexone and Bupropion medication",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,139,302,357,391,420,438,456,483,501,525,551,578,596,622,658,703,751,786,822,851,869,896,914,932,953,971,995,1019,1218,1261,1294,1387,1464,1553,1607,1840,1998,2051,2085,2107,2143,2178,2222,2267,2308,2341,2367,2402,2433,2464,2498,2529,2561,2599,2623,2643,2669,2692,2715,2733,2760,2778,2796,2814,2832,2857,2875,2901,2924,2942,2966,2990,3008,3032,3050,3072,3097,3115,3141,3159,3182,3200,3222,3246,3269,3296,3319,3343,3361,3379,3397,3422,3440,3458,3483,3501,3525,3547,3571,3599,3617,3642,3665,3683,3709,3727,3745,3768,3786,3831,3869,3918,3949,3983,4012,4058,4101,4144,4182,4208,4230,4252,4270,4288,4313,4331,4354,4372,4390,4415,4439,4457,4480,4504,4528,4546,4572,4590,4608,4632,4656,4679,4700,4718,4742,4760,4782,4805,4823,4846,4864,4896,4914,4932,4963,4985,5019,5053,5078,5096,5114,5139,5157,5175,5193,5216,5240,5258,5282,5304,5332,5350,5368,5386,5405,5430,5448,5476,5499,5517,5543,5567,5591,5609,5634,5659,5682,5710,5761,5788,5822,5853,5877,5900,5926,5944,5966,5989,6007,6032,6050,6078,6096,6120,6145,6170,6188,6209,6237,6259,6282,6308,6326,6344,6369,6397,6421,6447,6474,6492,6517,6543,6561,6579,6597,6619,6637,6660,6683,6735,6785,6811,6843,6882,6926,6955,6991,7019,7049,7072,7095,7113,7131,7156,7174,7196,7221,7246,7271,7297,7315,7337,7360,7384,7402,7427,7445,7469,7493,7517,7542,7563,7581,7643,7696,7754,7809,7858,7906,7951,7991,8034,8073,8113,8139,8180,8218,8256,8292,8326,8356,8389,8416,8443,8475,8501,8526,8548,8570,8592,8614,8646,8672,8702,8724,8755,8783,8808,8830,8855,8881,8904,8927,8945,8963,8986,9011,9029,9047,9068,9092,9116,9144,9167,9185,9207,9225,9252,9270,9288,9306,9324,9342,9360,9383,9406,9428,9446,9467,9485,9509,9532,9558,9576,9594,9615,9636,9659,9677,9700,9718,9740,9763,9786,9804,9831,9854,9879,9897,9922,9940,9963,9985,10009,10030,10055,10079,10097,10115,10133,10151,10169,10192,10210,10228,10253,10271,10289,10313,10336,10360,10378,10404,10422,10446,10464,10488,10513,10537,10562,10585,10603,10621,10639,10662,10680,10698,10716,10734,10752,10773,10794,10812,10834,10857,10875,10899,10923,10945,10967,10992,11015,11038,11061,11089,11113,11131,11155,11178,11199,11220,11243,11261,11286,11304,11326,11349,11373,11400,11418,11436,11454,11472,11496,11514,11537,11560,11578,11596,11620,11647,11665,11690,11708,11730,11748,11771,11808,11840,11872,11908,11930,11952,11982,12014,12036,12058,12086,12119,12137,12155,12178,12202,12220,12245,12268,12292,12310,12335,12359,12377,12403,12421,12446,12468,12486,12510,12532,12556,12580,12598,12622,12640,12664,12687,12705,12728,12746,12769,12792,12817,12835,12859,12877,12898,12919,12941,12963,12986,13010,13034,13052,13074,13098,13119,13143,13161,13185,13203,13230,13248,13273,13298,13316,13338,13361,13379,13401,13426,13444,13465,13489,13507,13531,13555,13573,13595,13618,13636,13659,13677,13695,13713,13731,13749,13773,13791,13814,13836,13858,13879,13903,13926,13951,13969,13992,14014,14032,14057,14075,14099,14120,14143,14165,14183,14201,14219,14237,14268,14300,14333,14355,14373,14391,14415,14433,14451,14476,14494,14516,14539,14562,14585,14610,14628,14646,14664,14688,14712,14737,14755,14779,14797,14815,14839,14862,14886,14904,14922,14949,14967,14985,15003,15021,15044,15062,15087,15111,15129,15151,15176,15194,15219,15241,15263,15286,15309,15327,15351,15369,15391,15414,15436,15462,15480,15498,15516,15539,15561,15583,15601,15623,15649,15667,15685,15703,15808,15859,15917,15987,16045,16098,16150,16188,16236,16277,16320,16364,16401,16433,16467,16499,16536,16565,16592,16621,16653,16680,16708,16737,16773,16800,16831,16849,16870,16892,16910,16935,16957,16981,17004,17026,17047,17072,17090,17112,17130,17151,17173,17191,17209,17232,17250,17272,17290,17313,17338,17356,17374,17395,17413,17435,17453,17474,17496,17514,17540,17558,17582,17600,17623,17647,17672,17690,17711,17729,17751,17769,17791,17813,17831,17852,17874,17892,17915,17936,17954,17976,17997,18024,18042,18066,18084,18107,18125,18146,18167,18191,18214],{"intervention":93,"totalTrials":94,"cells":95},"Empagliflozin 10 MG",3,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":110,"PHASE3":123,"PHASE4":125,"NA":137},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":109,"soonestReadout":56},[101],{"nctId":54,"briefTitle":55,"status":102,"phases":103,"primaryCompletion":56,"completion":56,"start":104,"enrollment":105,"conditions":106,"interventions":108},"RECRUITING",[86],"2023-08-04",60,[107],"Heart Failure",[57],1,{"trials":111,"activeCount":109,"soonestReadout":116},[112],{"nctId":113,"briefTitle":114,"status":102,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":122},"NCT05726032","Empagliflozin in Patients With Cirrhosis and Ascites",[87],"2026-06-01","2023-09-11",20,[120,121],"Cirrhosis","Liver Failure",[93],{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":109,"soonestReadout":131},[127],{"nctId":128,"briefTitle":129,"status":102,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":31,"conditions":133,"interventions":135},"NCT05671991","Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease",[89],"2026-12-31","2023-03-01",[134],"End Stage Renal Disease on Dialysis",[136,93],"Empagliflozin 25 mg vs Placebo",{"trials":138,"activeCount":98},[],{"intervention":140,"totalTrials":141,"cells":142},"Buprenorphine",15,{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":203,"PHASE4":243,"NA":264},{"trials":144,"activeCount":98},[],{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":98},[149,160,168,174,186,192],{"nctId":150,"briefTitle":151,"status":152,"phases":153,"completion":154,"start":155,"enrollment":98,"conditions":156,"interventions":159},"NCT00000319","Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2","COMPLETED",[87],"2005-01","1996-06",[157,158],"Opioid-Related Disorders","Substance-Related Disorders",[140],{"nctId":161,"briefTitle":162,"status":152,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":98,"conditions":166,"interventions":167},"NCT00000202","Buprenorphine Maintenance for Opioid Addicts - 1",[87],"2006-05","1988-08",[157],[140],{"nctId":169,"briefTitle":170,"status":152,"phases":171,"primaryCompletion":164,"completion":164,"start":165,"enrollment":98,"conditions":172,"interventions":173},"NCT00000203","Buprenorphine Maintenance for Opioid Addicts - 2",[87],[157],[140],{"nctId":175,"briefTitle":176,"status":152,"phases":177,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":185},"NCT00634803","Clinical Trial of Integrated Treatment for Pain and Opioid Dependence",[86,87],"2015-05","2015-08","2009-09",90,[183,184],"Opiate Dependence","Chronic Pain",[140],{"nctId":187,"briefTitle":188,"status":152,"phases":189,"primaryCompletion":164,"completion":164,"start":165,"enrollment":98,"conditions":190,"interventions":191},"NCT00000204","Buprenorphine Maintenance for Opioid Addicts - 3",[87],[157],[140],{"nctId":193,"briefTitle":194,"status":152,"phases":195,"primaryCompletion":196,"completion":197,"start":198,"conditions":199,"interventions":202},"NCT00023283","Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1",[87],"2003-12","2004-02","2000-08",[200,157,201],"Heroin Dependence","Substance Abuse, Intravenous",[140],{"trials":204,"activeCount":109,"soonestReadout":237},[205,212,223,233],{"nctId":206,"briefTitle":207,"status":152,"phases":208,"completion":154,"enrollment":98,"conditions":209,"interventions":211},"NCT00000216","Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1",[88],[210,157,158],"Cocaine-Related Disorders",[140],{"nctId":213,"briefTitle":214,"status":152,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT02187198","Buprenorphine Treatment for Opioid Dependence",[88],"2022-02-01","2023-01-01","2015-03",9,[221],"Opioid Dependence",[140],{"nctId":224,"briefTitle":225,"status":152,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":231},"NCT00000311","Combining Behavioral Treatment With Agonist Maintenance - 1",[88],"1999-02","1995-02",168,[210,157,158],[140,232],"methadone",{"nctId":234,"briefTitle":235,"status":102,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":242},"NCT06494904","Standard Versus High Dose ED-Initiated Buprenorphine Induction",[88],"2027-09","2028-12","2024-12-06",360,[30],[140],{"trials":244,"activeCount":263,"soonestReadout":250},[245,254],{"nctId":246,"briefTitle":247,"status":248,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":105,"conditions":252,"interventions":253},"NCT07176351","Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic","NOT_YET_RECRUITING",[89],"2027-02","2026-04",[30],[140],{"nctId":255,"briefTitle":256,"status":102,"phases":257,"primaryCompletion":238,"completion":238,"start":258,"enrollment":259,"conditions":260,"interventions":261},"NCT06323824","Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.",[89],"2024-06-04",600,[30],[262,140],"Methadone",2,{"trials":265,"activeCount":98},[266,278,292],{"nctId":267,"briefTitle":268,"status":152,"phases":269,"primaryCompletion":270,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":275},"NCT00571961","Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir\u002FRitonavir)",[90],"2008-08","2007-01",12,[274],"HIV Infections",[276,277],"Kaletra","buprenorphine",{"nctId":279,"briefTitle":280,"status":152,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":291},"NCT03583138","HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)",[],"2015-12-15","2017-06-30","2014-06-23",159,[287,288,289,290],"Human Immunodeficiency Virus","Acquired Immunodeficiency Syndrome","Opiate Addiction","Drug Dependence",[277],{"nctId":293,"briefTitle":294,"status":152,"phases":295,"primaryCompletion":270,"completion":270,"start":296,"enrollment":297,"conditions":298,"interventions":301},"NCT02583243","Project BEST: Buprenorphine Entry Into Substance Abuse Treatment",[],"2005-05",209,[299,274,300,21],"Opioid-related Disorders","Hepatitis C, Chronic",[140],{"intervention":262,"totalTrials":303,"cells":304},5,{"EARLY_PHASE1":305,"PHASE1":318,"PHASE2":320,"PHASE3":334,"PHASE4":340,"NA":355},{"trials":306,"activeCount":98},[307],{"nctId":308,"briefTitle":309,"status":152,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT04027166","Cognitive Function and Pain Threshold in People Who Are Methadone Maintained",[85],"2021-03-10","2021-04-28","2019-07-01",27,[316],"Pain",[262,262],{"trials":319,"activeCount":98},[],{"trials":321,"activeCount":98},[322],{"nctId":323,"briefTitle":324,"status":152,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":331},"NCT00838981","Pharmacotherapy & CM for Opioid and Cocaine Dependence",[86,87],"2014-03","2008-05",91,[330],"Cocaine Dependence",[332,333,262],"Modafinil","Sugar Pill",{"trials":335,"activeCount":98},[336],{"nctId":224,"briefTitle":225,"status":152,"phases":337,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":338,"interventions":339},[88],[210,157,158],[140,232],{"trials":341,"activeCount":109,"soonestReadout":238},[342,351],{"nctId":343,"briefTitle":344,"status":152,"phases":345,"primaryCompletion":346,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":350},"NCT02396979","Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia",[89],"2014-12","2010-01",300,[287,288,289,290],[262],{"nctId":255,"briefTitle":256,"status":102,"phases":352,"primaryCompletion":238,"completion":238,"start":258,"enrollment":259,"conditions":353,"interventions":354},[89],[30],[262,140],{"trials":356,"activeCount":98},[],{"intervention":358,"totalTrials":263,"cells":359},"Aldosterone",{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":389},{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":98},[364],{"nctId":365,"briefTitle":366,"status":152,"phases":367,"primaryCompletion":368,"completion":368,"start":369,"enrollment":118,"conditions":370,"interventions":372},"NCT00700479","Studies on Aldosterone and Vascular Function",[86],"2008-06","2006-01",[371],"Inflammation",[373],"aldosterone",{"trials":375,"activeCount":98},[],{"trials":377,"activeCount":98},[],{"trials":379,"activeCount":109,"soonestReadout":384},[380],{"nctId":381,"briefTitle":382,"status":102,"phases":383,"primaryCompletion":384,"completion":384,"start":385,"enrollment":118,"conditions":386,"interventions":387},"NCT07281014","Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing",[89],"2027-08","2026-01-27",[107],[388,358],"Spironolactone 25mg",{"trials":390,"activeCount":98},[],{"intervention":392,"totalTrials":109,"cells":393},"Exogenous oxytocin intravenous infusion without nipple stimulation.",{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":400,"PHASE4":402,"NA":418},{"trials":395,"activeCount":98},[],{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":109,"soonestReadout":408},[404],{"nctId":405,"briefTitle":406,"status":102,"phases":407,"primaryCompletion":408,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":417},"NCT05079841","The Stimulation To Induce Mothers Study",[89],"2028-11","2029-03","2021-11-15",988,[413,414,415,416],"Oxytocin","Labor Pain","Induction of Labor Affected Fetus \u002F Newborn","Physiologic Effects of Drugs",[392],{"trials":419,"activeCount":98},[],{"intervention":136,"totalTrials":109,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":436},{"trials":423,"activeCount":98},[],{"trials":425,"activeCount":98},[],{"trials":427,"activeCount":98},[],{"trials":429,"activeCount":98},[],{"trials":431,"activeCount":109,"soonestReadout":131},[432],{"nctId":128,"briefTitle":129,"status":102,"phases":433,"primaryCompletion":131,"completion":131,"start":132,"enrollment":31,"conditions":434,"interventions":435},[89],[134],[136,93],{"trials":437,"activeCount":98},[],{"intervention":388,"totalTrials":109,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":454},{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":109,"soonestReadout":384},[450],{"nctId":381,"briefTitle":382,"status":102,"phases":451,"primaryCompletion":384,"completion":384,"start":385,"enrollment":118,"conditions":452,"interventions":453},[89],[107],[388,358],{"trials":455,"activeCount":98},[],{"intervention":457,"totalTrials":109,"cells":458},"Beta blocker",{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":467,"NA":481},{"trials":460,"activeCount":98},[],{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"trials":468,"activeCount":109,"soonestReadout":473},[469],{"nctId":470,"briefTitle":471,"status":102,"phases":472,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":479},"NCT05786417","LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions",[89],"2027-05-30","2023-05-10",741,[477,478],"Angina","Stable Ischemic Heart Disease",[457,480],"Calcium channel blocker",{"trials":482,"activeCount":98},[],{"intervention":480,"totalTrials":109,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":499},{"trials":486,"activeCount":98},[],{"trials":488,"activeCount":98},[],{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":98},[],{"trials":494,"activeCount":109,"soonestReadout":473},[495],{"nctId":470,"briefTitle":471,"status":102,"phases":496,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":497,"interventions":498},[89],[477,478],[457,480],{"trials":500,"activeCount":98},[],{"intervention":502,"totalTrials":109,"cells":503},"Bexagliflozin 20 mg",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":523},{"trials":505,"activeCount":98},[],{"trials":507,"activeCount":98},[],{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[],{"trials":513,"activeCount":109,"soonestReadout":237},[514],{"nctId":515,"briefTitle":516,"status":102,"phases":517,"primaryCompletion":237,"completion":237,"start":518,"enrollment":519,"conditions":520,"interventions":522},"NCT05612594","Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study",[89],"2024-03-27",164,[521],"Sleep Apnea",[502],{"trials":524,"activeCount":98},[],{"intervention":526,"totalTrials":109,"cells":527},"Desogestrel \u002F Ethinyl Estradiol Pill",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":536,"NA":549},{"trials":529,"activeCount":98},[],{"trials":531,"activeCount":98},[],{"trials":533,"activeCount":98},[],{"trials":535,"activeCount":98},[],{"trials":537,"activeCount":109,"soonestReadout":542},[538],{"nctId":539,"briefTitle":540,"status":102,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":548},"NCT06334315","Oral Contraceptive Pill (OCP) Pharmacogenomics",[89],"2028-05","2024-10-29",700,[546,547],"Contraception","Pharmacogenomic Drug Interaction",[526],{"trials":550,"activeCount":98},[],{"intervention":552,"totalTrials":109,"cells":553},"Artemether-lumefantrine",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":576},{"trials":555,"activeCount":98},[],{"trials":557,"activeCount":98},[],{"trials":559,"activeCount":98},[],{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":109,"soonestReadout":568},[564],{"nctId":565,"briefTitle":566,"status":102,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":574},"NCT06967519","OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa",[89],"2027-12","2025-12-18",380,[572,573],"Malaria","Hiv",[552,575],"artesunate-amodiaquine",{"trials":577,"activeCount":98},[],{"intervention":575,"totalTrials":109,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":594},{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[],{"trials":585,"activeCount":98},[],{"trials":587,"activeCount":98},[],{"trials":589,"activeCount":109,"soonestReadout":568},[590],{"nctId":565,"briefTitle":566,"status":102,"phases":591,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":592,"interventions":593},[89],[572,573],[552,575],{"trials":595,"activeCount":98},[],{"intervention":597,"totalTrials":109,"cells":598},"Athena strategy",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":607,"NA":620},{"trials":600,"activeCount":98},[],{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":98},[],{"trials":608,"activeCount":109,"soonestReadout":613},[609],{"nctId":610,"briefTitle":611,"status":102,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":619},"NCT05547048","Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women",[89],"2027-06-01","2027-06-30","2023-07-25",250,[35,30,618],"eHealth",[597],{"trials":621,"activeCount":98},[],{"intervention":623,"totalTrials":263,"cells":624},"Spravato",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":631,"PHASE4":643,"NA":645},{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":98},[],{"trials":632,"activeCount":109,"soonestReadout":637},[633],{"nctId":634,"briefTitle":635,"status":102,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":641},"NCT06713616","PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study",[88],"2030-12-31","2025-01-27",400,[21],[642,623],"Racemic ketamine",{"trials":644,"activeCount":98},[],{"trials":646,"activeCount":109,"soonestReadout":651},[647],{"nctId":648,"briefTitle":649,"status":102,"phases":650,"primaryCompletion":651,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":656},"NCT06725277","The OBSERVE Protocol",[],"2029-12","2024-01-21",450,[655],"Major Depression Disorder",[623,657],"IV Ketamine",{"intervention":659,"totalTrials":94,"cells":660},"Lisdexamfetamine Dimesylate",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":699,"NA":701},{"trials":662,"activeCount":98},[],{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":109,"soonestReadout":674},[669,680,690],{"nctId":670,"briefTitle":671,"status":672,"phases":673,"primaryCompletion":674,"completion":674,"start":675,"enrollment":105,"conditions":676,"interventions":679},"NCT04599504","Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)","ACTIVE_NOT_RECRUITING",[87,88],"2027-05","2022-01-02",[677,678],"Loss-of-control Eating","Obesity\u002FOverweight",[659],{"nctId":681,"briefTitle":682,"status":152,"phases":683,"primaryCompletion":684,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT03924193","Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment",[88],"2023-09-13","2019-03-25",141,[688,18],"Binge-Eating Disorder",[659],{"nctId":691,"briefTitle":692,"status":152,"phases":693,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":698},"NCT03926052","Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment",[88],"2024-11-18","2019-08-07",61,[688,18],[659],{"trials":700,"activeCount":98},[],{"trials":702,"activeCount":98},[],{"intervention":704,"totalTrials":94,"cells":705},"Aspirin",{"EARLY_PHASE1":706,"PHASE1":718,"PHASE2":720,"PHASE3":734,"PHASE4":747,"NA":749},{"trials":707,"activeCount":98},[708],{"nctId":709,"briefTitle":710,"status":711,"phases":712,"primaryCompletion":713,"completion":713,"start":714,"enrollment":109,"conditions":715,"interventions":717},"NCT02047539","Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis","TERMINATED",[85],"2021-03","2015-01",[716],"Clinical High Risk for Psychosis",[704],{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[722],{"nctId":723,"briefTitle":724,"status":152,"phases":725,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":731},"NCT00368238","Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects",[87],"2006-07","2005-10",96,[730],"Healthy Subjects",[732,704,733],"Recombinant human erythropoietin alfa","Clopidogrel",{"trials":735,"activeCount":109,"soonestReadout":740},[736],{"nctId":737,"briefTitle":738,"status":102,"phases":739,"primaryCompletion":740,"completion":740,"start":741,"enrollment":544,"conditions":742,"interventions":745},"NCT03907046","Anticoagulation in ICH Survivors for Stroke Prevention and Recovery",[88],"2027-04","2020-01-28",[743,744],"Intracerebral Hemorrhage","Atrial Fibrillation",[746,704],"Apixaban",{"trials":748,"activeCount":98},[],{"trials":750,"activeCount":98},[],{"intervention":752,"totalTrials":263,"cells":753},"Enoxaparin",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":770,"PHASE4":782,"NA":784},{"trials":755,"activeCount":98},[],{"trials":757,"activeCount":98},[],{"trials":759,"activeCount":98},[760],{"nctId":761,"briefTitle":762,"status":711,"phases":763,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":769},"NCT03003390","Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial",[87],"2019-08-16","2017-04-05",51,[768],"Deep Venous Thrombosis",[752],{"trials":771,"activeCount":109,"soonestReadout":776},[772],{"nctId":773,"briefTitle":774,"status":102,"phases":775,"primaryCompletion":776,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":781},"NCT04924322","Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies",[87,88],"2026-04-30","2026-07-31","2022-05-11",258,[768],[752],{"trials":783,"activeCount":98},[],{"trials":785,"activeCount":98},[],{"intervention":787,"totalTrials":263,"cells":788},"Elagolix 200 MG",{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":795,"PHASE4":818,"NA":820},{"trials":790,"activeCount":98},[],{"trials":792,"activeCount":98},[],{"trials":794,"activeCount":98},[],{"trials":796,"activeCount":109,"soonestReadout":812},[797,808],{"nctId":798,"briefTitle":799,"status":152,"phases":800,"primaryCompletion":801,"completion":801,"start":802,"enrollment":803,"conditions":804,"interventions":807},"NCT04173169","Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis",[88],"2025-05-02","2022-03-15",103,[805,806],"Infertility","Endometriosis",[787],{"nctId":809,"briefTitle":810,"status":102,"phases":811,"primaryCompletion":812,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":817},"NCT06375811","Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp",[88],"2026-06-30","2026-09-30","2024-03-16",297,[805,806],[787],{"trials":819,"activeCount":98},[],{"trials":821,"activeCount":98},[],{"intervention":823,"totalTrials":109,"cells":824},"Anakinra",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":847,"NA":849},{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"trials":830,"activeCount":98},[],{"trials":832,"activeCount":109,"soonestReadout":837},[833],{"nctId":834,"briefTitle":835,"status":248,"phases":836,"primaryCompletion":837,"completion":838,"start":839,"enrollment":840,"conditions":841,"interventions":845},"NCT07281027","COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"",[88],"2030-03-31","2030-09-30","2026-07-01",438,[842,843,844],"New Onset Refractory Status Epilepticus","New-Onset Refractory Status Epilepticus","Febrile Infection-Related Epilepsy Syndrome (FIRES)",[823,846],"Tocilizumab",{"trials":848,"activeCount":98},[],{"trials":850,"activeCount":98},[],{"intervention":846,"totalTrials":109,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":865,"NA":867},{"trials":854,"activeCount":98},[],{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":109,"soonestReadout":837},[861],{"nctId":834,"briefTitle":835,"status":248,"phases":862,"primaryCompletion":837,"completion":838,"start":839,"enrollment":840,"conditions":863,"interventions":864},[88],[842,843,844],[823,846],{"trials":866,"activeCount":98},[],{"trials":868,"activeCount":98},[],{"intervention":870,"totalTrials":109,"cells":871},"Naltrexone Pill",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":892,"NA":894},{"trials":873,"activeCount":98},[],{"trials":875,"activeCount":98},[],{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":109,"soonestReadout":884},[880],{"nctId":881,"briefTitle":882,"status":102,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":888,"interventions":889},"NCT05827159","Emergency Department-Initiated Medications for Alcohol Use Disorder",[88],"2027-12-01","2028-03-01","2024-08-17",240,[27],[870,890,891],"Naltrexone","Gabapentin Pill",{"trials":893,"activeCount":98},[],{"trials":895,"activeCount":98},[],{"intervention":891,"totalTrials":109,"cells":897},{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":902,"PHASE3":904,"PHASE4":910,"NA":912},{"trials":899,"activeCount":98},[],{"trials":901,"activeCount":98},[],{"trials":903,"activeCount":98},[],{"trials":905,"activeCount":109,"soonestReadout":884},[906],{"nctId":881,"briefTitle":882,"status":102,"phases":907,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":908,"interventions":909},[88],[27],[870,890,891],{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":98},[],{"intervention":642,"totalTrials":109,"cells":915},{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":928,"NA":930},{"trials":917,"activeCount":98},[],{"trials":919,"activeCount":98},[],{"trials":921,"activeCount":98},[],{"trials":923,"activeCount":109,"soonestReadout":637},[924],{"nctId":634,"briefTitle":635,"status":102,"phases":925,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":926,"interventions":927},[88],[21],[642,623],{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"intervention":83,"totalTrials":109,"cells":933},{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":949,"NA":951},{"trials":935,"activeCount":98},[],{"trials":937,"activeCount":98},[],{"trials":939,"activeCount":98},[],{"trials":941,"activeCount":109,"soonestReadout":82},[942],{"nctId":80,"briefTitle":81,"status":672,"phases":943,"primaryCompletion":82,"completion":944,"start":945,"enrollment":946,"conditions":947,"interventions":948},[87,88],"2027-01","2021-06-29",160,[677,678],[83],{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[],{"intervention":746,"totalTrials":109,"cells":954},{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":961,"PHASE4":967,"NA":969},{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":109,"soonestReadout":740},[963],{"nctId":737,"briefTitle":738,"status":102,"phases":964,"primaryCompletion":740,"completion":740,"start":741,"enrollment":544,"conditions":965,"interventions":966},[88],[743,744],[746,704],{"trials":968,"activeCount":98},[],{"trials":970,"activeCount":98},[],{"intervention":972,"totalTrials":109,"cells":973},"Green Tea Extract",{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":980,"PHASE4":991,"NA":993},{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":109,"soonestReadout":812},[982],{"nctId":983,"briefTitle":984,"status":672,"phases":985,"primaryCompletion":812,"completion":813,"start":986,"enrollment":987,"conditions":988,"interventions":990},"NCT05364008","FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea",[88],"2023-01-05",33,[989],"Leiomyoma, Uterine",[972],{"trials":992,"activeCount":98},[],{"trials":994,"activeCount":98},[],{"intervention":996,"totalTrials":109,"cells":997},"Naltrexone and Bupropion (NB) medication",{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1015,"NA":1017},{"trials":999,"activeCount":98},[],{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[],{"trials":1005,"activeCount":109,"soonestReadout":674},[1006],{"nctId":1007,"briefTitle":1008,"status":672,"phases":1009,"primaryCompletion":674,"completion":674,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1014},"NCT04605081","Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)",[87,88],"2022-01-10",100,[1013,678],"Loss-of-Control Eating",[996],{"trials":1016,"activeCount":98},[],{"trials":1018,"activeCount":98},[],{"intervention":890,"totalTrials":1020,"cells":1021},19,{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1036,"PHASE3":1142,"PHASE4":1180,"NA":1203},{"trials":1023,"activeCount":98},[],{"trials":1025,"activeCount":98},[1026],{"nctId":1027,"briefTitle":1028,"status":152,"phases":1029,"primaryCompletion":1030,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1035},"NCT01625611","Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors",[86],"2021-06-30","2011-02",59,[1034],"Alcohol Drinking",[890],{"trials":1037,"activeCount":98},[1038,1048,1057,1067,1077,1086,1096,1102,1116,1124,1133],{"nctId":1039,"briefTitle":1040,"status":152,"phases":1041,"completion":1042,"start":1043,"enrollment":1044,"conditions":1045,"interventions":1046},"NCT00129246","Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain",[86,87],"2005-12","2004-12",40,[33,24],[890,1047],"Bupropion",{"nctId":1049,"briefTitle":1050,"status":1051,"phases":1052,"primaryCompletion":1053,"completion":1053,"start":1054,"enrollment":98,"conditions":1055,"interventions":1056},"NCT00000196","Neurobiology of Opioid Dependence: 5 - 5","WITHDRAWN",[87],"1998-01","1993-01",[157],[890],{"nctId":1058,"briefTitle":1059,"status":152,"phases":1060,"completion":1061,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1065},"NCT00383045","HIV Risk Reduction and Drug Abuse Treatment in Malaysia",[87],"2007-08","2003-04",180,[183],[1066,890],"Buprenorphine\u002FSubutex",{"nctId":1068,"briefTitle":1069,"status":152,"phases":1070,"primaryCompletion":1071,"completion":1072,"start":154,"enrollment":1073,"conditions":1074,"interventions":1075},"NCT00105482","Targeted Interventions for Weight-Concerned Smokers",[87],"2009-04","2009-10",172,[24],[890,1076],"Transdermal nicotine replacement",{"nctId":1078,"briefTitle":1079,"status":1051,"phases":1080,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":98,"conditions":1084,"interventions":1085},"NCT00398008","HIV Risk Reduction and Drug Abuse Treatment in Iran",[87],"2006-12","2008-12","2004-10",[183,274],[1066,890],{"nctId":1087,"briefTitle":1088,"status":152,"phases":1089,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":219,"conditions":1093,"interventions":1095},"NCT01057862","Investigation of Naltrexone for Pathological Gambling",[87],"2016-02","2017-01","2009-02",[1094],"Pathological Gambling",[890],{"nctId":1097,"briefTitle":1098,"status":1051,"phases":1099,"primaryCompletion":1053,"completion":1053,"start":1054,"enrollment":98,"conditions":1100,"interventions":1101},"NCT00000195","Neurobiology of Opioid Dependence: 4 - 4",[87],[157],[890],{"nctId":1103,"briefTitle":1104,"status":152,"phases":1105,"primaryCompletion":1106,"completion":1107,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1113},"NCT00000451","Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone\u002FSertraline)",[87],"2005-08","2005-11","2003-01",198,[1111,1112],"Alcoholism","Alcohol Dependence",[1114,1115],"sertraline","naltrexone",{"nctId":1117,"briefTitle":1118,"status":152,"phases":1119,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1044,"conditions":1122,"interventions":1123},"NCT00502216","Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers",[86,87],"2009-06","2007-07",[33,24],[890,70],{"nctId":1125,"briefTitle":1126,"status":711,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":1129,"enrollment":303,"conditions":1130,"interventions":1132},"NCT03132571","Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia",[87],"2018-07-31","2017-06-01",[15,1131,18],"Diabetes Mellitus, Type 2",[890,1047],{"nctId":1134,"briefTitle":1135,"status":152,"phases":1136,"primaryCompletion":1137,"completion":1137,"start":1138,"enrollment":31,"conditions":1139,"interventions":1140},"NCT00773422","The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse",[87],"2016-11","2008-01",[33],[1115,1141],"varenicline",{"trials":1143,"activeCount":109,"soonestReadout":884},[1144,1156,1160,1171],{"nctId":1145,"briefTitle":1146,"status":152,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1153},"NCT00338962","Naltrexone & SSRI in Alcoholics With Depression\u002FPTSD",[88],"2015-07","2001-10",88,[1111,21,1152],"PTSD",[1154,1155,890],"paroxetine","desipramine",{"nctId":881,"briefTitle":882,"status":102,"phases":1157,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":1158,"interventions":1159},[88],[27],[870,890,891],{"nctId":1161,"briefTitle":1162,"status":152,"phases":1163,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":1168,"interventions":1169},"NCT01389167","Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia",[88],"2016-09","2017-05","2011-09",320,[183],[1170,890],"Vivitrol",{"nctId":1172,"briefTitle":1173,"status":152,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":766,"conditions":1177,"interventions":1179},"NCT01227044","Reducing Heavy Drinking to Optimize HIV\u002FAIDS Treatment and Prevention",[87,88],"2017-08","2011-04",[1178],"Reduction in Heavy Drinking in Patients With HIV",[890],{"trials":1181,"activeCount":98},[1182,1194],{"nctId":1183,"briefTitle":1184,"status":152,"phases":1185,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":1188,"conditions":1189,"interventions":1193},"NCT00568958","Naltrexone for Heavy Drinking in Young Adults",[89],"2012-12","2008-02",140,[1190,1191,1111,1192],"Alcohol Consumption","Alcoholic Intoxication","Alcohol-induced Disorders",[1115],{"nctId":1195,"briefTitle":1196,"status":152,"phases":1197,"primaryCompletion":1198,"completion":1198,"start":1199,"enrollment":946,"conditions":1200,"interventions":1202},"NCT00000448","Naltrexone Treatment for Alcoholic Women",[89],"2000-12","1995-10",[1111,1201],"Eating Disorder",[1115],{"trials":1204,"activeCount":98},[1205],{"nctId":1206,"briefTitle":1207,"status":152,"phases":1208,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1217},"NCT01866098","Naltrexone for Antipsychotic-Induced Weight Gain",[90],"2019-04-07","2013-05",144,[15,1213,1214,1215,1216],"Schizoaffective Disorder","Schizophreniform Disorder","Bipolar Disorder","Severe Major Depression With Psychotic Features",[890],{"intervention":1219,"totalTrials":94,"cells":1220},"Eszopiclone",{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1227,"PHASE4":1239,"NA":1250},{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[],{"trials":1228,"activeCount":109,"soonestReadout":1233},[1229],{"nctId":1230,"briefTitle":1231,"status":102,"phases":1232,"primaryCompletion":1233,"completion":1234,"start":1235,"enrollment":616,"conditions":1236,"interventions":1238},"NCT07332442","Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea",[88],"2030-01","2030-06","2026-05",[521,1237],"Obstructive Sleep Apnea",[1219],{"trials":1240,"activeCount":98},[1241],{"nctId":1242,"briefTitle":1243,"status":711,"phases":1244,"primaryCompletion":1082,"completion":1082,"start":1245,"enrollment":1246,"conditions":1247,"interventions":1249},"NCT00511134","Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban",[89],"2007-04",4,[1248,24],"Insomnia",[1219,1047],{"trials":1251,"activeCount":98},[1252],{"nctId":1253,"briefTitle":1254,"status":152,"phases":1255,"primaryCompletion":1176,"completion":1176,"start":1256,"enrollment":1257,"conditions":1258,"interventions":1260},"NCT00645944","Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia",[90],"2008-04",39,[1248,15,1213,1259],"Sleep Disorders",[1219],{"intervention":1262,"totalTrials":263,"cells":1263},"Naltrexone and Bupropion Combination",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1281,"NA":1283},{"trials":1265,"activeCount":98},[],{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":98},[],{"trials":1271,"activeCount":109,"soonestReadout":1276},[1272],{"nctId":1273,"briefTitle":1274,"status":102,"phases":1275,"primaryCompletion":1276,"completion":1277,"start":1278,"enrollment":946,"conditions":1279,"interventions":1280},"NCT05157698","Pharmacological and Behavioral Treatment After Bariatric Surgery",[87,88],"2027-01-12","2028-01-12","2022-01-13",[18],[1262],{"trials":1282,"activeCount":98},[],{"trials":1284,"activeCount":98},[1285],{"nctId":1286,"briefTitle":1287,"status":152,"phases":1288,"primaryCompletion":1164,"completion":1164,"start":346,"enrollment":1289,"conditions":1290,"interventions":1292},"NCT02317744","Treatment of Binge Eating Disorder in Obesity: Naltrexone\u002F Bupropion Combination Versus Placebo",[90],22,[1291],"Binge Eating Disorder",[1293],"Naltrexone and bupropion combination",{"intervention":1295,"totalTrials":1296,"cells":1297},"Psilocybin",8,{"EARLY_PHASE1":1298,"PHASE1":1319,"PHASE2":1371,"PHASE3":1381,"PHASE4":1383,"NA":1385},{"trials":1299,"activeCount":263,"soonestReadout":131},[1300,1309],{"nctId":1301,"briefTitle":1302,"status":102,"phases":1303,"primaryCompletion":131,"completion":131,"start":1304,"enrollment":1305,"conditions":1306,"interventions":1308},"NCT06464367","Mechanistic Studies of Psilocybin in Headache Disorders",[85],"2025-05-19",50,[1307],"Migraine",[1295],{"nctId":1310,"briefTitle":1311,"status":248,"phases":1312,"primaryCompletion":1313,"completion":884,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1318},"NCT07118332","Psilocybin as a Treatment for Chronic Pain in Smokers",[85],"2027-10-01","2025-10-01",10,[1317],"Smokers With Chronic Pain",[1295],{"trials":1320,"activeCount":94,"soonestReadout":1332},[1321,1328,1338,1347,1361],{"nctId":1322,"briefTitle":1323,"status":102,"phases":1324,"primaryCompletion":944,"completion":944,"start":1325,"enrollment":272,"conditions":1326,"interventions":1327},"NCT06160284","Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)",[86],"2025-05-28",[30],[1295],{"nctId":1329,"briefTitle":1330,"status":672,"phases":1331,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":31,"conditions":1335,"interventions":1337},"NCT05370911","Effects of Repeated Psilocybin Dosing in OCD",[86],"2026-07","2027-07","2023-07-20",[1336],"Obsessive-Compulsive Disorder",[1295],{"nctId":1339,"briefTitle":1340,"status":152,"phases":1341,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":28,"conditions":1344,"interventions":1345},"NCT03356483","Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.",[86],"2024-07-25","2018-11-13",[1336],[1295,1346],"Niacin",{"nctId":1348,"briefTitle":1349,"status":102,"phases":1350,"primaryCompletion":568,"completion":568,"start":1351,"enrollment":1305,"conditions":1352,"interventions":1360},"NCT06442423","Open-Label Psilocybin Study in Transdiagnostic Population",[86],"2024-10-17",[1353,1354,1355,1356,1152,1357,1358,1359],"Transdiagnostic","Depression - Major Depressive Disorder","Anxiety","PTSD Symptoms","Substance Use","Substance Use Disorder (SUD)","OCD",[1295],{"nctId":1362,"briefTitle":1363,"status":152,"phases":1364,"primaryCompletion":1365,"completion":1365,"start":1366,"enrollment":1367,"conditions":1368,"interventions":1370},"NCT04218539","Repeat Dosing of Psilocybin in Migraine Headache",[86],"2023-11-05","2021-08-10",18,[1369],"Migraine Headache",[1295],{"trials":1372,"activeCount":109,"soonestReadout":1377},[1373],{"nctId":1374,"briefTitle":1375,"status":248,"phases":1376,"primaryCompletion":1377,"completion":1377,"start":1235,"enrollment":1044,"conditions":1378,"interventions":1380},"NCT07610369","The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease",[87],"2030-05",[21,1379],"Parkinson's Disease (PD)",[1295,1295],{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[],{"intervention":42,"totalTrials":1296,"cells":1388},{"EARLY_PHASE1":1389,"PHASE1":1419,"PHASE2":1444,"PHASE3":1458,"PHASE4":1460,"NA":1462},{"trials":1390,"activeCount":98},[1391,1402,1410],{"nctId":1392,"briefTitle":1393,"status":152,"phases":1394,"primaryCompletion":1395,"completion":1395,"start":1396,"enrollment":1397,"conditions":1398,"interventions":1401},"NCT00708994","Cannabinoids, Neural Synchrony, and Information Processing",[85],"2012-12-03","2008-02-25",42,[1399,1400],"Cannabis","Psychotic Disorders",[42],{"nctId":1403,"briefTitle":1404,"status":152,"phases":1405,"primaryCompletion":1406,"completion":1406,"start":1186,"enrollment":1407,"conditions":1408,"interventions":1409},"NCT01853020","Cannabinoids and Cerebellar-Motor Functioning",[85],"2015-04-07",57,[1399,1400],[42],{"nctId":1411,"briefTitle":1412,"status":152,"phases":1413,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1418},"NCT01595620","Cannabinoid Modulation of Pain",[85],"2012-04-19","2011-11-09",6,[316],[42,42],{"trials":1420,"activeCount":263,"soonestReadout":41},[1421,1427,1435],{"nctId":39,"briefTitle":40,"status":672,"phases":1422,"primaryCompletion":41,"completion":568,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1426},[86],"2015-02",80,[1399,1400],[42],{"nctId":1428,"briefTitle":1429,"status":152,"phases":1430,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":36,"conditions":1433,"interventions":1434},"NCT00624715","Cannabinoid Receptor Function & Alcoholism",[86],"2010-06-22","2007-08-09",[1111],[42],{"nctId":1436,"briefTitle":1437,"status":102,"phases":1438,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":1011,"conditions":1442,"interventions":1443},"NCT02781519","Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans",[86],"2026-06","2026-12","2015-06",[1399],[42],{"trials":1445,"activeCount":263,"soonestReadout":74},[1446,1451],{"nctId":72,"briefTitle":73,"status":248,"phases":1447,"primaryCompletion":74,"completion":74,"start":1448,"enrollment":1305,"conditions":1449,"interventions":1450},[87],"2025-08-31",[42],[42],{"nctId":1452,"briefTitle":1453,"status":102,"phases":1454,"primaryCompletion":568,"completion":568,"start":1455,"enrollment":1315,"conditions":1456,"interventions":1457},"NCT06647524","Pilot fMRI Studies of Aging-Related Effects of THC",[87],"2025-07-01",[42],[42],{"trials":1459,"activeCount":98},[],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[],{"intervention":1465,"totalTrials":1466,"cells":1467},"Pembrolizumab",7,{"EARLY_PHASE1":1468,"PHASE1":1481,"PHASE2":1483,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1469,"activeCount":109,"soonestReadout":568},[1470],{"nctId":1471,"briefTitle":1472,"status":102,"phases":1473,"primaryCompletion":568,"completion":568,"start":1474,"enrollment":118,"conditions":1475,"interventions":1479},"NCT04645602","Merck IIT: RRP Pembro and Lenvatinib",[85],"2025-07-18",[1476,1477,1478],"Human Papilloma Virus","Recurrent Respiratory Papillomatosis","Pulmonary Disease",[1480,1465],"Lenvatinib",{"trials":1482,"activeCount":98},[],{"trials":1484,"activeCount":94,"soonestReadout":51},[1485,1497,1507,1516,1528,1535],{"nctId":1486,"briefTitle":1487,"status":711,"phases":1488,"primaryCompletion":1325,"completion":1325,"start":1489,"enrollment":1367,"conditions":1490,"interventions":1496},"NCT04955743","Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma",[87],"2022-02-09",[1491,1492,1493,1494,1465,1480,1495],"Melanoma","Renal Cell Carcinoma","Brain Metastases","PD1\u002FPD-L1 Experienced","Metastatic Melanoma",[1465,1480],{"nctId":1498,"briefTitle":1499,"status":711,"phases":1500,"primaryCompletion":1501,"completion":1502,"start":1503,"enrollment":219,"conditions":1504,"interventions":1506},"NCT02892201","Pembrolizumab in HNSCC With Residual Disease After Radiation",[87],"2020-02","2020-03","2016-09-08",[1505],"Head and Neck Squamous Cell Carcinoma",[1465],{"nctId":1508,"briefTitle":1509,"status":152,"phases":1510,"primaryCompletion":1511,"completion":1511,"start":1164,"enrollment":1512,"conditions":1513,"interventions":1515},"NCT02899793","Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer",[87],"2024-07-17",25,[1514],"Recurrent Endometrial Cancer",[1465],{"nctId":1517,"briefTitle":1518,"status":102,"phases":1519,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1526},"NCT05313243","Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed\u002FRefractory T-cell Lymphoma",[87],"2028-04-30","2028-07-30","2023-07-10",32,[1525],"T-Cell Lymphoma",[1527,1465],"Brentuximab vedotin",{"nctId":49,"briefTitle":50,"status":672,"phases":1529,"primaryCompletion":51,"completion":51,"start":1530,"enrollment":285,"conditions":1531,"interventions":1533},[87],"2021-02-04",[1532],"Advanced Non-small Cell Lung Cancer",[52,1534,1465],"NC318 400 mg",{"nctId":1536,"briefTitle":1537,"status":102,"phases":1538,"primaryCompletion":1539,"completion":1539,"start":1540,"enrollment":31,"conditions":1541,"interventions":1545},"NCT07172256","CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs",[87],"2031-02","2026-05-07",[1505,1542,1543,1544],"HPV Positive Oropharyngeal Squamous Cell Carcinoma","New Diagnosis Tumor","Locally Advanced",[1546,1465],"CUE-101",{"trials":1548,"activeCount":98},[],{"trials":1550,"activeCount":98},[],{"trials":1552,"activeCount":98},[],{"intervention":1554,"totalTrials":1246,"cells":1555},"Sacituzumab Govitecan",{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1557,"activeCount":98},[],{"trials":1559,"activeCount":98},[],{"trials":1561,"activeCount":1246,"soonestReadout":116},[1562,1570,1580,1591],{"nctId":1563,"briefTitle":1564,"status":672,"phases":1565,"primaryCompletion":1440,"completion":250,"start":1566,"enrollment":1305,"conditions":1567,"interventions":1569},"NCT04251416","A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma",[87],"2020-03-17",[1568],"Endometrial Carcinoma",[1554],{"nctId":1571,"briefTitle":1572,"status":102,"phases":1573,"primaryCompletion":116,"completion":1574,"start":1575,"enrollment":118,"conditions":1576,"interventions":1578},"NCT05838521","A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer",[87],"2028-06-01","2023-06-02",[1577],"Cervical Cancer",[1579],"Sacituzumab govitecan",{"nctId":1581,"briefTitle":1582,"status":102,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":105,"conditions":1586,"interventions":1588},"NCT06963905","Saci Nivo Rela for TNBC",[86,87],"2030-12","2025-12-29",[1587],"Metastatic Triple-negative Breast Cancer",[1589,1554,1590],"Relatlimab FDC + Nivolumab","Nivolumab",{"nctId":1592,"briefTitle":1593,"status":672,"phases":1594,"primaryCompletion":1595,"completion":1596,"start":1597,"enrollment":118,"conditions":1598,"interventions":1600},"NCT06028932","A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients",[87],"2026-11-01","2027-11-01","2024-01-08",[1599],"Ovarian Carcinoma",[1579],{"trials":1602,"activeCount":98},[],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":98},[],{"intervention":1608,"totalTrials":1609,"cells":1610},"Ketamine",23,{"EARLY_PHASE1":1611,"PHASE1":1641,"PHASE2":1707,"PHASE3":1796,"PHASE4":1806,"NA":1819},{"trials":1612,"activeCount":98},[1613,1622,1631],{"nctId":1614,"briefTitle":1615,"status":152,"phases":1616,"primaryCompletion":1617,"completion":1617,"start":1618,"enrollment":1619,"conditions":1620,"interventions":1621},"NCT02037035","Examining The Effect Of Ketamine On Glutamate\u002FGlutamine Cycling",[85],"2021-06","2013-07",36,[21],[1608],{"nctId":1623,"briefTitle":1624,"status":152,"phases":1625,"primaryCompletion":1626,"completion":1626,"start":1627,"enrollment":1367,"conditions":1628,"interventions":1630},"NCT02083926","Ketamine Infusion for Social Anxiety Disorder",[85],"2016-09-27","2015-01-02",[1629],"Social Anxiety Disorder",[1608],{"nctId":1632,"briefTitle":1633,"status":152,"phases":1634,"primaryCompletion":1635,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1640},"NCT03842800","Characterizing Clinical and Pharmacological Neuroimaging Biomarkers",[85],"2018-08-31","2013-04-01",143,[1639],"Cognitive Impairment",[1608],{"trials":1642,"activeCount":109,"soonestReadout":1695},[1643,1651,1660,1669,1679,1691,1699],{"nctId":1644,"briefTitle":1645,"status":152,"phases":1646,"primaryCompletion":1647,"completion":1647,"start":1423,"enrollment":1648,"conditions":1649,"interventions":1650},"NCT02289248","Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine",[86],"2016-10",16,[21],[1608],{"nctId":1652,"briefTitle":1653,"status":152,"phases":1654,"primaryCompletion":1120,"completion":180,"start":1655,"enrollment":31,"conditions":1656,"interventions":1657},"NCT00690170","Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects",[86],"2002-12",[730],[1608,1658,1659],"Nicotine","Ketamine and Nicotine",{"nctId":1661,"briefTitle":1662,"status":152,"phases":1663,"primaryCompletion":1664,"completion":1664,"start":1665,"enrollment":987,"conditions":1666,"interventions":1667},"NCT02675530","Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism",[86],"2011-12","2007-12",[15],[1668],"ketamine",{"nctId":1670,"briefTitle":1671,"status":152,"phases":1672,"primaryCompletion":1673,"completion":1673,"start":1674,"enrollment":1675,"conditions":1676,"interventions":1678},"NCT01209845","Ketamine for Low Mood States in the ER",[86],"2010-12","2010-04",14,[21,1677],"Suicide Ideation",[1668],{"nctId":1680,"briefTitle":1681,"status":152,"phases":1682,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1689},"NCT03367533","Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial",[86],"2022-07-08","2018-11-29",13,[1687,1688,1215],"Depressive Disorder, Major","Post Traumatic Stress Disorder",[1608,1690],"Perampanel",{"nctId":1692,"briefTitle":1693,"status":102,"phases":1694,"primaryCompletion":1695,"completion":1695,"start":1696,"enrollment":1305,"conditions":1697,"interventions":1698},"NCT05915013","Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response",[86],"2032-12","2023-09-07",[1687,1688],[1608,1690],{"nctId":1700,"briefTitle":1701,"status":711,"phases":1702,"primaryCompletion":1502,"completion":1502,"start":1441,"enrollment":94,"conditions":1703,"interventions":1705},"NCT02708849","The Sustained Effects of Ketamine",[86],[1704],"Mental Disorders",[1608,1706],"Lamotrigine",{"trials":1708,"activeCount":263,"soonestReadout":1713},[1709,1721,1728,1737,1746,1755,1764,1776,1785],{"nctId":1710,"briefTitle":1711,"status":102,"phases":1712,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1719},"NCT05737693","Enhancing Week-long Psychological Treatment for PTSD With Ketamine",[87],"2030-08-01","2031-08-01","2023-08-21",162,[1718],"Posttraumatic Stress Disorder",[1608,1720],"Midazolam",{"nctId":1722,"briefTitle":1723,"status":152,"phases":1724,"primaryCompletion":1664,"completion":1664,"start":1092,"enrollment":1315,"conditions":1725,"interventions":1727},"NCT01349231","Ketamine Infusion for Obsessive-Compulsive Disorder",[87],[1726],"Obsessive-compulsive Disorder",[1668],{"nctId":1729,"briefTitle":1730,"status":711,"phases":1731,"primaryCompletion":1732,"completion":1732,"start":1733,"enrollment":1289,"conditions":1734,"interventions":1736},"NCT03395314","Ketamine in Borderline Personality Disorder",[87],"2022-05-06","2018-02-15",[1735],"Borderline Personality Disorder",[1608,1720],{"nctId":1738,"briefTitle":1739,"status":711,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1745},"NCT02727998","Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy",[87],"2021-11-28","2015-12",28,[1718],[1608,1720],{"nctId":1747,"briefTitle":1748,"status":152,"phases":1749,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":766,"conditions":1752,"interventions":1754},"NCT04944017","Ketamine for the Treatment of Depression in Parkinson's Disease",[87],"2025-09-24","2021-11-23",[1753,21],"Parkinson's Disease",[1608],{"nctId":1756,"briefTitle":1757,"status":1051,"phases":1758,"primaryCompletion":1759,"completion":1759,"start":1759,"enrollment":98,"conditions":1760,"interventions":1762},"NCT01768767","Trial of Ketamine and Lithium Therapy in Bipolar Depression",[87],"2013-01",[1761],"Bipolar Depression",[1608,1763],"Ketamine\u002FLithium",{"nctId":1765,"briefTitle":1766,"status":102,"phases":1767,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":31,"conditions":1770,"interventions":1774},"NCT05786066","The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects",[87],"2033-03","2023-04-03",[1771,1772,1215,1688,1773],"Depressive Disorder","Major Depressive Disorder","Suicidal Ideation",[1775,1608],"Perampanel 6 MG",{"nctId":1777,"briefTitle":1778,"status":152,"phases":1779,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":1609,"conditions":1782,"interventions":1783},"NCT02487485","Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects",[87],"2020-01","2016-03",[21],[1608,1784],"sirolimus",{"nctId":1786,"briefTitle":1787,"status":711,"phases":1788,"primaryCompletion":1789,"completion":1790,"start":1791,"enrollment":272,"conditions":1792,"interventions":1795},"NCT04613453","Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine",[87],"2024-07-31","2024-12-03","2022-01-21",[1793,1794],"Adolescent Suicide","Adolescent Depression",[1608,1720],{"trials":1797,"activeCount":98},[1798],{"nctId":1799,"briefTitle":1800,"status":711,"phases":1801,"primaryCompletion":1802,"completion":986,"start":1803,"enrollment":94,"conditions":1804,"interventions":1805},"NCT03889756","Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy",[87,88],"2019-12-18","2019-07-17",[1772],[1608,1720],{"trials":1807,"activeCount":98},[1808],{"nctId":1809,"briefTitle":1810,"status":152,"phases":1811,"primaryCompletion":1812,"completion":1813,"start":1814,"enrollment":1815,"conditions":1816,"interventions":1818},"NCT02579928","Ketamine Infusion for Adolescent Depression and Anxiety",[89],"2018-09-28","2019-09","2015-10",17,[1772,1817],"Anxiety Disorder",[1608,1720],{"trials":1820,"activeCount":109,"soonestReadout":944},[1821,1831],{"nctId":1822,"briefTitle":1823,"status":102,"phases":1824,"primaryCompletion":944,"completion":1825,"start":1826,"enrollment":1827,"conditions":1828,"interventions":1830},"NCT02734602","Imaging SV2A in Mood Disorders",[90],"2027-03","2016-04",130,[1772,1829],"Post-Traumatic Stress Disorder",[1608],{"nctId":1832,"briefTitle":1833,"status":152,"phases":1834,"primaryCompletion":1090,"completion":1090,"start":1835,"enrollment":1836,"conditions":1837,"interventions":1839},"NCT01691092","PET Imaging of mGLuR5 With Drug Challenge",[90],"2012-06",79,[1772,1838],"Post-Traumatic Stress Disorder (PTSD)",[1608],{"intervention":70,"totalTrials":1815,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1863,"PHASE2":1891,"PHASE3":1964,"PHASE4":1966,"NA":1977},{"trials":1843,"activeCount":98},[1844,1854],{"nctId":1845,"briefTitle":1846,"status":152,"phases":1847,"primaryCompletion":714,"completion":1441,"start":1848,"enrollment":303,"conditions":1849,"interventions":1852},"NCT02193256","Varenicline + Prazosin for Heavy Drinking Smokers",[85],"2014-07",[1850,1851],"Cigarette Smoking","Alcohol Use Disorders",[70,1853],"Prazosin",{"nctId":1855,"briefTitle":1856,"status":711,"phases":1857,"primaryCompletion":1186,"completion":1186,"start":1858,"enrollment":1466,"conditions":1859,"interventions":1861},"NCT00931021","Smoking Cessation Treatment for Head and Neck Cancer Patients",[85],"2009-07",[1860],"Smoking Cessation",[70,1862],"Nicotine Patch",{"trials":1864,"activeCount":109,"soonestReadout":61},[1865,1871,1882],{"nctId":68,"briefTitle":69,"status":102,"phases":1866,"primaryCompletion":61,"completion":61,"start":1867,"enrollment":1044,"conditions":1868,"interventions":1870},[86],"2024-04-01",[1850,1869,1860],"E-Cigarette Use",[70],{"nctId":1872,"briefTitle":1873,"status":152,"phases":1874,"primaryCompletion":1875,"completion":1876,"start":1877,"enrollment":1878,"conditions":1879,"interventions":1881},"NCT02151591","New Approaches to Smoking Cessation in Heavy Drinkers",[86],"2018-06-01","2018-08-01","2017-03-01",26,[24,1850,1190,1880],"Heavy Drinking",[70],{"nctId":1883,"briefTitle":1884,"status":152,"phases":1885,"primaryCompletion":1886,"completion":1887,"start":1835,"enrollment":1648,"conditions":1888,"interventions":1890},"NCT01624428","Varenicline on Reward Responses and Cognition in Adolescent Smokers",[86],"2013-11","2013-12",[1889],"Tobacco Use Disorders",[70],{"trials":1892,"activeCount":263,"soonestReadout":1944},[1893,1903,1913,1919,1927,1931,1940,1949,1953],{"nctId":1894,"briefTitle":1895,"status":152,"phases":1896,"primaryCompletion":1897,"completion":1897,"start":1898,"enrollment":1899,"conditions":1900,"interventions":1901},"NCT04198116","Combining Varenicline and Guanfacine for Smoking Cessation",[87],"2025-04-30","2020-11-01",165,[1860],[70,1902],"Guanfacine ER",{"nctId":1904,"briefTitle":1905,"status":152,"phases":1906,"primaryCompletion":1907,"completion":1907,"start":1908,"enrollment":1909,"conditions":1910,"interventions":1912},"NCT01553136","Varenicline Treatment of Alcohol Dependence in Smokers",[87],"2016-05","2012-09",131,[1111,1911,33,1034],"Alcohol Abuse",[70],{"nctId":1914,"briefTitle":1915,"status":152,"phases":1916,"primaryCompletion":1137,"completion":1137,"start":1245,"enrollment":105,"conditions":1917,"interventions":1918},"NCT00580645","Do Treatments for Smoking Cessation Affect Alcohol Drinking?",[87],[1034],[1141],{"nctId":1920,"briefTitle":1921,"status":152,"phases":1922,"primaryCompletion":1137,"completion":1137,"start":1072,"enrollment":1923,"conditions":1924,"interventions":1926},"NCT01000987","Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders",[87],44,[1925],"Alcohol Reactivity",[1141],{"nctId":1117,"briefTitle":1118,"status":152,"phases":1928,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1044,"conditions":1929,"interventions":1930},[86,87],[33,24],[890,70],{"nctId":1932,"briefTitle":1933,"status":152,"phases":1934,"primaryCompletion":1647,"completion":1647,"start":1245,"enrollment":1935,"conditions":1936,"interventions":1938},"NCT00580853","The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior",[87],62,[1937],"Smoking Lapse Behavior",[1141,1939],"bupropion",{"nctId":1941,"briefTitle":1942,"status":672,"phases":1943,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":31,"conditions":1946,"interventions":1948},"NCT06006143","Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2",[87],"2026-08-31","2025-06-16",[27,573,1947],"Tobacco Use Disorder",[70],{"nctId":1134,"briefTitle":1135,"status":152,"phases":1950,"primaryCompletion":1137,"completion":1137,"start":1138,"enrollment":31,"conditions":1951,"interventions":1952},[87],[33],[1115,1141],{"nctId":1954,"briefTitle":1955,"status":102,"phases":1956,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":1959,"conditions":1960,"interventions":1963},"NCT06609369","Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse",[87],"2029-06","2025-04-21",114,[1961,1962,1248],"Tobacco Use","Tobacco Cessation",[70],{"trials":1965,"activeCount":98},[],{"trials":1967,"activeCount":98},[1968],{"nctId":1969,"briefTitle":1970,"status":152,"phases":1971,"primaryCompletion":1972,"completion":1972,"start":1973,"enrollment":1512,"conditions":1974,"interventions":1975},"NCT02562521","A Smoking Cessation Intervention for Yale Dining Employees",[89],"2016-12","2015-09",[1860],[1976,70],"Nicotine replacement therapy",{"trials":1978,"activeCount":98},[1979,1988],{"nctId":1980,"briefTitle":1981,"status":152,"phases":1982,"primaryCompletion":1120,"completion":1983,"start":1984,"enrollment":28,"conditions":1985,"interventions":1986},"NCT00567320","Efficacy of Varenicline in Methadone-Stabilized Cocaine Users",[90],"2009-08","2007-03",[330,24],[70,1987],"Sugar pill or Placebo",{"nctId":1989,"briefTitle":1990,"status":152,"phases":1991,"primaryCompletion":1992,"completion":1993,"start":1061,"enrollment":1994,"conditions":1995,"interventions":1996},"NCT00606892","Varenicline and Nicotine Interactions in Humans (VA)",[90],"2008-11","2009-11",37,[1860],[70,1997],"IV Nic",{"intervention":1590,"totalTrials":1246,"cells":1999},{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2027,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2001,"activeCount":98},[],{"trials":2003,"activeCount":109,"soonestReadout":2008},[2004,2016],{"nctId":2005,"briefTitle":2006,"status":672,"phases":2007,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":1878,"conditions":2011,"interventions":2013},"NCT04495257","A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)",[86],"2026-02-28","2026-08-28","2020-09-14",[2012,1492],"Advanced Melanoma",[1590,2014,2015],"Ipilimumab","APX005M",{"nctId":2017,"briefTitle":2018,"status":152,"phases":2019,"primaryCompletion":2020,"completion":2021,"start":2022,"enrollment":1397,"conditions":2023,"interventions":2025},"NCT03502330","APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma",[86],"2022-01-05","2024-05-15","2018-06-09",[2012,2024,1492],"Non-small Cell Lung Cancer",[2015,2026,1590],"Cabiralizumab",{"trials":2028,"activeCount":109,"soonestReadout":1584},[2029,2033],{"nctId":1581,"briefTitle":1582,"status":102,"phases":2030,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":105,"conditions":2031,"interventions":2032},[86,87],[1587],[1589,1554,1590],{"nctId":2034,"briefTitle":2035,"status":1051,"phases":2036,"primaryCompletion":2037,"completion":2038,"start":2039,"enrollment":98,"conditions":2040,"interventions":2043},"NCT04044209","A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed\u002FRefractory AML and High Risk MDS",[87],"2021-09","2023-09","2020-02-12",[2041,2042],"Myelodysplastic Syndromes","Acute Myeloid Leukemia",[2044,1590],"AG-120",{"trials":2046,"activeCount":98},[],{"trials":2048,"activeCount":98},[],{"trials":2050,"activeCount":98},[],{"intervention":2052,"totalTrials":263,"cells":2053},"Bupivacaine-Liposomal Bupivacaine",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2055,"activeCount":98},[],{"trials":2057,"activeCount":98},[],{"trials":2059,"activeCount":263,"soonestReadout":237},[2060,2071],{"nctId":2061,"briefTitle":2062,"status":102,"phases":2063,"primaryCompletion":237,"completion":2064,"start":2065,"enrollment":616,"conditions":2066,"interventions":2069},"NCT05279092","Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study",[87],"2028-03","2022-09-08",[2067,2068],"Total Knee Replacement","Knee Arthroplasty",[2052,2070],"Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate",{"nctId":2072,"briefTitle":2073,"status":102,"phases":2074,"primaryCompletion":237,"completion":2064,"start":2075,"enrollment":2076,"conditions":2077,"interventions":2078},"NCT05736549","Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2",[87],"2023-02-07",66,[2067,2068],[2052,2070],{"trials":2080,"activeCount":98},[],{"trials":2082,"activeCount":98},[],{"trials":2084,"activeCount":98},[],{"intervention":2070,"totalTrials":263,"cells":2086},{"EARLY_PHASE1":2087,"PHASE1":2089,"PHASE2":2091,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2088,"activeCount":98},[],{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":263,"soonestReadout":237},[2093,2097],{"nctId":2061,"briefTitle":2062,"status":102,"phases":2094,"primaryCompletion":237,"completion":2064,"start":2065,"enrollment":616,"conditions":2095,"interventions":2096},[87],[2067,2068],[2052,2070],{"nctId":2072,"briefTitle":2073,"status":102,"phases":2098,"primaryCompletion":237,"completion":2064,"start":2075,"enrollment":2076,"conditions":2099,"interventions":2100},[87],[2067,2068],[2052,2070],{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[],{"trials":2106,"activeCount":98},[],{"intervention":2108,"totalTrials":263,"cells":2109},"Semaglutide Pen Injector",{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"trials":2115,"activeCount":263,"soonestReadout":1440},[2116,2127],{"nctId":2117,"briefTitle":2118,"status":672,"phases":2119,"primaryCompletion":1440,"completion":944,"start":2120,"enrollment":105,"conditions":2121,"interventions":2126},"NCT05067621","Semaglutide Effects in Obese Youth With Prediabetes\u002FNew Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease",[87],"2023-07-17",[2122,2123,2124,2125],"Type 2 Diabetes Mellitus","Impaired Glucose Tolerance","Non-Alcoholic Fatty Liver Disease","Obesity, Childhood",[2108],{"nctId":2128,"briefTitle":2129,"status":102,"phases":2130,"primaryCompletion":1520,"completion":2131,"start":2132,"enrollment":2133,"conditions":2134,"interventions":2136},"NCT06411210","Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment",[87],"2028-06-30","2024-07-16",54,[2135,18],"Diabetes type1",[2108],{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"intervention":2144,"totalTrials":263,"cells":2145},"Naltrexone Hydrochloride",{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2160,"PHASE3":2172,"PHASE4":2174,"NA":2176},{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":109,"soonestReadout":2154},[2150],{"nctId":2151,"briefTitle":2152,"status":102,"phases":2153,"primaryCompletion":2154,"completion":2154,"start":2155,"enrollment":118,"conditions":2156,"interventions":2158},"NCT07224087","Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients",[86],"2027-12-31","2026-03-02",[18,1860,2157],"Bariatric Surgery Patients",[2144,2159],"Bupropion HCl Extended Release",{"trials":2161,"activeCount":109,"soonestReadout":637},[2162],{"nctId":2163,"briefTitle":2164,"status":248,"phases":2165,"primaryCompletion":637,"completion":2166,"start":839,"enrollment":2167,"conditions":2168,"interventions":2169},"NCT07398404","A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients",[86,87],"2031-06-30",64,[18,1860,2157],[2170,2171],"Naltrexone hydrochloride","Bupropion Hydrochloride Extended-release",{"trials":2173,"activeCount":98},[],{"trials":2175,"activeCount":98},[],{"trials":2177,"activeCount":98},[],{"intervention":1853,"totalTrials":1246,"cells":2179},{"EARLY_PHASE1":2180,"PHASE1":2186,"PHASE2":2188,"PHASE3":2207,"PHASE4":2218,"NA":2220},{"trials":2181,"activeCount":98},[2182],{"nctId":1845,"briefTitle":1846,"status":152,"phases":2183,"primaryCompletion":714,"completion":1441,"start":1848,"enrollment":303,"conditions":2184,"interventions":2185},[85],[1850,1851],[70,1853],{"trials":2187,"activeCount":98},[],{"trials":2189,"activeCount":109,"soonestReadout":812},[2190,2198],{"nctId":2191,"briefTitle":2192,"status":152,"phases":2193,"primaryCompletion":2194,"completion":2195,"start":180,"enrollment":1011,"conditions":2196,"interventions":2197},"NCT00585780","Prazosin to Reduce Stress-Induced Alcohol\u002FDrug Craving and Relapse",[86,87],"2018-08","2019-05-13",[1112],[1853],{"nctId":2199,"briefTitle":2200,"status":102,"phases":2201,"primaryCompletion":812,"completion":614,"start":2202,"enrollment":2203,"conditions":2204,"interventions":2206},"NCT04793685","Prazosin for Alcohol Use Disorder With Withdrawal Symptoms",[87],"2021-07-01",150,[2205],"Alcohol Withdrawal",[1853],{"trials":2208,"activeCount":98},[2209],{"nctId":2210,"briefTitle":2211,"status":152,"phases":2212,"primaryCompletion":2213,"completion":2213,"start":2214,"enrollment":728,"conditions":2215,"interventions":2217},"NCT00744055","Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).",[88],"2014-10","2009-01",[1112,2216],"Stress Disorders, Post-Traumatic",[1853],{"trials":2219,"activeCount":98},[],{"trials":2221,"activeCount":98},[],{"intervention":2223,"totalTrials":94,"cells":2224},"docetaxel",{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2239,"PHASE3":2261,"PHASE4":2263,"NA":2265},{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[2229],{"nctId":2230,"briefTitle":2231,"status":711,"phases":2232,"primaryCompletion":1983,"completion":1072,"start":164,"enrollment":28,"conditions":2233,"interventions":2237},"NCT00303888","Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer",[86],[2234,2235,2236],"Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cavity Cancer",[2223,2238],"idronoxil",{"trials":2240,"activeCount":109,"soonestReadout":1825},[2241,2252],{"nctId":2242,"briefTitle":2243,"status":672,"phases":2244,"primaryCompletion":1825,"completion":1825,"start":2245,"enrollment":2246,"conditions":2247,"interventions":2249},"NCT03456843","Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer",[87],"2018-03-20",190,[2248],"Stage IV Prostate Adenocarcinoma AJCC v7",[2250,2251],"Antiandrogen Therapy","Docetaxel",{"nctId":2253,"briefTitle":2254,"status":152,"phases":2255,"completion":164,"start":2256,"enrollment":16,"conditions":2257,"interventions":2259},"NCT00004923","Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors",[86,87],"1999-04",[2258],"Unspecified Adult Solid Tumor, Protocol Specific",[2223,2260],"irinotecan hydrochloride",{"trials":2262,"activeCount":98},[],{"trials":2264,"activeCount":98},[],{"trials":2266,"activeCount":98},[],{"intervention":2268,"totalTrials":263,"cells":2269},"Digoxin",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2284,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2271,"activeCount":98},[],{"trials":2273,"activeCount":98},[2274],{"nctId":2275,"briefTitle":2276,"status":152,"phases":2277,"primaryCompletion":2278,"completion":2278,"start":2279,"enrollment":2280,"conditions":2281,"interventions":2283},"NCT03559868","Inhibition of Sterile Inflammation by Digoxin",[86],"2023-05-05","2021-03-01",45,[2282],"Inflammatory Response",[2268,2268],{"trials":2285,"activeCount":109,"soonestReadout":2290},[2286],{"nctId":2287,"briefTitle":2288,"status":102,"phases":2289,"primaryCompletion":2290,"completion":2290,"start":2291,"enrollment":1211,"conditions":2292,"interventions":2301},"NCT06588699","Digoxin In NASH (CODIN)",[87],"2029-01","2025-06-05",[2293,2294,2295,2296,2297,2298,2299,2300],"NASH","NAFLD","MASH - Metabolic Dysfunction-Associated Steatohepatitis","Mash","MASH With Fibrosis","MASLD","Fatty Liver Disease","Fatty Liver Disease, Nonalcoholic",[2268],{"trials":2303,"activeCount":98},[],{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[],{"intervention":2309,"totalTrials":263,"cells":2310},"propranolol",{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2325,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2312,"activeCount":98},[],{"trials":2314,"activeCount":98},[2315],{"nctId":2316,"briefTitle":2317,"status":711,"phases":2318,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":1416,"conditions":2321,"interventions":2323},"NCT01978457","Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction",[86],"2019-12","2012-10",[2322],"Cocaine Dependent Subjects",[2324,2309],"cocaine hydrochloride",{"trials":2326,"activeCount":109,"soonestReadout":2008},[2327],{"nctId":2328,"briefTitle":2329,"status":672,"phases":2330,"primaryCompletion":2008,"completion":2008,"start":2331,"enrollment":118,"conditions":2332,"interventions":2333},"NCT03588754","Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?",[87],"2018-09-15",[1034],[2334],"Propranolol",{"trials":2336,"activeCount":98},[],{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[],{"intervention":1902,"totalTrials":263,"cells":2342},{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2361,"PHASE4":2363,"NA":2365},{"trials":2344,"activeCount":98},[],{"trials":2346,"activeCount":98},[],{"trials":2348,"activeCount":109,"soonestReadout":1944},[2349,2353],{"nctId":1894,"briefTitle":1895,"status":152,"phases":2350,"primaryCompletion":1897,"completion":1897,"start":1898,"enrollment":1899,"conditions":2351,"interventions":2352},[87],[1860],[70,1902],{"nctId":2354,"briefTitle":2355,"status":102,"phases":2356,"primaryCompletion":1944,"completion":1944,"start":2357,"enrollment":946,"conditions":2358,"interventions":2360},"NCT03764098","Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders",[87],"2020-08-10",[2359],"Alcohol Use",[1902],{"trials":2362,"activeCount":98},[],{"trials":2364,"activeCount":98},[],{"trials":2366,"activeCount":98},[],{"intervention":2368,"totalTrials":263,"cells":2369},"afatinib",{"EARLY_PHASE1":2370,"PHASE1":2372,"PHASE2":2374,"PHASE3":2396,"PHASE4":2398,"NA":2400},{"trials":2371,"activeCount":98},[],{"trials":2373,"activeCount":98},[],{"trials":2375,"activeCount":109,"soonestReadout":1332},[2376,2387],{"nctId":2377,"briefTitle":2378,"status":152,"phases":2379,"primaryCompletion":2380,"completion":2381,"start":2382,"enrollment":1305,"conditions":2383,"interventions":2385},"NCT02979977","Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck",[87],"2025-01-18","2026-01-18","2017-03-24",[2384],"Squamous Cell Cancers of the Head and Neck",[2386,2368],"cetuximab",{"nctId":2388,"briefTitle":2389,"status":102,"phases":2390,"primaryCompletion":1332,"completion":2391,"start":1441,"enrollment":1305,"conditions":2392,"interventions":2394},"NCT02491099","A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma",[87],"2028-07",[2393],"HER2\u002FNeu+ Uterine Serous Carcinoma",[2395],"Afatinib",{"trials":2397,"activeCount":98},[],{"trials":2399,"activeCount":98},[],{"trials":2401,"activeCount":98},[],{"intervention":2403,"totalTrials":263,"cells":2404},"MDMA",{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2417,"PHASE3":2427,"PHASE4":2429,"NA":2431},{"trials":2406,"activeCount":98},[],{"trials":2408,"activeCount":98},[2409],{"nctId":2410,"briefTitle":2411,"status":1051,"phases":2412,"primaryCompletion":2413,"completion":2413,"start":2414,"enrollment":98,"conditions":2415,"interventions":2416},"NCT03752918","The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.",[86],"2028-01","2024-05",[1688],[2403,1346],{"trials":2418,"activeCount":109,"soonestReadout":2423},[2419],{"nctId":2420,"briefTitle":2421,"status":102,"phases":2422,"primaryCompletion":2423,"completion":2423,"start":2424,"enrollment":1315,"conditions":2425,"interventions":2426},"NCT06683014","MDMA in Borderline Personality Disorder",[87],"2026-09","2025-09-05",[1735],[2403],{"trials":2428,"activeCount":98},[],{"trials":2430,"activeCount":98},[],{"trials":2432,"activeCount":98},[],{"intervention":2434,"totalTrials":263,"cells":2435},"Fluzone",{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2448,"PHASE3":2458,"PHASE4":2460,"NA":2462},{"trials":2437,"activeCount":98},[],{"trials":2439,"activeCount":98},[2440],{"nctId":2441,"briefTitle":2442,"status":152,"phases":2443,"primaryCompletion":1742,"completion":1742,"start":2213,"enrollment":766,"conditions":2444,"interventions":2447},"NCT02267733","Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients",[86],[2445,2446],"Influenza","Gammopathy",[2434],{"trials":2449,"activeCount":109,"soonestReadout":740},[2450],{"nctId":2451,"briefTitle":2452,"status":102,"phases":2453,"primaryCompletion":740,"completion":740,"start":2454,"enrollment":728,"conditions":2455,"interventions":2456},"NCT05291676","Systems Investigation of Vaccine Responses in Aging and Frailty",[87],"2023-11-06",[2445],[2434,2457],"Fluad",{"trials":2459,"activeCount":98},[],{"trials":2461,"activeCount":98},[],{"trials":2463,"activeCount":98},[],{"intervention":2465,"totalTrials":263,"cells":2466},"Valbenazine",{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2480,"PHASE3":2492,"PHASE4":2494,"NA":2496},{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[2471],{"nctId":2472,"briefTitle":2473,"status":1051,"phases":2474,"primaryCompletion":2475,"completion":2475,"start":2476,"enrollment":98,"conditions":2477,"interventions":2479},"NCT05053321","Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine",[86],"2025-10-18","2024-10-18",[2478],"Tardive Dyskinesia",[2465],{"trials":2481,"activeCount":109,"soonestReadout":2486},[2482],{"nctId":2483,"briefTitle":2484,"status":102,"phases":2485,"primaryCompletion":2486,"completion":2486,"start":2487,"enrollment":118,"conditions":2488,"interventions":2490},"NCT05207085","Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults",[87],"2027-02-15","2024-02-02",[2489],"Trichotillomania (Hair-Pulling Disorder)",[2491],"Valbenazine Oral",{"trials":2493,"activeCount":98},[],{"trials":2495,"activeCount":98},[],{"trials":2497,"activeCount":98},[],{"intervention":2499,"totalTrials":263,"cells":2500},"Nimodipine",{"EARLY_PHASE1":2501,"PHASE1":2503,"PHASE2":2513,"PHASE3":2523,"PHASE4":2525,"NA":2527},{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[2505],{"nctId":2506,"briefTitle":2507,"status":152,"phases":2508,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":98,"conditions":2511,"interventions":2512},"NCT00000280","Glutaminergic Agents for Cocaine Abuse - 5",[86],"1999-08","1994-09",[210],[2499],{"trials":2514,"activeCount":109,"soonestReadout":2519},[2515],{"nctId":2516,"briefTitle":2517,"status":248,"phases":2518,"primaryCompletion":2519,"completion":2519,"start":2520,"enrollment":303,"conditions":2521,"interventions":2522},"NCT06900998","Pilot Study: Effects of Nimodipine on Alcohol Drinking",[87],"2032-06-30","2026-09-01",[27],[2499],{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[],{"intervention":2530,"totalTrials":263,"cells":2531},"Pregnenolone",{"EARLY_PHASE1":2532,"PHASE1":2544,"PHASE2":2546,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2533,"activeCount":98},[2534],{"nctId":2535,"briefTitle":2536,"status":152,"phases":2537,"primaryCompletion":2538,"completion":2538,"start":2539,"enrollment":2540,"conditions":2541,"interventions":2542},"NCT03953612","The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders",[85],"2023-05-08","2019-03-12",58,[210],[2530,2543],"Placebos",{"trials":2545,"activeCount":98},[],{"trials":2547,"activeCount":109,"soonestReadout":2552},[2548],{"nctId":2549,"briefTitle":2550,"status":102,"phases":2551,"primaryCompletion":2552,"completion":2552,"start":1597,"enrollment":2203,"conditions":2553,"interventions":2554},"NCT05781009","Pregnenolone for the Treatment of Alcohol Use Disorder",[87],"2028-07-31",[27],[2530],{"trials":2556,"activeCount":98},[],{"trials":2558,"activeCount":98},[],{"trials":2560,"activeCount":98},[],{"intervention":1527,"totalTrials":263,"cells":2562},{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2564,"activeCount":98},[],{"trials":2566,"activeCount":98},[],{"trials":2568,"activeCount":109,"soonestReadout":1520},[2569,2573],{"nctId":1517,"briefTitle":1518,"status":102,"phases":2570,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":2571,"interventions":2572},[87],[1525],[1527,1465],{"nctId":2574,"briefTitle":2575,"status":1051,"phases":2576,"primaryCompletion":2038,"completion":2577,"start":2578,"enrollment":98,"conditions":2579,"interventions":2589},"NCT04138875","A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)",[87],"2023-12","2022-01",[2580,2581,2582,2583,2584,2585,2586,2587,2588],"PTLD","Lymphoid Tumor","Hematopoietic\u002FLymphoid Cancer","Plasmacytic Hyperplasia PTLD","Infectious Mononucleosis","Florid Follicular Hyperplasia PTLD","Polymorphic PTLD","Monomorphic PTLD","Classical Hodgkin Lymphoma Type PTLD",[2590,2591,2592],"Rituximab","Brentuximab Vedotin","Bendamustine",{"trials":2594,"activeCount":98},[],{"trials":2596,"activeCount":98},[],{"trials":2598,"activeCount":98},[],{"intervention":2600,"totalTrials":109,"cells":2601},"Relugolix 120 MG [Orgovyx]",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2617,"PHASE4":2619,"NA":2621},{"trials":2603,"activeCount":98},[],{"trials":2605,"activeCount":98},[],{"trials":2607,"activeCount":109,"soonestReadout":2612},[2608],{"nctId":2609,"briefTitle":2610,"status":102,"phases":2611,"primaryCompletion":2612,"completion":2612,"start":2613,"enrollment":105,"conditions":2614,"interventions":2616},"NCT06111781","The SUGAR Study; SBRT and Relugolix) for Prostate Cancer",[87],"2028-02","2024-04-15",[2615],"Prostate Cancer",[2600],{"trials":2618,"activeCount":98},[],{"trials":2620,"activeCount":98},[],{"trials":2622,"activeCount":98},[],{"intervention":62,"totalTrials":109,"cells":2624},{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2626,"activeCount":98},[],{"trials":2628,"activeCount":98},[],{"trials":2630,"activeCount":109,"soonestReadout":61},[2631],{"nctId":59,"briefTitle":60,"status":672,"phases":2632,"primaryCompletion":61,"completion":61,"start":2633,"enrollment":1512,"conditions":2634,"interventions":2636},[87],"2018-12-06",[2635],"Small Cell Lung Cancer",[62],{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[],{"trials":2642,"activeCount":98},[],{"intervention":2644,"totalTrials":109,"cells":2645},"[11C]UCB-J PET",{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2663,"PHASE4":2665,"NA":2667},{"trials":2647,"activeCount":98},[],{"trials":2649,"activeCount":98},[],{"trials":2651,"activeCount":109,"soonestReadout":2656},[2652],{"nctId":2653,"briefTitle":2654,"status":102,"phases":2655,"primaryCompletion":2656,"completion":2657,"start":2658,"enrollment":2659,"conditions":2660,"interventions":2662},"NCT05465538","SV2A in Older Adults",[86,87],"2026-12-30","2027-09-30","2022-07-06",24,[2661],"Cannabis Use",[2644],{"trials":2664,"activeCount":98},[],{"trials":2666,"activeCount":98},[],{"trials":2668,"activeCount":98},[],{"intervention":2670,"totalTrials":109,"cells":2671},"Sacituzumab tirumotecan",{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2676,"PHASE3":2686,"PHASE4":2688,"NA":2690},{"trials":2673,"activeCount":98},[],{"trials":2675,"activeCount":98},[],{"trials":2677,"activeCount":109,"soonestReadout":542},[2678],{"nctId":2679,"briefTitle":2680,"status":248,"phases":2681,"primaryCompletion":542,"completion":2682,"start":1235,"enrollment":118,"conditions":2683,"interventions":2685},"NCT07458113","Sac-TMT for Active TNBC Brain Metastases",[87],"2029-05",[2684],"Metastatic Triple Negative Breast Cancers",[2670],{"trials":2687,"activeCount":98},[],{"trials":2689,"activeCount":98},[],{"trials":2691,"activeCount":98},[],{"intervention":2693,"totalTrials":109,"cells":2694},"Ertugliflozin",{"EARLY_PHASE1":2695,"PHASE1":2697,"PHASE2":2699,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2696,"activeCount":98},[],{"trials":2698,"activeCount":98},[],{"trials":2700,"activeCount":109,"soonestReadout":2705},[2701],{"nctId":2702,"briefTitle":2703,"status":102,"phases":2704,"primaryCompletion":2705,"completion":2705,"start":311,"enrollment":105,"conditions":2706,"interventions":2707},"NCT04438213","Ertugliflozin in Chronic Heart Failure",[87],"2025-12-30",[107],[2693,2708],"Metolazone",{"trials":2710,"activeCount":98},[],{"trials":2712,"activeCount":98},[],{"trials":2714,"activeCount":98},[],{"intervention":2708,"totalTrials":109,"cells":2716},{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2727,"PHASE4":2729,"NA":2731},{"trials":2718,"activeCount":98},[],{"trials":2720,"activeCount":98},[],{"trials":2722,"activeCount":109,"soonestReadout":2705},[2723],{"nctId":2702,"briefTitle":2703,"status":102,"phases":2724,"primaryCompletion":2705,"completion":2705,"start":311,"enrollment":105,"conditions":2725,"interventions":2726},[87],[107],[2693,2708],{"trials":2728,"activeCount":98},[],{"trials":2730,"activeCount":98},[],{"trials":2732,"activeCount":98},[],{"intervention":2734,"totalTrials":109,"cells":2735},"Ribociclib 400mg",{"EARLY_PHASE1":2736,"PHASE1":2738,"PHASE2":2740,"PHASE3":2754,"PHASE4":2756,"NA":2758},{"trials":2737,"activeCount":98},[],{"trials":2739,"activeCount":98},[],{"trials":2741,"activeCount":109,"soonestReadout":2746},[2742],{"nctId":2743,"briefTitle":2744,"status":102,"phases":2745,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":1188,"conditions":2748,"interventions":2750},"NCT06953882","Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy",[87],"2030-09","2025-07-09",[2749],"HER2 Negative Breast Cancer",[2734,2751,2752,2753],"Letrozole 2.5mg","Anastrazole 1mg","Goserelin 3.6 MG",{"trials":2755,"activeCount":98},[],{"trials":2757,"activeCount":98},[],{"trials":2759,"activeCount":98},[],{"intervention":2751,"totalTrials":109,"cells":2761},{"EARLY_PHASE1":2762,"PHASE1":2764,"PHASE2":2766,"PHASE3":2772,"PHASE4":2774,"NA":2776},{"trials":2763,"activeCount":98},[],{"trials":2765,"activeCount":98},[],{"trials":2767,"activeCount":109,"soonestReadout":2746},[2768],{"nctId":2743,"briefTitle":2744,"status":102,"phases":2769,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":1188,"conditions":2770,"interventions":2771},[87],[2749],[2734,2751,2752,2753],{"trials":2773,"activeCount":98},[],{"trials":2775,"activeCount":98},[],{"trials":2777,"activeCount":98},[],{"intervention":2752,"totalTrials":109,"cells":2779},{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2784,"PHASE3":2790,"PHASE4":2792,"NA":2794},{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[],{"trials":2785,"activeCount":109,"soonestReadout":2746},[2786],{"nctId":2743,"briefTitle":2744,"status":102,"phases":2787,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":1188,"conditions":2788,"interventions":2789},[87],[2749],[2734,2751,2752,2753],{"trials":2791,"activeCount":98},[],{"trials":2793,"activeCount":98},[],{"trials":2795,"activeCount":98},[],{"intervention":2753,"totalTrials":109,"cells":2797},{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2799,"activeCount":98},[],{"trials":2801,"activeCount":98},[],{"trials":2803,"activeCount":109,"soonestReadout":2746},[2804],{"nctId":2743,"briefTitle":2744,"status":102,"phases":2805,"primaryCompletion":2746,"completion":2746,"start":2747,"enrollment":1188,"conditions":2806,"interventions":2807},[87],[2749],[2734,2751,2752,2753],{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[],{"trials":2813,"activeCount":98},[],{"intervention":2250,"totalTrials":109,"cells":2815},{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2826,"PHASE4":2828,"NA":2830},{"trials":2817,"activeCount":98},[],{"trials":2819,"activeCount":98},[],{"trials":2821,"activeCount":109,"soonestReadout":1825},[2822],{"nctId":2242,"briefTitle":2243,"status":672,"phases":2823,"primaryCompletion":1825,"completion":1825,"start":2245,"enrollment":2246,"conditions":2824,"interventions":2825},[87],[2248],[2250,2251],{"trials":2827,"activeCount":98},[],{"trials":2829,"activeCount":98},[],{"trials":2831,"activeCount":98},[],{"intervention":2833,"totalTrials":109,"cells":2834},"CBD 300mg",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2851,"PHASE4":2853,"NA":2855},{"trials":2836,"activeCount":98},[],{"trials":2838,"activeCount":98},[],{"trials":2840,"activeCount":109,"soonestReadout":2845},[2841],{"nctId":2842,"briefTitle":2843,"status":102,"phases":2844,"primaryCompletion":2845,"completion":2845,"start":2846,"enrollment":2847,"conditions":2848,"interventions":2849},"NCT06544291","Combined THC and CBD for OUD and Chronic Pain",[87],"2028-01-28","2024-10-22",147,[184,30],[2833,2850],"CBD 600mg",{"trials":2852,"activeCount":98},[],{"trials":2854,"activeCount":98},[],{"trials":2856,"activeCount":98},[],{"intervention":2850,"totalTrials":109,"cells":2858},{"EARLY_PHASE1":2859,"PHASE1":2861,"PHASE2":2863,"PHASE3":2869,"PHASE4":2871,"NA":2873},{"trials":2860,"activeCount":98},[],{"trials":2862,"activeCount":98},[],{"trials":2864,"activeCount":109,"soonestReadout":2845},[2865],{"nctId":2842,"briefTitle":2843,"status":102,"phases":2866,"primaryCompletion":2845,"completion":2845,"start":2846,"enrollment":2847,"conditions":2867,"interventions":2868},[87],[184,30],[2833,2850],{"trials":2870,"activeCount":98},[],{"trials":2872,"activeCount":98},[],{"trials":2874,"activeCount":98},[],{"intervention":2876,"totalTrials":109,"cells":2877},"Spironolactone Pill",{"EARLY_PHASE1":2878,"PHASE1":2880,"PHASE2":2882,"PHASE3":2895,"PHASE4":2897,"NA":2899},{"trials":2879,"activeCount":98},[],{"trials":2881,"activeCount":98},[],{"trials":2883,"activeCount":109,"soonestReadout":2888},[2884],{"nctId":2885,"briefTitle":2886,"status":672,"phases":2887,"primaryCompletion":2888,"completion":2889,"start":2890,"enrollment":946,"conditions":2891,"interventions":2894},"NCT04760717","Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke",[87],"2026-02-02","2026-11","2021-03-19",[743,2892,2893],"Ischemic Stroke","Spironolactone",[2876],{"trials":2896,"activeCount":98},[],{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":98},[],{"intervention":2902,"totalTrials":109,"cells":2903},"Scapular-site insertion of etonogestrel contraceptive implant",{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2908,"PHASE3":2918,"PHASE4":2920,"NA":2922},{"trials":2905,"activeCount":98},[],{"trials":2907,"activeCount":98},[],{"trials":2909,"activeCount":109,"soonestReadout":2914},[2910],{"nctId":2911,"briefTitle":2912,"status":102,"phases":2913,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":1935,"conditions":2916,"interventions":2917},"NCT07201402","Long Term Evaluation of Scapular-inserted Contraceptive Implants",[87],"2027-10","2026-05-08",[546],[2902],{"trials":2919,"activeCount":98},[],{"trials":2921,"activeCount":98},[],{"trials":2923,"activeCount":98},[],{"intervention":1589,"totalTrials":109,"cells":2925},{"EARLY_PHASE1":2926,"PHASE1":2928,"PHASE2":2930,"PHASE3":2936,"PHASE4":2938,"NA":2940},{"trials":2927,"activeCount":98},[],{"trials":2929,"activeCount":98},[],{"trials":2931,"activeCount":109,"soonestReadout":1584},[2932],{"nctId":1581,"briefTitle":1582,"status":102,"phases":2933,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":105,"conditions":2934,"interventions":2935},[86,87],[1587],[1589,1554,1590],{"trials":2937,"activeCount":98},[],{"trials":2939,"activeCount":98},[],{"trials":2941,"activeCount":98},[],{"intervention":2943,"totalTrials":109,"cells":2944},"mFOLFIRINOX",{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2960,"PHASE4":2962,"NA":2964},{"trials":2946,"activeCount":98},[],{"trials":2948,"activeCount":98},[],{"trials":2950,"activeCount":109,"soonestReadout":2955},[2951],{"nctId":2952,"briefTitle":2953,"status":672,"phases":2954,"primaryCompletion":2955,"completion":250,"start":2956,"enrollment":1743,"conditions":2957,"interventions":2959},"NCT03991962","Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma",[87],"2026-08","2019-09-24",[2958],"Pancreatic Cancer",[2943],{"trials":2961,"activeCount":98},[],{"trials":2963,"activeCount":98},[],{"trials":2965,"activeCount":98},[],{"intervention":2967,"totalTrials":109,"cells":2968},"Fezolinetant",{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2984,"PHASE4":2986,"NA":2988},{"trials":2970,"activeCount":98},[],{"trials":2972,"activeCount":98},[],{"trials":2974,"activeCount":109,"soonestReadout":2064},[2975],{"nctId":2976,"briefTitle":2977,"status":102,"phases":2978,"primaryCompletion":2064,"completion":2064,"start":2979,"enrollment":2980,"conditions":2981,"interventions":2983},"NCT06917313","FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy",[87],"2025-12-05",92,[2982],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)",[2967],{"trials":2985,"activeCount":98},[],{"trials":2987,"activeCount":98},[],{"trials":2989,"activeCount":98},[],{"intervention":2457,"totalTrials":109,"cells":2991},{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":3002,"PHASE4":3004,"NA":3006},{"trials":2993,"activeCount":98},[],{"trials":2995,"activeCount":98},[],{"trials":2997,"activeCount":109,"soonestReadout":740},[2998],{"nctId":2451,"briefTitle":2452,"status":102,"phases":2999,"primaryCompletion":740,"completion":740,"start":2454,"enrollment":728,"conditions":3000,"interventions":3001},[87],[2445],[2434,2457],{"trials":3003,"activeCount":98},[],{"trials":3005,"activeCount":98},[],{"trials":3007,"activeCount":98},[],{"intervention":3009,"totalTrials":109,"cells":3010},"Testosterone Cypionate",{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3026,"PHASE4":3028,"NA":3030},{"trials":3012,"activeCount":98},[],{"trials":3014,"activeCount":98},[],{"trials":3016,"activeCount":109,"soonestReadout":568},[3017],{"nctId":3018,"briefTitle":3019,"status":102,"phases":3020,"primaryCompletion":568,"completion":2064,"start":3021,"enrollment":1878,"conditions":3022,"interventions":3024},"NCT06100705","Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC",[87],"2023-12-20",[3023],"Metastatic Castration-resistant Prostate Cancer",[3009,3025],"Sipuleucel-T",{"trials":3027,"activeCount":98},[],{"trials":3029,"activeCount":98},[],{"trials":3031,"activeCount":98},[],{"intervention":3025,"totalTrials":109,"cells":3033},{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3044,"PHASE4":3046,"NA":3048},{"trials":3035,"activeCount":98},[],{"trials":3037,"activeCount":98},[],{"trials":3039,"activeCount":109,"soonestReadout":568},[3040],{"nctId":3018,"briefTitle":3019,"status":102,"phases":3041,"primaryCompletion":568,"completion":2064,"start":3021,"enrollment":1878,"conditions":3042,"interventions":3043},[87],[3023],[3009,3025],{"trials":3045,"activeCount":98},[],{"trials":3047,"activeCount":98},[],{"trials":3049,"activeCount":98},[],{"intervention":3051,"totalTrials":109,"cells":3052},"Apremilast 60mg",{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3057,"PHASE3":3066,"PHASE4":3068,"NA":3070},{"trials":3054,"activeCount":98},[],{"trials":3056,"activeCount":98},[],{"trials":3058,"activeCount":109,"soonestReadout":3063},[3059],{"nctId":3060,"briefTitle":3061,"status":102,"phases":3062,"primaryCompletion":3063,"completion":3063,"start":1235,"enrollment":1424,"conditions":3064,"interventions":3065},"NCT07029529","Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder",[87],"2030-08",[27],[3051],{"trials":3067,"activeCount":98},[],{"trials":3069,"activeCount":98},[],{"trials":3071,"activeCount":98},[],{"intervention":3073,"totalTrials":109,"cells":3074},"ketamine hydrochloride",{"EARLY_PHASE1":3075,"PHASE1":3077,"PHASE2":3079,"PHASE3":3091,"PHASE4":3093,"NA":3095},{"trials":3076,"activeCount":98},[],{"trials":3078,"activeCount":98},[],{"trials":3080,"activeCount":109,"soonestReadout":3085},[3081],{"nctId":3082,"briefTitle":3083,"status":102,"phases":3084,"primaryCompletion":3085,"completion":3086,"start":3087,"enrollment":3088,"conditions":3089,"interventions":3090},"NCT06402955","Imaging Depression in Parkinson's Disease",[87],"2029-01-01","2029-12-01","2024-09-01",120,[1753,1772],[3073],{"trials":3092,"activeCount":98},[],{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[],{"intervention":1775,"totalTrials":109,"cells":3098},{"EARLY_PHASE1":3099,"PHASE1":3101,"PHASE2":3103,"PHASE3":3109,"PHASE4":3111,"NA":3113},{"trials":3100,"activeCount":98},[],{"trials":3102,"activeCount":98},[],{"trials":3104,"activeCount":109,"soonestReadout":1768},[3105],{"nctId":1765,"briefTitle":1766,"status":102,"phases":3106,"primaryCompletion":1768,"completion":1768,"start":1769,"enrollment":31,"conditions":3107,"interventions":3108},[87],[1771,1772,1215,1688,1773],[1775,1608],{"trials":3110,"activeCount":98},[],{"trials":3112,"activeCount":98},[],{"trials":3114,"activeCount":98},[],{"intervention":3116,"totalTrials":109,"cells":3117},"inulin",{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3135,"PHASE4":3137,"NA":3139},{"trials":3119,"activeCount":98},[],{"trials":3121,"activeCount":98},[],{"trials":3123,"activeCount":109,"soonestReadout":3128},[3124],{"nctId":3125,"briefTitle":3126,"status":248,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":3130,"conditions":3131,"interventions":3133},"NCT07189585","Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis",[87],"2027-07-31","2026-04-01",84,[3132],"Knee Osteoarthritis",[3116,3134],"Maltodextrin",{"trials":3136,"activeCount":98},[],{"trials":3138,"activeCount":98},[],{"trials":3140,"activeCount":98},[],{"intervention":3134,"totalTrials":109,"cells":3142},{"EARLY_PHASE1":3143,"PHASE1":3145,"PHASE2":3147,"PHASE3":3153,"PHASE4":3155,"NA":3157},{"trials":3144,"activeCount":98},[],{"trials":3146,"activeCount":98},[],{"trials":3148,"activeCount":109,"soonestReadout":3128},[3149],{"nctId":3125,"briefTitle":3126,"status":248,"phases":3150,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":3130,"conditions":3151,"interventions":3152},[87],[3132],[3116,3134],{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[],{"trials":3158,"activeCount":98},[],{"intervention":3160,"totalTrials":109,"cells":3161},"Fluoxetine - immediate treatment",{"EARLY_PHASE1":3162,"PHASE1":3164,"PHASE2":3166,"PHASE3":3176,"PHASE4":3178,"NA":3180},{"trials":3163,"activeCount":98},[],{"trials":3165,"activeCount":98},[],{"trials":3167,"activeCount":109,"soonestReadout":812},[3168],{"nctId":3169,"briefTitle":3170,"status":102,"phases":3171,"primaryCompletion":812,"completion":131,"start":3172,"enrollment":1011,"conditions":3173,"interventions":3174},"NCT04131829","Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD",[86,87],"2019-10-14",[1336],[3160,3175],"Fluoxetine - delayed treatment",{"trials":3177,"activeCount":98},[],{"trials":3179,"activeCount":98},[],{"trials":3181,"activeCount":98},[],{"intervention":3175,"totalTrials":109,"cells":3183},{"EARLY_PHASE1":3184,"PHASE1":3186,"PHASE2":3188,"PHASE3":3194,"PHASE4":3196,"NA":3198},{"trials":3185,"activeCount":98},[],{"trials":3187,"activeCount":98},[],{"trials":3189,"activeCount":109,"soonestReadout":812},[3190],{"nctId":3169,"briefTitle":3170,"status":102,"phases":3191,"primaryCompletion":812,"completion":131,"start":3172,"enrollment":1011,"conditions":3192,"interventions":3193},[86,87],[1336],[3160,3175],{"trials":3195,"activeCount":98},[],{"trials":3197,"activeCount":98},[],{"trials":3199,"activeCount":98},[],{"intervention":3201,"totalTrials":109,"cells":3202},"Cabotegravir\u002FRilpivirine",{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3216,"PHASE4":3218,"NA":3220},{"trials":3204,"activeCount":98},[],{"trials":3206,"activeCount":98},[],{"trials":3208,"activeCount":109,"soonestReadout":1825},[3209],{"nctId":3210,"briefTitle":3211,"status":672,"phases":3212,"primaryCompletion":1825,"completion":1825,"start":3213,"enrollment":1305,"conditions":3214,"interventions":3215},"NCT06411223","Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs",[87],"2024-08-01",[573],[3201],{"trials":3217,"activeCount":98},[],{"trials":3219,"activeCount":98},[],{"trials":3221,"activeCount":98},[],{"intervention":3223,"totalTrials":109,"cells":3224},"Metformin + Standard of Care",{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3229,"PHASE3":3240,"PHASE4":3242,"NA":3244},{"trials":3226,"activeCount":98},[],{"trials":3228,"activeCount":98},[],{"trials":3230,"activeCount":109,"soonestReadout":3235},[3231],{"nctId":3232,"briefTitle":3233,"status":102,"phases":3234,"primaryCompletion":3235,"completion":3235,"start":3236,"enrollment":31,"conditions":3237,"interventions":3239},"NCT06090227","AMPK-activation by Metformin in FSGS: AMP-FSGS",[86,87],"2027-11","2023-12-14",[3238],"Focal Segmental Glomerulosclerosis",[3223],{"trials":3241,"activeCount":98},[],{"trials":3243,"activeCount":98},[],{"trials":3245,"activeCount":98},[],{"intervention":3247,"totalTrials":109,"cells":3248},"Dapagliflozin",{"EARLY_PHASE1":3249,"PHASE1":3251,"PHASE2":3253,"PHASE3":3263,"PHASE4":3265,"NA":3267},{"trials":3250,"activeCount":98},[],{"trials":3252,"activeCount":98},[],{"trials":3254,"activeCount":109,"soonestReadout":1235},[3255],{"nctId":3256,"briefTitle":3257,"status":672,"phases":3258,"primaryCompletion":1235,"completion":1235,"start":3259,"enrollment":31,"conditions":3260,"interventions":3262},"NCT06111768","Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study",[87],"2024-05-30",[3261],"Cardiorenal Syndrome",[3247],{"trials":3264,"activeCount":98},[],{"trials":3266,"activeCount":98},[],{"trials":3268,"activeCount":98},[],{"intervention":3270,"totalTrials":109,"cells":3271},"Varenicline 1mg BID",{"EARLY_PHASE1":3272,"PHASE1":3274,"PHASE2":3276,"PHASE3":3290,"PHASE4":3292,"NA":3294},{"trials":3273,"activeCount":98},[],{"trials":3275,"activeCount":98},[],{"trials":3277,"activeCount":109,"soonestReadout":3282},[3278],{"nctId":3279,"briefTitle":3280,"status":102,"phases":3281,"primaryCompletion":3282,"completion":3283,"start":3284,"enrollment":3285,"conditions":3286,"interventions":3289},"NCT07040566","A Trial of Varenicline for E-cigarette Cessation",[87],"2030-07-30","2030-10-30","2025-10-14",326,[3287,3288,24],"E-cigarette Use","Vaping",[3270],{"trials":3291,"activeCount":98},[],{"trials":3293,"activeCount":98},[],{"trials":3295,"activeCount":98},[],{"intervention":3297,"totalTrials":109,"cells":3298},"Elacestrant",{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3313,"PHASE4":3315,"NA":3317},{"trials":3300,"activeCount":98},[],{"trials":3302,"activeCount":98},[],{"trials":3304,"activeCount":109,"soonestReadout":237},[3305],{"nctId":3306,"briefTitle":3307,"status":102,"phases":3308,"primaryCompletion":237,"completion":237,"start":3309,"enrollment":1305,"conditions":3310,"interventions":3312},"NCT06923527","Circulating Tumor DNA",[87],"2025-09-30",[3311],"ER+ Breast Cancer",[3297],{"trials":3314,"activeCount":98},[],{"trials":3316,"activeCount":98},[],{"trials":3318,"activeCount":98},[],{"intervention":3320,"totalTrials":109,"cells":3321},"Luspatercept",{"EARLY_PHASE1":3322,"PHASE1":3324,"PHASE2":3326,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3323,"activeCount":98},[],{"trials":3325,"activeCount":98},[],{"trials":3327,"activeCount":109,"soonestReadout":3063},[3328],{"nctId":3329,"briefTitle":3330,"status":102,"phases":3331,"primaryCompletion":3063,"completion":3063,"start":3332,"enrollment":105,"conditions":3333,"interventions":3335},"NCT07096297","Luspatercept + Darbepoetin in MDS",[87],"2025-12-16",[3334],"MDS (Myelodysplastic Syndrome)",[3320,3336],"Darbeopoetin",{"trials":3338,"activeCount":98},[],{"trials":3340,"activeCount":98},[],{"trials":3342,"activeCount":98},[],{"intervention":3336,"totalTrials":109,"cells":3344},{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3355,"PHASE4":3357,"NA":3359},{"trials":3346,"activeCount":98},[],{"trials":3348,"activeCount":98},[],{"trials":3350,"activeCount":109,"soonestReadout":3063},[3351],{"nctId":3329,"briefTitle":3330,"status":102,"phases":3352,"primaryCompletion":3063,"completion":3063,"start":3332,"enrollment":105,"conditions":3353,"interventions":3354},[87],[3334],[3320,3336],{"trials":3356,"activeCount":98},[],{"trials":3358,"activeCount":98},[],{"trials":3360,"activeCount":98},[],{"intervention":52,"totalTrials":109,"cells":3362},{"EARLY_PHASE1":3363,"PHASE1":3365,"PHASE2":3367,"PHASE3":3373,"PHASE4":3375,"NA":3377},{"trials":3364,"activeCount":98},[],{"trials":3366,"activeCount":98},[],{"trials":3368,"activeCount":109,"soonestReadout":51},[3369],{"nctId":49,"briefTitle":50,"status":672,"phases":3370,"primaryCompletion":51,"completion":51,"start":1530,"enrollment":285,"conditions":3371,"interventions":3372},[87],[1532],[52,1534,1465],{"trials":3374,"activeCount":98},[],{"trials":3376,"activeCount":98},[],{"trials":3378,"activeCount":98},[],{"intervention":1534,"totalTrials":109,"cells":3380},{"EARLY_PHASE1":3381,"PHASE1":3383,"PHASE2":3385,"PHASE3":3391,"PHASE4":3393,"NA":3395},{"trials":3382,"activeCount":98},[],{"trials":3384,"activeCount":98},[],{"trials":3386,"activeCount":109,"soonestReadout":51},[3387],{"nctId":49,"briefTitle":50,"status":672,"phases":3388,"primaryCompletion":51,"completion":51,"start":1530,"enrollment":285,"conditions":3389,"interventions":3390},[87],[1532],[52,1534,1465],{"trials":3392,"activeCount":98},[],{"trials":3394,"activeCount":98},[],{"trials":3396,"activeCount":98},[],{"intervention":3398,"totalTrials":109,"cells":3399},"Psilocybin 10 mg",{"EARLY_PHASE1":3400,"PHASE1":3402,"PHASE2":3404,"PHASE3":3416,"PHASE4":3418,"NA":3420},{"trials":3401,"activeCount":98},[],{"trials":3403,"activeCount":98},[],{"trials":3405,"activeCount":109,"soonestReadout":1957},[3406],{"nctId":3407,"briefTitle":3408,"status":248,"phases":3409,"primaryCompletion":1957,"completion":1957,"start":1439,"enrollment":2280,"conditions":3410,"interventions":3413},"NCT07306364","Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain",[87],[3411,3412,1295],"Chronic Low Back Pain (CLBP)","Physical Therapy",[3398,3414,3415],"Psilocybin 25 mg","Niacin 100 mg",{"trials":3417,"activeCount":98},[],{"trials":3419,"activeCount":98},[],{"trials":3421,"activeCount":98},[],{"intervention":3414,"totalTrials":109,"cells":3423},{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3428,"PHASE3":3434,"PHASE4":3436,"NA":3438},{"trials":3425,"activeCount":98},[],{"trials":3427,"activeCount":98},[],{"trials":3429,"activeCount":109,"soonestReadout":1957},[3430],{"nctId":3407,"briefTitle":3408,"status":248,"phases":3431,"primaryCompletion":1957,"completion":1957,"start":1439,"enrollment":2280,"conditions":3432,"interventions":3433},[87],[3411,3412,1295],[3398,3414,3415],{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":98},[],{"trials":3439,"activeCount":98},[],{"intervention":3415,"totalTrials":109,"cells":3441},{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3446,"PHASE3":3452,"PHASE4":3454,"NA":3456},{"trials":3443,"activeCount":98},[],{"trials":3445,"activeCount":98},[],{"trials":3447,"activeCount":109,"soonestReadout":1957},[3448],{"nctId":3407,"briefTitle":3408,"status":248,"phases":3449,"primaryCompletion":1957,"completion":1957,"start":1439,"enrollment":2280,"conditions":3450,"interventions":3451},[87],[3411,3412,1295],[3398,3414,3415],{"trials":3453,"activeCount":98},[],{"trials":3455,"activeCount":98},[],{"trials":3457,"activeCount":98},[],{"intervention":3459,"totalTrials":109,"cells":3460},"Elotuzumab",{"EARLY_PHASE1":3461,"PHASE1":3463,"PHASE2":3465,"PHASE3":3477,"PHASE4":3479,"NA":3481},{"trials":3462,"activeCount":98},[],{"trials":3464,"activeCount":98},[],{"trials":3466,"activeCount":109,"soonestReadout":3471},[3467],{"nctId":3468,"briefTitle":3469,"status":672,"phases":3470,"primaryCompletion":3471,"completion":1440,"start":3472,"enrollment":2659,"conditions":3473,"interventions":3475},"NCT05002816","Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma",[86,87],"2026-01-22","2022-02-21",[3474],"Multiple Myeloma",[3459,3476],"Belantamab mafodotin",{"trials":3478,"activeCount":98},[],{"trials":3480,"activeCount":98},[],{"trials":3482,"activeCount":98},[],{"intervention":3476,"totalTrials":109,"cells":3484},{"EARLY_PHASE1":3485,"PHASE1":3487,"PHASE2":3489,"PHASE3":3495,"PHASE4":3497,"NA":3499},{"trials":3486,"activeCount":98},[],{"trials":3488,"activeCount":98},[],{"trials":3490,"activeCount":109,"soonestReadout":3471},[3491],{"nctId":3468,"briefTitle":3469,"status":672,"phases":3492,"primaryCompletion":3471,"completion":1440,"start":3472,"enrollment":2659,"conditions":3493,"interventions":3494},[86,87],[3474],[3459,3476],{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[],{"trials":3500,"activeCount":98},[],{"intervention":3502,"totalTrials":109,"cells":3503},"Adalimumab",{"EARLY_PHASE1":3504,"PHASE1":3506,"PHASE2":3508,"PHASE3":3519,"PHASE4":3521,"NA":3523},{"trials":3505,"activeCount":98},[],{"trials":3507,"activeCount":98},[],{"trials":3509,"activeCount":109,"soonestReadout":3514},[3510],{"nctId":3511,"briefTitle":3512,"status":248,"phases":3513,"primaryCompletion":3514,"completion":3514,"start":1235,"enrollment":3515,"conditions":3516,"interventions":3518},"NCT06996652","An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)",[87],"2029-08",108,[3517],"REM Sleep Behavior Disorder",[3502],{"trials":3520,"activeCount":98},[],{"trials":3522,"activeCount":98},[],{"trials":3524,"activeCount":98},[],{"intervention":2893,"totalTrials":109,"cells":3526},{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3528,"activeCount":98},[],{"trials":3530,"activeCount":98},[],{"trials":3532,"activeCount":109,"soonestReadout":3537},[3533],{"nctId":3534,"briefTitle":3535,"status":672,"phases":3536,"primaryCompletion":3537,"completion":3538,"start":2454,"enrollment":31,"conditions":3539,"interventions":3540},"NCT06004830","Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1",[87],"2026-05-01","2027-01-01",[27,573],[2893],{"trials":3542,"activeCount":98},[],{"trials":3544,"activeCount":98},[],{"trials":3546,"activeCount":98},[],{"intervention":3548,"totalTrials":109,"cells":3549},"Trastuzumab Deruxtecan",{"EARLY_PHASE1":3550,"PHASE1":3552,"PHASE2":3554,"PHASE3":3565,"PHASE4":3567,"NA":3569},{"trials":3551,"activeCount":98},[],{"trials":3553,"activeCount":98},[],{"trials":3555,"activeCount":109,"soonestReadout":3560},[3556],{"nctId":3557,"briefTitle":3558,"status":102,"phases":3559,"primaryCompletion":3560,"completion":3560,"start":3561,"enrollment":1044,"conditions":3562,"interventions":3564},"NCT06750484","Trial of Trastuzumab Deruxtecan in Previously Treated HER2",[87],"2028-12-31","2025-06-20",[3563],"Breast Cancer Metastatic",[3548],{"trials":3566,"activeCount":98},[],{"trials":3568,"activeCount":98},[],{"trials":3570,"activeCount":98},[],{"intervention":3572,"totalTrials":109,"cells":3573},"SV2A PET",{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3593,"PHASE4":3595,"NA":3597},{"trials":3575,"activeCount":98},[],{"trials":3577,"activeCount":98},[],{"trials":3579,"activeCount":109,"soonestReadout":568},[3580],{"nctId":3581,"briefTitle":3582,"status":102,"phases":3583,"primaryCompletion":568,"completion":1584,"start":3584,"enrollment":3585,"conditions":3586,"interventions":3591},"NCT05586581","SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy",[86,87],"2023-05-17",70,[3587,3588,3589,3590],"HIV Associated Neurocognitive Disorder","HIV Dementia","HIV Encephalitis","Healthy",[3572,3592],"TSPO PET",{"trials":3594,"activeCount":98},[],{"trials":3596,"activeCount":98},[],{"trials":3598,"activeCount":98},[],{"intervention":3592,"totalTrials":109,"cells":3600},{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3605,"PHASE3":3611,"PHASE4":3613,"NA":3615},{"trials":3602,"activeCount":98},[],{"trials":3604,"activeCount":98},[],{"trials":3606,"activeCount":109,"soonestReadout":568},[3607],{"nctId":3581,"briefTitle":3582,"status":102,"phases":3608,"primaryCompletion":568,"completion":1584,"start":3584,"enrollment":3585,"conditions":3609,"interventions":3610},[86,87],[3587,3588,3589,3590],[3572,3592],{"trials":3612,"activeCount":98},[],{"trials":3614,"activeCount":98},[],{"trials":3616,"activeCount":98},[],{"intervention":3618,"totalTrials":109,"cells":3619},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":3620,"PHASE1":3622,"PHASE2":3624,"PHASE3":3636,"PHASE4":3638,"NA":3640},{"trials":3621,"activeCount":98},[],{"trials":3623,"activeCount":98},[],{"trials":3625,"activeCount":109,"soonestReadout":3630},[3626],{"nctId":3627,"briefTitle":3628,"status":102,"phases":3629,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":1827,"conditions":3633,"interventions":3635},"NCT07273838","Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome",[87],"2028-08-31","2029-10-31","2026-03-05",[107,3634],"Acute Kidney Injury",[3618],{"trials":3637,"activeCount":98},[],{"trials":3639,"activeCount":98},[],{"trials":3641,"activeCount":98},[],{"intervention":3643,"totalTrials":109,"cells":3644},"Guselkumab",{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3659,"PHASE4":3661,"NA":3663},{"trials":3646,"activeCount":98},[],{"trials":3648,"activeCount":98},[],{"trials":3650,"activeCount":109,"soonestReadout":251},[3651],{"nctId":3652,"briefTitle":3653,"status":102,"phases":3654,"primaryCompletion":251,"completion":251,"start":3655,"enrollment":1315,"conditions":3656,"interventions":3658},"NCT06651489","Efficacy of Guselkumab in Treating Hailey Hailey Disease",[87],"2025-03-13",[3657],"Hailey Hailey Disease",[3643],{"trials":3660,"activeCount":98},[],{"trials":3662,"activeCount":98},[],{"trials":3664,"activeCount":98},[],{"intervention":1546,"totalTrials":109,"cells":3666},{"EARLY_PHASE1":3667,"PHASE1":3669,"PHASE2":3671,"PHASE3":3677,"PHASE4":3679,"NA":3681},{"trials":3668,"activeCount":98},[],{"trials":3670,"activeCount":98},[],{"trials":3672,"activeCount":109,"soonestReadout":1539},[3673],{"nctId":1536,"briefTitle":1537,"status":102,"phases":3674,"primaryCompletion":1539,"completion":1539,"start":1540,"enrollment":31,"conditions":3675,"interventions":3676},[87],[1505,1542,1543,1544],[1546,1465],{"trials":3678,"activeCount":98},[],{"trials":3680,"activeCount":98},[],{"trials":3682,"activeCount":98},[],{"intervention":3684,"totalTrials":109,"cells":3685},"Mogamulizumab",{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3690,"PHASE3":3703,"PHASE4":3705,"NA":3707},{"trials":3687,"activeCount":98},[],{"trials":3689,"activeCount":98},[],{"trials":3691,"activeCount":109,"soonestReadout":2889},[3692],{"nctId":3693,"briefTitle":3694,"status":102,"phases":3695,"primaryCompletion":2889,"completion":3235,"start":3696,"enrollment":1289,"conditions":3697,"interventions":3700},"NCT05996185","Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma",[87],"2024-10-09",[3698,3699],"T Cell Lymphoma","T-cell Lymphoma",[3684,3701,3702],"DA-EPOCH Protocol","CHOEP protocol",{"trials":3704,"activeCount":98},[],{"trials":3706,"activeCount":98},[],{"trials":3708,"activeCount":98},[],{"intervention":3701,"totalTrials":109,"cells":3710},{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3721,"PHASE4":3723,"NA":3725},{"trials":3712,"activeCount":98},[],{"trials":3714,"activeCount":98},[],{"trials":3716,"activeCount":109,"soonestReadout":2889},[3717],{"nctId":3693,"briefTitle":3694,"status":102,"phases":3718,"primaryCompletion":2889,"completion":3235,"start":3696,"enrollment":1289,"conditions":3719,"interventions":3720},[87],[3698,3699],[3684,3701,3702],{"trials":3722,"activeCount":98},[],{"trials":3724,"activeCount":98},[],{"trials":3726,"activeCount":98},[],{"intervention":3702,"totalTrials":109,"cells":3728},{"EARLY_PHASE1":3729,"PHASE1":3731,"PHASE2":3733,"PHASE3":3739,"PHASE4":3741,"NA":3743},{"trials":3730,"activeCount":98},[],{"trials":3732,"activeCount":98},[],{"trials":3734,"activeCount":109,"soonestReadout":2889},[3735],{"nctId":3693,"briefTitle":3694,"status":102,"phases":3736,"primaryCompletion":2889,"completion":3235,"start":3696,"enrollment":1289,"conditions":3737,"interventions":3738},[87],[3698,3699],[3684,3701,3702],{"trials":3740,"activeCount":98},[],{"trials":3742,"activeCount":98},[],{"trials":3744,"activeCount":98},[],{"intervention":3746,"totalTrials":109,"cells":3747},"semaglutide",{"EARLY_PHASE1":3748,"PHASE1":3750,"PHASE2":3752,"PHASE3":3762,"PHASE4":3764,"NA":3766},{"trials":3749,"activeCount":98},[],{"trials":3751,"activeCount":98},[],{"trials":3753,"activeCount":109,"soonestReadout":614},[3754],{"nctId":3755,"briefTitle":3756,"status":102,"phases":3757,"primaryCompletion":614,"completion":614,"start":3758,"enrollment":31,"conditions":3759,"interventions":3761},"NCT07040592","Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide",[87],"2026-01-15",[3760,35],"Alcohol Use Disorder (AUD)",[3746],{"trials":3763,"activeCount":98},[],{"trials":3765,"activeCount":98},[],{"trials":3767,"activeCount":98},[],{"intervention":2171,"totalTrials":109,"cells":3769},{"EARLY_PHASE1":3770,"PHASE1":3772,"PHASE2":3774,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3771,"activeCount":98},[],{"trials":3773,"activeCount":98},[],{"trials":3775,"activeCount":109,"soonestReadout":637},[3776],{"nctId":2163,"briefTitle":2164,"status":248,"phases":3777,"primaryCompletion":637,"completion":2166,"start":839,"enrollment":2167,"conditions":3778,"interventions":3779},[86,87],[18,1860,2157],[2170,2171],{"trials":3781,"activeCount":98},[],{"trials":3783,"activeCount":98},[],{"trials":3785,"activeCount":98},[],{"intervention":1720,"totalTrials":1466,"cells":3787},{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3792,"PHASE3":3810,"PHASE4":3816,"NA":3822},{"trials":3789,"activeCount":98},[],{"trials":3791,"activeCount":98},[],{"trials":3793,"activeCount":109,"soonestReadout":1713},[3794,3798,3802,3806],{"nctId":1710,"briefTitle":1711,"status":102,"phases":3795,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":3796,"interventions":3797},[87],[1718],[1608,1720],{"nctId":1729,"briefTitle":1730,"status":711,"phases":3799,"primaryCompletion":1732,"completion":1732,"start":1733,"enrollment":1289,"conditions":3800,"interventions":3801},[87],[1735],[1608,1720],{"nctId":1738,"briefTitle":1739,"status":711,"phases":3803,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":1743,"conditions":3804,"interventions":3805},[87],[1718],[1608,1720],{"nctId":1786,"briefTitle":1787,"status":711,"phases":3807,"primaryCompletion":1789,"completion":1790,"start":1791,"enrollment":272,"conditions":3808,"interventions":3809},[87],[1793,1794],[1608,1720],{"trials":3811,"activeCount":98},[3812],{"nctId":1799,"briefTitle":1800,"status":711,"phases":3813,"primaryCompletion":1802,"completion":986,"start":1803,"enrollment":94,"conditions":3814,"interventions":3815},[87,88],[1772],[1608,1720],{"trials":3817,"activeCount":98},[3818],{"nctId":1809,"briefTitle":1810,"status":152,"phases":3819,"primaryCompletion":1812,"completion":1813,"start":1814,"enrollment":1815,"conditions":3820,"interventions":3821},[89],[1772,1817],[1608,1720],{"trials":3823,"activeCount":98},[3824],{"nctId":3825,"briefTitle":3826,"status":152,"phases":3827,"completion":1043,"start":3828,"enrollment":639,"conditions":3829,"interventions":3830},"NCT00261261","Family-Centered Behavioral Preparation for Surgery",[90],"2001-01",[1355],[1720],{"intervention":3832,"totalTrials":94,"cells":3833},"Dronabinol",{"EARLY_PHASE1":3834,"PHASE1":3843,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3835,"activeCount":109,"soonestReadout":3537},[3836],{"nctId":3837,"briefTitle":3838,"status":102,"phases":3839,"primaryCompletion":3537,"completion":2520,"start":3840,"enrollment":1619,"conditions":3841,"interventions":3842},"NCT04025359","Effects of Dronabinol in Opioid Maintained Patients",[85],"2019-05-31",[316],[3832,3832],{"trials":3844,"activeCount":263,"soonestReadout":1439},[3845,3854],{"nctId":3846,"briefTitle":3847,"status":672,"phases":3848,"primaryCompletion":3849,"completion":3850,"start":3851,"enrollment":946,"conditions":3852,"interventions":3853},"NCT06034314","Oral Dronabinol-HIV",[86],"2026-10-01","2028-10-01","2023-09-21",[35],[3832],{"nctId":3855,"briefTitle":3856,"status":102,"phases":3857,"primaryCompletion":1439,"completion":1440,"start":3858,"enrollment":1044,"conditions":3859,"interventions":3860},"NCT02811510","Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I",[86],"2016-06",[1399],[3832],{"trials":3862,"activeCount":98},[],{"trials":3864,"activeCount":98},[],{"trials":3866,"activeCount":98},[],{"trials":3868,"activeCount":98},[],{"intervention":3870,"totalTrials":1246,"cells":3871},"Mavoglurant",{"EARLY_PHASE1":3872,"PHASE1":3889,"PHASE2":3910,"PHASE3":3912,"PHASE4":3914,"NA":3916},{"trials":3873,"activeCount":109,"soonestReadout":777},[3874,3882],{"nctId":3875,"briefTitle":3876,"status":152,"phases":3877,"primaryCompletion":3878,"completion":3878,"start":1875,"enrollment":1367,"conditions":3879,"interventions":3881},"NCT03341715","Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN",[85],"2019-11-13",[3880],"Familial Alcoholism Vulnerability",[3870],{"nctId":3883,"briefTitle":3884,"status":102,"phases":3885,"primaryCompletion":777,"completion":777,"start":3886,"enrollment":1424,"conditions":3887,"interventions":3888},"NCT05203965","Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant",[85],"2022-05-17",[3880],[3870],{"trials":3890,"activeCount":109,"soonestReadout":3904},[3891,3900],{"nctId":3892,"briefTitle":3893,"status":152,"phases":3894,"primaryCompletion":3895,"completion":3895,"start":3896,"enrollment":3897,"conditions":3898,"interventions":3899},"NCT03327792","Mavoglurant in Alcohol Drinking",[86],"2023-07-13","2018-02-07",34,[1034],[3870],{"nctId":3901,"briefTitle":3902,"status":102,"phases":3903,"primaryCompletion":3904,"completion":3904,"start":3905,"enrollment":3906,"conditions":3907,"interventions":3909},"NCT06136195","Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers",[86],"2026-05-31","2024-07-01",63,[1190,3908,3760],"Heavy Drinker",[3870],{"trials":3911,"activeCount":98},[],{"trials":3913,"activeCount":98},[],{"trials":3915,"activeCount":98},[],{"trials":3917,"activeCount":98},[],{"intervention":3919,"totalTrials":263,"cells":3920},"Active Ethanol",{"EARLY_PHASE1":3921,"PHASE1":3923,"PHASE2":3941,"PHASE3":3943,"PHASE4":3945,"NA":3947},{"trials":3922,"activeCount":98},[],{"trials":3924,"activeCount":263,"soonestReadout":1440},[3925,3934],{"nctId":3926,"briefTitle":3927,"status":672,"phases":3928,"primaryCompletion":1440,"completion":1440,"start":1781,"enrollment":1044,"conditions":3929,"interventions":3932},"NCT02710331","Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III",[86],[1399,3930,3931],"Alcohol Effect","Driving Under the Influence of Alcohol and Other Drugs",[3933,3919],"Active Dronabinol",{"nctId":3935,"briefTitle":3936,"status":672,"phases":3937,"primaryCompletion":1440,"completion":1440,"start":1742,"enrollment":1044,"conditions":3938,"interventions":3939},"NCT02404688","Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition",[86],[1399,3930,3931],[3940,3919],"Active delta-9-THC",{"trials":3942,"activeCount":98},[],{"trials":3944,"activeCount":98},[],{"trials":3946,"activeCount":98},[],{"trials":3948,"activeCount":98},[],{"intervention":3950,"totalTrials":263,"cells":3951},"Delta-9-THC Medium Dose",{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3975,"PHASE3":3977,"PHASE4":3979,"NA":3981},{"trials":3953,"activeCount":98},[],{"trials":3955,"activeCount":263,"soonestReadout":1596},[3956,3965],{"nctId":3957,"briefTitle":3958,"status":102,"phases":3959,"primaryCompletion":1596,"completion":1596,"start":3960,"enrollment":105,"conditions":3961,"interventions":3963},"NCT06948136","Acute Effects of THC in Older Adult",[86],"2025-06-06",[3962],"Age-related Cognitive Decline",[3964,3950],"Delta-9-THC Low Dose",{"nctId":3966,"briefTitle":3967,"status":102,"phases":3968,"primaryCompletion":3560,"completion":3560,"start":3969,"enrollment":3970,"conditions":3971,"interventions":3973},"NCT06058702","Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans",[86],"2024-09-16",215,[15,3972],"Cannabis Use Disorder",[3974,3950],"Delta-9-THC Very Low Dose",{"trials":3976,"activeCount":98},[],{"trials":3978,"activeCount":98},[],{"trials":3980,"activeCount":98},[],{"trials":3982,"activeCount":98},[],{"intervention":3984,"totalTrials":263,"cells":3985},"Active Oral Ethanol",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":4004,"PHASE3":4006,"PHASE4":4008,"NA":4010},{"trials":3987,"activeCount":98},[],{"trials":3989,"activeCount":263,"soonestReadout":1440},[3990,3997],{"nctId":3991,"briefTitle":3992,"status":672,"phases":3993,"primaryCompletion":1440,"completion":1440,"start":1781,"enrollment":1044,"conditions":3994,"interventions":3995},"NCT02710097","Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II",[86],[1399,3930,3931],[3996,3984],"Active inhaled cannabis",{"nctId":3998,"briefTitle":3999,"status":672,"phases":4000,"primaryCompletion":1440,"completion":1440,"start":1781,"enrollment":1044,"conditions":4001,"interventions":4002},"NCT02709954","Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I",[86],[1399,3930,3931],[4003,3984],"Active inhaled delta-9-THC",{"trials":4005,"activeCount":98},[],{"trials":4007,"activeCount":98},[],{"trials":4009,"activeCount":98},[],{"trials":4011,"activeCount":98},[],{"intervention":4013,"totalTrials":94,"cells":4014},"Atezolizumab",{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4038,"PHASE3":4052,"PHASE4":4054,"NA":4056},{"trials":4016,"activeCount":98},[],{"trials":4018,"activeCount":109,"soonestReadout":1233},[4019,4028],{"nctId":4020,"briefTitle":4021,"status":102,"phases":4022,"primaryCompletion":1233,"completion":1233,"start":4023,"enrollment":141,"conditions":4024,"interventions":4026},"NCT07113691","Iadademstat + SBRT With Atezo in ES-SCLC",[86],"2026-01-20",[4025],"Extensive Stage Small Cell Lung Cancer (ES-SCLC)",[4027,4013],"Iadademstat",{"nctId":4029,"briefTitle":4030,"status":711,"phases":4031,"primaryCompletion":4032,"completion":4033,"start":4034,"enrollment":263,"conditions":4035,"interventions":4037},"NCT02784483","Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma",[86],"2017-09-15","2019-04-22","2017-02-10",[4036],"Asymptomatic Myeloma",[4013],{"trials":4039,"activeCount":98},[4040],{"nctId":4041,"briefTitle":4042,"status":711,"phases":4043,"primaryCompletion":4044,"completion":4044,"start":4045,"enrollment":94,"conditions":4046,"interventions":4049},"NCT05776875","Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC",[87],"2024-12-05","2023-06-07",[4047,4048],"Hepatocellular Carcinoma","BCLC Stage B Hepatocellular Carcinoma",[4013,4050,4051],"Bevacizumab","Transarterial chemoembolization",{"trials":4053,"activeCount":98},[],{"trials":4055,"activeCount":98},[],{"trials":4057,"activeCount":98},[],{"intervention":4059,"totalTrials":94,"cells":4060},"Bupivacaine",{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4073,"PHASE3":4095,"PHASE4":4097,"NA":4099},{"trials":4062,"activeCount":98},[],{"trials":4064,"activeCount":109,"soonestReadout":131},[4065],{"nctId":4066,"briefTitle":4067,"status":102,"phases":4068,"primaryCompletion":131,"completion":131,"start":4069,"enrollment":272,"conditions":4070,"interventions":4072},"NCT06069791","Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1",[86],"2024-01-26",[4071],"Post-Traumatic Headache",[4059],{"trials":4074,"activeCount":98},[4075,4086],{"nctId":4076,"briefTitle":4077,"status":711,"phases":4078,"primaryCompletion":4079,"completion":4079,"start":4080,"enrollment":263,"conditions":4081,"interventions":4083},"NCT02044302","A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction",[87],"2016-01","2014-04",[4082],"Post-operative Pain",[4059,4084,4085],"Botulinum Toxins","Analgesics",{"nctId":4087,"briefTitle":4088,"status":152,"phases":4089,"primaryCompletion":4090,"completion":4090,"start":4091,"enrollment":946,"conditions":4092,"interventions":4094},"NCT06002152","Superficial Cervical Plexus Block and Quality of Recovery After Thyroidectomy",[87],"2026-02-03","2023-11-27",[4093],"Postoperative Pain",[4059],{"trials":4096,"activeCount":98},[],{"trials":4098,"activeCount":98},[],{"trials":4100,"activeCount":98},[],{"intervention":4102,"totalTrials":1246,"cells":4103},"Active Delta-9-THC",{"EARLY_PHASE1":4104,"PHASE1":4106,"PHASE2":4136,"PHASE3":4138,"PHASE4":4140,"NA":4142},{"trials":4105,"activeCount":98},[],{"trials":4107,"activeCount":109,"soonestReadout":1440},[4108,4116,4124,4132],{"nctId":4109,"briefTitle":4110,"status":152,"phases":4111,"primaryCompletion":4112,"completion":4112,"start":2956,"enrollment":1289,"conditions":4113,"interventions":4114},"NCT04199468","THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis",[86],"2022-06-21",[1399,1608],[4102,4115],"Active Ketamine",{"nctId":4117,"briefTitle":4118,"status":152,"phases":4119,"primaryCompletion":74,"completion":2705,"start":4120,"enrollment":4121,"conditions":4122,"interventions":4123},"NCT04920539","In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans",[86],"2022-02-08",56,[274,3590],[4102],{"nctId":4125,"briefTitle":4126,"status":152,"phases":4127,"primaryCompletion":4128,"completion":4128,"start":1423,"enrollment":22,"conditions":4129,"interventions":4130},"NCT02576912","Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone",[86],"2019-06-24",[3590],[4102,4131],"Active Pregnenolone",{"nctId":3935,"briefTitle":3936,"status":672,"phases":4133,"primaryCompletion":1440,"completion":1440,"start":1742,"enrollment":1044,"conditions":4134,"interventions":4135},[86],[1399,3930,3931],[3940,3919],{"trials":4137,"activeCount":98},[],{"trials":4139,"activeCount":98},[],{"trials":4141,"activeCount":98},[],{"trials":4143,"activeCount":98},[],{"intervention":47,"totalTrials":94,"cells":4145},{"EARLY_PHASE1":4146,"PHASE1":4148,"PHASE2":4174,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4147,"activeCount":98},[],{"trials":4149,"activeCount":109,"soonestReadout":46},[4150,4156,4166],{"nctId":44,"briefTitle":45,"status":672,"phases":4151,"primaryCompletion":46,"completion":2423,"start":4152,"enrollment":1367,"conditions":4153,"interventions":4154},[86],"2018-02-27",[1772],[47,4155],"Medium Dose Psilocybin",{"nctId":4157,"briefTitle":4158,"status":152,"phases":4159,"primaryCompletion":4160,"completion":4161,"start":4162,"enrollment":1675,"conditions":4163,"interventions":4164},"NCT03341689","Psilocybin for the Treatment of Migraine Headache",[86],"2021-04-30","2021-10-31","2017-11-01",[1369],[4165,47],"High Dose Psilocybin",{"nctId":4167,"briefTitle":4168,"status":711,"phases":4169,"primaryCompletion":4170,"completion":4170,"start":4171,"enrollment":272,"conditions":4172,"interventions":4173},"NCT03806985","Effects of Psilocybin in Concussion Headache",[86],"2023-06-27","2019-03-28",[4071],[47,4165],{"trials":4175,"activeCount":98},[],{"trials":4177,"activeCount":98},[],{"trials":4179,"activeCount":98},[],{"trials":4181,"activeCount":98},[],{"intervention":3933,"totalTrials":263,"cells":4183},{"EARLY_PHASE1":4184,"PHASE1":4186,"PHASE2":4200,"PHASE3":4202,"PHASE4":4204,"NA":4206},{"trials":4185,"activeCount":98},[],{"trials":4187,"activeCount":109,"soonestReadout":1440},[4188,4192],{"nctId":3926,"briefTitle":3927,"status":672,"phases":4189,"primaryCompletion":1440,"completion":1440,"start":1781,"enrollment":1044,"conditions":4190,"interventions":4191},[86],[1399,3930,3931],[3933,3919],{"nctId":4193,"briefTitle":4194,"status":152,"phases":4195,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":1685,"conditions":4198,"interventions":4199},"NCT02811939","Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I",[86],"2017-06-09","2016-04-07",[3590],[3933,4131],{"trials":4201,"activeCount":98},[],{"trials":4203,"activeCount":98},[],{"trials":4205,"activeCount":98},[],{"trials":4207,"activeCount":98},[],{"intervention":2015,"totalTrials":263,"cells":4209},{"EARLY_PHASE1":4210,"PHASE1":4212,"PHASE2":4222,"PHASE3":4224,"PHASE4":4226,"NA":4228},{"trials":4211,"activeCount":98},[],{"trials":4213,"activeCount":109,"soonestReadout":2008},[4214,4218],{"nctId":2005,"briefTitle":2006,"status":672,"phases":4215,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":1878,"conditions":4216,"interventions":4217},[86],[2012,1492],[1590,2014,2015],{"nctId":2017,"briefTitle":2018,"status":152,"phases":4219,"primaryCompletion":2020,"completion":2021,"start":2022,"enrollment":1397,"conditions":4220,"interventions":4221},[86],[2012,2024,1492],[2015,2026,1590],{"trials":4223,"activeCount":98},[],{"trials":4225,"activeCount":98},[],{"trials":4227,"activeCount":98},[],{"trials":4229,"activeCount":98},[],{"intervention":1690,"totalTrials":263,"cells":4231},{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4244,"PHASE3":4246,"PHASE4":4248,"NA":4250},{"trials":4233,"activeCount":98},[],{"trials":4235,"activeCount":109,"soonestReadout":1695},[4236,4240],{"nctId":1680,"briefTitle":1681,"status":152,"phases":4237,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":1685,"conditions":4238,"interventions":4239},[86],[1687,1688,1215],[1608,1690],{"nctId":1692,"briefTitle":1693,"status":102,"phases":4241,"primaryCompletion":1695,"completion":1695,"start":1696,"enrollment":1305,"conditions":4242,"interventions":4243},[86],[1687,1688],[1608,1690],{"trials":4245,"activeCount":98},[],{"trials":4247,"activeCount":98},[],{"trials":4249,"activeCount":98},[],{"trials":4251,"activeCount":98},[],{"intervention":4027,"totalTrials":109,"cells":4253},{"EARLY_PHASE1":4254,"PHASE1":4256,"PHASE2":4262,"PHASE3":4264,"PHASE4":4266,"NA":4268},{"trials":4255,"activeCount":98},[],{"trials":4257,"activeCount":109,"soonestReadout":1233},[4258],{"nctId":4020,"briefTitle":4021,"status":102,"phases":4259,"primaryCompletion":1233,"completion":1233,"start":4023,"enrollment":141,"conditions":4260,"interventions":4261},[86],[4025],[4027,4013],{"trials":4263,"activeCount":98},[],{"trials":4265,"activeCount":98},[],{"trials":4267,"activeCount":98},[],{"trials":4269,"activeCount":98},[],{"intervention":3964,"totalTrials":109,"cells":4271},{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4280,"PHASE3":4282,"PHASE4":4284,"NA":4286},{"trials":4273,"activeCount":98},[],{"trials":4275,"activeCount":109,"soonestReadout":1596},[4276],{"nctId":3957,"briefTitle":3958,"status":102,"phases":4277,"primaryCompletion":1596,"completion":1596,"start":3960,"enrollment":105,"conditions":4278,"interventions":4279},[86],[3962],[3964,3950],{"trials":4281,"activeCount":98},[],{"trials":4283,"activeCount":98},[],{"trials":4285,"activeCount":98},[],{"trials":4287,"activeCount":98},[],{"intervention":4289,"totalTrials":109,"cells":4290},"BHV-700",{"EARLY_PHASE1":4291,"PHASE1":4293,"PHASE2":4305,"PHASE3":4307,"PHASE4":4309,"NA":4311},{"trials":4292,"activeCount":98},[],{"trials":4294,"activeCount":109,"soonestReadout":4299},[4295],{"nctId":4296,"briefTitle":4297,"status":672,"phases":4298,"primaryCompletion":4299,"completion":2423,"start":4300,"enrollment":303,"conditions":4301,"interventions":4304},"NCT07125261","BHV-7000 Responsive Neurostimulation System (RNS) Study",[86],"2026-03","2025-10-07",[4302,4303],"Epilepsy","Seizures",[4289],{"trials":4306,"activeCount":98},[],{"trials":4308,"activeCount":98},[],{"trials":4310,"activeCount":98},[],{"trials":4312,"activeCount":98},[],{"intervention":3996,"totalTrials":109,"cells":4314},{"EARLY_PHASE1":4315,"PHASE1":4317,"PHASE2":4323,"PHASE3":4325,"PHASE4":4327,"NA":4329},{"trials":4316,"activeCount":98},[],{"trials":4318,"activeCount":109,"soonestReadout":1440},[4319],{"nctId":3991,"briefTitle":3992,"status":672,"phases":4320,"primaryCompletion":1440,"completion":1440,"start":1781,"enrollment":1044,"conditions":4321,"interventions":4322},[86],[1399,3930,3931],[3996,3984],{"trials":4324,"activeCount":98},[],{"trials":4326,"activeCount":98},[],{"trials":4328,"activeCount":98},[],{"trials":4330,"activeCount":98},[],{"intervention":4332,"totalTrials":109,"cells":4333},"Amiloride",{"EARLY_PHASE1":4334,"PHASE1":4336,"PHASE2":4346,"PHASE3":4348,"PHASE4":4350,"NA":4352},{"trials":4335,"activeCount":98},[],{"trials":4337,"activeCount":109,"soonestReadout":1574},[4338],{"nctId":4339,"briefTitle":4340,"status":102,"phases":4341,"primaryCompletion":1574,"completion":1574,"start":4342,"enrollment":1305,"conditions":4343,"interventions":4344},"NCT05753059","Mechanisms of Diuretic Resistance in Heart Failure, Aim 2",[86],"2023-08-10",[107],[4332,4345],"Bendroflumethiazide",{"trials":4347,"activeCount":98},[],{"trials":4349,"activeCount":98},[],{"trials":4351,"activeCount":98},[],{"trials":4353,"activeCount":98},[],{"intervention":4345,"totalTrials":109,"cells":4355},{"EARLY_PHASE1":4356,"PHASE1":4358,"PHASE2":4364,"PHASE3":4366,"PHASE4":4368,"NA":4370},{"trials":4357,"activeCount":98},[],{"trials":4359,"activeCount":109,"soonestReadout":1574},[4360],{"nctId":4339,"briefTitle":4340,"status":102,"phases":4361,"primaryCompletion":1574,"completion":1574,"start":4342,"enrollment":1305,"conditions":4362,"interventions":4363},[86],[107],[4332,4345],{"trials":4365,"activeCount":98},[],{"trials":4367,"activeCount":98},[],{"trials":4369,"activeCount":98},[],{"trials":4371,"activeCount":98},[],{"intervention":4003,"totalTrials":109,"cells":4373},{"EARLY_PHASE1":4374,"PHASE1":4376,"PHASE2":4382,"PHASE3":4384,"PHASE4":4386,"NA":4388},{"trials":4375,"activeCount":98},[],{"trials":4377,"activeCount":109,"soonestReadout":1440},[4378],{"nctId":3998,"briefTitle":3999,"status":672,"phases":4379,"primaryCompletion":1440,"completion":1440,"start":1781,"enrollment":1044,"conditions":4380,"interventions":4381},[86],[1399,3930,3931],[4003,3984],{"trials":4383,"activeCount":98},[],{"trials":4385,"activeCount":98},[],{"trials":4387,"activeCount":98},[],{"trials":4389,"activeCount":98},[],{"intervention":4391,"totalTrials":109,"cells":4392},"Dapagliflozin 10mg",{"EARLY_PHASE1":4393,"PHASE1":4395,"PHASE2":4407,"PHASE3":4409,"PHASE4":4411,"NA":4413},{"trials":4394,"activeCount":98},[],{"trials":4396,"activeCount":109,"soonestReadout":568},[4397],{"nctId":4398,"briefTitle":4399,"status":102,"phases":4400,"primaryCompletion":568,"completion":568,"start":4401,"enrollment":118,"conditions":4402,"interventions":4406},"NCT05989347","Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy",[86],"2024-10-15",[4403,4404,4405],"Breast Cancer","Hyperinsulinism","HER2-negative Breast Cancer",[4391],{"trials":4408,"activeCount":98},[],{"trials":4410,"activeCount":98},[],{"trials":4412,"activeCount":98},[],{"trials":4414,"activeCount":98},[],{"intervention":4416,"totalTrials":109,"cells":4417},"Ammonium Chloride",{"EARLY_PHASE1":4418,"PHASE1":4420,"PHASE2":4431,"PHASE3":4433,"PHASE4":4435,"NA":4437},{"trials":4419,"activeCount":98},[],{"trials":4421,"activeCount":109,"soonestReadout":4426},[4422],{"nctId":4423,"briefTitle":4424,"status":102,"phases":4425,"primaryCompletion":4426,"completion":4426,"start":4427,"enrollment":1305,"conditions":4428,"interventions":4430},"NCT06209359","Mechanisms of Diuretic Resistance in Heart Failure, Aim 3",[86],"2029-03-01","2024-07-24",[107,4429],"Diuretic Resistance",[4416],{"trials":4432,"activeCount":98},[],{"trials":4434,"activeCount":98},[],{"trials":4436,"activeCount":98},[],{"trials":4438,"activeCount":98},[],{"intervention":2014,"totalTrials":109,"cells":4440},{"EARLY_PHASE1":4441,"PHASE1":4443,"PHASE2":4449,"PHASE3":4451,"PHASE4":4453,"NA":4455},{"trials":4442,"activeCount":98},[],{"trials":4444,"activeCount":109,"soonestReadout":2008},[4445],{"nctId":2005,"briefTitle":2006,"status":672,"phases":4446,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":1878,"conditions":4447,"interventions":4448},[86],[2012,1492],[1590,2014,2015],{"trials":4450,"activeCount":98},[],{"trials":4452,"activeCount":98},[],{"trials":4454,"activeCount":98},[],{"trials":4456,"activeCount":98},[],{"intervention":4458,"totalTrials":109,"cells":4459},"Apremilast",{"EARLY_PHASE1":4460,"PHASE1":4462,"PHASE2":4472,"PHASE3":4474,"PHASE4":4476,"NA":4478},{"trials":4461,"activeCount":98},[],{"trials":4463,"activeCount":109,"soonestReadout":4468},[4464],{"nctId":4465,"briefTitle":4466,"status":672,"phases":4467,"primaryCompletion":4468,"completion":4468,"start":4469,"enrollment":1315,"conditions":4470,"interventions":4471},"NCT06324435","Apremilast for Alcohol Use Disorder Treatment in Women and Men",[86],"2026-08-30","2024-05-08",[27],[4458],{"trials":4473,"activeCount":98},[],{"trials":4475,"activeCount":98},[],{"trials":4477,"activeCount":98},[],{"trials":4479,"activeCount":98},[],{"intervention":4481,"totalTrials":109,"cells":4482},"Semaglutide 1.0 mg",{"EARLY_PHASE1":4483,"PHASE1":4485,"PHASE2":4496,"PHASE3":4498,"PHASE4":4500,"NA":4502},{"trials":4484,"activeCount":98},[],{"trials":4486,"activeCount":109,"soonestReadout":4491},[4487],{"nctId":4488,"briefTitle":4489,"status":102,"phases":4490,"primaryCompletion":4491,"completion":4491,"start":4492,"enrollment":1315,"conditions":4493,"interventions":4495},"NCT07223983","Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)",[86],"2026-10-31","2026-03-06",[27,4494,2157],"Weight Loss",[4481],{"trials":4497,"activeCount":98},[],{"trials":4499,"activeCount":98},[],{"trials":4501,"activeCount":98},[],{"trials":4503,"activeCount":98},[],{"intervention":4505,"totalTrials":109,"cells":4506},"[11C]OMAR",{"EARLY_PHASE1":4507,"PHASE1":4509,"PHASE2":4520,"PHASE3":4522,"PHASE4":4524,"NA":4526},{"trials":4508,"activeCount":98},[],{"trials":4510,"activeCount":109,"soonestReadout":4515},[4511],{"nctId":4512,"briefTitle":4513,"status":102,"phases":4514,"primaryCompletion":4515,"completion":4515,"start":4516,"enrollment":31,"conditions":4517,"interventions":4519},"NCT05683184","OMAR Opioid Use Disorder",[86],"2026-12-15","2023-03-10",[4518,30],"Healthy Control",[4505],{"trials":4521,"activeCount":98},[],{"trials":4523,"activeCount":98},[],{"trials":4525,"activeCount":98},[],{"trials":4527,"activeCount":98},[],{"intervention":4155,"totalTrials":109,"cells":4529},{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4538,"PHASE3":4540,"PHASE4":4542,"NA":4544},{"trials":4531,"activeCount":98},[],{"trials":4533,"activeCount":109,"soonestReadout":46},[4534],{"nctId":44,"briefTitle":45,"status":672,"phases":4535,"primaryCompletion":46,"completion":2423,"start":4152,"enrollment":1367,"conditions":4536,"interventions":4537},[86],[1772],[47,4155],{"trials":4539,"activeCount":98},[],{"trials":4541,"activeCount":98},[],{"trials":4543,"activeCount":98},[],{"trials":4545,"activeCount":98},[],{"intervention":4547,"totalTrials":109,"cells":4548},"0.3mg\u002Fkg\u002Fmin Dimethyltryptamine + Normal Saline",{"EARLY_PHASE1":4549,"PHASE1":4551,"PHASE2":4564,"PHASE3":4566,"PHASE4":4568,"NA":4570},{"trials":4550,"activeCount":98},[],{"trials":4552,"activeCount":109,"soonestReadout":4557},[4553],{"nctId":4554,"briefTitle":4555,"status":102,"phases":4556,"primaryCompletion":4557,"completion":4557,"start":4558,"enrollment":3906,"conditions":4559,"interventions":4561},"NCT06070649","The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)",[86],"2026-08-01","2025-08-04",[3760,4560,2359],"Alcohol-Related Disorders",[4547,4562,4563],"0.2 mg\u002Fkg\u002Fmin + Dimethyltryptamine 0.01mg\u002Fkg\u002Fmin","25 mg Diphenhydramine (5 min) + Normal Saline",{"trials":4565,"activeCount":98},[],{"trials":4567,"activeCount":98},[],{"trials":4569,"activeCount":98},[],{"trials":4571,"activeCount":98},[],{"intervention":4562,"totalTrials":109,"cells":4573},{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4582,"PHASE3":4584,"PHASE4":4586,"NA":4588},{"trials":4575,"activeCount":98},[],{"trials":4577,"activeCount":109,"soonestReadout":4557},[4578],{"nctId":4554,"briefTitle":4555,"status":102,"phases":4579,"primaryCompletion":4557,"completion":4557,"start":4558,"enrollment":3906,"conditions":4580,"interventions":4581},[86],[3760,4560,2359],[4547,4562,4563],{"trials":4583,"activeCount":98},[],{"trials":4585,"activeCount":98},[],{"trials":4587,"activeCount":98},[],{"trials":4589,"activeCount":98},[],{"intervention":4563,"totalTrials":109,"cells":4591},{"EARLY_PHASE1":4592,"PHASE1":4594,"PHASE2":4600,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4593,"activeCount":98},[],{"trials":4595,"activeCount":109,"soonestReadout":4557},[4596],{"nctId":4554,"briefTitle":4555,"status":102,"phases":4597,"primaryCompletion":4557,"completion":4557,"start":4558,"enrollment":3906,"conditions":4598,"interventions":4599},[86],[3760,4560,2359],[4547,4562,4563],{"trials":4601,"activeCount":98},[],{"trials":4603,"activeCount":98},[],{"trials":4605,"activeCount":98},[],{"trials":4607,"activeCount":98},[],{"intervention":4609,"totalTrials":109,"cells":4610},"Hyperinsulinemic-euglycemic clamp",{"EARLY_PHASE1":4611,"PHASE1":4613,"PHASE2":4624,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4612,"activeCount":98},[],{"trials":4614,"activeCount":109,"soonestReadout":4619},[4615],{"nctId":4616,"briefTitle":4617,"status":102,"phases":4618,"primaryCompletion":4619,"completion":4619,"start":4620,"enrollment":141,"conditions":4621,"interventions":4623},"NCT06105931","Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes",[86],"2028-06","2023-12-13",[4622,18],"type1diabetes",[4609],{"trials":4625,"activeCount":98},[],{"trials":4627,"activeCount":98},[],{"trials":4629,"activeCount":98},[],{"trials":4631,"activeCount":98},[],{"intervention":4633,"totalTrials":109,"cells":4634},"Bumetanide",{"EARLY_PHASE1":4635,"PHASE1":4637,"PHASE2":4648,"PHASE3":4650,"PHASE4":4652,"NA":4654},{"trials":4636,"activeCount":98},[],{"trials":4638,"activeCount":109,"soonestReadout":4643},[4639],{"nctId":4640,"briefTitle":4641,"status":102,"phases":4642,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":4645,"conditions":4646,"interventions":4647},"NCT05323487","Mechanisms of Diuretic Resistance in Heart Failure, Aim 1",[86],"2027-05-01","2022-06-01",75,[107],[4633],{"trials":4649,"activeCount":98},[],{"trials":4651,"activeCount":98},[],{"trials":4653,"activeCount":98},[],{"trials":4655,"activeCount":98},[],{"intervention":4657,"totalTrials":109,"cells":4658},"Brexanolone",{"EARLY_PHASE1":4659,"PHASE1":4661,"PHASE2":4671,"PHASE3":4673,"PHASE4":4675,"NA":4677},{"trials":4660,"activeCount":98},[],{"trials":4662,"activeCount":109,"soonestReadout":4667},[4663],{"nctId":4664,"briefTitle":4665,"status":672,"phases":4666,"primaryCompletion":4667,"completion":4667,"start":4668,"enrollment":1512,"conditions":4669,"interventions":4670},"NCT05223829","Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder",[86],"2025-12-31","2023-08-01",[1152,27],[4657],{"trials":4672,"activeCount":98},[],{"trials":4674,"activeCount":98},[],{"trials":4676,"activeCount":98},[],{"trials":4678,"activeCount":98},[],{"intervention":66,"totalTrials":109,"cells":4680},{"EARLY_PHASE1":4681,"PHASE1":4683,"PHASE2":4692,"PHASE3":4694,"PHASE4":4696,"NA":4698},{"trials":4682,"activeCount":98},[],{"trials":4684,"activeCount":109,"soonestReadout":61},[4685],{"nctId":64,"briefTitle":65,"status":102,"phases":4686,"primaryCompletion":61,"completion":61,"start":4687,"enrollment":2659,"conditions":4688,"interventions":4690},[86],"2024-11-19",[316,4689],"Pain, Postoperative",[66,4691],"Acetaminophen 650mg Liquid",{"trials":4693,"activeCount":98},[],{"trials":4695,"activeCount":98},[],{"trials":4697,"activeCount":98},[],{"trials":4699,"activeCount":98},[],{"intervention":4691,"totalTrials":109,"cells":4701},{"EARLY_PHASE1":4702,"PHASE1":4704,"PHASE2":4710,"PHASE3":4712,"PHASE4":4714,"NA":4716},{"trials":4703,"activeCount":98},[],{"trials":4705,"activeCount":109,"soonestReadout":61},[4706],{"nctId":64,"briefTitle":65,"status":102,"phases":4707,"primaryCompletion":61,"completion":61,"start":4687,"enrollment":2659,"conditions":4708,"interventions":4709},[86],[316,4689],[66,4691],{"trials":4711,"activeCount":98},[],{"trials":4713,"activeCount":98},[],{"trials":4715,"activeCount":98},[],{"trials":4717,"activeCount":98},[],{"intervention":4719,"totalTrials":109,"cells":4720},"0.1 mg\u002Fkg Dimethyltryptamine",{"EARLY_PHASE1":4721,"PHASE1":4723,"PHASE2":4734,"PHASE3":4736,"PHASE4":4738,"NA":4740},{"trials":4722,"activeCount":98},[],{"trials":4724,"activeCount":109,"soonestReadout":839},[4725],{"nctId":4726,"briefTitle":4727,"status":672,"phases":4728,"primaryCompletion":839,"completion":4729,"start":4730,"enrollment":31,"conditions":4731,"interventions":4732},"NCT04711915","Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans",[86],"2026-12-01","2021-03-17",[1772,21],[4719,4733],"0.3 mg\u002Fkg Dimethyltryptamine",{"trials":4735,"activeCount":98},[],{"trials":4737,"activeCount":98},[],{"trials":4739,"activeCount":98},[],{"trials":4741,"activeCount":98},[],{"intervention":4733,"totalTrials":109,"cells":4743},{"EARLY_PHASE1":4744,"PHASE1":4746,"PHASE2":4752,"PHASE3":4754,"PHASE4":4756,"NA":4758},{"trials":4745,"activeCount":98},[],{"trials":4747,"activeCount":109,"soonestReadout":839},[4748],{"nctId":4726,"briefTitle":4727,"status":672,"phases":4749,"primaryCompletion":839,"completion":4729,"start":4730,"enrollment":31,"conditions":4750,"interventions":4751},[86],[1772,21],[4719,4733],{"trials":4753,"activeCount":98},[],{"trials":4755,"activeCount":98},[],{"trials":4757,"activeCount":98},[],{"trials":4759,"activeCount":98},[],{"intervention":4761,"totalTrials":109,"cells":4762},"Inhaled THC",{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4774,"PHASE3":4776,"PHASE4":4778,"NA":4780},{"trials":4764,"activeCount":98},[],{"trials":4766,"activeCount":109,"soonestReadout":884},[4767],{"nctId":4768,"briefTitle":4769,"status":102,"phases":4770,"primaryCompletion":884,"completion":884,"start":4771,"enrollment":1011,"conditions":4772,"interventions":4773},"NCT04704271","Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II",[86],"2019-10-09",[1399],[4761],{"trials":4775,"activeCount":98},[],{"trials":4777,"activeCount":98},[],{"trials":4779,"activeCount":98},[],{"trials":4781,"activeCount":98},[],{"intervention":4783,"totalTrials":109,"cells":4784},"18F-TPP",{"EARLY_PHASE1":4785,"PHASE1":4787,"PHASE2":4797,"PHASE3":4799,"PHASE4":4801,"NA":4803},{"trials":4786,"activeCount":98},[],{"trials":4788,"activeCount":109,"soonestReadout":4793},[4789],{"nctId":4790,"briefTitle":4791,"status":248,"phases":4792,"primaryCompletion":4793,"completion":4793,"start":1439,"enrollment":2659,"conditions":4794,"interventions":4796},"NCT07506616","Membrane Potential Mapping with18F-TPP",[86],"2033-08",[4795],"Membrane Potential Mapping",[4783],{"trials":4798,"activeCount":98},[],{"trials":4800,"activeCount":98},[],{"trials":4802,"activeCount":98},[],{"trials":4804,"activeCount":98},[],{"intervention":2159,"totalTrials":109,"cells":4806},{"EARLY_PHASE1":4807,"PHASE1":4809,"PHASE2":4815,"PHASE3":4817,"PHASE4":4819,"NA":4821},{"trials":4808,"activeCount":98},[],{"trials":4810,"activeCount":109,"soonestReadout":2154},[4811],{"nctId":2151,"briefTitle":2152,"status":102,"phases":4812,"primaryCompletion":2154,"completion":2154,"start":2155,"enrollment":118,"conditions":4813,"interventions":4814},[86],[18,1860,2157],[2144,2159],{"trials":4816,"activeCount":98},[],{"trials":4818,"activeCount":98},[],{"trials":4820,"activeCount":98},[],{"trials":4822,"activeCount":98},[],{"intervention":4824,"totalTrials":109,"cells":4825},"AB821",{"EARLY_PHASE1":4826,"PHASE1":4828,"PHASE2":4838,"PHASE3":4840,"PHASE4":4842,"NA":4844},{"trials":4827,"activeCount":98},[],{"trials":4829,"activeCount":109,"soonestReadout":384},[4830],{"nctId":4831,"briefTitle":4832,"status":102,"phases":4833,"primaryCompletion":384,"completion":384,"start":4834,"enrollment":1305,"conditions":4835,"interventions":4837},"NCT07027488","AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors",[86],"2025-08-05",[4836,2012],"Advanced Melanoma and Normal or Impaired",[4824],{"trials":4839,"activeCount":98},[],{"trials":4841,"activeCount":98},[],{"trials":4843,"activeCount":98},[],{"trials":4845,"activeCount":98},[],{"intervention":3974,"totalTrials":109,"cells":4847},{"EARLY_PHASE1":4848,"PHASE1":4850,"PHASE2":4856,"PHASE3":4858,"PHASE4":4860,"NA":4862},{"trials":4849,"activeCount":98},[],{"trials":4851,"activeCount":109,"soonestReadout":3560},[4852],{"nctId":3966,"briefTitle":3967,"status":102,"phases":4853,"primaryCompletion":3560,"completion":3560,"start":3969,"enrollment":3970,"conditions":4854,"interventions":4855},[86],[15,3972],[3974,3950],{"trials":4857,"activeCount":98},[],{"trials":4859,"activeCount":98},[],{"trials":4861,"activeCount":98},[],{"trials":4863,"activeCount":98},[],{"intervention":4865,"totalTrials":109,"cells":4866},"[ 18F]3F4AP",{"EARLY_PHASE1":4867,"PHASE1":4869,"PHASE2":4888,"PHASE3":4890,"PHASE4":4892,"NA":4894},{"trials":4868,"activeCount":98},[],{"trials":4870,"activeCount":109,"soonestReadout":4875},[4871],{"nctId":4872,"briefTitle":4873,"status":102,"phases":4874,"primaryCompletion":4875,"completion":4875,"start":4876,"enrollment":4877,"conditions":4878,"interventions":4885},"NCT06999434","Exploring the Utility of [18F]3F4AP for Demyelination Imaging",[86],"2030-05-05","2025-05-05",105,[4879,4880,4881,4882,4883,4884],"Demyelinating Disorders","MCI","Alzheimer's Disease (AD)","MS (Multiple Sclerosis)","SCI - Spinal Cord Injury","Spinal Radiculopathy",[4865,4886,4887],"[18F]MK6240","[11C]PIB",{"trials":4889,"activeCount":98},[],{"trials":4891,"activeCount":98},[],{"trials":4893,"activeCount":98},[],{"trials":4895,"activeCount":98},[],{"intervention":4886,"totalTrials":109,"cells":4897},{"EARLY_PHASE1":4898,"PHASE1":4900,"PHASE2":4906,"PHASE3":4908,"PHASE4":4910,"NA":4912},{"trials":4899,"activeCount":98},[],{"trials":4901,"activeCount":109,"soonestReadout":4875},[4902],{"nctId":4872,"briefTitle":4873,"status":102,"phases":4903,"primaryCompletion":4875,"completion":4875,"start":4876,"enrollment":4877,"conditions":4904,"interventions":4905},[86],[4879,4880,4881,4882,4883,4884],[4865,4886,4887],{"trials":4907,"activeCount":98},[],{"trials":4909,"activeCount":98},[],{"trials":4911,"activeCount":98},[],{"trials":4913,"activeCount":98},[],{"intervention":4887,"totalTrials":109,"cells":4915},{"EARLY_PHASE1":4916,"PHASE1":4918,"PHASE2":4924,"PHASE3":4926,"PHASE4":4928,"NA":4930},{"trials":4917,"activeCount":98},[],{"trials":4919,"activeCount":109,"soonestReadout":4875},[4920],{"nctId":4872,"briefTitle":4873,"status":102,"phases":4921,"primaryCompletion":4875,"completion":4875,"start":4876,"enrollment":4877,"conditions":4922,"interventions":4923},[86],[4879,4880,4881,4882,4883,4884],[4865,4886,4887],{"trials":4925,"activeCount":98},[],{"trials":4927,"activeCount":98},[],{"trials":4929,"activeCount":98},[],{"trials":4931,"activeCount":98},[],{"intervention":4933,"totalTrials":263,"cells":4934},"[11C]APP311",{"EARLY_PHASE1":4935,"PHASE1":4945,"PHASE2":4947,"PHASE3":4949,"PHASE4":4951,"NA":4953},{"trials":4936,"activeCount":109,"soonestReadout":473},[4937],{"nctId":4938,"briefTitle":4939,"status":102,"phases":4940,"primaryCompletion":473,"completion":4941,"start":4942,"enrollment":766,"conditions":4943,"interventions":4944},"NCT05472818","SV2A Density Cannabis Use Disorder",[85],"2032-05","2022-04-12",[3972,3590],[4933],{"trials":4946,"activeCount":98},[],{"trials":4948,"activeCount":98},[],{"trials":4950,"activeCount":98},[],{"trials":4952,"activeCount":98},[],{"trials":4954,"activeCount":109,"soonestReadout":1440},[4955],{"nctId":4956,"briefTitle":4957,"status":102,"phases":4958,"primaryCompletion":1440,"completion":1440,"start":4959,"enrollment":616,"conditions":4960,"interventions":4962},"NCT03995121","SV2 PET Imaging With [11C]APP311",[],"2017-12-01",[4961,3972,3590],"Schizophrenia and Other Psychotic Disorders",[4933],{"intervention":1480,"totalTrials":263,"cells":4964},{"EARLY_PHASE1":4965,"PHASE1":4971,"PHASE2":4973,"PHASE3":4979,"PHASE4":4981,"NA":4983},{"trials":4966,"activeCount":109,"soonestReadout":568},[4967],{"nctId":1471,"briefTitle":1472,"status":102,"phases":4968,"primaryCompletion":568,"completion":568,"start":1474,"enrollment":118,"conditions":4969,"interventions":4970},[85],[1476,1477,1478],[1480,1465],{"trials":4972,"activeCount":98},[],{"trials":4974,"activeCount":98},[4975],{"nctId":1486,"briefTitle":1487,"status":711,"phases":4976,"primaryCompletion":1325,"completion":1325,"start":1489,"enrollment":1367,"conditions":4977,"interventions":4978},[87],[1491,1492,1493,1494,1465,1480,1495],[1465,1480],{"trials":4980,"activeCount":98},[],{"trials":4982,"activeCount":98},[],{"trials":4984,"activeCount":98},[],{"intervention":4986,"totalTrials":263,"cells":4987},"Scopolamine",{"EARLY_PHASE1":4988,"PHASE1":5001,"PHASE2":5011,"PHASE3":5013,"PHASE4":5015,"NA":5017},{"trials":4989,"activeCount":109,"soonestReadout":4994},[4990],{"nctId":4991,"briefTitle":4992,"status":102,"phases":4993,"primaryCompletion":4994,"completion":4994,"start":4995,"enrollment":25,"conditions":4996,"interventions":4999},"NCT04366518","Toward a Computationally-Informed, Personalized Treatment for Hallucinations",[85],"2032-08","2021-07-15",[4997,4998],"Hallucinations, Auditory","Psychosis",[5000,4986],"Rivastigmine Transdermal System",{"trials":5002,"activeCount":98},[5003],{"nctId":5004,"briefTitle":5005,"status":1051,"phases":5006,"primaryCompletion":1455,"completion":1455,"start":5007,"enrollment":98,"conditions":5008,"interventions":5010},"NCT06014385","PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor",[86],"2025-03",[5009],"Muscarinic Receptor Occupancy",[4986],{"trials":5012,"activeCount":98},[],{"trials":5014,"activeCount":98},[],{"trials":5016,"activeCount":98},[],{"trials":5018,"activeCount":98},[],{"intervention":5020,"totalTrials":263,"cells":5021},"Dichloroacetate",{"EARLY_PHASE1":5022,"PHASE1":5043,"PHASE2":5045,"PHASE3":5047,"PHASE4":5049,"NA":5051},{"trials":5023,"activeCount":109,"soonestReadout":3537},[5024,5034],{"nctId":5025,"briefTitle":5026,"status":152,"phases":5027,"primaryCompletion":5028,"completion":5028,"start":5029,"enrollment":5030,"conditions":5031,"interventions":5033},"NCT03356457","Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes",[85],"2019-03-20","2017-11-30",21,[5032],"Hyperglycaemia (Diabetic)",[5020],{"nctId":5035,"briefTitle":5036,"status":102,"phases":5037,"primaryCompletion":3537,"completion":812,"start":5038,"enrollment":1648,"conditions":5039,"interventions":5042},"NCT05317455","Regulation of Brain Glucose Metabolism in Type 1 Diabetes",[85],"2025-05-13",[5040,5041],"Diabetes Mellitus, Type 1","Hypoglycemia Unawareness",[5020],{"trials":5044,"activeCount":98},[],{"trials":5046,"activeCount":98},[],{"trials":5048,"activeCount":98},[],{"trials":5050,"activeCount":98},[],{"trials":5052,"activeCount":98},[],{"intervention":5054,"totalTrials":109,"cells":5055},"Zimberelimab",{"EARLY_PHASE1":5056,"PHASE1":5068,"PHASE2":5070,"PHASE3":5072,"PHASE4":5074,"NA":5076},{"trials":5057,"activeCount":109,"soonestReadout":5062},[5058],{"nctId":5059,"briefTitle":5060,"status":672,"phases":5061,"primaryCompletion":5062,"completion":131,"start":5063,"enrollment":19,"conditions":5064,"interventions":5066},"NCT04656535","AB154 Combined With AB122 for Recurrent Glioblastoma",[85],"2026-03-17","2021-04-21",[5065],"Glioblastoma",[5054,5067],"Domvanalimab",{"trials":5069,"activeCount":98},[],{"trials":5071,"activeCount":98},[],{"trials":5073,"activeCount":98},[],{"trials":5075,"activeCount":98},[],{"trials":5077,"activeCount":98},[],{"intervention":5067,"totalTrials":109,"cells":5079},{"EARLY_PHASE1":5080,"PHASE1":5086,"PHASE2":5088,"PHASE3":5090,"PHASE4":5092,"NA":5094},{"trials":5081,"activeCount":109,"soonestReadout":5062},[5082],{"nctId":5059,"briefTitle":5060,"status":672,"phases":5083,"primaryCompletion":5062,"completion":131,"start":5063,"enrollment":19,"conditions":5084,"interventions":5085},[85],[5065],[5054,5067],{"trials":5087,"activeCount":98},[],{"trials":5089,"activeCount":98},[],{"trials":5091,"activeCount":98},[],{"trials":5093,"activeCount":98},[],{"trials":5095,"activeCount":98},[],{"intervention":5000,"totalTrials":109,"cells":5097},{"EARLY_PHASE1":5098,"PHASE1":5104,"PHASE2":5106,"PHASE3":5108,"PHASE4":5110,"NA":5112},{"trials":5099,"activeCount":109,"soonestReadout":4994},[5100],{"nctId":4991,"briefTitle":4992,"status":102,"phases":5101,"primaryCompletion":4994,"completion":4994,"start":4995,"enrollment":25,"conditions":5102,"interventions":5103},[85],[4997,4998],[5000,4986],{"trials":5105,"activeCount":98},[],{"trials":5107,"activeCount":98},[],{"trials":5109,"activeCount":98},[],{"trials":5111,"activeCount":98},[],{"trials":5113,"activeCount":98},[],{"intervention":5115,"totalTrials":109,"cells":5116},"400 mg Cannabidiol",{"EARLY_PHASE1":5117,"PHASE1":5129,"PHASE2":5131,"PHASE3":5133,"PHASE4":5135,"NA":5137},{"trials":5118,"activeCount":109,"soonestReadout":1944},[5119],{"nctId":5120,"briefTitle":5121,"status":102,"phases":5122,"primaryCompletion":1944,"completion":1944,"start":5123,"enrollment":3897,"conditions":5124,"interventions":5125},"NCT04587791","Cannabidiol in Opioid Use Disorder and Chronic Pain",[85],"2021-12-08",[184,30],[5115,5126,5127,5128],"800 mg Cannabidiol","1200 mg Cannabidiol","Beta carotene oral solution without CBD",{"trials":5130,"activeCount":98},[],{"trials":5132,"activeCount":98},[],{"trials":5134,"activeCount":98},[],{"trials":5136,"activeCount":98},[],{"trials":5138,"activeCount":98},[],{"intervention":5126,"totalTrials":109,"cells":5140},{"EARLY_PHASE1":5141,"PHASE1":5147,"PHASE2":5149,"PHASE3":5151,"PHASE4":5153,"NA":5155},{"trials":5142,"activeCount":109,"soonestReadout":1944},[5143],{"nctId":5120,"briefTitle":5121,"status":102,"phases":5144,"primaryCompletion":1944,"completion":1944,"start":5123,"enrollment":3897,"conditions":5145,"interventions":5146},[85],[184,30],[5115,5126,5127,5128],{"trials":5148,"activeCount":98},[],{"trials":5150,"activeCount":98},[],{"trials":5152,"activeCount":98},[],{"trials":5154,"activeCount":98},[],{"trials":5156,"activeCount":98},[],{"intervention":5127,"totalTrials":109,"cells":5158},{"EARLY_PHASE1":5159,"PHASE1":5165,"PHASE2":5167,"PHASE3":5169,"PHASE4":5171,"NA":5173},{"trials":5160,"activeCount":109,"soonestReadout":1944},[5161],{"nctId":5120,"briefTitle":5121,"status":102,"phases":5162,"primaryCompletion":1944,"completion":1944,"start":5123,"enrollment":3897,"conditions":5163,"interventions":5164},[85],[184,30],[5115,5126,5127,5128],{"trials":5166,"activeCount":98},[],{"trials":5168,"activeCount":98},[],{"trials":5170,"activeCount":98},[],{"trials":5172,"activeCount":98},[],{"trials":5174,"activeCount":98},[],{"intervention":5128,"totalTrials":109,"cells":5176},{"EARLY_PHASE1":5177,"PHASE1":5183,"PHASE2":5185,"PHASE3":5187,"PHASE4":5189,"NA":5191},{"trials":5178,"activeCount":109,"soonestReadout":1944},[5179],{"nctId":5120,"briefTitle":5121,"status":102,"phases":5180,"primaryCompletion":1944,"completion":1944,"start":5123,"enrollment":3897,"conditions":5181,"interventions":5182},[85],[184,30],[5115,5126,5127,5128],{"trials":5184,"activeCount":98},[],{"trials":5186,"activeCount":98},[],{"trials":5188,"activeCount":98},[],{"trials":5190,"activeCount":98},[],{"trials":5192,"activeCount":98},[],{"intervention":5194,"totalTrials":109,"cells":5195},"Psliocybin",{"EARLY_PHASE1":5196,"PHASE1":5206,"PHASE2":5208,"PHASE3":5210,"PHASE4":5212,"NA":5214},{"trials":5197,"activeCount":109,"soonestReadout":5202},[5198],{"nctId":5199,"briefTitle":5200,"status":248,"phases":5201,"primaryCompletion":5202,"completion":5202,"start":3129,"enrollment":118,"conditions":5203,"interventions":5205},"NCT07449351","Psilocybin Microdosing on Cognition, Mood and Quality of Life",[85],"2028-04-01",[5204],"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI",[5194],{"trials":5207,"activeCount":98},[],{"trials":5209,"activeCount":98},[],{"trials":5211,"activeCount":98},[],{"trials":5213,"activeCount":98},[],{"trials":5215,"activeCount":98},[],{"intervention":5217,"totalTrials":109,"cells":5218},"Very Low Dose THC",{"EARLY_PHASE1":5219,"PHASE1":5230,"PHASE2":5232,"PHASE3":5234,"PHASE4":5236,"NA":5238},{"trials":5220,"activeCount":109,"soonestReadout":1439},[5221],{"nctId":5222,"briefTitle":5223,"status":672,"phases":5224,"primaryCompletion":1439,"completion":1440,"start":5225,"enrollment":5030,"conditions":5226,"interventions":5228},"NCT02102113","Probing the Cannabinoid System in Individuals With a Family History of Psychosis",[85],"2014-01",[4998,2661,42,5227,15],"Marijuana",[5217,5229],"Low Dose THC",{"trials":5231,"activeCount":98},[],{"trials":5233,"activeCount":98},[],{"trials":5235,"activeCount":98},[],{"trials":5237,"activeCount":98},[],{"trials":5239,"activeCount":98},[],{"intervention":5229,"totalTrials":109,"cells":5241},{"EARLY_PHASE1":5242,"PHASE1":5248,"PHASE2":5250,"PHASE3":5252,"PHASE4":5254,"NA":5256},{"trials":5243,"activeCount":109,"soonestReadout":1439},[5244],{"nctId":5222,"briefTitle":5223,"status":672,"phases":5245,"primaryCompletion":1439,"completion":1440,"start":5225,"enrollment":5030,"conditions":5246,"interventions":5247},[85],[4998,2661,42,5227,15],[5217,5229],{"trials":5249,"activeCount":98},[],{"trials":5251,"activeCount":98},[],{"trials":5253,"activeCount":98},[],{"trials":5255,"activeCount":98},[],{"trials":5257,"activeCount":98},[],{"intervention":5259,"totalTrials":109,"cells":5260},"Fluzone® Quadrivalent",{"EARLY_PHASE1":5261,"PHASE1":5272,"PHASE2":5274,"PHASE3":5276,"PHASE4":5278,"NA":5280},{"trials":5262,"activeCount":109,"soonestReadout":1235},[5263],{"nctId":5264,"briefTitle":5265,"status":102,"phases":5266,"primaryCompletion":1235,"completion":1235,"start":5267,"enrollment":5268,"conditions":5269,"interventions":5271},"NCT06067555","Intradermal Influenza Vaccination",[85],"2024-01-24",249,[5270],"Vaccine Reaction",[5259,5259],{"trials":5273,"activeCount":98},[],{"trials":5275,"activeCount":98},[],{"trials":5277,"activeCount":98},[],{"trials":5279,"activeCount":98},[],{"trials":5281,"activeCount":98},[],{"intervention":5283,"totalTrials":109,"cells":5284},"[ 18F]GATT-44",{"EARLY_PHASE1":5285,"PHASE1":5294,"PHASE2":5296,"PHASE3":5298,"PHASE4":5300,"NA":5302},{"trials":5286,"activeCount":109,"soonestReadout":1233},[5287],{"nctId":5288,"briefTitle":5289,"status":102,"phases":5290,"primaryCompletion":1233,"completion":1233,"start":251,"enrollment":1523,"conditions":5291,"interventions":5293},"NCT07457736","Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1",[85],[5292],"Healthy Adult Participants",[5283],{"trials":5295,"activeCount":98},[],{"trials":5297,"activeCount":98},[],{"trials":5299,"activeCount":98},[],{"trials":5301,"activeCount":98},[],{"trials":5303,"activeCount":98},[],{"intervention":5305,"totalTrials":109,"cells":5306},"Dronabinol 5 MG",{"EARLY_PHASE1":5307,"PHASE1":5322,"PHASE2":5324,"PHASE3":5326,"PHASE4":5328,"NA":5330},{"trials":5308,"activeCount":109,"soonestReadout":812},[5309],{"nctId":5310,"briefTitle":5311,"status":102,"phases":5312,"primaryCompletion":812,"completion":1944,"start":5313,"enrollment":118,"conditions":5314,"interventions":5318},"NCT05906511","PK\u002FPD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults",[85],"2023-10-17",[5315,5316,5317],"Pain, Tolerance","Oral vs Vaporized THC","Abuse Liability",[5305,5319,5320,5321],"Dronabinol 10 MG","2mg Purified THC in an ethanolic solution","4mg Purified THC in an ethanolic solution",{"trials":5323,"activeCount":98},[],{"trials":5325,"activeCount":98},[],{"trials":5327,"activeCount":98},[],{"trials":5329,"activeCount":98},[],{"trials":5331,"activeCount":98},[],{"intervention":5319,"totalTrials":109,"cells":5333},{"EARLY_PHASE1":5334,"PHASE1":5340,"PHASE2":5342,"PHASE3":5344,"PHASE4":5346,"NA":5348},{"trials":5335,"activeCount":109,"soonestReadout":812},[5336],{"nctId":5310,"briefTitle":5311,"status":102,"phases":5337,"primaryCompletion":812,"completion":1944,"start":5313,"enrollment":118,"conditions":5338,"interventions":5339},[85],[5315,5316,5317],[5305,5319,5320,5321],{"trials":5341,"activeCount":98},[],{"trials":5343,"activeCount":98},[],{"trials":5345,"activeCount":98},[],{"trials":5347,"activeCount":98},[],{"trials":5349,"activeCount":98},[],{"intervention":5320,"totalTrials":109,"cells":5351},{"EARLY_PHASE1":5352,"PHASE1":5358,"PHASE2":5360,"PHASE3":5362,"PHASE4":5364,"NA":5366},{"trials":5353,"activeCount":109,"soonestReadout":812},[5354],{"nctId":5310,"briefTitle":5311,"status":102,"phases":5355,"primaryCompletion":812,"completion":1944,"start":5313,"enrollment":118,"conditions":5356,"interventions":5357},[85],[5315,5316,5317],[5305,5319,5320,5321],{"trials":5359,"activeCount":98},[],{"trials":5361,"activeCount":98},[],{"trials":5363,"activeCount":98},[],{"trials":5365,"activeCount":98},[],{"trials":5367,"activeCount":98},[],{"intervention":5321,"totalTrials":109,"cells":5369},{"EARLY_PHASE1":5370,"PHASE1":5376,"PHASE2":5378,"PHASE3":5380,"PHASE4":5382,"NA":5384},{"trials":5371,"activeCount":109,"soonestReadout":812},[5372],{"nctId":5310,"briefTitle":5311,"status":102,"phases":5373,"primaryCompletion":812,"completion":1944,"start":5313,"enrollment":118,"conditions":5374,"interventions":5375},[85],[5315,5316,5317],[5305,5319,5320,5321],{"trials":5377,"activeCount":98},[],{"trials":5379,"activeCount":98},[],{"trials":5381,"activeCount":98},[],{"trials":5383,"activeCount":98},[],{"trials":5385,"activeCount":98},[],{"intervention":78,"totalTrials":109,"cells":5387},{"EARLY_PHASE1":5388,"PHASE1":5395,"PHASE2":5397,"PHASE3":5399,"PHASE4":5401,"NA":5403},{"trials":5389,"activeCount":109,"soonestReadout":74},[5390],{"nctId":76,"briefTitle":77,"status":102,"phases":5391,"primaryCompletion":74,"completion":131,"start":5392,"enrollment":1044,"conditions":5393,"interventions":5394},[85],"2022-07-01",[806],[78],{"trials":5396,"activeCount":98},[],{"trials":5398,"activeCount":98},[],{"trials":5400,"activeCount":98},[],{"trials":5402,"activeCount":98},[],{"trials":5404,"activeCount":98},[],{"intervention":5406,"totalTrials":109,"cells":5407},"low dose Nicotine",{"EARLY_PHASE1":5408,"PHASE1":5420,"PHASE2":5422,"PHASE3":5424,"PHASE4":5426,"NA":5428},{"trials":5409,"activeCount":109,"soonestReadout":5414},[5410],{"nctId":5411,"briefTitle":5412,"status":102,"phases":5413,"primaryCompletion":5414,"completion":5415,"start":5416,"enrollment":3585,"conditions":5417,"interventions":5418},"NCT05176418","IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate",[85],"2026-01-30","2026-02-01","2022-09-09",[24],[5406,5419],"high dose Nicotine",{"trials":5421,"activeCount":98},[],{"trials":5423,"activeCount":98},[],{"trials":5425,"activeCount":98},[],{"trials":5427,"activeCount":98},[],{"trials":5429,"activeCount":98},[],{"intervention":5419,"totalTrials":109,"cells":5431},{"EARLY_PHASE1":5432,"PHASE1":5438,"PHASE2":5440,"PHASE3":5442,"PHASE4":5444,"NA":5446},{"trials":5433,"activeCount":109,"soonestReadout":5414},[5434],{"nctId":5411,"briefTitle":5412,"status":102,"phases":5435,"primaryCompletion":5414,"completion":5415,"start":5416,"enrollment":3585,"conditions":5436,"interventions":5437},[85],[24],[5406,5419],{"trials":5439,"activeCount":98},[],{"trials":5441,"activeCount":98},[],{"trials":5443,"activeCount":98},[],{"trials":5445,"activeCount":98},[],{"trials":5447,"activeCount":98},[],{"intervention":5449,"totalTrials":109,"cells":5450},"phosphate",{"EARLY_PHASE1":5451,"PHASE1":5466,"PHASE2":5468,"PHASE3":5470,"PHASE4":5472,"NA":5474},{"trials":5452,"activeCount":109,"soonestReadout":5457},[5453],{"nctId":5454,"briefTitle":5455,"status":102,"phases":5456,"primaryCompletion":5457,"completion":5457,"start":5458,"enrollment":31,"conditions":5459,"interventions":5465},"NCT03771105","The Impact of Phosphate Metabolism on Healthy Aging",[85],"2028-04","2019-01-01",[5460,5461,5462,5463,5464],"Hypophosphatemia","Rickets","Hypercalciuria","XLH","HHRH",[5449],{"trials":5467,"activeCount":98},[],{"trials":5469,"activeCount":98},[],{"trials":5471,"activeCount":98},[],{"trials":5473,"activeCount":98},[],{"trials":5475,"activeCount":98},[],{"intervention":5477,"totalTrials":109,"cells":5478},"Vitamin D 4000IU daily",{"EARLY_PHASE1":5479,"PHASE1":5481,"PHASE2":5483,"PHASE3":5485,"PHASE4":5487,"NA":5489},{"trials":5480,"activeCount":98},[],{"trials":5482,"activeCount":98},[],{"trials":5484,"activeCount":98},[],{"trials":5486,"activeCount":98},[],{"trials":5488,"activeCount":98},[],{"trials":5490,"activeCount":109,"soonestReadout":884},[5491],{"nctId":5492,"briefTitle":5493,"status":102,"phases":5494,"primaryCompletion":884,"completion":884,"start":1235,"enrollment":105,"conditions":5495,"interventions":5498},"NCT04355572","Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)",[90],[5496,5497],"Polycystic Ovarian Syndrome in Adolescent Females","Vitamin D Deficiency",[5477],{"intervention":657,"totalTrials":109,"cells":5500},{"EARLY_PHASE1":5501,"PHASE1":5503,"PHASE2":5505,"PHASE3":5507,"PHASE4":5509,"NA":5511},{"trials":5502,"activeCount":98},[],{"trials":5504,"activeCount":98},[],{"trials":5506,"activeCount":98},[],{"trials":5508,"activeCount":98},[],{"trials":5510,"activeCount":98},[],{"trials":5512,"activeCount":109,"soonestReadout":651},[5513],{"nctId":648,"briefTitle":649,"status":102,"phases":5514,"primaryCompletion":651,"completion":651,"start":652,"enrollment":653,"conditions":5515,"interventions":5516},[],[655],[623,657],{"intervention":5518,"totalTrials":109,"cells":5519},"Healthy Families PrEP Counselling Intervention",{"EARLY_PHASE1":5520,"PHASE1":5522,"PHASE2":5524,"PHASE3":5526,"PHASE4":5528,"NA":5530},{"trials":5521,"activeCount":98},[],{"trials":5523,"activeCount":98},[],{"trials":5525,"activeCount":98},[],{"trials":5527,"activeCount":98},[],{"trials":5529,"activeCount":98},[],{"trials":5531,"activeCount":109,"soonestReadout":5536},[5532],{"nctId":5533,"briefTitle":5534,"status":248,"phases":5535,"primaryCompletion":5536,"completion":5537,"start":2955,"enrollment":5538,"conditions":5539,"interventions":5542},"NCT06746675","Evaluating the Healthy Families PrEP Program for Women at Risk for HIV",[90],"2031-01","2032-01",660,[35,5540,5541],"Pregnancy","Pre-Exposure Prophylaxis of HIV Infection",[5518],{"intervention":5544,"totalTrials":109,"cells":5545},"Bavarostat",{"EARLY_PHASE1":5546,"PHASE1":5548,"PHASE2":5550,"PHASE3":5552,"PHASE4":5554,"NA":5556},{"trials":5547,"activeCount":98},[],{"trials":5549,"activeCount":98},[],{"trials":5551,"activeCount":98},[],{"trials":5553,"activeCount":98},[],{"trials":5555,"activeCount":98},[],{"trials":5557,"activeCount":109,"soonestReadout":5562},[5558],{"nctId":5559,"briefTitle":5560,"status":102,"phases":5561,"primaryCompletion":5562,"completion":5563,"start":5564,"enrollment":2203,"conditions":5565,"interventions":5566},"NCT06371404","Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat",[],"2030-06-01","2031-06-01","2024-06-05",[27,1688],[5544],{"intervention":5568,"totalTrials":109,"cells":5569},"5% Dextrose\u002FWater",{"EARLY_PHASE1":5570,"PHASE1":5572,"PHASE2":5574,"PHASE3":5576,"PHASE4":5578,"NA":5580},{"trials":5571,"activeCount":98},[],{"trials":5573,"activeCount":98},[],{"trials":5575,"activeCount":98},[],{"trials":5577,"activeCount":98},[],{"trials":5579,"activeCount":98},[],{"trials":5581,"activeCount":109,"soonestReadout":2131},[5582],{"nctId":5583,"briefTitle":5584,"status":102,"phases":5585,"primaryCompletion":2131,"completion":2131,"start":5586,"enrollment":1315,"conditions":5587,"interventions":5589},"NCT06872645","Exploring Water-free Sodium Storage",[90],"2025-10-03",[5588],"Peritoneal Dialysis, Heart Failure",[5568,5590],"1.5% standard PD fluid",{"intervention":5590,"totalTrials":109,"cells":5592},{"EARLY_PHASE1":5593,"PHASE1":5595,"PHASE2":5597,"PHASE3":5599,"PHASE4":5601,"NA":5603},{"trials":5594,"activeCount":98},[],{"trials":5596,"activeCount":98},[],{"trials":5598,"activeCount":98},[],{"trials":5600,"activeCount":98},[],{"trials":5602,"activeCount":98},[],{"trials":5604,"activeCount":109,"soonestReadout":2131},[5605],{"nctId":5583,"briefTitle":5584,"status":102,"phases":5606,"primaryCompletion":2131,"completion":2131,"start":5586,"enrollment":1315,"conditions":5607,"interventions":5608},[90],[5588],[5568,5590],{"intervention":5610,"totalTrials":109,"cells":5611},"Nirsevimab",{"EARLY_PHASE1":5612,"PHASE1":5614,"PHASE2":5616,"PHASE3":5618,"PHASE4":5620,"NA":5622},{"trials":5613,"activeCount":98},[],{"trials":5615,"activeCount":98},[],{"trials":5617,"activeCount":98},[],{"trials":5619,"activeCount":98},[],{"trials":5621,"activeCount":98},[],{"trials":5623,"activeCount":109,"soonestReadout":5628},[5624],{"nctId":5625,"briefTitle":5626,"status":102,"phases":5627,"primaryCompletion":5628,"completion":5628,"start":5629,"enrollment":5630,"conditions":5631,"interventions":5633},"NCT06172660","Real-World Effectiveness of Perinatal RSV Immunoprophylaxis",[],"2028-12-30","2024-10-28",3750,[5632],"RSV Infection",[5610],{"intervention":5635,"totalTrials":109,"cells":5636},"PF974",{"EARLY_PHASE1":5637,"PHASE1":5639,"PHASE2":5641,"PHASE3":5643,"PHASE4":5645,"NA":5647},{"trials":5638,"activeCount":98},[],{"trials":5640,"activeCount":98},[],{"trials":5642,"activeCount":98},[],{"trials":5644,"activeCount":98},[],{"trials":5646,"activeCount":98},[],{"trials":5648,"activeCount":109,"soonestReadout":5653},[5649],{"nctId":5650,"briefTitle":5651,"status":248,"phases":5652,"primaryCompletion":5653,"completion":5654,"start":5655,"enrollment":946,"conditions":5656,"interventions":5658},"NCT07488819","Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974",[],"2031-03-01","2032-03-01","2026-03-01",[5657,3760],"Post-Traumatic Stress Disorder, PTSD",[5635],{"intervention":5660,"totalTrials":109,"cells":5661},"Sodium Thiosulfate",{"EARLY_PHASE1":5662,"PHASE1":5664,"PHASE2":5666,"PHASE3":5668,"PHASE4":5670,"NA":5672},{"trials":5663,"activeCount":98},[],{"trials":5665,"activeCount":98},[],{"trials":5667,"activeCount":98},[],{"trials":5669,"activeCount":98},[],{"trials":5671,"activeCount":98},[],{"trials":5673,"activeCount":109,"soonestReadout":1332},[5674],{"nctId":5675,"briefTitle":5676,"status":102,"phases":5677,"primaryCompletion":1332,"completion":1332,"start":3284,"enrollment":4121,"conditions":5678,"interventions":5681},"NCT07228429","Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images",[],[5679,5680],"Systemic Sclerosis (SSc)","Calcinosis Cutis",[5660,5660],{"intervention":5683,"totalTrials":109,"cells":5684},"Serotonergic Psychedelic",{"EARLY_PHASE1":5685,"PHASE1":5687,"PHASE2":5689,"PHASE3":5691,"PHASE4":5693,"NA":5695},{"trials":5686,"activeCount":98},[],{"trials":5688,"activeCount":98},[],{"trials":5690,"activeCount":98},[],{"trials":5692,"activeCount":98},[],{"trials":5694,"activeCount":98},[],{"trials":5696,"activeCount":109,"soonestReadout":542},[5697],{"nctId":5698,"briefTitle":5699,"status":102,"phases":5700,"primaryCompletion":542,"completion":542,"start":5701,"enrollment":5702,"conditions":5703,"interventions":5709},"NCT06624137","Computer Game, Qualitative, and MEG\u002FEEG Assessment of Serotonergic Psychedelics",[],"2024-12-12",200,[1359,5704,3760,5705,1307,1152,5706,5707,1947,5708,30],"Major Depressive Disorder (MDD)","Healthy Volunteer","PTSD - Post Traumatic Stress Disorder","Addiction","Obsessive Compulsive Disorder (OCD)",[5683],{"intervention":5711,"totalTrials":1246,"cells":5712},"Exenatide",{"EARLY_PHASE1":5713,"PHASE1":5715,"PHASE2":5734,"PHASE3":5746,"PHASE4":5748,"NA":5759},{"trials":5714,"activeCount":98},[],{"trials":5716,"activeCount":98},[5717,5726],{"nctId":5718,"briefTitle":5719,"status":152,"phases":5720,"primaryCompletion":1618,"completion":5721,"start":5722,"enrollment":1815,"conditions":5723,"interventions":5725},"NCT01855490","Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes",[86],"2013-10","2012-01",[5724],"Type 1 Diabetes",[5711],{"nctId":5727,"briefTitle":5728,"status":152,"phases":5729,"primaryCompletion":1876,"completion":1876,"start":5730,"enrollment":1685,"conditions":5731,"interventions":5732},"NCT02302976","GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration",[86],"2014-11",[330],[2324,5733],"exenatide",{"trials":5735,"activeCount":98},[5736],{"nctId":5737,"briefTitle":5738,"status":152,"phases":5739,"primaryCompletion":5740,"completion":5741,"start":5742,"enrollment":1836,"conditions":5743,"interventions":5745},"NCT01928329","A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes",[87],"2018-06","2019-08","2013-09",[5744],"Type I Diabetes",[5711],{"trials":5747,"activeCount":98},[],{"trials":5749,"activeCount":98},[5750],{"nctId":5751,"briefTitle":5752,"status":1051,"phases":5753,"primaryCompletion":5754,"start":270,"enrollment":98,"conditions":5755,"interventions":5758},"NCT00845559","The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese\u002FPre-Diabetic Young Adults",[89],"2010-03",[18,5756,2123,5757],"Insulin Resistance","Cardiovascular Disease",[5711],{"trials":5760,"activeCount":98},[],{"intervention":1976,"totalTrials":263,"cells":5762},{"EARLY_PHASE1":5763,"PHASE1":5765,"PHASE2":5767,"PHASE3":5769,"PHASE4":5780,"NA":5786},{"trials":5764,"activeCount":98},[],{"trials":5766,"activeCount":98},[],{"trials":5768,"activeCount":98},[],{"trials":5770,"activeCount":98},[5771],{"nctId":5772,"briefTitle":5773,"status":152,"phases":5774,"primaryCompletion":5775,"completion":5775,"start":5776,"enrollment":5777,"conditions":5778,"interventions":5779},"NCT02896400","Optimizing Tobacco Dependence Treatment in the Emergency Department",[88],"2019-08-14","2017-02-13",1056,[1947],[1976],{"trials":5781,"activeCount":98},[5782],{"nctId":1969,"briefTitle":1970,"status":152,"phases":5783,"primaryCompletion":1972,"completion":1972,"start":1973,"enrollment":1512,"conditions":5784,"interventions":5785},[89],[1860],[1976,70],{"trials":5787,"activeCount":98},[],{"intervention":5789,"totalTrials":263,"cells":5790},"olanzapine",{"EARLY_PHASE1":5791,"PHASE1":5793,"PHASE2":5795,"PHASE3":5808,"PHASE4":5810,"NA":5820},{"trials":5792,"activeCount":98},[],{"trials":5794,"activeCount":98},[],{"trials":5796,"activeCount":98},[5797],{"nctId":5798,"briefTitle":5799,"status":152,"phases":5800,"primaryCompletion":2979,"completion":5801,"start":5802,"enrollment":5803,"conditions":5804,"interventions":5806},"NCT05676294","The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery",[87],"2025-12-06","2023-06-26",384,[5805],"Postoperative Nausea and Vomiting",[5807],"Olanzapine",{"trials":5809,"activeCount":98},[],{"trials":5811,"activeCount":98},[5812],{"nctId":5813,"briefTitle":5814,"status":152,"phases":5815,"primaryCompletion":1655,"conditions":5816,"interventions":5817},"NCT00237861","Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia",[89],[15],[5818,5789,5819],"risperidone","quetiapine",{"trials":5821,"activeCount":98},[],{"intervention":5823,"totalTrials":263,"cells":5824},"extended-release guanfacine",{"EARLY_PHASE1":5825,"PHASE1":5827,"PHASE2":5829,"PHASE3":5831,"PHASE4":5833,"NA":5851},{"trials":5826,"activeCount":98},[],{"trials":5828,"activeCount":98},[],{"trials":5830,"activeCount":98},[],{"trials":5832,"activeCount":98},[],{"trials":5834,"activeCount":98},[5835,5842],{"nctId":5836,"briefTitle":5837,"status":152,"phases":5838,"primaryCompletion":326,"completion":326,"start":1664,"enrollment":1935,"conditions":5839,"interventions":5841},"NCT01238575","Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder",[89],[5840],"Pervasive Development Disorders",[5823],{"nctId":5843,"briefTitle":5844,"status":152,"phases":5845,"primaryCompletion":1972,"completion":1972,"start":5846,"enrollment":3897,"conditions":5847,"interventions":5850},"NCT01547000","Guanfacine in Children With Tic Disorders",[89],"2012-04",[5848,5849],"Tourette Disorder","Tourette Syndrome",[5823],{"trials":5852,"activeCount":98},[],{"intervention":5854,"totalTrials":109,"cells":5855},"Acarbose",{"EARLY_PHASE1":5856,"PHASE1":5858,"PHASE2":5860,"PHASE3":5862,"PHASE4":5864,"NA":5875},{"trials":5857,"activeCount":98},[],{"trials":5859,"activeCount":98},[],{"trials":5861,"activeCount":98},[],{"trials":5863,"activeCount":98},[],{"trials":5865,"activeCount":98},[5866],{"nctId":5867,"briefTitle":5868,"status":711,"phases":5869,"primaryCompletion":5870,"completion":5870,"start":5871,"enrollment":1609,"conditions":5872,"interventions":5874},"NCT00846521","Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity",[89],"2008-09","2006-09",[5873,5756,2123,5757],"Pediatric Obesity",[5854],{"trials":5876,"activeCount":98},[],{"intervention":5878,"totalTrials":109,"cells":5879},"nicotine replacement patch",{"EARLY_PHASE1":5880,"PHASE1":5882,"PHASE2":5884,"PHASE3":5886,"PHASE4":5888,"NA":5898},{"trials":5881,"activeCount":98},[],{"trials":5883,"activeCount":98},[],{"trials":5885,"activeCount":98},[],{"trials":5887,"activeCount":98},[],{"trials":5889,"activeCount":98},[5890],{"nctId":5891,"briefTitle":5892,"status":152,"phases":5893,"completion":5894,"enrollment":5895,"conditions":5896,"interventions":5897},"NCT00000454","Smoking Cessation in Alcoholism Treatment",[89],"2002-08",112,[1111,33],[5878],{"trials":5899,"activeCount":98},[],{"intervention":5901,"totalTrials":109,"cells":5902},"Rifapentine daily",{"EARLY_PHASE1":5903,"PHASE1":5905,"PHASE2":5907,"PHASE3":5909,"PHASE4":5911,"NA":5924},{"trials":5904,"activeCount":98},[],{"trials":5906,"activeCount":98},[],{"trials":5908,"activeCount":98},[],{"trials":5910,"activeCount":98},[],{"trials":5912,"activeCount":98},[5913],{"nctId":5914,"briefTitle":5915,"status":1051,"phases":5916,"primaryCompletion":5917,"completion":5918,"start":5919,"enrollment":98,"conditions":5920,"interventions":5922},"NCT04551573","A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects",[89],"2021-10","2021-11","2021-05",[5921,573],"Tuberculosis",[5901,5923],"Rifapentine weekly",{"trials":5925,"activeCount":98},[],{"intervention":5923,"totalTrials":109,"cells":5927},{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5932,"PHASE3":5934,"PHASE4":5936,"NA":5942},{"trials":5929,"activeCount":98},[],{"trials":5931,"activeCount":98},[],{"trials":5933,"activeCount":98},[],{"trials":5935,"activeCount":98},[],{"trials":5937,"activeCount":98},[5938],{"nctId":5914,"briefTitle":5915,"status":1051,"phases":5939,"primaryCompletion":5917,"completion":5918,"start":5919,"enrollment":98,"conditions":5940,"interventions":5941},[89],[5921,573],[5901,5923],{"trials":5943,"activeCount":98},[],{"intervention":5945,"totalTrials":109,"cells":5946},"esomeprazole",{"EARLY_PHASE1":5947,"PHASE1":5949,"PHASE2":5951,"PHASE3":5953,"PHASE4":5955,"NA":5964},{"trials":5948,"activeCount":98},[],{"trials":5950,"activeCount":98},[],{"trials":5952,"activeCount":98},[],{"trials":5954,"activeCount":98},[],{"trials":5956,"activeCount":98},[5957],{"nctId":5958,"briefTitle":5959,"status":152,"phases":5960,"primaryCompletion":327,"completion":327,"start":154,"enrollment":272,"conditions":5961,"interventions":5963},"NCT00719160","The Effect of Protein on Calcium Absorption and Gastric Acid Production",[89],[5962],"Osteoporosis",[5945],{"trials":5965,"activeCount":98},[],{"intervention":5967,"totalTrials":109,"cells":5968},"Latanoprost 0.005%",{"EARLY_PHASE1":5969,"PHASE1":5971,"PHASE2":5973,"PHASE3":5975,"PHASE4":5977,"NA":5987},{"trials":5970,"activeCount":98},[],{"trials":5972,"activeCount":98},[],{"trials":5974,"activeCount":98},[],{"trials":5976,"activeCount":98},[],{"trials":5978,"activeCount":98},[5979],{"nctId":5980,"briefTitle":5981,"status":152,"phases":5982,"primaryCompletion":1071,"completion":1071,"start":5983,"enrollment":1815,"conditions":5984,"interventions":5986},"NCT00224289","Effect of Age on Latanoprost 0.005% in Patients With Glaucoma",[89],"2005-03",[5985],"Glaucoma",[5967],{"trials":5988,"activeCount":98},[],{"intervention":5819,"totalTrials":109,"cells":5990},{"EARLY_PHASE1":5991,"PHASE1":5993,"PHASE2":5995,"PHASE3":5997,"PHASE4":5999,"NA":6005},{"trials":5992,"activeCount":98},[],{"trials":5994,"activeCount":98},[],{"trials":5996,"activeCount":98},[],{"trials":5998,"activeCount":98},[],{"trials":6000,"activeCount":98},[6001],{"nctId":5813,"briefTitle":5814,"status":152,"phases":6002,"primaryCompletion":1655,"conditions":6003,"interventions":6004},[89],[15],[5818,5789,5819],{"trials":6006,"activeCount":98},[],{"intervention":6008,"totalTrials":109,"cells":6009},"MoviPrep",{"EARLY_PHASE1":6010,"PHASE1":6012,"PHASE2":6014,"PHASE3":6016,"PHASE4":6018,"NA":6030},{"trials":6011,"activeCount":98},[],{"trials":6013,"activeCount":98},[],{"trials":6015,"activeCount":98},[],{"trials":6017,"activeCount":98},[],{"trials":6019,"activeCount":98},[6020],{"nctId":6021,"briefTitle":6022,"status":152,"phases":6023,"primaryCompletion":3905,"completion":3905,"start":6024,"enrollment":6025,"conditions":6026,"interventions":6028},"NCT05054036","MoviPrep® Versus GoLYTELY® Bowel Preparation in Hospitalized Patients Undergoing Colonoscopy",[89],"2022-01-12",520,[6027],"Bowel Preparation Before Colonoscopy",[6008,6029],"Golytely",{"trials":6031,"activeCount":98},[],{"intervention":6029,"totalTrials":109,"cells":6033},{"EARLY_PHASE1":6034,"PHASE1":6036,"PHASE2":6038,"PHASE3":6040,"PHASE4":6042,"NA":6048},{"trials":6035,"activeCount":98},[],{"trials":6037,"activeCount":98},[],{"trials":6039,"activeCount":98},[],{"trials":6041,"activeCount":98},[],{"trials":6043,"activeCount":98},[6044],{"nctId":6021,"briefTitle":6022,"status":152,"phases":6045,"primaryCompletion":3905,"completion":3905,"start":6024,"enrollment":6025,"conditions":6046,"interventions":6047},[89],[6027],[6008,6029],{"trials":6049,"activeCount":98},[],{"intervention":6051,"totalTrials":109,"cells":6052},"Normal saline",{"EARLY_PHASE1":6053,"PHASE1":6055,"PHASE2":6057,"PHASE3":6059,"PHASE4":6061,"NA":6076},{"trials":6054,"activeCount":98},[],{"trials":6056,"activeCount":98},[],{"trials":6058,"activeCount":98},[],{"trials":6060,"activeCount":98},[],{"trials":6062,"activeCount":98},[6063],{"nctId":6064,"briefTitle":6065,"status":1051,"phases":6066,"primaryCompletion":6067,"completion":6068,"start":6069,"enrollment":98,"conditions":6070,"interventions":6074},"NCT06237465","Botulinum Toxin-A for Hidradenitis Suppurativa",[89],"2025-06","2026-01","2025-01",[6071,6072,6073],"Hidradenitis Suppurativa","Hidradenitis Suppurativa \\(HS\\)","Hidradenitis Suppurativa, Acne Inversa",[6051,6075],"Botulinum toxin type A",{"trials":6077,"activeCount":98},[],{"intervention":6075,"totalTrials":109,"cells":6079},{"EARLY_PHASE1":6080,"PHASE1":6082,"PHASE2":6084,"PHASE3":6086,"PHASE4":6088,"NA":6094},{"trials":6081,"activeCount":98},[],{"trials":6083,"activeCount":98},[],{"trials":6085,"activeCount":98},[],{"trials":6087,"activeCount":98},[],{"trials":6089,"activeCount":98},[6090],{"nctId":6064,"briefTitle":6065,"status":1051,"phases":6091,"primaryCompletion":6067,"completion":6068,"start":6069,"enrollment":98,"conditions":6092,"interventions":6093},[89],[6071,6072,6073],[6051,6075],{"trials":6095,"activeCount":98},[],{"intervention":6097,"totalTrials":109,"cells":6098},"Corticosteroid",{"EARLY_PHASE1":6099,"PHASE1":6101,"PHASE2":6103,"PHASE3":6105,"PHASE4":6107,"NA":6118},{"trials":6100,"activeCount":98},[],{"trials":6102,"activeCount":98},[],{"trials":6104,"activeCount":98},[],{"trials":6106,"activeCount":98},[],{"trials":6108,"activeCount":98},[6109],{"nctId":6110,"briefTitle":6111,"status":711,"phases":6112,"primaryCompletion":6113,"completion":6113,"start":218,"enrollment":141,"conditions":6114,"interventions":6117},"NCT02392286","Corticosteroid Dosage for Crohn's Disease Flare",[89],"2016-12-19",[6115,6116],"Crohn's Disease","Inflammatory Bowel Disease",[6097],{"trials":6119,"activeCount":98},[],{"intervention":6121,"totalTrials":109,"cells":6122},"Vaccination to prevent hepatitis B virus infection",{"EARLY_PHASE1":6123,"PHASE1":6125,"PHASE2":6127,"PHASE3":6129,"PHASE4":6131,"NA":6143},{"trials":6124,"activeCount":98},[],{"trials":6126,"activeCount":98},[],{"trials":6128,"activeCount":98},[],{"trials":6130,"activeCount":98},[],{"trials":6132,"activeCount":98},[6133],{"nctId":6134,"briefTitle":6135,"status":152,"phases":6136,"primaryCompletion":6137,"completion":6137,"start":6138,"enrollment":6139,"conditions":6140,"interventions":6142},"NCT01259453","Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules",[89],"2006-08","2003-05",595,[6141],"Hepatitis B",[6121],{"trials":6144,"activeCount":98},[],{"intervention":6146,"totalTrials":109,"cells":6147},"60% oxygen",{"EARLY_PHASE1":6148,"PHASE1":6150,"PHASE2":6152,"PHASE3":6154,"PHASE4":6156,"NA":6168},{"trials":6149,"activeCount":98},[],{"trials":6151,"activeCount":98},[],{"trials":6153,"activeCount":98},[],{"trials":6155,"activeCount":98},[],{"trials":6157,"activeCount":98},[6158],{"nctId":6159,"briefTitle":6160,"status":1051,"phases":6161,"primaryCompletion":6162,"completion":6163,"start":1972,"enrollment":98,"conditions":6164,"interventions":6166},"NCT02509182","The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy",[89],"2017-07","2018-07",[6165],"Hyperoxia",[6146,6167],"100% oxygen",{"trials":6169,"activeCount":98},[],{"intervention":6167,"totalTrials":109,"cells":6171},{"EARLY_PHASE1":6172,"PHASE1":6174,"PHASE2":6176,"PHASE3":6178,"PHASE4":6180,"NA":6186},{"trials":6173,"activeCount":98},[],{"trials":6175,"activeCount":98},[],{"trials":6177,"activeCount":98},[],{"trials":6179,"activeCount":98},[],{"trials":6181,"activeCount":98},[6182],{"nctId":6159,"briefTitle":6160,"status":1051,"phases":6183,"primaryCompletion":6162,"completion":6163,"start":1972,"enrollment":98,"conditions":6184,"interventions":6185},[89],[6165],[6146,6167],{"trials":6187,"activeCount":98},[],{"intervention":6189,"totalTrials":109,"cells":6190},"Paliperidone",{"EARLY_PHASE1":6191,"PHASE1":6193,"PHASE2":6195,"PHASE3":6197,"PHASE4":6199,"NA":6207},{"trials":6192,"activeCount":98},[],{"trials":6194,"activeCount":98},[],{"trials":6196,"activeCount":98},[],{"trials":6198,"activeCount":98},[],{"trials":6200,"activeCount":98},[6201],{"nctId":6202,"briefTitle":6203,"status":1051,"phases":6204,"primaryCompletion":1993,"completion":1993,"start":5870,"enrollment":98,"conditions":6205,"interventions":6206},"NCT00766064","Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)",[89],[1718],[6189],{"trials":6208,"activeCount":98},[],{"intervention":6210,"totalTrials":109,"cells":6211},"Povidone-Iodine",{"EARLY_PHASE1":6212,"PHASE1":6214,"PHASE2":6216,"PHASE3":6218,"PHASE4":6220,"NA":6235},{"trials":6213,"activeCount":98},[],{"trials":6215,"activeCount":98},[],{"trials":6217,"activeCount":98},[],{"trials":6219,"activeCount":98},[],{"trials":6221,"activeCount":98},[6222],{"nctId":6223,"briefTitle":6224,"status":1051,"phases":6225,"primaryCompletion":6226,"completion":1617,"start":6163,"enrollment":98,"conditions":6227,"interventions":6234},"NCT02975921","Betadine Pleurodesis Via Tunneled Pleural Catheters",[89],"2020-09",[6228,6229,6230,6231,6232,6233],"Pleural Effusion","Pleurodesis","Malignant Pleural Effusion","Pleural Effusion Due to Congestive Heart Failure","Pleural Effusion in Conditions Classified Elsewhere","Pleural Effusions, Chronic",[6210],{"trials":6236,"activeCount":98},[],{"intervention":6238,"totalTrials":109,"cells":6239},"Xenical + behavioral intervention",{"EARLY_PHASE1":6240,"PHASE1":6242,"PHASE2":6244,"PHASE3":6246,"PHASE4":6248,"NA":6257},{"trials":6241,"activeCount":98},[],{"trials":6243,"activeCount":98},[],{"trials":6245,"activeCount":98},[],{"trials":6247,"activeCount":98},[],{"trials":6249,"activeCount":98},[6250],{"nctId":6251,"briefTitle":6252,"status":152,"phases":6253,"primaryCompletion":1673,"completion":1673,"start":1061,"enrollment":1836,"conditions":6254,"interventions":6256},"NCT00516919","Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons",[89],[18,6255],"Binge Eating",[6238],{"trials":6258,"activeCount":98},[],{"intervention":6260,"totalTrials":109,"cells":6261},"Sibutramine",{"EARLY_PHASE1":6262,"PHASE1":6264,"PHASE2":6266,"PHASE3":6268,"PHASE4":6270,"NA":6280},{"trials":6263,"activeCount":98},[],{"trials":6265,"activeCount":98},[],{"trials":6267,"activeCount":98},[],{"trials":6269,"activeCount":98},[],{"trials":6271,"activeCount":98},[6272],{"nctId":6273,"briefTitle":6274,"status":152,"phases":6275,"primaryCompletion":2320,"completion":2320,"start":6276,"enrollment":6277,"conditions":6278,"interventions":6279},"NCT00537810","Treatment of Binge Eating in Obese Patients in Primary Care",[89],"2007-09",104,[18,6255],[6260],{"trials":6281,"activeCount":98},[],{"intervention":6283,"totalTrials":109,"cells":6284},"Liposomal bupivacaine",{"EARLY_PHASE1":6285,"PHASE1":6287,"PHASE2":6289,"PHASE3":6291,"PHASE4":6293,"NA":6306},{"trials":6286,"activeCount":98},[],{"trials":6288,"activeCount":98},[],{"trials":6290,"activeCount":98},[],{"trials":6292,"activeCount":98},[],{"trials":6294,"activeCount":98},[6295],{"nctId":6296,"briefTitle":6297,"status":711,"phases":6298,"primaryCompletion":6299,"completion":6299,"start":216,"enrollment":2847,"conditions":6300,"interventions":6303},"NCT04393207","TAP Block Using Liposomal Bupivacaine for Post-cesarean Delivery Analgesia- Walking Towards Recovery",[89],"2023-11-28",[6301,6302],"Opioid Use","Pain, Acute",[6283,6304,6305],"Dexamethasone and methylprednisolone","Control group",{"trials":6307,"activeCount":98},[],{"intervention":6304,"totalTrials":109,"cells":6309},{"EARLY_PHASE1":6310,"PHASE1":6312,"PHASE2":6314,"PHASE3":6316,"PHASE4":6318,"NA":6324},{"trials":6311,"activeCount":98},[],{"trials":6313,"activeCount":98},[],{"trials":6315,"activeCount":98},[],{"trials":6317,"activeCount":98},[],{"trials":6319,"activeCount":98},[6320],{"nctId":6296,"briefTitle":6297,"status":711,"phases":6321,"primaryCompletion":6299,"completion":6299,"start":216,"enrollment":2847,"conditions":6322,"interventions":6323},[89],[6301,6302],[6283,6304,6305],{"trials":6325,"activeCount":98},[],{"intervention":6305,"totalTrials":109,"cells":6327},{"EARLY_PHASE1":6328,"PHASE1":6330,"PHASE2":6332,"PHASE3":6334,"PHASE4":6336,"NA":6342},{"trials":6329,"activeCount":98},[],{"trials":6331,"activeCount":98},[],{"trials":6333,"activeCount":98},[],{"trials":6335,"activeCount":98},[],{"trials":6337,"activeCount":98},[6338],{"nctId":6296,"briefTitle":6297,"status":711,"phases":6339,"primaryCompletion":6299,"completion":6299,"start":216,"enrollment":2847,"conditions":6340,"interventions":6341},[89],[6301,6302],[6283,6304,6305],{"trials":6343,"activeCount":98},[],{"intervention":6345,"totalTrials":109,"cells":6346},"Sugammadex",{"EARLY_PHASE1":6347,"PHASE1":6349,"PHASE2":6351,"PHASE3":6353,"PHASE4":6355,"NA":6367},{"trials":6348,"activeCount":98},[],{"trials":6350,"activeCount":98},[],{"trials":6352,"activeCount":98},[],{"trials":6354,"activeCount":98},[],{"trials":6356,"activeCount":98},[6357],{"nctId":6358,"briefTitle":6359,"status":152,"phases":6360,"primaryCompletion":6361,"completion":6362,"start":6363,"enrollment":181,"conditions":6364,"interventions":6366},"NCT03196167","Sugammadex and Decreased Time to Extubation",[89],"2020-10-01","2020-10-10","2017-05-13",[6365],"Coronary Artery Bypass Graft and\u002For Aortic Valve Replacement Surgery",[6345],{"trials":6368,"activeCount":98},[],{"intervention":6370,"totalTrials":109,"cells":6371},"Platelet Transfusion",{"EARLY_PHASE1":6372,"PHASE1":6374,"PHASE2":6376,"PHASE3":6378,"PHASE4":6380,"NA":6395},{"trials":6373,"activeCount":98},[],{"trials":6375,"activeCount":98},[],{"trials":6377,"activeCount":98},[],{"trials":6379,"activeCount":98},[],{"trials":6381,"activeCount":98},[6382],{"nctId":6383,"briefTitle":6384,"status":152,"phases":6385,"primaryCompletion":6386,"completion":6387,"start":6388,"enrollment":1305,"conditions":6389,"interventions":6394},"NCT05796557","ECMO Hemostatic Transfusions in Children",[89],"2025-01-02","2025-03-25","2023-12-12",[6390,6391,6392,6393],"Extracorporeal Membrane Oxygenation Complication","Hemorrhage","Thromboembolism","Transfusion Adverse Reaction",[6370],{"trials":6396,"activeCount":98},[],{"intervention":6398,"totalTrials":109,"cells":6399},"Dexamethasone",{"EARLY_PHASE1":6400,"PHASE1":6402,"PHASE2":6404,"PHASE3":6406,"PHASE4":6408,"NA":6419},{"trials":6401,"activeCount":98},[],{"trials":6403,"activeCount":98},[],{"trials":6405,"activeCount":98},[],{"trials":6407,"activeCount":98},[],{"trials":6409,"activeCount":98},[6410],{"nctId":6411,"briefTitle":6412,"status":152,"phases":6413,"primaryCompletion":1867,"completion":1867,"start":6414,"enrollment":2659,"conditions":6415,"interventions":6418},"NCT04067609","Postoperative Dexamethasone on Post-Cesarean Pain",[89],"2020-07-20",[6416,6417],"Post-Cesarean Pain","Cesarean Section Complications",[6398],{"trials":6420,"activeCount":98},[],{"intervention":6422,"totalTrials":109,"cells":6423},"Tranexamic Acid",{"EARLY_PHASE1":6424,"PHASE1":6426,"PHASE2":6428,"PHASE3":6430,"PHASE4":6432,"NA":6445},{"trials":6425,"activeCount":98},[],{"trials":6427,"activeCount":98},[],{"trials":6429,"activeCount":98},[],{"trials":6431,"activeCount":98},[],{"trials":6433,"activeCount":98},[6434],{"nctId":6435,"briefTitle":6436,"status":711,"phases":6437,"primaryCompletion":6438,"completion":6439,"start":6440,"enrollment":1416,"conditions":6441,"interventions":6444},"NCT02908516","Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures",[89],"2017-11-14","2017-12-15","2017-09-18",[6442,6443],"Hip Fractures","Blood Loss",[6422],{"trials":6446,"activeCount":98},[],{"intervention":6448,"totalTrials":109,"cells":6449},"Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler",{"EARLY_PHASE1":6450,"PHASE1":6452,"PHASE2":6454,"PHASE3":6456,"PHASE4":6458,"NA":6472},{"trials":6451,"activeCount":98},[],{"trials":6453,"activeCount":98},[],{"trials":6455,"activeCount":98},[],{"trials":6457,"activeCount":98},[],{"trials":6459,"activeCount":98},[6460],{"nctId":6461,"briefTitle":6462,"status":152,"phases":6463,"primaryCompletion":6464,"completion":6465,"start":6466,"enrollment":6467,"conditions":6468,"interventions":6470},"NCT04490057","A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV",[89],"2024-10-24","2025-10-24","2020-07-27",323,[6469],"Tobacco Use Cessation",[6448,6471],"Varenicline or bupropion",{"trials":6473,"activeCount":98},[],{"intervention":6471,"totalTrials":109,"cells":6475},{"EARLY_PHASE1":6476,"PHASE1":6478,"PHASE2":6480,"PHASE3":6482,"PHASE4":6484,"NA":6490},{"trials":6477,"activeCount":98},[],{"trials":6479,"activeCount":98},[],{"trials":6481,"activeCount":98},[],{"trials":6483,"activeCount":98},[],{"trials":6485,"activeCount":98},[6486],{"nctId":6461,"briefTitle":6462,"status":152,"phases":6487,"primaryCompletion":6464,"completion":6465,"start":6466,"enrollment":6467,"conditions":6488,"interventions":6489},[89],[6469],[6448,6471],{"trials":6491,"activeCount":98},[],{"intervention":6493,"totalTrials":109,"cells":6494},"Ocrelizumab",{"EARLY_PHASE1":6495,"PHASE1":6497,"PHASE2":6499,"PHASE3":6501,"PHASE4":6503,"NA":6515},{"trials":6496,"activeCount":98},[],{"trials":6498,"activeCount":98},[],{"trials":6500,"activeCount":98},[],{"trials":6502,"activeCount":98},[],{"trials":6504,"activeCount":98},[6505],{"nctId":6506,"briefTitle":6507,"status":711,"phases":6508,"primaryCompletion":6509,"completion":6509,"start":6510,"enrollment":94,"conditions":6511,"interventions":6514},"NCT04877457","Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.",[89],"2023-06-12","2022-02-15",[6512,6513],"Radiologically Isolated Syndrome","Multiple Sclerosis",[6493],{"trials":6516,"activeCount":98},[],{"intervention":6518,"totalTrials":109,"cells":6519},"LCZ 696",{"EARLY_PHASE1":6520,"PHASE1":6522,"PHASE2":6524,"PHASE3":6526,"PHASE4":6528,"NA":6541},{"trials":6521,"activeCount":98},[],{"trials":6523,"activeCount":98},[],{"trials":6525,"activeCount":98},[],{"trials":6527,"activeCount":98},[],{"trials":6529,"activeCount":98},[6530],{"nctId":6531,"briefTitle":6532,"status":152,"phases":6533,"primaryCompletion":6534,"completion":6534,"start":6535,"enrollment":19,"conditions":6536,"interventions":6537},"NCT04649229","Mechanisms Underlying Hypotensive Response to ARB\u002FNEP Inhibition - Aim 3",[89],"2025-05-22","2021-05-27",[107],[6518,6538,6539,6540],"Para-aminohippurate","Iohexol","Aprepitant",{"trials":6542,"activeCount":98},[],{"intervention":6538,"totalTrials":109,"cells":6544},{"EARLY_PHASE1":6545,"PHASE1":6547,"PHASE2":6549,"PHASE3":6551,"PHASE4":6553,"NA":6559},{"trials":6546,"activeCount":98},[],{"trials":6548,"activeCount":98},[],{"trials":6550,"activeCount":98},[],{"trials":6552,"activeCount":98},[],{"trials":6554,"activeCount":98},[6555],{"nctId":6531,"briefTitle":6532,"status":152,"phases":6556,"primaryCompletion":6534,"completion":6534,"start":6535,"enrollment":19,"conditions":6557,"interventions":6558},[89],[107],[6518,6538,6539,6540],{"trials":6560,"activeCount":98},[],{"intervention":6539,"totalTrials":109,"cells":6562},{"EARLY_PHASE1":6563,"PHASE1":6565,"PHASE2":6567,"PHASE3":6569,"PHASE4":6571,"NA":6577},{"trials":6564,"activeCount":98},[],{"trials":6566,"activeCount":98},[],{"trials":6568,"activeCount":98},[],{"trials":6570,"activeCount":98},[],{"trials":6572,"activeCount":98},[6573],{"nctId":6531,"briefTitle":6532,"status":152,"phases":6574,"primaryCompletion":6534,"completion":6534,"start":6535,"enrollment":19,"conditions":6575,"interventions":6576},[89],[107],[6518,6538,6539,6540],{"trials":6578,"activeCount":98},[],{"intervention":6540,"totalTrials":109,"cells":6580},{"EARLY_PHASE1":6581,"PHASE1":6583,"PHASE2":6585,"PHASE3":6587,"PHASE4":6589,"NA":6595},{"trials":6582,"activeCount":98},[],{"trials":6584,"activeCount":98},[],{"trials":6586,"activeCount":98},[],{"trials":6588,"activeCount":98},[],{"trials":6590,"activeCount":98},[6591],{"nctId":6531,"briefTitle":6532,"status":152,"phases":6592,"primaryCompletion":6534,"completion":6534,"start":6535,"enrollment":19,"conditions":6593,"interventions":6594},[89],[107],[6518,6538,6539,6540],{"trials":6596,"activeCount":98},[],{"intervention":6598,"totalTrials":109,"cells":6599},"Nicoderm CQ nicotine patch",{"EARLY_PHASE1":6600,"PHASE1":6602,"PHASE2":6604,"PHASE3":6606,"PHASE4":6608,"NA":6617},{"trials":6601,"activeCount":98},[],{"trials":6603,"activeCount":98},[],{"trials":6605,"activeCount":98},[],{"trials":6607,"activeCount":98},[],{"trials":6609,"activeCount":98},[6610],{"nctId":6611,"briefTitle":6612,"status":152,"phases":6613,"primaryCompletion":726,"completion":726,"start":5894,"enrollment":728,"conditions":6614,"interventions":6615},"NCT00064844","Combination Nicotine Replacement for Alcoholic Smokers",[89],[33,1111],[6598,6616],"Nicotine gum - Nicorette®",{"trials":6618,"activeCount":98},[],{"intervention":6616,"totalTrials":109,"cells":6620},{"EARLY_PHASE1":6621,"PHASE1":6623,"PHASE2":6625,"PHASE3":6627,"PHASE4":6629,"NA":6635},{"trials":6622,"activeCount":98},[],{"trials":6624,"activeCount":98},[],{"trials":6626,"activeCount":98},[],{"trials":6628,"activeCount":98},[],{"trials":6630,"activeCount":98},[6631],{"nctId":6611,"briefTitle":6612,"status":152,"phases":6632,"primaryCompletion":726,"completion":726,"start":5894,"enrollment":728,"conditions":6633,"interventions":6634},[89],[33,1111],[6598,6616],{"trials":6636,"activeCount":98},[],{"intervention":6638,"totalTrials":109,"cells":6639},"Burosumab Injection [Crysvita]",{"EARLY_PHASE1":6640,"PHASE1":6642,"PHASE2":6644,"PHASE3":6646,"PHASE4":6648,"NA":6658},{"trials":6641,"activeCount":98},[],{"trials":6643,"activeCount":98},[],{"trials":6645,"activeCount":98},[],{"trials":6647,"activeCount":98},[],{"trials":6649,"activeCount":98},[6650],{"nctId":6651,"briefTitle":6652,"status":152,"phases":6653,"primaryCompletion":6654,"completion":6654,"start":3878,"enrollment":1315,"conditions":6655,"interventions":6657},"NCT04146935","Examining the Effect of Burosumab on Muscle Function",[89],"2022-08-25",[6656],"X-linked Hypophosphatemia",[6638],{"trials":6659,"activeCount":98},[],{"intervention":6661,"totalTrials":109,"cells":6662},"Ranolazine",{"EARLY_PHASE1":6663,"PHASE1":6665,"PHASE2":6667,"PHASE3":6669,"PHASE4":6671,"NA":6681},{"trials":6664,"activeCount":98},[],{"trials":6666,"activeCount":98},[],{"trials":6668,"activeCount":98},[],{"trials":6670,"activeCount":98},[],{"trials":6672,"activeCount":98},[6673],{"nctId":6674,"briefTitle":6675,"status":152,"phases":6676,"primaryCompletion":6677,"completion":6677,"start":4080,"enrollment":28,"conditions":6678,"interventions":6680},"NCT02052011","Ranolazine and Microvascular Angina by PET in the Emergency Department",[89],"2015-11",[6679],"Microvascular Angina",[6661],{"trials":6682,"activeCount":98},[],{"intervention":6684,"totalTrials":1246,"cells":6685},"Letrozole",{"EARLY_PHASE1":6686,"PHASE1":6688,"PHASE2":6700,"PHASE3":6710,"PHASE4":6731,"NA":6733},{"trials":6687,"activeCount":98},[],{"trials":6689,"activeCount":98},[6690],{"nctId":6691,"briefTitle":6692,"status":152,"phases":6693,"primaryCompletion":6694,"completion":6694,"start":6695,"enrollment":1257,"conditions":6696,"interventions":6698},"NCT04177693","Pharmacokinetics and Hepatic Safety of EGCG",[86],"2022-01-31","2020-11-24",[6697],"Uterine Fibroids",[6699,6684],"Clomiphene Citrate",{"trials":6701,"activeCount":98},[6702],{"nctId":6703,"briefTitle":6704,"status":711,"phases":6705,"primaryCompletion":6706,"completion":6706,"start":1984,"enrollment":303,"conditions":6707,"interventions":6709},"NCT00461773","Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer",[87],"2010-05",[6708,4403],"Hormone-Sensitive Breast Cancer",[6684,4050],{"trials":6711,"activeCount":98},[6712,6721],{"nctId":6713,"briefTitle":6714,"status":152,"phases":6715,"primaryCompletion":1210,"completion":1210,"start":1092,"enrollment":6716,"conditions":6717,"interventions":6719},"NCT00719186","Pregnancy in Polycystic Ovary Syndrome II",[88],750,[5540,6718],"Polycystic Ovary Syndrome",[6720,6684],"Clomiphene citrate",{"nctId":6722,"briefTitle":6723,"status":152,"phases":6724,"primaryCompletion":5721,"completion":326,"start":6725,"enrollment":6726,"conditions":6727,"interventions":6729},"NCT01044862","Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation",[88],"2010-06",900,[5540,6728],"Unexplained Infertility",[6684,6699,6730],"Follicle Stimulating Hormone",{"trials":6732,"activeCount":98},[],{"trials":6734,"activeCount":98},[],{"intervention":6736,"totalTrials":1246,"cells":6737},"Rapamycin",{"EARLY_PHASE1":6738,"PHASE1":6740,"PHASE2":6752,"PHASE3":6771,"PHASE4":6781,"NA":6783},{"trials":6739,"activeCount":98},[],{"trials":6741,"activeCount":98},[6742],{"nctId":6743,"briefTitle":6744,"status":711,"phases":6745,"primaryCompletion":6746,"completion":6746,"start":6747,"enrollment":1367,"conditions":6748,"interventions":6750},"NCT00402415","Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy",[86],"2008-07","2006-02",[6749],"Tumors",[6751,6736],"Sunitinib malate",{"trials":6753,"activeCount":98},[6754,6762],{"nctId":6755,"briefTitle":6756,"status":152,"phases":6757,"primaryCompletion":6706,"completion":6706,"start":1081,"enrollment":6758,"conditions":6759,"interventions":6760},"NCT00411788","A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer",[87],11,[4403],[6736,6761],"Trastuzumab",{"nctId":6763,"briefTitle":6764,"status":711,"phases":6765,"primaryCompletion":6766,"completion":6766,"start":1187,"enrollment":263,"conditions":6767,"interventions":6769},"NCT00623012","Rapamycin for Prevention of Chronic Graft-Versus-Host Disease",[86,87],"2013-08",[6768],"Graft Versus Host Disease",[6736,6770],"Tacrolimus",{"trials":6772,"activeCount":98},[6773],{"nctId":6774,"briefTitle":6775,"status":711,"phases":6776,"primaryCompletion":6777,"completion":6777,"start":1120,"enrollment":5030,"conditions":6778,"interventions":6780},"NCT00920309","Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy",[87,88],"2010-07",[6779],"Autosomal Dominant Polycystic Kidney Disease",[6736],{"trials":6782,"activeCount":98},[],{"trials":6784,"activeCount":98},[],{"intervention":6699,"totalTrials":94,"cells":6786},{"EARLY_PHASE1":6787,"PHASE1":6789,"PHASE2":6795,"PHASE3":6797,"PHASE4":6807,"NA":6809},{"trials":6788,"activeCount":98},[],{"trials":6790,"activeCount":98},[6791],{"nctId":6691,"briefTitle":6692,"status":152,"phases":6792,"primaryCompletion":6694,"completion":6694,"start":6695,"enrollment":1257,"conditions":6793,"interventions":6794},[86],[6697],[6699,6684],{"trials":6796,"activeCount":98},[],{"trials":6798,"activeCount":98},[6799,6803],{"nctId":6713,"briefTitle":6714,"status":152,"phases":6800,"primaryCompletion":1210,"completion":1210,"start":1092,"enrollment":6716,"conditions":6801,"interventions":6802},[88],[5540,6718],[6720,6684],{"nctId":6722,"briefTitle":6723,"status":152,"phases":6804,"primaryCompletion":5721,"completion":326,"start":6725,"enrollment":6726,"conditions":6805,"interventions":6806},[88],[5540,6728],[6684,6699,6730],{"trials":6808,"activeCount":98},[],{"trials":6810,"activeCount":98},[],{"intervention":1706,"totalTrials":94,"cells":6812},{"EARLY_PHASE1":6813,"PHASE1":6815,"PHASE2":6821,"PHASE3":6829,"PHASE4":6839,"NA":6841},{"trials":6814,"activeCount":98},[],{"trials":6816,"activeCount":98},[6817],{"nctId":1700,"briefTitle":1701,"status":711,"phases":6818,"primaryCompletion":1502,"completion":1502,"start":1441,"enrollment":94,"conditions":6819,"interventions":6820},[86],[1704],[1608,1706],{"trials":6822,"activeCount":98},[6823],{"nctId":6824,"briefTitle":6825,"status":1051,"phases":6826,"primaryCompletion":1053,"completion":1053,"start":1054,"enrollment":98,"conditions":6827,"interventions":6828},"NCT00000192","Neurobiology of Opioid Dependence: 1 - 1",[87],[157],[1706],{"trials":6830,"activeCount":98},[6831],{"nctId":6832,"briefTitle":6833,"status":1051,"phases":6834,"primaryCompletion":3858,"completion":3858,"start":1835,"enrollment":98,"conditions":6835,"interventions":6836},"NCT00571246","The Use of Anticonvulsants for Treatment of Patients With Alcohol Dependence and Post Traumatic Stress Disorder",[88],[1112,1688],[6837,6838],"Topiramate","lamotrigine",{"trials":6840,"activeCount":98},[],{"trials":6842,"activeCount":98},[],{"intervention":6844,"totalTrials":94,"cells":6845},"Glycine",{"EARLY_PHASE1":6846,"PHASE1":6848,"PHASE2":6850,"PHASE3":6868,"PHASE4":6878,"NA":6880},{"trials":6847,"activeCount":98},[],{"trials":6849,"activeCount":98},[],{"trials":6851,"activeCount":98},[6852,6859],{"nctId":6853,"briefTitle":6854,"status":152,"phases":6855,"primaryCompletion":1742,"completion":1742,"start":6856,"enrollment":118,"conditions":6857,"interventions":6858},"NCT00338598","Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism",[87],"2003-06",[1111,15],[6844],{"nctId":6860,"briefTitle":6861,"status":152,"phases":6862,"primaryCompletion":6863,"completion":6863,"start":6864,"enrollment":1315,"conditions":6865,"interventions":6866},"NCT00268749","Glycine Treatment of Prodromal Symptoms",[87],"2004-11","2002-07",[15],[6867],"glycine",{"trials":6869,"activeCount":98},[6870],{"nctId":6871,"briefTitle":6872,"status":152,"phases":6873,"primaryCompletion":1858,"completion":1858,"start":6874,"enrollment":1296,"conditions":6875,"interventions":6877},"NCT00291226","Glycine vs Placebo for the Schizophrenia Prodrome",[87,88],"2006-03",[6876],"Schizophrenia Prodrome",[6844],{"trials":6879,"activeCount":98},[],{"trials":6881,"activeCount":98},[],{"intervention":6883,"totalTrials":94,"cells":6884},"NB medication",{"EARLY_PHASE1":6885,"PHASE1":6887,"PHASE2":6889,"PHASE3":6891,"PHASE4":6922,"NA":6924},{"trials":6886,"activeCount":98},[],{"trials":6888,"activeCount":98},[],{"trials":6890,"activeCount":98},[],{"trials":6892,"activeCount":98},[6893,6903,6913],{"nctId":6894,"briefTitle":6895,"status":152,"phases":6896,"primaryCompletion":6897,"completion":6898,"start":6899,"enrollment":6900,"conditions":6901,"interventions":6902},"NCT03047005","Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy",[87,88],"2021-12-16","2022-12-16","2017-08-28",68,[688,18],[6883],{"nctId":6904,"briefTitle":6905,"status":152,"phases":6906,"primaryCompletion":6907,"completion":6898,"start":6908,"enrollment":6909,"conditions":6910,"interventions":6912},"NCT03045341","Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment",[87,88],"2021-07-23","2017-02-27",136,[6911,18],"Binge-eating Disorder",[6883],{"nctId":6914,"briefTitle":6915,"status":152,"phases":6916,"primaryCompletion":6917,"completion":6898,"start":6918,"enrollment":28,"conditions":6919,"interventions":6920},"NCT03063606","Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment",[87,88],"2021-12-01","2017-09-05",[688,18],[6921],"NB Medication",{"trials":6923,"activeCount":98},[],{"trials":6925,"activeCount":98},[],{"intervention":6927,"totalTrials":263,"cells":6928},"mecamylamine",{"EARLY_PHASE1":6929,"PHASE1":6931,"PHASE2":6933,"PHASE3":6942,"PHASE4":6951,"NA":6953},{"trials":6930,"activeCount":98},[],{"trials":6932,"activeCount":98},[],{"trials":6934,"activeCount":98},[6935],{"nctId":6936,"briefTitle":6937,"status":152,"phases":6938,"primaryCompletion":1148,"completion":1148,"start":6939,"enrollment":6909,"conditions":6940,"interventions":6941},"NCT00342563","Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients",[87],"2004-05",[1111],[6927],{"trials":6943,"activeCount":98},[6944],{"nctId":6945,"briefTitle":6946,"status":152,"phases":6947,"primaryCompletion":1848,"completion":1848,"start":1061,"enrollment":5030,"conditions":6948,"interventions":6949},"NCT00563797","Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence",[88],[1112,21],[6950],"Mecamylamine",{"trials":6952,"activeCount":98},[],{"trials":6954,"activeCount":98},[],{"intervention":6956,"totalTrials":263,"cells":6957},"Methotrexate",{"EARLY_PHASE1":6958,"PHASE1":6970,"PHASE2":6972,"PHASE3":6974,"PHASE4":6987,"NA":6989},{"trials":6959,"activeCount":98},[6960],{"nctId":6961,"briefTitle":6962,"status":152,"phases":6963,"primaryCompletion":2213,"completion":2213,"start":6964,"enrollment":1878,"conditions":6965,"interventions":6967},"NCT00612274","Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation",[85],"2007-10",[6966],"Stem Cell Transplantation",[6968,6969,6956],"tacrolimus","Sirolimus",{"trials":6971,"activeCount":98},[],{"trials":6973,"activeCount":98},[],{"trials":6975,"activeCount":98},[6976],{"nctId":6977,"briefTitle":6978,"status":152,"phases":6979,"primaryCompletion":5741,"completion":6980,"start":6981,"enrollment":6982,"conditions":6983,"interventions":6986},"NCT02152696","Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location",[88],"2019-08-19","2014-07-25",255,[6984,6985],"Persistent Pregnancy of Unknown Location","Ectopic Pregnancy",[6956],{"trials":6988,"activeCount":98},[],{"trials":6990,"activeCount":98},[],{"intervention":6992,"totalTrials":263,"cells":6993},"acamprosate",{"EARLY_PHASE1":6994,"PHASE1":6996,"PHASE2":6998,"PHASE3":7006,"PHASE4":7015,"NA":7017},{"trials":6995,"activeCount":98},[],{"trials":6997,"activeCount":98},[],{"trials":6999,"activeCount":98},[7000],{"nctId":7001,"briefTitle":7002,"status":152,"phases":7003,"completion":1655,"enrollment":3088,"conditions":7004,"interventions":7005},"NCT00004552","Acamprosate Treatment: Mechanisms of Action",[87],[1111],[6992],{"trials":7007,"activeCount":98},[7008],{"nctId":7009,"briefTitle":7010,"status":152,"phases":7011,"primaryCompletion":1148,"completion":1148,"start":5871,"enrollment":1609,"conditions":7012,"interventions":7013},"NCT00463346","Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism",[88],[1112,15],[7014],"Acamprosate",{"trials":7016,"activeCount":98},[],{"trials":7018,"activeCount":98},[],{"intervention":7020,"totalTrials":263,"cells":7021},"D-serine",{"EARLY_PHASE1":7022,"PHASE1":7024,"PHASE2":7026,"PHASE3":7028,"PHASE4":7045,"NA":7047},{"trials":7023,"activeCount":98},[],{"trials":7025,"activeCount":98},[],{"trials":7027,"activeCount":98},[],{"trials":7029,"activeCount":98},[7030,7038],{"nctId":7031,"briefTitle":7032,"status":152,"phases":7033,"start":7034,"enrollment":7035,"conditions":7036,"interventions":7037},"NCT00237848","D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia",[88],"2005-02",72,[15,1213],[7020],{"nctId":7039,"briefTitle":7040,"status":152,"phases":7041,"primaryCompletion":1673,"completion":1908,"start":7042,"enrollment":6277,"conditions":7043,"interventions":7044},"NCT00237809","D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia",[88],"2002-09",[15,1213],[7020],{"trials":7046,"activeCount":98},[],{"trials":7048,"activeCount":98},[],{"intervention":7050,"totalTrials":109,"cells":7051},"BHV-0223",{"EARLY_PHASE1":7052,"PHASE1":7054,"PHASE2":7056,"PHASE3":7058,"PHASE4":7068,"NA":7070},{"trials":7053,"activeCount":98},[],{"trials":7055,"activeCount":98},[],{"trials":7057,"activeCount":98},[],{"trials":7059,"activeCount":98},[7060],{"nctId":7061,"briefTitle":7062,"status":152,"phases":7063,"primaryCompletion":2319,"completion":7064,"start":1091,"enrollment":1289,"conditions":7065,"interventions":7067},"NCT03017508","Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder",[87,88],"2021-01-29",[1629,7066],"Performance Anxiety",[7050],{"trials":7069,"activeCount":98},[],{"trials":7071,"activeCount":98},[],{"intervention":7073,"totalTrials":109,"cells":7074},"Fermented Soy",{"EARLY_PHASE1":7075,"PHASE1":7077,"PHASE2":7079,"PHASE3":7081,"PHASE4":7091,"NA":7093},{"trials":7076,"activeCount":98},[],{"trials":7078,"activeCount":98},[],{"trials":7080,"activeCount":98},[],{"trials":7082,"activeCount":98},[7083],{"nctId":7084,"briefTitle":7085,"status":711,"phases":7086,"primaryCompletion":7087,"completion":7087,"start":7088,"enrollment":1020,"conditions":7089,"interventions":7090},"NCT03532308","Nutrition and Prostate Cancer",[88],"2019-12-14","2018-11-21",[2615],[7073],{"trials":7092,"activeCount":98},[],{"trials":7094,"activeCount":98},[],{"intervention":1154,"totalTrials":109,"cells":7096},{"EARLY_PHASE1":7097,"PHASE1":7099,"PHASE2":7101,"PHASE3":7103,"PHASE4":7109,"NA":7111},{"trials":7098,"activeCount":98},[],{"trials":7100,"activeCount":98},[],{"trials":7102,"activeCount":98},[],{"trials":7104,"activeCount":98},[7105],{"nctId":1145,"briefTitle":1146,"status":152,"phases":7106,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":7107,"interventions":7108},[88],[1111,21,1152],[1154,1155,890],{"trials":7110,"activeCount":98},[],{"trials":7112,"activeCount":98},[],{"intervention":1155,"totalTrials":109,"cells":7114},{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7119,"PHASE3":7121,"PHASE4":7127,"NA":7129},{"trials":7116,"activeCount":98},[],{"trials":7118,"activeCount":98},[],{"trials":7120,"activeCount":98},[],{"trials":7122,"activeCount":98},[7123],{"nctId":1145,"briefTitle":1146,"status":152,"phases":7124,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":7125,"interventions":7126},[88],[1111,21,1152],[1154,1155,890],{"trials":7128,"activeCount":98},[],{"trials":7130,"activeCount":98},[],{"intervention":7132,"totalTrials":109,"cells":7133},"Orlistat",{"EARLY_PHASE1":7134,"PHASE1":7136,"PHASE2":7138,"PHASE3":7140,"PHASE4":7152,"NA":7154},{"trials":7135,"activeCount":98},[],{"trials":7137,"activeCount":98},[],{"trials":7139,"activeCount":98},[],{"trials":7141,"activeCount":98},[7142],{"nctId":7143,"briefTitle":7144,"status":152,"phases":7145,"primaryCompletion":7146,"completion":7147,"start":179,"enrollment":7148,"conditions":7149,"interventions":7151},"NCT02432209","Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility",[88],"2019-11-30","2020-05",379,[7150],"Infertility, Female",[7132],{"trials":7153,"activeCount":98},[],{"trials":7155,"activeCount":98},[],{"intervention":6837,"totalTrials":109,"cells":7157},{"EARLY_PHASE1":7158,"PHASE1":7160,"PHASE2":7162,"PHASE3":7164,"PHASE4":7170,"NA":7172},{"trials":7159,"activeCount":98},[],{"trials":7161,"activeCount":98},[],{"trials":7163,"activeCount":98},[],{"trials":7165,"activeCount":98},[7166],{"nctId":6832,"briefTitle":6833,"status":1051,"phases":7167,"primaryCompletion":3858,"completion":3858,"start":1835,"enrollment":98,"conditions":7168,"interventions":7169},[88],[1112,1688],[6837,6838],{"trials":7171,"activeCount":98},[],{"trials":7173,"activeCount":98},[],{"intervention":7175,"totalTrials":109,"cells":7176},"ethyl-eicosapentaenoic acid",{"EARLY_PHASE1":7177,"PHASE1":7179,"PHASE2":7181,"PHASE3":7183,"PHASE4":7192,"NA":7194},{"trials":7178,"activeCount":98},[],{"trials":7180,"activeCount":98},[],{"trials":7182,"activeCount":98},[],{"trials":7184,"activeCount":98},[7185],{"nctId":7186,"briefTitle":7187,"status":152,"phases":7188,"primaryCompletion":1106,"completion":1106,"start":7189,"enrollment":1466,"conditions":7190,"interventions":7191},"NCT00634361","Ethyl-EPA Treatment of Prodromal Patients",[87,88],"2001-09",[6876],[7175],{"trials":7193,"activeCount":98},[],{"trials":7195,"activeCount":98},[],{"intervention":7197,"totalTrials":109,"cells":7198},"pioglitazone",{"EARLY_PHASE1":7199,"PHASE1":7201,"PHASE2":7203,"PHASE3":7205,"PHASE4":7217,"NA":7219},{"trials":7200,"activeCount":98},[],{"trials":7202,"activeCount":98},[],{"trials":7204,"activeCount":98},[],{"trials":7206,"activeCount":98},[7207],{"nctId":7208,"briefTitle":7209,"status":152,"phases":7210,"primaryCompletion":6677,"completion":6677,"start":7034,"enrollment":7211,"conditions":7212,"interventions":7216},"NCT00091949","Insulin Resistance Intervention After Stroke Trial",[88],3876,[7213,7214,7215],"Stroke","Myocardial Infarction","Diabetes",[7197],{"trials":7218,"activeCount":98},[],{"trials":7220,"activeCount":98},[],{"intervention":7222,"totalTrials":109,"cells":7223},"Dietary Supplement containing resistant starch",{"EARLY_PHASE1":7224,"PHASE1":7226,"PHASE2":7228,"PHASE3":7230,"PHASE4":7242,"NA":7244},{"trials":7225,"activeCount":98},[],{"trials":7227,"activeCount":98},[],{"trials":7229,"activeCount":98},[],{"trials":7231,"activeCount":98},[7232],{"nctId":7233,"briefTitle":7234,"status":711,"phases":7235,"primaryCompletion":7236,"completion":7236,"start":7237,"enrollment":7238,"conditions":7239,"interventions":7241},"NCT04342689","The Role of Resistant Starch in COVID-19 Infection",[87,88],"2021-04-15","2020-06-03",226,[7240],"COVID-19",[7222],{"trials":7243,"activeCount":98},[],{"trials":7245,"activeCount":98},[],{"intervention":7247,"totalTrials":109,"cells":7248},"Lidocaine patch",{"EARLY_PHASE1":7249,"PHASE1":7251,"PHASE2":7253,"PHASE3":7255,"PHASE4":7267,"NA":7269},{"trials":7250,"activeCount":98},[],{"trials":7252,"activeCount":98},[],{"trials":7254,"activeCount":98},[],{"trials":7256,"activeCount":98},[7257],{"nctId":7258,"briefTitle":7259,"status":152,"phases":7260,"primaryCompletion":7261,"completion":7261,"start":7262,"enrollment":7263,"conditions":7264,"interventions":7266},"NCT04443569","Lidocaine Patches After Cesarean Section",[88],"2022-08-31","2021-10-10",93,[4093,7265,6301],"Obstetric Pain",[7247],{"trials":7268,"activeCount":98},[],{"trials":7270,"activeCount":98},[],{"intervention":7272,"totalTrials":109,"cells":7273},"mitomycin C",{"EARLY_PHASE1":7274,"PHASE1":7276,"PHASE2":7278,"PHASE3":7280,"PHASE4":7293,"NA":7295},{"trials":7275,"activeCount":98},[],{"trials":7277,"activeCount":98},[],{"trials":7279,"activeCount":98},[],{"trials":7281,"activeCount":98},[7282],{"nctId":7283,"briefTitle":7284,"status":152,"phases":7285,"primaryCompletion":7286,"completion":7286,"start":7287,"conditions":7288,"interventions":7291},"NCT00002507","Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer",[88],"2002-10","1992-11",[7289,7290],"Carcinoma of Unknown Primary","Head and Neck Cancer",[7272,7292],"porfiromycin",{"trials":7294,"activeCount":98},[],{"trials":7296,"activeCount":98},[],{"intervention":7292,"totalTrials":109,"cells":7298},{"EARLY_PHASE1":7299,"PHASE1":7301,"PHASE2":7303,"PHASE3":7305,"PHASE4":7311,"NA":7313},{"trials":7300,"activeCount":98},[],{"trials":7302,"activeCount":98},[],{"trials":7304,"activeCount":98},[],{"trials":7306,"activeCount":98},[7307],{"nctId":7283,"briefTitle":7284,"status":152,"phases":7308,"primaryCompletion":7286,"completion":7286,"start":7287,"conditions":7309,"interventions":7310},[88],[7289,7290],[7272,7292],{"trials":7312,"activeCount":98},[],{"trials":7314,"activeCount":98},[],{"intervention":7316,"totalTrials":109,"cells":7317},"Aripiprazole",{"EARLY_PHASE1":7318,"PHASE1":7320,"PHASE2":7322,"PHASE3":7324,"PHASE4":7333,"NA":7335},{"trials":7319,"activeCount":98},[],{"trials":7321,"activeCount":98},[],{"trials":7323,"activeCount":98},[],{"trials":7325,"activeCount":98},[7326],{"nctId":7327,"briefTitle":7328,"status":152,"phases":7329,"primaryCompletion":7330,"completion":7330,"start":197,"enrollment":141,"conditions":7331,"interventions":7332},"NCT00237874","Aripiprazole Treatment of Prodromal Patients",[87,88],"2007-02",[15,4998],[7316],{"trials":7334,"activeCount":98},[],{"trials":7336,"activeCount":98},[],{"intervention":7338,"totalTrials":109,"cells":7339},"Botox",{"EARLY_PHASE1":7340,"PHASE1":7342,"PHASE2":7344,"PHASE3":7346,"PHASE4":7356,"NA":7358},{"trials":7341,"activeCount":98},[],{"trials":7343,"activeCount":98},[],{"trials":7345,"activeCount":98},[],{"trials":7347,"activeCount":98},[7348],{"nctId":7349,"briefTitle":7350,"status":152,"phases":7351,"primaryCompletion":7352,"completion":1148,"start":1138,"enrollment":1512,"conditions":7353,"interventions":7355},"NCT00660192","Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches",[87,88],"2012-07",[7354],"Refractory Migraine",[7338],{"trials":7357,"activeCount":98},[],{"trials":7359,"activeCount":98},[],{"intervention":7361,"totalTrials":109,"cells":7362},"Furosemide",{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7367,"PHASE3":7369,"PHASE4":7380,"NA":7382},{"trials":7364,"activeCount":98},[],{"trials":7366,"activeCount":98},[],{"trials":7368,"activeCount":98},[],{"trials":7370,"activeCount":98},[7371],{"nctId":7372,"briefTitle":7373,"status":152,"phases":7374,"primaryCompletion":7375,"completion":7375,"start":7376,"enrollment":16,"conditions":7377,"interventions":7378},"NCT05093621","Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure",[88],"2023-06-30","2021-02-08",[107],[7361,7379],"Torsemide",{"trials":7381,"activeCount":98},[],{"trials":7383,"activeCount":98},[],{"intervention":7379,"totalTrials":109,"cells":7385},{"EARLY_PHASE1":7386,"PHASE1":7388,"PHASE2":7390,"PHASE3":7392,"PHASE4":7398,"NA":7400},{"trials":7387,"activeCount":98},[],{"trials":7389,"activeCount":98},[],{"trials":7391,"activeCount":98},[],{"trials":7393,"activeCount":98},[7394],{"nctId":7372,"briefTitle":7373,"status":152,"phases":7395,"primaryCompletion":7375,"completion":7375,"start":7376,"enrollment":16,"conditions":7396,"interventions":7397},[88],[107],[7361,7379],{"trials":7399,"activeCount":98},[],{"trials":7401,"activeCount":98},[],{"intervention":7403,"totalTrials":109,"cells":7404},"Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination",{"EARLY_PHASE1":7405,"PHASE1":7407,"PHASE2":7409,"PHASE3":7411,"PHASE4":7423,"NA":7425},{"trials":7406,"activeCount":98},[],{"trials":7408,"activeCount":98},[],{"trials":7410,"activeCount":98},[],{"trials":7412,"activeCount":98},[7413],{"nctId":7414,"briefTitle":7415,"status":152,"phases":7416,"primaryCompletion":7417,"completion":7418,"start":7419,"enrollment":7420,"conditions":7421,"interventions":7422},"NCT03539900","Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder",[87,88],"2022-04-19","2023-03-22","2018-04-17",89,[688],[7403],{"trials":7424,"activeCount":98},[],{"trials":7426,"activeCount":98},[],{"intervention":6730,"totalTrials":109,"cells":7428},{"EARLY_PHASE1":7429,"PHASE1":7431,"PHASE2":7433,"PHASE3":7435,"PHASE4":7441,"NA":7443},{"trials":7430,"activeCount":98},[],{"trials":7432,"activeCount":98},[],{"trials":7434,"activeCount":98},[],{"trials":7436,"activeCount":98},[7437],{"nctId":6722,"briefTitle":6723,"status":152,"phases":7438,"primaryCompletion":5721,"completion":326,"start":6725,"enrollment":6726,"conditions":7439,"interventions":7440},[88],[5540,6728],[6684,6699,6730],{"trials":7442,"activeCount":98},[],{"trials":7444,"activeCount":98},[],{"intervention":7446,"totalTrials":109,"cells":7447},"Early Non-responder: BWL continued with medication added",{"EARLY_PHASE1":7448,"PHASE1":7450,"PHASE2":7452,"PHASE3":7454,"PHASE4":7465,"NA":7467},{"trials":7449,"activeCount":98},[],{"trials":7451,"activeCount":98},[],{"trials":7453,"activeCount":98},[],{"trials":7455,"activeCount":98},[7456],{"nctId":7457,"briefTitle":7458,"status":152,"phases":7459,"primaryCompletion":7460,"completion":7460,"start":7461,"enrollment":1878,"conditions":7462,"interventions":7464},"NCT04662801","Weight Regain Treatment Post-Bariatric Surgery",[87,88],"2022-09-13","2021-08-05",[7463],"Obesity, Overweight",[7446],{"trials":7466,"activeCount":98},[],{"trials":7468,"activeCount":98},[],{"intervention":7470,"totalTrials":109,"cells":7471},"Standard of Care (SOC) and Colchicine+Rosuvastatin",{"EARLY_PHASE1":7472,"PHASE1":7474,"PHASE2":7476,"PHASE3":7478,"PHASE4":7489,"NA":7491},{"trials":7473,"activeCount":98},[],{"trials":7475,"activeCount":98},[],{"trials":7477,"activeCount":98},[],{"trials":7479,"activeCount":98},[7480],{"nctId":7481,"briefTitle":7482,"status":152,"phases":7483,"primaryCompletion":7484,"completion":7484,"start":7485,"enrollment":616,"conditions":7486,"interventions":7488},"NCT04472611","Colchicine\u002FStatins for the Prevention of COVID-19 Complications (COLSTAT) Trial",[88],"2022-03-30","2020-10-30",[7487],"SARS-CoV-2",[7470],{"trials":7490,"activeCount":98},[],{"trials":7492,"activeCount":98},[],{"intervention":7494,"totalTrials":109,"cells":7495},"Paricalcitol",{"EARLY_PHASE1":7496,"PHASE1":7498,"PHASE2":7500,"PHASE3":7502,"PHASE4":7513,"NA":7515},{"trials":7497,"activeCount":98},[],{"trials":7499,"activeCount":98},[],{"trials":7501,"activeCount":98},[],{"trials":7503,"activeCount":98},[7504],{"nctId":7505,"briefTitle":7506,"status":152,"phases":7507,"primaryCompletion":7508,"completion":7508,"start":271,"enrollment":987,"conditions":7509,"interventions":7512},"NCT00417612","Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets",[88],"2012-08",[7510,7511],"Hypophosphatemia, Familial","Hyperparathyroidism",[7494],{"trials":7514,"activeCount":98},[],{"trials":7516,"activeCount":98},[],{"intervention":7518,"totalTrials":109,"cells":7519},"Melatonin",{"EARLY_PHASE1":7520,"PHASE1":7522,"PHASE2":7524,"PHASE3":7526,"PHASE4":7538,"NA":7540},{"trials":7521,"activeCount":98},[],{"trials":7523,"activeCount":98},[],{"trials":7525,"activeCount":98},[],{"trials":7527,"activeCount":98},[7528],{"nctId":7529,"briefTitle":7530,"status":711,"phases":7531,"primaryCompletion":7532,"completion":7532,"start":7533,"enrollment":7534,"conditions":7535,"interventions":7537},"NCT02654314","Prevention of Delirium in Inpatients Utilizing Melatonin",[88],"2017-11-03","2016-07",277,[7536],"Delirium",[7518],{"trials":7539,"activeCount":98},[],{"trials":7541,"activeCount":98},[],{"intervention":7543,"totalTrials":109,"cells":7544},"Naltrexone and Bupropion",{"EARLY_PHASE1":7545,"PHASE1":7547,"PHASE2":7549,"PHASE3":7551,"PHASE4":7559,"NA":7561},{"trials":7546,"activeCount":98},[],{"trials":7548,"activeCount":98},[],{"trials":7550,"activeCount":98},[],{"trials":7552,"activeCount":98},[7553],{"nctId":7554,"briefTitle":7555,"status":152,"phases":7556,"primaryCompletion":4044,"completion":4044,"start":695,"enrollment":94,"conditions":7557,"interventions":7558},"NCT03946111","Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders",[87,88],[688,18],[7543],{"trials":7560,"activeCount":98},[],{"trials":7562,"activeCount":98},[],{"intervention":1170,"totalTrials":109,"cells":7564},{"EARLY_PHASE1":7565,"PHASE1":7567,"PHASE2":7569,"PHASE3":7571,"PHASE4":7577,"NA":7579},{"trials":7566,"activeCount":98},[],{"trials":7568,"activeCount":98},[],{"trials":7570,"activeCount":98},[],{"trials":7572,"activeCount":98},[7573],{"nctId":1161,"briefTitle":1162,"status":152,"phases":7574,"primaryCompletion":1164,"completion":1165,"start":1166,"enrollment":1167,"conditions":7575,"interventions":7576},[88],[183],[1170,890],{"trials":7578,"activeCount":98},[],{"trials":7580,"activeCount":98},[],{"intervention":7582,"totalTrials":1416,"cells":7583},"N-Acetylcysteine",{"EARLY_PHASE1":7584,"PHASE1":7596,"PHASE2":7598,"PHASE3":7637,"PHASE4":7639,"NA":7641},{"trials":7585,"activeCount":98},[7586],{"nctId":7587,"briefTitle":7588,"status":711,"phases":7589,"primaryCompletion":7590,"completion":7590,"start":7591,"enrollment":303,"conditions":7592,"interventions":7593},"NCT02335060","N-acetylcysteine Effects on Tetrahydrocannabinol",[85],"2014-09-16","2014-05-02",[3590],[7594,7595],"Delta-9-THC","N-acetylcysteine",{"trials":7597,"activeCount":98},[],{"trials":7599,"activeCount":98},[7600,7607,7615,7621,7629],{"nctId":7601,"briefTitle":7602,"status":711,"phases":7603,"primaryCompletion":1176,"completion":1176,"start":7604,"enrollment":1315,"conditions":7605,"interventions":7606},"NCT00539513","N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder",[87],"2006-06",[1336],[7582],{"nctId":7608,"briefTitle":7609,"status":152,"phases":7610,"primaryCompletion":5225,"completion":5225,"start":6777,"enrollment":28,"conditions":7611,"interventions":7614},"NCT01172288","N-acetylcysteine (NAC) for Children With Tourette Syndrome",[87],[7612,7613],"Tourettes Syndrome","Tic",[7582],{"nctId":7616,"briefTitle":7617,"status":152,"phases":7618,"primaryCompletion":5776,"completion":1733,"start":7352,"enrollment":6758,"conditions":7619,"interventions":7620},"NCT01172275","N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder",[87],[1336],[7582],{"nctId":7622,"briefTitle":7623,"status":711,"phases":7624,"primaryCompletion":7625,"completion":7625,"start":6276,"enrollment":1416,"conditions":7626,"interventions":7628},"NCT00539188","N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD",[87],"2010-11",[1735,7627],"Self-Injurious Behavior",[7582],{"nctId":7630,"briefTitle":7631,"status":152,"phases":7632,"primaryCompletion":5846,"completion":326,"start":1072,"enrollment":1257,"conditions":7633,"interventions":7636},"NCT00993265","N-Acetylcysteine for Pediatric Trichotillomania",[87],[7634,7635],"Trichotillomania","Hair Pulling",[7582],{"trials":7638,"activeCount":98},[],{"trials":7640,"activeCount":98},[],{"trials":7642,"activeCount":98},[],{"intervention":4050,"totalTrials":303,"cells":7644},{"EARLY_PHASE1":7645,"PHASE1":7647,"PHASE2":7649,"PHASE3":7690,"PHASE4":7692,"NA":7694},{"trials":7646,"activeCount":98},[],{"trials":7648,"activeCount":98},[],{"trials":7650,"activeCount":98},[7651,7663,7673,7677,7681],{"nctId":7652,"briefTitle":7653,"status":152,"phases":7654,"primaryCompletion":7655,"completion":7655,"start":7656,"enrollment":7657,"conditions":7658,"interventions":7661},"NCT03093155","Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab",[87],"2022-12-29","2017-04-03",78,[7659,2234,7660],"Epithelial Ovarian Cancer","Primary Peritoneal Cancer",[7662,4050],"Ixabepilone",{"nctId":7664,"briefTitle":7665,"status":152,"phases":7666,"primaryCompletion":1031,"completion":1031,"start":164,"enrollment":1878,"conditions":7667,"interventions":7669},"NCT00335829","Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery",[87],[7668],"Liver Cancer",[7670,7671,7672],"bevacizumab","chemotherapy","embolization therapy",{"nctId":6703,"briefTitle":6704,"status":711,"phases":7674,"primaryCompletion":6706,"completion":6706,"start":1984,"enrollment":303,"conditions":7675,"interventions":7676},[87],[6708,4403],[6684,4050],{"nctId":4041,"briefTitle":4042,"status":711,"phases":7678,"primaryCompletion":4044,"completion":4044,"start":4045,"enrollment":94,"conditions":7679,"interventions":7680},[87],[4047,4048],[4013,4050,4051],{"nctId":7682,"briefTitle":7683,"status":152,"phases":7684,"primaryCompletion":1210,"completion":1848,"start":327,"enrollment":1257,"conditions":7685,"interventions":7688},"NCT00673673","FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer",[87],[7686,7687],"Gastroesophageal Cancer","Gastric Cancer",[7689,7670],"FOLFOX",{"trials":7691,"activeCount":98},[],{"trials":7693,"activeCount":98},[],{"trials":7695,"activeCount":98},[],{"intervention":7697,"totalTrials":303,"cells":7698},"Sorafenib",{"EARLY_PHASE1":7699,"PHASE1":7701,"PHASE2":7720,"PHASE3":7748,"PHASE4":7750,"NA":7752},{"trials":7700,"activeCount":98},[],{"trials":7702,"activeCount":98},[7703,7713],{"nctId":7704,"briefTitle":7705,"status":152,"phases":7706,"primaryCompletion":7707,"completion":7707,"start":7352,"enrollment":2659,"conditions":7708,"interventions":7711},"NCT01640665","Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors",[86],"2014-08",[7709,7710],"Metastatic Breast Cancer","Gastrointestinal Tumors",[7697,7712],"Capecitabine",{"nctId":7714,"briefTitle":7715,"status":152,"phases":7716,"primaryCompletion":1210,"completion":7717,"start":1072,"enrollment":272,"conditions":7718,"interventions":7719},"NCT01561833","A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients",[86],"2013-06",[3698],[7697],{"trials":7721,"activeCount":98},[7722,7730,7739],{"nctId":7723,"briefTitle":7724,"status":152,"phases":7725,"primaryCompletion":218,"completion":218,"start":1092,"enrollment":1305,"conditions":7726,"interventions":7728},"NCT00844883","Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma",[87],[4047,7727],"Hepatoma",[7729],"sorafenib",{"nctId":7731,"briefTitle":7732,"status":152,"phases":7733,"primaryCompletion":6766,"completion":6766,"start":1984,"enrollment":1815,"conditions":7734,"interventions":7736},"NCT00461851","Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced\u002FMetastatic Bladder Carcinoma",[87],[7735],"Bladder Cancer",[7737,7738,7697],"Gemcitabine","Carboplatin",{"nctId":7740,"briefTitle":7741,"status":152,"phases":7742,"primaryCompletion":5742,"completion":7743,"start":7744,"enrollment":1315,"conditions":7745,"interventions":7747},"NCT01714609","The Effect of Sorafenib on Portal Pressure",[87],"2014-09","2011-08",[7746],"Clinically Significant Portal Hypertension",[7697],{"trials":7749,"activeCount":98},[],{"trials":7751,"activeCount":98},[],{"trials":7753,"activeCount":98},[],{"intervention":7755,"totalTrials":1246,"cells":7756},"filgrastim",{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7770,"PHASE3":7803,"PHASE4":7805,"NA":7807},{"trials":7758,"activeCount":98},[],{"trials":7760,"activeCount":98},[7761],{"nctId":7762,"briefTitle":7763,"status":711,"phases":7764,"primaryCompletion":7765,"completion":7765,"start":7766,"conditions":7767,"interventions":7768},"NCT00002948","High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer",[86],"2004-01","1996-10",[2258],[7755,7769],"topotecan hydrochloride",{"trials":7771,"activeCount":98},[7772,7782,7794],{"nctId":7773,"briefTitle":7774,"status":152,"phases":7775,"primaryCompletion":7776,"completion":7776,"start":7777,"enrollment":272,"conditions":7778,"interventions":7780},"NCT00002635","Aminocamptothecin in Treating Patients With T-cell Lymphoma",[87],"2000-04","1995-05",[7779],"Lymphoma",[7755,7781],"aminocamptothecin",{"nctId":7783,"briefTitle":7784,"status":152,"phases":7785,"primaryCompletion":1198,"completion":1198,"start":7786,"enrollment":1044,"conditions":7787,"interventions":7788},"NCT00002680","Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer",[87],"1994-02",[4403],[7755,7789,7790,7791,7792,7793],"cyclophosphamide","megestrol acetate","melphalan","tamoxifen citrate","thiotepa",{"nctId":7795,"briefTitle":7796,"status":152,"phases":7797,"primaryCompletion":7798,"completion":7798,"start":7786,"enrollment":7420,"conditions":7799,"interventions":7800},"NCT00002679","Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer",[87],"2002-01",[4403],[7755,7789,7801,7802,7792],"doxorubicin hydrochloride","paclitaxel",{"trials":7804,"activeCount":98},[],{"trials":7806,"activeCount":98},[],{"trials":7808,"activeCount":98},[],{"intervention":7810,"totalTrials":1246,"cells":7811},"Cannabidiol",{"EARLY_PHASE1":7812,"PHASE1":7832,"PHASE2":7834,"PHASE3":7852,"PHASE4":7854,"NA":7856},{"trials":7813,"activeCount":98},[7814,7824],{"nctId":7815,"briefTitle":7816,"status":152,"phases":7817,"primaryCompletion":7818,"completion":7818,"start":7819,"enrollment":1020,"conditions":7820,"interventions":7823},"NCT04777643","Sex Differences in Neural Response to Cannabidiol",[85],"2023-04-27","2022-06-07",[7821,7822],"CBD","Neural Responses",[7810],{"nctId":7825,"briefTitle":7826,"status":152,"phases":7827,"primaryCompletion":7828,"completion":7828,"start":7829,"enrollment":314,"conditions":7830,"interventions":7831},"NCT01180374","The Effects of Cannabidiol and ∆-9-THC in Humans",[85],"2014-10-06","2010-02-01",[3590],[7810,7594],{"trials":7833,"activeCount":98},[],{"trials":7835,"activeCount":98},[7836,7845],{"nctId":7837,"briefTitle":7838,"status":152,"phases":7839,"primaryCompletion":7840,"completion":7841,"start":7842,"enrollment":1367,"conditions":7843,"interventions":7844},"NCT02504151","Cannabidiol Treatment in Patients With Early Psychosis",[87],"2018-03-02","2018-03-09","2016-01-28",[15,1213],[7810],{"nctId":7846,"briefTitle":7847,"status":152,"phases":7848,"primaryCompletion":1887,"completion":1887,"start":1092,"enrollment":7849,"conditions":7850,"interventions":7851},"NCT00588731","Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia",[87],41,[15,1213],[7810],{"trials":7853,"activeCount":98},[],{"trials":7855,"activeCount":98},[],{"trials":7857,"activeCount":98},[],{"intervention":6761,"totalTrials":1246,"cells":7859},{"EARLY_PHASE1":7860,"PHASE1":7862,"PHASE2":7864,"PHASE3":7900,"PHASE4":7902,"NA":7904},{"trials":7861,"activeCount":98},[],{"trials":7863,"activeCount":98},[],{"trials":7865,"activeCount":98},[7866,7876,7880,7892],{"nctId":7867,"briefTitle":7868,"status":152,"phases":7869,"primaryCompletion":7870,"completion":7870,"start":7871,"enrollment":696,"conditions":7872,"interventions":7874},"NCT01367002","Evaluation of Carboplatin\u002FPaclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer",[87],"2022-06-30","2011-06",[7873],"Endometrial Cancer",[7875,6761],"Carboplatin\u002FPaclitaxel",{"nctId":6755,"briefTitle":6756,"status":152,"phases":7877,"primaryCompletion":6706,"completion":6706,"start":1081,"enrollment":6758,"conditions":7878,"interventions":7879},[87],[4403],[6736,6761],{"nctId":7881,"briefTitle":7882,"status":152,"phases":7883,"primaryCompletion":2194,"completion":2194,"start":5742,"enrollment":1305,"conditions":7884,"interventions":7886},"NCT01855828","Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer",[87],[7885],"Her2-Positive Breast Cancer",[7887,6761,7888,7889,7890,7891],"Pertuzumab","Paclitaxel","5-fluorouracil","Epirubicin","Cyclophosphamide",{"nctId":7893,"briefTitle":7894,"status":1051,"phases":7895,"primaryCompletion":7743,"completion":1973,"start":7744,"enrollment":98,"conditions":7896,"interventions":7898},"NCT01427244","Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease",[87],[7897],"Paget's Disease of the Vulva",[7899],"trastuzumab",{"trials":7901,"activeCount":98},[],{"trials":7903,"activeCount":98},[],{"trials":7905,"activeCount":98},[],{"intervention":2543,"totalTrials":1246,"cells":7907},{"EARLY_PHASE1":7908,"PHASE1":7914,"PHASE2":7933,"PHASE3":7945,"PHASE4":7947,"NA":7949},{"trials":7909,"activeCount":98},[7910],{"nctId":2535,"briefTitle":2536,"status":152,"phases":7911,"primaryCompletion":2538,"completion":2538,"start":2539,"enrollment":2540,"conditions":7912,"interventions":7913},[85],[210],[2530,2543],{"trials":7915,"activeCount":98},[7916,7925],{"nctId":7917,"briefTitle":7918,"status":152,"phases":7919,"primaryCompletion":7920,"completion":7920,"start":7921,"enrollment":6758,"conditions":7922,"interventions":7923},"NCT03708315","BXCL501 for Agitation in Schizophrenia",[86],"2023-05-26","2020-03-09",[15,1213],[7924,2543],"Dexmedetomidine Hydrochloride",{"nctId":7926,"briefTitle":7927,"status":152,"phases":7928,"primaryCompletion":7929,"completion":7929,"start":313,"enrollment":1315,"conditions":7930,"interventions":7931},"NCT04015869","Effect of Allopregnanolone on Stress-induced Craving",[86],"2023-09-01",[27],[7932,2543],"Allopregnanolone",{"trials":7934,"activeCount":98},[7935],{"nctId":7936,"briefTitle":7937,"status":152,"phases":7938,"primaryCompletion":7939,"completion":7940,"start":7941,"enrollment":1305,"conditions":7942,"interventions":7943},"NCT02955186","Saracatinib and Alcohol Drinking",[87],"2019-04-24","2019-06-07","2017-05-09",[1034],[7944,2543],"Saracatinib",{"trials":7946,"activeCount":98},[],{"trials":7948,"activeCount":98},[],{"trials":7950,"activeCount":98},[],{"intervention":7802,"totalTrials":1246,"cells":7952},{"EARLY_PHASE1":7953,"PHASE1":7955,"PHASE2":7957,"PHASE3":7985,"PHASE4":7987,"NA":7989},{"trials":7954,"activeCount":98},[],{"trials":7956,"activeCount":98},[],{"trials":7958,"activeCount":98},[7959,7963,7971,7975],{"nctId":7795,"briefTitle":7796,"status":152,"phases":7960,"primaryCompletion":7798,"completion":7798,"start":7786,"enrollment":7420,"conditions":7961,"interventions":7962},[87],[4403],[7755,7789,7801,7802,7792],{"nctId":7964,"briefTitle":7965,"status":152,"phases":7966,"completion":6747,"start":7967,"enrollment":1743,"conditions":7968,"interventions":7970},"NCT00004924","Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer",[87],"1999-03",[7969],"Lung Cancer",[2260,7802],{"nctId":7881,"briefTitle":7882,"status":152,"phases":7972,"primaryCompletion":2194,"completion":2194,"start":5742,"enrollment":1305,"conditions":7973,"interventions":7974},[87],[7885],[7887,6761,7888,7889,7890,7891],{"nctId":7976,"briefTitle":7977,"status":152,"phases":7978,"primaryCompletion":7979,"completion":7979,"start":7980,"enrollment":1315,"conditions":7981,"interventions":7982},"NCT00003111","Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer",[87],"2004-04","1997-04",[7969],[7983,7984,2260,7802],"carboplatin","cisplatin",{"trials":7986,"activeCount":98},[],{"trials":7988,"activeCount":98},[],{"trials":7990,"activeCount":98},[],{"intervention":2260,"totalTrials":1246,"cells":7992},{"EARLY_PHASE1":7993,"PHASE1":7995,"PHASE2":7997,"PHASE3":8028,"PHASE4":8030,"NA":8032},{"trials":7994,"activeCount":98},[],{"trials":7996,"activeCount":98},[],{"trials":7998,"activeCount":98},[7999,8016,8020,8024],{"nctId":8000,"briefTitle":8001,"status":152,"phases":8002,"primaryCompletion":8003,"completion":8004,"start":8005,"enrollment":19,"conditions":8006,"interventions":8012},"NCT02047474","Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer",[87],"2022-08-16","2024-01-14","2014-03-25",[8007,8008,8009,8010,8011],"Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Stage I Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer",[8013,8014,2260,8015],"oxaliplatin","leucovorin calcium","fluorouracil",{"nctId":7964,"briefTitle":7965,"status":152,"phases":8017,"completion":6747,"start":7967,"enrollment":1743,"conditions":8018,"interventions":8019},[87],[7969],[2260,7802],{"nctId":2253,"briefTitle":2254,"status":152,"phases":8021,"completion":164,"start":2256,"enrollment":16,"conditions":8022,"interventions":8023},[86,87],[2258],[2223,2260],{"nctId":7976,"briefTitle":7977,"status":152,"phases":8025,"primaryCompletion":7979,"completion":7979,"start":7980,"enrollment":1315,"conditions":8026,"interventions":8027},[87],[7969],[7983,7984,2260,7802],{"trials":8029,"activeCount":98},[],{"trials":8031,"activeCount":98},[],{"trials":8033,"activeCount":98},[],{"intervention":8035,"totalTrials":94,"cells":8036},"Vorinostat",{"EARLY_PHASE1":8037,"PHASE1":8039,"PHASE2":8056,"PHASE3":8067,"PHASE4":8069,"NA":8071},{"trials":8038,"activeCount":98},[],{"trials":8040,"activeCount":98},[8041,8049],{"nctId":8042,"briefTitle":8043,"status":152,"phases":8044,"primaryCompletion":7352,"completion":7352,"start":8045,"enrollment":1815,"conditions":8046,"interventions":8048},"NCT00821951","Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer",[86],"2009-05",[8047],"Non-Small Cell Lung Cancer (NSCLC)",[8035],{"nctId":8050,"briefTitle":8051,"status":152,"phases":8052,"primaryCompletion":7717,"completion":7717,"start":1082,"enrollment":2659,"conditions":8053,"interventions":8055},"NCT00719875","HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer",[86],[8054],"Advanced Breast Cancer",[8035],{"trials":8057,"activeCount":98},[8058],{"nctId":8059,"briefTitle":8060,"status":711,"phases":8061,"primaryCompletion":1166,"completion":1166,"start":2214,"enrollment":1815,"conditions":8062,"interventions":8065},"NCT00785798","Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas",[86,87],[8063,8064],"Relapsed Lymphomas","Refractory Lymphomas",[8035,8066],"Pegylated Liposomal Doxorubicin (PLD), Doxil",{"trials":8068,"activeCount":98},[],{"trials":8070,"activeCount":98},[],{"trials":8072,"activeCount":98},[],{"intervention":7737,"totalTrials":94,"cells":8074},{"EARLY_PHASE1":8075,"PHASE1":8077,"PHASE2":8079,"PHASE3":8107,"PHASE4":8109,"NA":8111},{"trials":8076,"activeCount":98},[],{"trials":8078,"activeCount":98},[],{"trials":8080,"activeCount":98},[8081,8093,8103],{"nctId":8082,"briefTitle":8083,"status":711,"phases":8084,"primaryCompletion":8085,"completion":8085,"start":8086,"enrollment":109,"conditions":8087,"interventions":8089},"NCT02994251","A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma",[87],"2018-11-06","2017-06-21",[8088],"Unresectable Intrahepatic Cholangiocarcinoma",[8090,8091,8092],"gemcitabine","Cisplatin","Conventional TACE (transarterial chemoembolization) with Doxorubicin\u002FMitomycin-C",{"nctId":8094,"briefTitle":8095,"status":1051,"phases":8096,"primaryCompletion":8097,"completion":8098,"start":8099,"enrollment":98,"conditions":8100,"interventions":8102},"NCT04045730","The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.",[87],"2019-12-31","2021-07-31","2019-11-15",[8101],"Pancreas Adenocarcinoma",[7737],{"nctId":7731,"briefTitle":7732,"status":152,"phases":8104,"primaryCompletion":6766,"completion":6766,"start":1984,"enrollment":1815,"conditions":8105,"interventions":8106},[87],[7735],[7737,7738,7697],{"trials":8108,"activeCount":98},[],{"trials":8110,"activeCount":98},[],{"trials":8112,"activeCount":98},[],{"intervention":7789,"totalTrials":94,"cells":8114},{"EARLY_PHASE1":8115,"PHASE1":8117,"PHASE2":8119,"PHASE3":8133,"PHASE4":8135,"NA":8137},{"trials":8116,"activeCount":98},[],{"trials":8118,"activeCount":98},[],{"trials":8120,"activeCount":98},[8121,8125,8129],{"nctId":7783,"briefTitle":7784,"status":152,"phases":8122,"primaryCompletion":1198,"completion":1198,"start":7786,"enrollment":1044,"conditions":8123,"interventions":8124},[87],[4403],[7755,7789,7790,7791,7792,7793],{"nctId":7795,"briefTitle":7796,"status":152,"phases":8126,"primaryCompletion":7798,"completion":7798,"start":7786,"enrollment":7420,"conditions":8127,"interventions":8128},[87],[4403],[7755,7789,7801,7802,7792],{"nctId":7881,"briefTitle":7882,"status":152,"phases":8130,"primaryCompletion":2194,"completion":2194,"start":5742,"enrollment":1305,"conditions":8131,"interventions":8132},[87],[7885],[7887,6761,7888,7889,7890,7891],{"trials":8134,"activeCount":98},[],{"trials":8136,"activeCount":98},[],{"trials":8138,"activeCount":98},[],{"intervention":8140,"totalTrials":94,"cells":8141},"PF-04457845",{"EARLY_PHASE1":8142,"PHASE1":8153,"PHASE2":8163,"PHASE3":8174,"PHASE4":8176,"NA":8178},{"trials":8143,"activeCount":98},[8144],{"nctId":8145,"briefTitle":8146,"status":152,"phases":8147,"primaryCompletion":8148,"completion":8148,"start":8149,"enrollment":28,"conditions":8150,"interventions":8152},"NCT01665573","Cannabinoid Augmentation of Fear Response in Humans",[85],"2015-10-16","2012-07-17",[8151],"Fear Conditioning",[8140],{"trials":8154,"activeCount":98},[8155],{"nctId":8156,"briefTitle":8157,"status":711,"phases":8158,"primaryCompletion":8159,"completion":8159,"start":8160,"enrollment":303,"conditions":8161,"interventions":8162},"NCT02134080","FAAH Inhibitor Trial for Adults With Tourette Syndrome",[86],"2017-03","2014-05",[5849],[8140],{"trials":8164,"activeCount":98},[8165],{"nctId":8166,"briefTitle":8167,"status":152,"phases":8168,"primaryCompletion":8169,"completion":8169,"start":8170,"enrollment":3585,"conditions":8171,"interventions":8173},"NCT01618656","Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal",[87],"2016-03-11","2012-09-12",[8172],"Cannabis Dependence",[8140],{"trials":8175,"activeCount":98},[],{"trials":8177,"activeCount":98},[],{"trials":8179,"activeCount":98},[],{"intervention":413,"totalTrials":94,"cells":8181},{"EARLY_PHASE1":8182,"PHASE1":8191,"PHASE2":8193,"PHASE3":8212,"PHASE4":8214,"NA":8216},{"trials":8183,"activeCount":98},[8184],{"nctId":8185,"briefTitle":8186,"status":152,"phases":8187,"primaryCompletion":1742,"completion":1742,"start":7743,"enrollment":1878,"conditions":8188,"interventions":8190},"NCT02238379","Intranasal Oxytocin Administration and the Neural Correlates of Social and Non-Social Visual Perception",[85],[8189],"Social Perception",[413],{"trials":8192,"activeCount":98},[],{"trials":8194,"activeCount":98},[8195,8203],{"nctId":8196,"briefTitle":8197,"status":152,"phases":8198,"primaryCompletion":8199,"completion":8199,"start":179,"enrollment":6758,"conditions":8200,"interventions":8202},"NCT02546570","Oxytocin and Affect Processing in Posttraumatic Stress Disorder",[87],"2016-08",[8201],"Posttraumatic Stress Disorder (PTSD)",[413],{"nctId":8204,"briefTitle":8205,"status":711,"phases":8206,"primaryCompletion":8207,"completion":8207,"start":8208,"enrollment":303,"conditions":8209,"interventions":8211},"NCT03370510","Translating Neuroprediction Into Precision Medicine Via Brain Priming",[87],"2021-07-28","2018-12-07",[8210],"Autism Spectrum Disorder",[413],{"trials":8213,"activeCount":98},[],{"trials":8215,"activeCount":98},[],{"trials":8217,"activeCount":98},[],{"intervention":8219,"totalTrials":94,"cells":8220},"incobotulinumtoxinA",{"EARLY_PHASE1":8221,"PHASE1":8223,"PHASE2":8225,"PHASE3":8250,"PHASE4":8252,"NA":8254},{"trials":8222,"activeCount":98},[],{"trials":8224,"activeCount":98},[],{"trials":8226,"activeCount":98},[8227,8236,8243],{"nctId":8228,"briefTitle":8229,"status":152,"phases":8230,"primaryCompletion":1973,"completion":1973,"start":7508,"enrollment":987,"conditions":8231,"interventions":8234},"NCT02419313","Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach",[87],[8232,8233],"Parkinson","Tremor",[8219,8235],"Saline",{"nctId":8237,"briefTitle":8238,"status":711,"phases":8239,"primaryCompletion":1441,"completion":1148,"start":1908,"enrollment":272,"conditions":8240,"interventions":8241},"NCT01931865","IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and\u002For Radiation",[87],[316],[8242],"IncobotulinumtoxinA",{"nctId":8244,"briefTitle":8245,"status":152,"phases":8246,"primaryCompletion":179,"completion":179,"start":1908,"enrollment":2659,"conditions":8247,"interventions":8249},"NCT01931878","Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.",[87],[8248],"Restless Leg Syndrome",[8219],{"trials":8251,"activeCount":98},[],{"trials":8253,"activeCount":98},[],{"trials":8255,"activeCount":98},[],{"intervention":1784,"totalTrials":94,"cells":8257},{"EARLY_PHASE1":8258,"PHASE1":8264,"PHASE2":8280,"PHASE3":8286,"PHASE4":8288,"NA":8290},{"trials":8259,"activeCount":98},[8260],{"nctId":6961,"briefTitle":6962,"status":152,"phases":8261,"primaryCompletion":2213,"completion":2213,"start":6964,"enrollment":1878,"conditions":8262,"interventions":8263},[85],[6966],[6968,6969,6956],{"trials":8265,"activeCount":98},[8266],{"nctId":8267,"briefTitle":8268,"status":152,"phases":8269,"primaryCompletion":8270,"completion":8270,"enrollment":1648,"conditions":8271,"interventions":8274},"NCT00433485","Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants",[86],"2008-03",[8272,8273],"Neoplastic Syndrome","Non-melanomatous Skin Cancer",[1784,8275,8276,8277,8278,8279],"comparative genomic hybridization","gene expression analysis","microarray analysis","protein expression analysis","proteomic profiling",{"trials":8281,"activeCount":98},[8282],{"nctId":1777,"briefTitle":1778,"status":152,"phases":8283,"primaryCompletion":1780,"completion":1780,"start":1781,"enrollment":1609,"conditions":8284,"interventions":8285},[87],[21],[1608,1784],{"trials":8287,"activeCount":98},[],{"trials":8289,"activeCount":98},[],{"trials":8291,"activeCount":98},[],{"intervention":6968,"totalTrials":94,"cells":8293},{"EARLY_PHASE1":8294,"PHASE1":8300,"PHASE2":8314,"PHASE3":8320,"PHASE4":8322,"NA":8324},{"trials":8295,"activeCount":98},[8296],{"nctId":6961,"briefTitle":6962,"status":152,"phases":8297,"primaryCompletion":2213,"completion":2213,"start":6964,"enrollment":1878,"conditions":8298,"interventions":8299},[85],[6966],[6968,6969,6956],{"trials":8301,"activeCount":98},[8302],{"nctId":8303,"briefTitle":8304,"status":152,"phases":8305,"primaryCompletion":327,"completion":327,"start":7034,"enrollment":118,"conditions":8306,"interventions":8310},"NCT00104975","Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer",[86],[8307,8308,7779,2041,8309],"Chronic Myeloproliferative Disorders","Leukemia","Myelodysplastic\u002FMyeloproliferative Neoplasms",[8311,8312,8313,7791,6968,7793],"alemtuzumab","therapeutic allogeneic lymphocytes","fludarabine phosphate",{"trials":8315,"activeCount":98},[8316],{"nctId":6763,"briefTitle":6764,"status":711,"phases":8317,"primaryCompletion":6766,"completion":6766,"start":1187,"enrollment":263,"conditions":8318,"interventions":8319},[86,87],[6768],[6736,6770],{"trials":8321,"activeCount":98},[],{"trials":8323,"activeCount":98},[],{"trials":8325,"activeCount":98},[],{"intervention":7738,"totalTrials":94,"cells":8327},{"EARLY_PHASE1":8328,"PHASE1":8330,"PHASE2":8332,"PHASE3":8350,"PHASE4":8352,"NA":8354},{"trials":8329,"activeCount":98},[],{"trials":8331,"activeCount":98},[],{"trials":8333,"activeCount":98},[8334,8342,8346],{"nctId":8335,"briefTitle":8336,"status":711,"phases":8337,"primaryCompletion":1164,"completion":1164,"start":6677,"enrollment":94,"conditions":8338,"interventions":8340},"NCT02590003","Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer",[87],[8339],"Carcinoma, Non-small Cell Lung",[7738,8341],"Nab-paclitaxel",{"nctId":7976,"briefTitle":7977,"status":152,"phases":8343,"primaryCompletion":7979,"completion":7979,"start":7980,"enrollment":1315,"conditions":8344,"interventions":8345},[87],[7969],[7983,7984,2260,7802],{"nctId":7731,"briefTitle":7732,"status":152,"phases":8347,"primaryCompletion":6766,"completion":6766,"start":1984,"enrollment":1815,"conditions":8348,"interventions":8349},[87],[7735],[7737,7738,7697],{"trials":8351,"activeCount":98},[],{"trials":8353,"activeCount":98},[],{"trials":8355,"activeCount":98},[],{"intervention":8357,"totalTrials":263,"cells":8358},"ganirelix acetate",{"EARLY_PHASE1":8359,"PHASE1":8368,"PHASE2":8370,"PHASE3":8383,"PHASE4":8385,"NA":8387},{"trials":8360,"activeCount":98},[8361],{"nctId":8362,"briefTitle":8363,"status":152,"phases":8364,"primaryCompletion":5846,"completion":1186,"start":1187,"enrollment":1743,"conditions":8365,"interventions":8366},"NCT00757185","Compromised Microcirculation in Women With Polycystic Ovary Syndrome",[85],[6718],[8357,8367],"methyl testosterone",{"trials":8369,"activeCount":98},[],{"trials":8371,"activeCount":98},[8372],{"nctId":8373,"briefTitle":8374,"status":152,"phases":8375,"primaryCompletion":1186,"completion":1210,"start":6747,"enrollment":8376,"conditions":8377,"interventions":8379},"NCT01153581","Sex Hormones and Orthostatic Tolerance",[87],109,[8378],"Orthostatic Intolerance",[8380,8381,8382],"Ganirelix acetate","17β-Oestradiol","Progesterone",{"trials":8384,"activeCount":98},[],{"trials":8386,"activeCount":98},[],{"trials":8388,"activeCount":98},[],{"intervention":7769,"totalTrials":263,"cells":8390},{"EARLY_PHASE1":8391,"PHASE1":8393,"PHASE2":8399,"PHASE3":8410,"PHASE4":8412,"NA":8414},{"trials":8392,"activeCount":98},[],{"trials":8394,"activeCount":98},[8395],{"nctId":7762,"briefTitle":7763,"status":711,"phases":8396,"primaryCompletion":7765,"completion":7765,"start":7766,"conditions":8397,"interventions":8398},[86],[2258],[7755,7769],{"trials":8400,"activeCount":98},[8401],{"nctId":8402,"briefTitle":8403,"status":152,"phases":8404,"primaryCompletion":8405,"completion":8405,"start":8406,"enrollment":1512,"conditions":8407,"interventions":8408},"NCT00002950","Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer",[86,87],"2002-02-10","1996-09-26",[2258],[8409,7769],"sargramostim",{"trials":8411,"activeCount":98},[],{"trials":8413,"activeCount":98},[],{"trials":8415,"activeCount":98},[],{"intervention":2590,"totalTrials":263,"cells":8417},{"EARLY_PHASE1":8418,"PHASE1":8420,"PHASE2":8422,"PHASE3":8437,"PHASE4":8439,"NA":8441},{"trials":8419,"activeCount":98},[],{"trials":8421,"activeCount":98},[],{"trials":8423,"activeCount":98},[8424,8433],{"nctId":8425,"briefTitle":8426,"status":152,"phases":8427,"primaryCompletion":6162,"completion":8428,"start":8160,"enrollment":8429,"conditions":8430,"interventions":8432},"NCT02110706","BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis",[87],"2018-05",52,[8431],"Myasthenia Gravis",[2590],{"nctId":2574,"briefTitle":2575,"status":1051,"phases":8434,"primaryCompletion":2038,"completion":2577,"start":2578,"enrollment":98,"conditions":8435,"interventions":8436},[87],[2580,2581,2582,2583,2584,2585,2586,2587,2588],[2590,2591,2592],{"trials":8438,"activeCount":98},[],{"trials":8440,"activeCount":98},[],{"trials":8442,"activeCount":98},[],{"intervention":8444,"totalTrials":263,"cells":8445},"Flumazenil",{"EARLY_PHASE1":8446,"PHASE1":8448,"PHASE2":8450,"PHASE3":8469,"PHASE4":8471,"NA":8473},{"trials":8447,"activeCount":98},[],{"trials":8449,"activeCount":98},[],{"trials":8451,"activeCount":98},[8452,8462],{"nctId":8453,"briefTitle":8454,"status":1051,"phases":8455,"primaryCompletion":8456,"completion":8456,"start":8457,"enrollment":98,"conditions":8458,"interventions":8461},"NCT02048969","Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS",[86,87],"2017-10","2014-06",[8459,8460],"Hepatic Encephalopathy","Liver Cirrhosis",[8444],{"nctId":8463,"briefTitle":8464,"status":152,"phases":8465,"primaryCompletion":8466,"completion":8466,"start":1054,"enrollment":1315,"conditions":8467,"interventions":8468},"NCT00000246","Rapid Benzodiazepine Detoxification Using Flumazenil - 1",[87],"1994-12",[158],[8444],{"trials":8470,"activeCount":98},[],{"trials":8472,"activeCount":98},[],{"trials":8474,"activeCount":98},[],{"intervention":7712,"totalTrials":263,"cells":8476},{"EARLY_PHASE1":8477,"PHASE1":8479,"PHASE2":8485,"PHASE3":8495,"PHASE4":8497,"NA":8499},{"trials":8478,"activeCount":98},[],{"trials":8480,"activeCount":98},[8481],{"nctId":7704,"briefTitle":7705,"status":152,"phases":8482,"primaryCompletion":7707,"completion":7707,"start":7352,"enrollment":2659,"conditions":8483,"interventions":8484},[86],[7709,7710],[7697,7712],{"trials":8486,"activeCount":98},[8487],{"nctId":8488,"briefTitle":8489,"status":152,"phases":8490,"primaryCompletion":8491,"completion":8491,"start":1081,"enrollment":1512,"conditions":8492,"interventions":8493},"NCT00411762","A Phase I\u002FII, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma",[86,87],"2009-12",[2958],[7712,8494],"PHY906",{"trials":8496,"activeCount":98},[],{"trials":8498,"activeCount":98},[],{"trials":8500,"activeCount":98},[],{"intervention":732,"totalTrials":263,"cells":8502},{"EARLY_PHASE1":8503,"PHASE1":8505,"PHASE2":8507,"PHASE3":8520,"PHASE4":8522,"NA":8524},{"trials":8504,"activeCount":98},[],{"trials":8506,"activeCount":98},[],{"trials":8508,"activeCount":98},[8509,8516],{"nctId":8510,"briefTitle":8511,"status":152,"phases":8512,"primaryCompletion":8270,"completion":8270,"start":8513,"enrollment":1923,"conditions":8514,"interventions":8515},"NCT00367991","Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction",[87],"2006-11",[7214],[732],{"nctId":723,"briefTitle":724,"status":152,"phases":8517,"completion":726,"start":727,"enrollment":728,"conditions":8518,"interventions":8519},[87],[730],[732,704,733],{"trials":8521,"activeCount":98},[],{"trials":8523,"activeCount":98},[],{"trials":8525,"activeCount":98},[],{"intervention":8091,"totalTrials":263,"cells":8527},{"EARLY_PHASE1":8528,"PHASE1":8530,"PHASE2":8532,"PHASE3":8542,"PHASE4":8544,"NA":8546},{"trials":8529,"activeCount":98},[],{"trials":8531,"activeCount":98},[],{"trials":8533,"activeCount":98},[8534,8538],{"nctId":8082,"briefTitle":8083,"status":711,"phases":8535,"primaryCompletion":8085,"completion":8085,"start":8086,"enrollment":109,"conditions":8536,"interventions":8537},[87],[8088],[8090,8091,8092],{"nctId":7976,"briefTitle":7977,"status":152,"phases":8539,"primaryCompletion":7979,"completion":7979,"start":7980,"enrollment":1315,"conditions":8540,"interventions":8541},[87],[7969],[7983,7984,2260,7802],{"trials":8543,"activeCount":98},[],{"trials":8545,"activeCount":98},[],{"trials":8547,"activeCount":98},[],{"intervention":7791,"totalTrials":263,"cells":8549},{"EARLY_PHASE1":8550,"PHASE1":8552,"PHASE2":8558,"PHASE3":8564,"PHASE4":8566,"NA":8568},{"trials":8551,"activeCount":98},[],{"trials":8553,"activeCount":98},[8554],{"nctId":8303,"briefTitle":8304,"status":152,"phases":8555,"primaryCompletion":327,"completion":327,"start":7034,"enrollment":118,"conditions":8556,"interventions":8557},[86],[8307,8308,7779,2041,8309],[8311,8312,8313,7791,6968,7793],{"trials":8559,"activeCount":98},[8560],{"nctId":7783,"briefTitle":7784,"status":152,"phases":8561,"primaryCompletion":1198,"completion":1198,"start":7786,"enrollment":1044,"conditions":8562,"interventions":8563},[87],[4403],[7755,7789,7790,7791,7792,7793],{"trials":8565,"activeCount":98},[],{"trials":8567,"activeCount":98},[],{"trials":8569,"activeCount":98},[],{"intervention":7792,"totalTrials":263,"cells":8571},{"EARLY_PHASE1":8572,"PHASE1":8574,"PHASE2":8576,"PHASE3":8586,"PHASE4":8588,"NA":8590},{"trials":8573,"activeCount":98},[],{"trials":8575,"activeCount":98},[],{"trials":8577,"activeCount":98},[8578,8582],{"nctId":7783,"briefTitle":7784,"status":152,"phases":8579,"primaryCompletion":1198,"completion":1198,"start":7786,"enrollment":1044,"conditions":8580,"interventions":8581},[87],[4403],[7755,7789,7790,7791,7792,7793],{"nctId":7795,"briefTitle":7796,"status":152,"phases":8583,"primaryCompletion":7798,"completion":7798,"start":7786,"enrollment":7420,"conditions":8584,"interventions":8585},[87],[4403],[7755,7789,7801,7802,7792],{"trials":8587,"activeCount":98},[],{"trials":8589,"activeCount":98},[],{"trials":8591,"activeCount":98},[],{"intervention":7793,"totalTrials":263,"cells":8593},{"EARLY_PHASE1":8594,"PHASE1":8596,"PHASE2":8602,"PHASE3":8608,"PHASE4":8610,"NA":8612},{"trials":8595,"activeCount":98},[],{"trials":8597,"activeCount":98},[8598],{"nctId":8303,"briefTitle":8304,"status":152,"phases":8599,"primaryCompletion":327,"completion":327,"start":7034,"enrollment":118,"conditions":8600,"interventions":8601},[86],[8307,8308,7779,2041,8309],[8311,8312,8313,7791,6968,7793],{"trials":8603,"activeCount":98},[8604],{"nctId":7783,"briefTitle":7784,"status":152,"phases":8605,"primaryCompletion":1198,"completion":1198,"start":7786,"enrollment":1044,"conditions":8606,"interventions":8607},[87],[4403],[7755,7789,7790,7791,7792,7793],{"trials":8609,"activeCount":98},[],{"trials":8611,"activeCount":98},[],{"trials":8613,"activeCount":98},[],{"intervention":8615,"totalTrials":263,"cells":8616},"MK-3475",{"EARLY_PHASE1":8617,"PHASE1":8619,"PHASE2":8621,"PHASE3":8640,"PHASE4":8642,"NA":8644},{"trials":8618,"activeCount":98},[],{"trials":8620,"activeCount":98},[],{"trials":8622,"activeCount":98},[8623,8632],{"nctId":8624,"briefTitle":8625,"status":152,"phases":8626,"primaryCompletion":8627,"completion":8627,"start":326,"enrollment":8628,"conditions":8629,"interventions":8631},"NCT02085070","MK-3475 in Melanoma and NSCLC Patients With Brain Metastases",[87],"2020-02-27",65,[1491,8630,1493],"Non-Small Cell Lung Cancer",[8615],{"nctId":8633,"briefTitle":8634,"status":152,"phases":8635,"primaryCompletion":8636,"completion":8636,"start":8637,"enrollment":696,"conditions":8638,"interventions":8639},"NCT02407171","Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC",[86,87],"2019-02-19","2015-04-01",[1491,7969],[8615],{"trials":8641,"activeCount":98},[],{"trials":8643,"activeCount":98},[],{"trials":8645,"activeCount":98},[],{"intervention":7944,"totalTrials":263,"cells":8647},{"EARLY_PHASE1":8648,"PHASE1":8650,"PHASE2":8660,"PHASE3":8666,"PHASE4":8668,"NA":8670},{"trials":8649,"activeCount":98},[],{"trials":8651,"activeCount":98},[8652],{"nctId":8653,"briefTitle":8654,"status":152,"phases":8655,"primaryCompletion":8656,"completion":8657,"start":6677,"enrollment":303,"conditions":8658,"interventions":8659},"NCT02732587","Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers",[86],"2016-03-15","2016-03-23",[1034],[7944],{"trials":8661,"activeCount":98},[8662],{"nctId":7936,"briefTitle":7937,"status":152,"phases":8663,"primaryCompletion":7939,"completion":7940,"start":7941,"enrollment":1305,"conditions":8664,"interventions":8665},[87],[1034],[7944,2543],{"trials":8667,"activeCount":98},[],{"trials":8669,"activeCount":98},[],{"trials":8671,"activeCount":98},[],{"intervention":8673,"totalTrials":263,"cells":8674},"everolimus",{"EARLY_PHASE1":8675,"PHASE1":8677,"PHASE2":8679,"PHASE3":8696,"PHASE4":8698,"NA":8700},{"trials":8676,"activeCount":98},[],{"trials":8678,"activeCount":98},[],{"trials":8680,"activeCount":98},[8681,8688],{"nctId":8682,"briefTitle":8683,"status":711,"phases":8684,"primaryCompletion":7604,"completion":7604,"start":6747,"enrollment":94,"conditions":8685,"interventions":8686},"NCT00402662","A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma",[87],[1495],[8673,8687],"Imatinib",{"nctId":8689,"briefTitle":8690,"status":711,"phases":8691,"primaryCompletion":2279,"completion":2279,"start":8692,"enrollment":1815,"conditions":8693,"interventions":8694},"NCT02236572","Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w\u002F ER Pos\u002FHER2 Neg, Low Risk Score",[87],"2014-11-29",[4403],[8695],"Everolimus",{"trials":8697,"activeCount":98},[],{"trials":8699,"activeCount":98},[],{"trials":8701,"activeCount":98},[],{"intervention":1066,"totalTrials":263,"cells":8703},{"EARLY_PHASE1":8704,"PHASE1":8706,"PHASE2":8708,"PHASE3":8718,"PHASE4":8720,"NA":8722},{"trials":8705,"activeCount":98},[],{"trials":8707,"activeCount":98},[],{"trials":8709,"activeCount":98},[8710,8714],{"nctId":1058,"briefTitle":1059,"status":152,"phases":8711,"completion":1061,"start":1062,"enrollment":1063,"conditions":8712,"interventions":8713},[87],[183],[1066,890],{"nctId":1078,"briefTitle":1079,"status":1051,"phases":8715,"primaryCompletion":1081,"completion":1082,"start":1083,"enrollment":98,"conditions":8716,"interventions":8717},[87],[183,274],[1066,890],{"trials":8719,"activeCount":98},[],{"trials":8721,"activeCount":98},[],{"trials":8723,"activeCount":98},[],{"intervention":8725,"totalTrials":263,"cells":8726},"memantine",{"EARLY_PHASE1":8727,"PHASE1":8729,"PHASE2":8731,"PHASE3":8749,"PHASE4":8751,"NA":8753},{"trials":8728,"activeCount":98},[],{"trials":8730,"activeCount":98},[],{"trials":8732,"activeCount":98},[8733,8742],{"nctId":8734,"briefTitle":8735,"status":152,"phases":8736,"primaryCompletion":8737,"completion":7744,"start":7604,"enrollment":8738,"conditions":8739,"interventions":8740},"NCT00630955","Family History Study of Alcohol Consumption Using Memantine",[87],"2011-05",111,[1034],[8725,8741],"Memantine",{"nctId":8743,"briefTitle":8744,"status":152,"phases":8745,"primaryCompletion":1907,"completion":1907,"start":1664,"enrollment":8746,"conditions":8747,"interventions":8748},"NCT01585168","Functional Neuroimaging of Alcoholism Vulnerability (PIT)",[87],71,[3590],[8741],{"trials":8750,"activeCount":98},[],{"trials":8752,"activeCount":98},[],{"trials":8754,"activeCount":98},[],{"intervention":8756,"totalTrials":263,"cells":8757},"Zonisamide",{"EARLY_PHASE1":8758,"PHASE1":8760,"PHASE2":8762,"PHASE3":8777,"PHASE4":8779,"NA":8781},{"trials":8759,"activeCount":98},[],{"trials":8761,"activeCount":98},[],{"trials":8763,"activeCount":98},[8764,8771],{"nctId":8765,"briefTitle":8766,"status":711,"phases":8767,"primaryCompletion":1618,"completion":1618,"start":8768,"enrollment":94,"conditions":8769,"interventions":8770},"NCT01566370","Zonisamide for Heavy Drinkers With Bipolar Disorder",[87],"2012-05",[1851,1215],[8756],{"nctId":8772,"briefTitle":8773,"status":152,"phases":8774,"primaryCompletion":5458,"completion":5458,"start":7717,"enrollment":2659,"conditions":8775,"interventions":8776},"NCT01847469","Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence",[87],[1112,1838],[8756],{"trials":8778,"activeCount":98},[],{"trials":8780,"activeCount":98},[],{"trials":8782,"activeCount":98},[],{"intervention":8784,"totalTrials":109,"cells":8785},"DEBIRI",{"EARLY_PHASE1":8786,"PHASE1":8788,"PHASE2":8790,"PHASE3":8802,"PHASE4":8804,"NA":8806},{"trials":8787,"activeCount":98},[],{"trials":8789,"activeCount":98},[],{"trials":8791,"activeCount":98},[8792],{"nctId":8793,"briefTitle":8794,"status":152,"phases":8795,"primaryCompletion":8796,"completion":8797,"start":8798,"enrollment":1675,"conditions":8799,"interventions":8801},"NCT02015754","Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer",[87],"2015-06-02","2016-12-13","2014-02",[8800],"Colorectal Cancer",[8784],{"trials":8803,"activeCount":98},[],{"trials":8805,"activeCount":98},[],{"trials":8807,"activeCount":98},[],{"intervention":8809,"totalTrials":109,"cells":8810},"N-acetylcysteine and ketamine",{"EARLY_PHASE1":8811,"PHASE1":8813,"PHASE2":8815,"PHASE3":8824,"PHASE4":8826,"NA":8828},{"trials":8812,"activeCount":98},[],{"trials":8814,"activeCount":98},[],{"trials":8816,"activeCount":98},[8817],{"nctId":8818,"briefTitle":8819,"status":152,"phases":8820,"primaryCompletion":1031,"completion":1031,"start":369,"enrollment":1648,"conditions":8821,"interventions":8823},"NCT00611897","N-acetylcysteine and NMDA Antagonist Interactions",[86,87],[8822],"Cognitive Dysfunction",[8809],{"trials":8825,"activeCount":98},[],{"trials":8827,"activeCount":98},[],{"trials":8829,"activeCount":98},[],{"intervention":8831,"totalTrials":109,"cells":8832},"Tumor infiltrating lymphocytes (TIL) LN-145",{"EARLY_PHASE1":8833,"PHASE1":8835,"PHASE2":8837,"PHASE3":8849,"PHASE4":8851,"NA":8853},{"trials":8834,"activeCount":98},[],{"trials":8836,"activeCount":98},[],{"trials":8838,"activeCount":98},[8839],{"nctId":8840,"briefTitle":8841,"status":152,"phases":8842,"primaryCompletion":8843,"completion":8844,"start":8845,"enrollment":1416,"conditions":8846,"interventions":8848},"NCT04111510","Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer",[87],"2023-01-30","2023-05-11","2019-12-23",[8847],"Metastatic Triple Negative Breast Cancer",[8831],{"trials":8850,"activeCount":98},[],{"trials":8852,"activeCount":98},[],{"trials":8854,"activeCount":98},[],{"intervention":8856,"totalTrials":109,"cells":8857},"Aspirin 81 mg",{"EARLY_PHASE1":8858,"PHASE1":8860,"PHASE2":8862,"PHASE3":8875,"PHASE4":8877,"NA":8879},{"trials":8859,"activeCount":98},[],{"trials":8861,"activeCount":98},[],{"trials":8863,"activeCount":98},[8864],{"nctId":8865,"briefTitle":8866,"status":711,"phases":8867,"primaryCompletion":8868,"completion":8868,"start":8869,"enrollment":1305,"conditions":8870,"interventions":8874},"NCT04402385","Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)",[87],"2022-06-22","2020-08-06",[8871,8872,8873],"Pre-Eclampsia","Stage 1 Hypertension","Elevated Blood Pressure",[8856],{"trials":8876,"activeCount":98},[],{"trials":8878,"activeCount":98},[],{"trials":8880,"activeCount":98},[],{"intervention":8882,"totalTrials":109,"cells":8883},"Selegiline",{"EARLY_PHASE1":8884,"PHASE1":8886,"PHASE2":8888,"PHASE3":8898,"PHASE4":8900,"NA":8902},{"trials":8885,"activeCount":98},[],{"trials":8887,"activeCount":98},[],{"trials":8889,"activeCount":98},[8890],{"nctId":8891,"briefTitle":8892,"status":152,"phases":8893,"primaryCompletion":1186,"completion":1186,"start":8894,"enrollment":8895,"conditions":8896,"interventions":8897},"NCT00129311","Usefulness of Selegiline as an Aid to Quit Smoking - 1",[87],"2004-07",101,[6469],[8882],{"trials":8899,"activeCount":98},[],{"trials":8901,"activeCount":98},[],{"trials":8903,"activeCount":98},[],{"intervention":8905,"totalTrials":109,"cells":8906},"conventional TACE in combination with sorafenib, administered on a continuous schedule",{"EARLY_PHASE1":8907,"PHASE1":8909,"PHASE2":8911,"PHASE3":8921,"PHASE4":8923,"NA":8925},{"trials":8908,"activeCount":98},[],{"trials":8910,"activeCount":98},[],{"trials":8912,"activeCount":98},[8913],{"nctId":8914,"briefTitle":8915,"status":1051,"phases":8916,"primaryCompletion":8917,"completion":8917,"start":3858,"enrollment":98,"conditions":8918,"interventions":8919},"NCT02908165","Randomized Phase II Trial of Chemoembolization and Sorafenib",[87],"2020-06",[4047],[8905,8920],"conventional TACE in combination with sorafenib, administered on a sequential schedule",{"trials":8922,"activeCount":98},[],{"trials":8924,"activeCount":98},[],{"trials":8926,"activeCount":98},[],{"intervention":8920,"totalTrials":109,"cells":8928},{"EARLY_PHASE1":8929,"PHASE1":8931,"PHASE2":8933,"PHASE3":8939,"PHASE4":8941,"NA":8943},{"trials":8930,"activeCount":98},[],{"trials":8932,"activeCount":98},[],{"trials":8934,"activeCount":98},[8935],{"nctId":8914,"briefTitle":8915,"status":1051,"phases":8936,"primaryCompletion":8917,"completion":8917,"start":3858,"enrollment":98,"conditions":8937,"interventions":8938},[87],[4047],[8905,8920],{"trials":8940,"activeCount":98},[],{"trials":8942,"activeCount":98},[],{"trials":8944,"activeCount":98},[],{"intervention":7662,"totalTrials":109,"cells":8946},{"EARLY_PHASE1":8947,"PHASE1":8949,"PHASE2":8951,"PHASE3":8957,"PHASE4":8959,"NA":8961},{"trials":8948,"activeCount":98},[],{"trials":8950,"activeCount":98},[],{"trials":8952,"activeCount":98},[8953],{"nctId":7652,"briefTitle":7653,"status":152,"phases":8954,"primaryCompletion":7655,"completion":7655,"start":7656,"enrollment":7657,"conditions":8955,"interventions":8956},[87],[7659,2234,7660],[7662,4050],{"trials":8958,"activeCount":98},[],{"trials":8960,"activeCount":98},[],{"trials":8962,"activeCount":98},[],{"intervention":8964,"totalTrials":109,"cells":8965},"ESP block with bupivacaine",{"EARLY_PHASE1":8966,"PHASE1":8968,"PHASE2":8970,"PHASE3":8980,"PHASE4":8982,"NA":8984},{"trials":8967,"activeCount":98},[],{"trials":8969,"activeCount":98},[],{"trials":8971,"activeCount":98},[8972],{"nctId":8973,"briefTitle":8974,"status":1051,"phases":8975,"primaryCompletion":674,"completion":674,"start":8976,"enrollment":98,"conditions":8977,"interventions":8979},"NCT04168710","Ultrasound Guided Emergency Physician Performed Erector Spinae Nerve Block for Rib Fracture Analgesia",[86,87],"2025-05-01",[8978],"Rib Fractures",[8964],{"trials":8981,"activeCount":98},[],{"trials":8983,"activeCount":98},[],{"trials":8985,"activeCount":98},[],{"intervention":8987,"totalTrials":109,"cells":8988},"Glasdegib",{"EARLY_PHASE1":8989,"PHASE1":8991,"PHASE2":8993,"PHASE3":9005,"PHASE4":9007,"NA":9009},{"trials":8990,"activeCount":98},[],{"trials":8992,"activeCount":98},[],{"trials":8994,"activeCount":98},[8995],{"nctId":8996,"briefTitle":8997,"status":711,"phases":8998,"primaryCompletion":8999,"completion":8999,"start":9000,"enrollment":109,"conditions":9001,"interventions":9003},"NCT04051996","GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia",[87],"2020-06-09","2019-12-06",[9002],"ACUTE MYELOID LEUKEMIA",[8987,9004],"Decitabine",{"trials":9006,"activeCount":98},[],{"trials":9008,"activeCount":98},[],{"trials":9010,"activeCount":98},[],{"intervention":9004,"totalTrials":109,"cells":9012},{"EARLY_PHASE1":9013,"PHASE1":9015,"PHASE2":9017,"PHASE3":9023,"PHASE4":9025,"NA":9027},{"trials":9014,"activeCount":98},[],{"trials":9016,"activeCount":98},[],{"trials":9018,"activeCount":98},[9019],{"nctId":8996,"briefTitle":8997,"status":711,"phases":9020,"primaryCompletion":8999,"completion":8999,"start":9000,"enrollment":109,"conditions":9021,"interventions":9022},[87],[9002],[8987,9004],{"trials":9024,"activeCount":98},[],{"trials":9026,"activeCount":98},[],{"trials":9028,"activeCount":98},[],{"intervention":7781,"totalTrials":109,"cells":9030},{"EARLY_PHASE1":9031,"PHASE1":9033,"PHASE2":9035,"PHASE3":9041,"PHASE4":9043,"NA":9045},{"trials":9032,"activeCount":98},[],{"trials":9034,"activeCount":98},[],{"trials":9036,"activeCount":98},[9037],{"nctId":7773,"briefTitle":7774,"status":152,"phases":9038,"primaryCompletion":7776,"completion":7776,"start":7777,"enrollment":272,"conditions":9039,"interventions":9040},[87],[7779],[7755,7781],{"trials":9042,"activeCount":98},[],{"trials":9044,"activeCount":98},[],{"trials":9046,"activeCount":98},[],{"intervention":9048,"totalTrials":109,"cells":9049},"Clonidine",{"EARLY_PHASE1":9050,"PHASE1":9052,"PHASE2":9054,"PHASE3":9062,"PHASE4":9064,"NA":9066},{"trials":9051,"activeCount":98},[],{"trials":9053,"activeCount":98},[],{"trials":9055,"activeCount":98},[9056],{"nctId":9057,"briefTitle":9058,"status":152,"phases":9059,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":98,"conditions":9060,"interventions":9061},"NCT00000279","Novel Medications for Opiate Detoxification - 4",[87],[157,158],[9048],{"trials":9063,"activeCount":98},[],{"trials":9065,"activeCount":98},[],{"trials":9067,"activeCount":98},[],{"intervention":9069,"totalTrials":109,"cells":9070},"combined TAS-102 and TAS-OX",{"EARLY_PHASE1":9071,"PHASE1":9073,"PHASE2":9075,"PHASE3":9086,"PHASE4":9088,"NA":9090},{"trials":9072,"activeCount":98},[],{"trials":9074,"activeCount":98},[],{"trials":9076,"activeCount":98},[9077],{"nctId":9078,"briefTitle":9079,"status":152,"phases":9080,"primaryCompletion":9081,"completion":9081,"start":9082,"enrollment":7849,"conditions":9083,"interventions":9085},"NCT02848079","TAS-OX for Refractory Metastatic Colon Cancer",[86,87],"2020-06-02","2016-10-31",[9084],"Colorectal Neoplasms",[9069],{"trials":9087,"activeCount":98},[],{"trials":9089,"activeCount":98},[],{"trials":9091,"activeCount":98},[],{"intervention":9093,"totalTrials":109,"cells":9094},"Standard Dose YPT-01",{"EARLY_PHASE1":9095,"PHASE1":9097,"PHASE2":9099,"PHASE3":9110,"PHASE4":9112,"NA":9114},{"trials":9096,"activeCount":98},[],{"trials":9098,"activeCount":98},[],{"trials":9100,"activeCount":98},[9101],{"nctId":9102,"briefTitle":9103,"status":152,"phases":9104,"primaryCompletion":7920,"completion":9105,"start":9106,"enrollment":1296,"conditions":9107,"interventions":9109},"NCT04684641","CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)",[86,87],"2023-06-22","2021-03-29",[9108],"Cystic Fibrosis",[9093],{"trials":9111,"activeCount":98},[],{"trials":9113,"activeCount":98},[],{"trials":9115,"activeCount":98},[],{"intervention":9117,"totalTrials":109,"cells":9118},"MEK 162 therapy or molecularly targeted therapy",{"EARLY_PHASE1":9119,"PHASE1":9121,"PHASE2":9123,"PHASE3":9138,"PHASE4":9140,"NA":9142},{"trials":9120,"activeCount":98},[],{"trials":9122,"activeCount":98},[],{"trials":9124,"activeCount":98},[9125],{"nctId":9126,"briefTitle":9127,"status":152,"phases":9128,"primaryCompletion":9129,"completion":9129,"start":8160,"enrollment":9130,"conditions":9131,"interventions":9137},"NCT02094872","Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic",[87],"2018-12",49,[9132,9133,9134,9135,9136],"Recurrent Melanoma","Stage IIIA Melanoma","Stage IIIB Melanoma","Stage IIIC Melanoma","Stage IV Melanoma",[9117],{"trials":9139,"activeCount":98},[],{"trials":9141,"activeCount":98},[],{"trials":9143,"activeCount":98},[],{"intervention":9145,"totalTrials":109,"cells":9146},"Guanfacine 3mg\u002Fday",{"EARLY_PHASE1":9147,"PHASE1":9149,"PHASE2":9151,"PHASE3":9161,"PHASE4":9163,"NA":9165},{"trials":9148,"activeCount":98},[],{"trials":9150,"activeCount":98},[],{"trials":9152,"activeCount":98},[9153],{"nctId":9154,"briefTitle":9155,"status":152,"phases":9156,"primaryCompletion":9157,"completion":9157,"start":8457,"enrollment":3585,"conditions":9158,"interventions":9159},"NCT02164422","Does Guanfacine Attenuate Stress-Induced Drinking?",[87],"2020-03-31",[1034],[9145,9160],"Guanfacine 1.5mg\u002Fday",{"trials":9162,"activeCount":98},[],{"trials":9164,"activeCount":98},[],{"trials":9166,"activeCount":98},[],{"intervention":9160,"totalTrials":109,"cells":9168},{"EARLY_PHASE1":9169,"PHASE1":9171,"PHASE2":9173,"PHASE3":9179,"PHASE4":9181,"NA":9183},{"trials":9170,"activeCount":98},[],{"trials":9172,"activeCount":98},[],{"trials":9174,"activeCount":98},[9175],{"nctId":9154,"briefTitle":9155,"status":152,"phases":9176,"primaryCompletion":9157,"completion":9157,"start":8457,"enrollment":3585,"conditions":9177,"interventions":9178},[87],[1034],[9145,9160],{"trials":9180,"activeCount":98},[],{"trials":9182,"activeCount":98},[],{"trials":9184,"activeCount":98},[],{"intervention":9186,"totalTrials":109,"cells":9187},"CDX-1401",{"EARLY_PHASE1":9188,"PHASE1":9190,"PHASE2":9192,"PHASE3":9201,"PHASE4":9203,"NA":9205},{"trials":9189,"activeCount":98},[],{"trials":9191,"activeCount":98},[],{"trials":9193,"activeCount":98},[9194],{"nctId":9195,"briefTitle":9196,"status":1051,"phases":9197,"primaryCompletion":6162,"completion":6162,"start":1148,"enrollment":98,"conditions":9198,"interventions":9199},"NCT02495636","Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer",[87],[8630],[9186,9200],"MPDL3280A",{"trials":9202,"activeCount":98},[],{"trials":9204,"activeCount":98},[],{"trials":9206,"activeCount":98},[],{"intervention":9200,"totalTrials":109,"cells":9208},{"EARLY_PHASE1":9209,"PHASE1":9211,"PHASE2":9213,"PHASE3":9219,"PHASE4":9221,"NA":9223},{"trials":9210,"activeCount":98},[],{"trials":9212,"activeCount":98},[],{"trials":9214,"activeCount":98},[9215],{"nctId":9195,"briefTitle":9196,"status":1051,"phases":9216,"primaryCompletion":6162,"completion":6162,"start":1148,"enrollment":98,"conditions":9217,"interventions":9218},[87],[8630],[9186,9200],{"trials":9220,"activeCount":98},[],{"trials":9222,"activeCount":98},[],{"trials":9224,"activeCount":98},[],{"intervention":9226,"totalTrials":109,"cells":9227},"CVL-562 (PF-06412562) 1 mg",{"EARLY_PHASE1":9228,"PHASE1":9230,"PHASE2":9232,"PHASE3":9246,"PHASE4":9248,"NA":9250},{"trials":9229,"activeCount":98},[],{"trials":9231,"activeCount":98},[],{"trials":9233,"activeCount":98},[9234],{"nctId":9235,"briefTitle":9236,"status":152,"phases":9237,"primaryCompletion":9238,"completion":9238,"start":9239,"enrollment":5895,"conditions":9240,"interventions":9242},"NCT04457310","A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia",[87],"2024-03-22","2021-03-02",[9241],"Early Course Schizophrenia Spectrum Disorder",[9226,9243,9244,9245],"CVL-562 (PF-06412562) 4 mg","CVL-562 (PF-06412562) 15 mg","CVL-562 (PF-06412562) 25 mg",{"trials":9247,"activeCount":98},[],{"trials":9249,"activeCount":98},[],{"trials":9251,"activeCount":98},[],{"intervention":9243,"totalTrials":109,"cells":9253},{"EARLY_PHASE1":9254,"PHASE1":9256,"PHASE2":9258,"PHASE3":9264,"PHASE4":9266,"NA":9268},{"trials":9255,"activeCount":98},[],{"trials":9257,"activeCount":98},[],{"trials":9259,"activeCount":98},[9260],{"nctId":9235,"briefTitle":9236,"status":152,"phases":9261,"primaryCompletion":9238,"completion":9238,"start":9239,"enrollment":5895,"conditions":9262,"interventions":9263},[87],[9241],[9226,9243,9244,9245],{"trials":9265,"activeCount":98},[],{"trials":9267,"activeCount":98},[],{"trials":9269,"activeCount":98},[],{"intervention":9244,"totalTrials":109,"cells":9271},{"EARLY_PHASE1":9272,"PHASE1":9274,"PHASE2":9276,"PHASE3":9282,"PHASE4":9284,"NA":9286},{"trials":9273,"activeCount":98},[],{"trials":9275,"activeCount":98},[],{"trials":9277,"activeCount":98},[9278],{"nctId":9235,"briefTitle":9236,"status":152,"phases":9279,"primaryCompletion":9238,"completion":9238,"start":9239,"enrollment":5895,"conditions":9280,"interventions":9281},[87],[9241],[9226,9243,9244,9245],{"trials":9283,"activeCount":98},[],{"trials":9285,"activeCount":98},[],{"trials":9287,"activeCount":98},[],{"intervention":9245,"totalTrials":109,"cells":9289},{"EARLY_PHASE1":9290,"PHASE1":9292,"PHASE2":9294,"PHASE3":9300,"PHASE4":9302,"NA":9304},{"trials":9291,"activeCount":98},[],{"trials":9293,"activeCount":98},[],{"trials":9295,"activeCount":98},[9296],{"nctId":9235,"briefTitle":9236,"status":152,"phases":9297,"primaryCompletion":9238,"completion":9238,"start":9239,"enrollment":5895,"conditions":9298,"interventions":9299},[87],[9241],[9226,9243,9244,9245],{"trials":9301,"activeCount":98},[],{"trials":9303,"activeCount":98},[],{"trials":9305,"activeCount":98},[],{"intervention":8092,"totalTrials":109,"cells":9307},{"EARLY_PHASE1":9308,"PHASE1":9310,"PHASE2":9312,"PHASE3":9318,"PHASE4":9320,"NA":9322},{"trials":9309,"activeCount":98},[],{"trials":9311,"activeCount":98},[],{"trials":9313,"activeCount":98},[9314],{"nctId":8082,"briefTitle":8083,"status":711,"phases":9315,"primaryCompletion":8085,"completion":8085,"start":8086,"enrollment":109,"conditions":9316,"interventions":9317},[87],[8088],[8090,8091,8092],{"trials":9319,"activeCount":98},[],{"trials":9321,"activeCount":98},[],{"trials":9323,"activeCount":98},[],{"intervention":7790,"totalTrials":109,"cells":9325},{"EARLY_PHASE1":9326,"PHASE1":9328,"PHASE2":9330,"PHASE3":9336,"PHASE4":9338,"NA":9340},{"trials":9327,"activeCount":98},[],{"trials":9329,"activeCount":98},[],{"trials":9331,"activeCount":98},[9332],{"nctId":7783,"briefTitle":7784,"status":152,"phases":9333,"primaryCompletion":1198,"completion":1198,"start":7786,"enrollment":1044,"conditions":9334,"interventions":9335},[87],[4403],[7755,7789,7790,7791,7792,7793],{"trials":9337,"activeCount":98},[],{"trials":9339,"activeCount":98},[],{"trials":9341,"activeCount":98},[],{"intervention":8066,"totalTrials":109,"cells":9343},{"EARLY_PHASE1":9344,"PHASE1":9346,"PHASE2":9348,"PHASE3":9354,"PHASE4":9356,"NA":9358},{"trials":9345,"activeCount":98},[],{"trials":9347,"activeCount":98},[],{"trials":9349,"activeCount":98},[9350],{"nctId":8059,"briefTitle":8060,"status":711,"phases":9351,"primaryCompletion":1166,"completion":1166,"start":2214,"enrollment":1815,"conditions":9352,"interventions":9353},[86,87],[8063,8064],[8035,8066],{"trials":9355,"activeCount":98},[],{"trials":9357,"activeCount":98},[],{"trials":9359,"activeCount":98},[],{"intervention":9361,"totalTrials":109,"cells":9362},"Folfirinox",{"EARLY_PHASE1":9363,"PHASE1":9365,"PHASE2":9367,"PHASE3":9377,"PHASE4":9379,"NA":9381},{"trials":9364,"activeCount":98},[],{"trials":9366,"activeCount":98},[],{"trials":9368,"activeCount":98},[9369],{"nctId":9370,"briefTitle":9371,"status":152,"phases":9372,"primaryCompletion":346,"completion":1742,"start":9373,"enrollment":4645,"conditions":9374,"interventions":9376},"NCT01523457","Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer",[87],"2011-10",[9375,2958],"Metastatic Pancreatic Cancer",[9361],{"trials":9378,"activeCount":98},[],{"trials":9380,"activeCount":98},[],{"trials":9382,"activeCount":98},[],{"intervention":9384,"totalTrials":109,"cells":9385},"Testosterone replacement",{"EARLY_PHASE1":9386,"PHASE1":9388,"PHASE2":9390,"PHASE3":9400,"PHASE4":9402,"NA":9404},{"trials":9387,"activeCount":98},[],{"trials":9389,"activeCount":98},[],{"trials":9391,"activeCount":98},[9392],{"nctId":9393,"briefTitle":9394,"status":152,"phases":9395,"primaryCompletion":714,"completion":714,"start":5846,"enrollment":141,"conditions":9396,"interventions":9399},"NCT01873989","Testosterone Replacement for Male Opioid Agonist Maintained Patients",[86,87],[184,9397,9398],"Opioid Addiction","Symptomatic Hypogonadism",[9384],{"trials":9401,"activeCount":98},[],{"trials":9403,"activeCount":98},[],{"trials":9405,"activeCount":98},[],{"intervention":9407,"totalTrials":109,"cells":9408},"NicVAX",{"EARLY_PHASE1":9409,"PHASE1":9411,"PHASE2":9413,"PHASE3":9422,"PHASE4":9424,"NA":9426},{"trials":9410,"activeCount":98},[],{"trials":9412,"activeCount":98},[],{"trials":9414,"activeCount":98},[9415],{"nctId":9416,"briefTitle":9417,"status":152,"phases":9418,"primaryCompletion":1031,"completion":1031,"start":180,"enrollment":1675,"conditions":9419,"interventions":9420},"NCT00996034","Nicotine Vaccination and Nicotinic Receptor Occupancy",[87],[24],[9407,9421],"Nicotine bitartrate",{"trials":9423,"activeCount":98},[],{"trials":9425,"activeCount":98},[],{"trials":9427,"activeCount":98},[],{"intervention":9421,"totalTrials":109,"cells":9429},{"EARLY_PHASE1":9430,"PHASE1":9432,"PHASE2":9434,"PHASE3":9440,"PHASE4":9442,"NA":9444},{"trials":9431,"activeCount":98},[],{"trials":9433,"activeCount":98},[],{"trials":9435,"activeCount":98},[9436],{"nctId":9416,"briefTitle":9417,"status":152,"phases":9437,"primaryCompletion":1031,"completion":1031,"start":180,"enrollment":1675,"conditions":9438,"interventions":9439},[87],[24],[9407,9421],{"trials":9441,"activeCount":98},[],{"trials":9443,"activeCount":98},[],{"trials":9445,"activeCount":98},[],{"intervention":9447,"totalTrials":109,"cells":9448},"Mazindol",{"EARLY_PHASE1":9449,"PHASE1":9451,"PHASE2":9453,"PHASE3":9461,"PHASE4":9463,"NA":9465},{"trials":9450,"activeCount":98},[],{"trials":9452,"activeCount":98},[],{"trials":9454,"activeCount":98},[9455],{"nctId":9456,"briefTitle":9457,"status":152,"phases":9458,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":98,"conditions":9459,"interventions":9460},"NCT00000277","Mazindol for Cocaine Abuse - 2",[87],[210],[9447],{"trials":9462,"activeCount":98},[],{"trials":9464,"activeCount":98},[],{"trials":9466,"activeCount":98},[],{"intervention":2386,"totalTrials":109,"cells":9468},{"EARLY_PHASE1":9469,"PHASE1":9471,"PHASE2":9473,"PHASE3":9479,"PHASE4":9481,"NA":9483},{"trials":9470,"activeCount":98},[],{"trials":9472,"activeCount":98},[],{"trials":9474,"activeCount":98},[9475],{"nctId":2377,"briefTitle":2378,"status":152,"phases":9476,"primaryCompletion":2380,"completion":2381,"start":2382,"enrollment":1305,"conditions":9477,"interventions":9478},[87],[2384],[2386,2368],{"trials":9480,"activeCount":98},[],{"trials":9482,"activeCount":98},[],{"trials":9484,"activeCount":98},[],{"intervention":9486,"totalTrials":109,"cells":9487},"CPX-351",{"EARLY_PHASE1":9488,"PHASE1":9490,"PHASE2":9492,"PHASE3":9503,"PHASE4":9505,"NA":9507},{"trials":9489,"activeCount":98},[],{"trials":9491,"activeCount":98},[],{"trials":9493,"activeCount":98},[9494],{"nctId":9495,"briefTitle":9496,"status":1051,"phases":9497,"primaryCompletion":9498,"completion":9498,"start":9499,"enrollment":98,"conditions":9500,"interventions":9502},"NCT04109690","CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.",[86,87],"2021-07-27","2019-12-30",[9501],"MDS",[9486],{"trials":9504,"activeCount":98},[],{"trials":9506,"activeCount":98},[],{"trials":9508,"activeCount":98},[],{"intervention":9510,"totalTrials":109,"cells":9511},"Endotoxin",{"EARLY_PHASE1":9512,"PHASE1":9514,"PHASE2":9516,"PHASE3":9526,"PHASE4":9528,"NA":9530},{"trials":9513,"activeCount":98},[],{"trials":9515,"activeCount":98},[],{"trials":9517,"activeCount":98},[9518],{"nctId":9519,"briefTitle":9520,"status":152,"phases":9521,"primaryCompletion":9522,"completion":9522,"start":9523,"enrollment":314,"conditions":9524,"interventions":9525},"NCT04527185","Effect of Endotoxin on Alcohol Consumption",[87],"2024-10-31","2022-02-27",[27],[9510],{"trials":9527,"activeCount":98},[],{"trials":9529,"activeCount":98},[],{"trials":9531,"activeCount":98},[],{"intervention":9533,"totalTrials":109,"cells":9534},"Fluzone High Dose Vaccine",{"EARLY_PHASE1":9535,"PHASE1":9537,"PHASE2":9539,"PHASE3":9552,"PHASE4":9554,"NA":9556},{"trials":9536,"activeCount":98},[],{"trials":9538,"activeCount":98},[],{"trials":9540,"activeCount":98},[9541],{"nctId":9542,"briefTitle":9543,"status":152,"phases":9544,"primaryCompletion":8456,"completion":5740,"start":1973,"enrollment":9545,"conditions":9546,"interventions":9550},"NCT02566265","Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients",[87],122,[2445,3474,9547,9548,9549],"Waldenstrom's Macroglobulinemia","Plasma Cell Disorders","MGUS",[9533,9551],"Standard of care\u002FPlacebo",{"trials":9553,"activeCount":98},[],{"trials":9555,"activeCount":98},[],{"trials":9557,"activeCount":98},[],{"intervention":9551,"totalTrials":109,"cells":9559},{"EARLY_PHASE1":9560,"PHASE1":9562,"PHASE2":9564,"PHASE3":9570,"PHASE4":9572,"NA":9574},{"trials":9561,"activeCount":98},[],{"trials":9563,"activeCount":98},[],{"trials":9565,"activeCount":98},[9566],{"nctId":9542,"briefTitle":9543,"status":152,"phases":9567,"primaryCompletion":8456,"completion":5740,"start":1973,"enrollment":9545,"conditions":9568,"interventions":9569},[87],[2445,3474,9547,9548,9549],[9533,9551],{"trials":9571,"activeCount":98},[],{"trials":9573,"activeCount":98},[],{"trials":9575,"activeCount":98},[],{"intervention":7875,"totalTrials":109,"cells":9577},{"EARLY_PHASE1":9578,"PHASE1":9580,"PHASE2":9582,"PHASE3":9588,"PHASE4":9590,"NA":9592},{"trials":9579,"activeCount":98},[],{"trials":9581,"activeCount":98},[],{"trials":9583,"activeCount":98},[9584],{"nctId":7867,"briefTitle":7868,"status":152,"phases":9585,"primaryCompletion":7870,"completion":7870,"start":7871,"enrollment":696,"conditions":9586,"interventions":9587},[87],[7873],[7875,6761],{"trials":9589,"activeCount":98},[],{"trials":9591,"activeCount":98},[],{"trials":9593,"activeCount":98},[],{"intervention":9595,"totalTrials":109,"cells":9596},"Pomalidomide",{"EARLY_PHASE1":9597,"PHASE1":9599,"PHASE2":9601,"PHASE3":9609,"PHASE4":9611,"NA":9613},{"trials":9598,"activeCount":98},[],{"trials":9600,"activeCount":98},[],{"trials":9602,"activeCount":98},[9603],{"nctId":9604,"briefTitle":9605,"status":152,"phases":9606,"primaryCompletion":5730,"completion":5730,"start":7871,"enrollment":1044,"conditions":9607,"interventions":9608},"NCT01319422","Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed\u002FRefractory Multiple Myeloma",[87],[3474],[9595],{"trials":9610,"activeCount":98},[],{"trials":9612,"activeCount":98},[],{"trials":9614,"activeCount":98},[],{"intervention":9616,"totalTrials":109,"cells":9617},"Memantine Hydrochloride",{"EARLY_PHASE1":9618,"PHASE1":9620,"PHASE2":9622,"PHASE3":9630,"PHASE4":9632,"NA":9634},{"trials":9619,"activeCount":98},[],{"trials":9621,"activeCount":98},[],{"trials":9623,"activeCount":98},[9624],{"nctId":9625,"briefTitle":9626,"status":152,"phases":9627,"primaryCompletion":1664,"completion":1664,"start":1665,"enrollment":36,"conditions":9628,"interventions":9629},"NCT00585169","Memantine Treatment Study of Pathological Gambling",[87],[1094],[9616],{"trials":9631,"activeCount":98},[],{"trials":9633,"activeCount":98},[],{"trials":9635,"activeCount":98},[],{"intervention":9637,"totalTrials":109,"cells":9638},"Ontak",{"EARLY_PHASE1":9639,"PHASE1":9641,"PHASE2":9643,"PHASE3":9653,"PHASE4":9655,"NA":9657},{"trials":9640,"activeCount":98},[],{"trials":9642,"activeCount":98},[],{"trials":9644,"activeCount":98},[9645],{"nctId":9646,"briefTitle":9647,"status":152,"phases":9648,"primaryCompletion":1665,"completion":1138,"start":1107,"enrollment":9130,"conditions":9649,"interventions":9651},"NCT00337987","A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma",[87],[9650],"Peripheral T-Cell Lymphoma",[9637,9652],"CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy",{"trials":9654,"activeCount":98},[],{"trials":9656,"activeCount":98},[],{"trials":9658,"activeCount":98},[],{"intervention":9652,"totalTrials":109,"cells":9660},{"EARLY_PHASE1":9661,"PHASE1":9663,"PHASE2":9665,"PHASE3":9671,"PHASE4":9673,"NA":9675},{"trials":9662,"activeCount":98},[],{"trials":9664,"activeCount":98},[],{"trials":9666,"activeCount":98},[9667],{"nctId":9646,"briefTitle":9647,"status":152,"phases":9668,"primaryCompletion":1665,"completion":1138,"start":1107,"enrollment":9130,"conditions":9669,"interventions":9670},[87],[9650],[9637,9652],{"trials":9672,"activeCount":98},[],{"trials":9674,"activeCount":98},[],{"trials":9676,"activeCount":98},[],{"intervention":9678,"totalTrials":109,"cells":9679},"CERC-501",{"EARLY_PHASE1":9680,"PHASE1":9682,"PHASE2":9684,"PHASE3":9694,"PHASE4":9696,"NA":9698},{"trials":9681,"activeCount":98},[],{"trials":9683,"activeCount":98},[],{"trials":9685,"activeCount":98},[9686],{"nctId":9687,"briefTitle":9688,"status":152,"phases":9689,"primaryCompletion":9690,"completion":9690,"start":9691,"enrollment":1815,"conditions":9692,"interventions":9693},"NCT02800928","Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?",[87],"2018-01-02","2016-06-30",[33],[9678],{"trials":9695,"activeCount":98},[],{"trials":9697,"activeCount":98},[],{"trials":9699,"activeCount":98},[],{"intervention":8687,"totalTrials":109,"cells":9701},{"EARLY_PHASE1":9702,"PHASE1":9704,"PHASE2":9706,"PHASE3":9712,"PHASE4":9714,"NA":9716},{"trials":9703,"activeCount":98},[],{"trials":9705,"activeCount":98},[],{"trials":9707,"activeCount":98},[9708],{"nctId":8682,"briefTitle":8683,"status":711,"phases":9709,"primaryCompletion":7604,"completion":7604,"start":6747,"enrollment":94,"conditions":9710,"interventions":9711},[87],[1495],[8673,8687],{"trials":9713,"activeCount":98},[],{"trials":9715,"activeCount":98},[],{"trials":9717,"activeCount":98},[],{"intervention":9719,"totalTrials":109,"cells":9720},"mAb hOKT3gamma1(Ala-Ala), Teplizumab",{"EARLY_PHASE1":9721,"PHASE1":9723,"PHASE2":9725,"PHASE3":9734,"PHASE4":9736,"NA":9738},{"trials":9722,"activeCount":98},[],{"trials":9724,"activeCount":98},[],{"trials":9726,"activeCount":98},[9727],{"nctId":9728,"briefTitle":9729,"status":152,"phases":9730,"primaryCompletion":7744,"completion":6766,"start":5871,"enrollment":3906,"conditions":9731,"interventions":9733},"NCT00378508","Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes",[87],[9732],"Type 1 Diabetes Mellitus",[9719],{"trials":9735,"activeCount":98},[],{"trials":9737,"activeCount":98},[],{"trials":9739,"activeCount":98},[],{"intervention":9741,"totalTrials":109,"cells":9742},"TAP block with liposomal bupivacaine and bupivacaine",{"EARLY_PHASE1":9743,"PHASE1":9745,"PHASE2":9747,"PHASE3":9757,"PHASE4":9759,"NA":9761},{"trials":9744,"activeCount":98},[],{"trials":9746,"activeCount":98},[],{"trials":9748,"activeCount":98},[9749],{"nctId":9750,"briefTitle":9751,"status":152,"phases":9752,"primaryCompletion":9753,"completion":9753,"start":1898,"enrollment":1424,"conditions":9754,"interventions":9756},"NCT04345341","Efficacy of Laparoscopic-assisted Transversus Abdominus Plane (TAP) Block Compared to Ultrasound-guided TAP Block in Minimally Invasive Gynecologic Surgeries: A Prospective, Randomized Control Trial.",[87],"2023-10-15",[9755],"the Efficacy of Analgesia of Laparoscopic TAP Block in Minimally Invasive Gynecology Surgeries",[9741],{"trials":9758,"activeCount":98},[],{"trials":9760,"activeCount":98},[],{"trials":9762,"activeCount":98},[],{"intervention":9764,"totalTrials":109,"cells":9765},"AZD0530 100mg daily",{"EARLY_PHASE1":9766,"PHASE1":9768,"PHASE2":9770,"PHASE3":9780,"PHASE4":9782,"NA":9784},{"trials":9767,"activeCount":98},[],{"trials":9769,"activeCount":98},[],{"trials":9771,"activeCount":98},[9772],{"nctId":9773,"briefTitle":9774,"status":152,"phases":9775,"primaryCompletion":4152,"completion":4152,"start":346,"enrollment":285,"conditions":9776,"interventions":9778},"NCT02167256","A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",[87],[9777],"Alzheimer's Disease",[9764,9779],"AZD0530 125mg daily",{"trials":9781,"activeCount":98},[],{"trials":9783,"activeCount":98},[],{"trials":9785,"activeCount":98},[],{"intervention":9779,"totalTrials":109,"cells":9787},{"EARLY_PHASE1":9788,"PHASE1":9790,"PHASE2":9792,"PHASE3":9798,"PHASE4":9800,"NA":9802},{"trials":9789,"activeCount":98},[],{"trials":9791,"activeCount":98},[],{"trials":9793,"activeCount":98},[9794],{"nctId":9773,"briefTitle":9774,"status":152,"phases":9795,"primaryCompletion":4152,"completion":4152,"start":346,"enrollment":285,"conditions":9796,"interventions":9797},[87],[9777],[9764,9779],{"trials":9799,"activeCount":98},[],{"trials":9801,"activeCount":98},[],{"trials":9803,"activeCount":98},[],{"intervention":9805,"totalTrials":109,"cells":9806},"Toradol",{"EARLY_PHASE1":9807,"PHASE1":9809,"PHASE2":9811,"PHASE3":9825,"PHASE4":9827,"NA":9829},{"trials":9808,"activeCount":98},[],{"trials":9810,"activeCount":98},[],{"trials":9812,"activeCount":98},[9813],{"nctId":9814,"briefTitle":9815,"status":152,"phases":9816,"primaryCompletion":9817,"completion":9817,"start":9818,"enrollment":9819,"conditions":9820,"interventions":9824},"NCT03111381","Toradol to Reduce Ureteroscopic Symptoms Trial",[87],"2020-06-01","2017-08-01",94,[9821,9822,9823,4689],"Urinary Lithiasis","Kidney Diseases","Kidney Stone",[9805],{"trials":9826,"activeCount":98},[],{"trials":9828,"activeCount":98},[],{"trials":9830,"activeCount":98},[],{"intervention":9832,"totalTrials":109,"cells":9833},"Dronabinol and Palmitoylethanolamide",{"EARLY_PHASE1":9834,"PHASE1":9836,"PHASE2":9838,"PHASE3":9848,"PHASE4":9850,"NA":9852},{"trials":9835,"activeCount":98},[],{"trials":9837,"activeCount":98},[],{"trials":9839,"activeCount":98},[9840],{"nctId":9841,"briefTitle":9842,"status":152,"phases":9843,"primaryCompletion":9844,"completion":9844,"start":9845,"enrollment":1815,"conditions":9846,"interventions":9847},"NCT03066193","Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome",[87],"2018-06-28","2017-02-01",[5849],[9832],{"trials":9849,"activeCount":98},[],{"trials":9851,"activeCount":98},[],{"trials":9853,"activeCount":98},[],{"intervention":9855,"totalTrials":109,"cells":9856},"All-trans retinoic acid",{"EARLY_PHASE1":9857,"PHASE1":9859,"PHASE2":9861,"PHASE3":9873,"PHASE4":9875,"NA":9877},{"trials":9858,"activeCount":98},[],{"trials":9860,"activeCount":98},[],{"trials":9862,"activeCount":98},[9863],{"nctId":9864,"briefTitle":9865,"status":711,"phases":9866,"primaryCompletion":9867,"completion":9868,"start":9869,"enrollment":263,"conditions":9870,"interventions":9872},"NCT03359174","An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis",[87],"2020-12-01","2021-01-01","2018-05-29",[9871],"Cholangitis, Sclerosing",[9855],{"trials":9874,"activeCount":98},[],{"trials":9876,"activeCount":98},[],{"trials":9878,"activeCount":98},[],{"intervention":1076,"totalTrials":109,"cells":9880},{"EARLY_PHASE1":9881,"PHASE1":9883,"PHASE2":9885,"PHASE3":9891,"PHASE4":9893,"NA":9895},{"trials":9882,"activeCount":98},[],{"trials":9884,"activeCount":98},[],{"trials":9886,"activeCount":98},[9887],{"nctId":1068,"briefTitle":1069,"status":152,"phases":9888,"primaryCompletion":1071,"completion":1072,"start":154,"enrollment":1073,"conditions":9889,"interventions":9890},[87],[24],[890,1076],{"trials":9892,"activeCount":98},[],{"trials":9894,"activeCount":98},[],{"trials":9896,"activeCount":98},[],{"intervention":9898,"totalTrials":109,"cells":9899},"tPA standard dosage",{"EARLY_PHASE1":9900,"PHASE1":9902,"PHASE2":9904,"PHASE3":9916,"PHASE4":9918,"NA":9920},{"trials":9901,"activeCount":98},[],{"trials":9903,"activeCount":98},[],{"trials":9905,"activeCount":98},[9906],{"nctId":9907,"briefTitle":9908,"status":1051,"phases":9909,"primaryCompletion":9910,"completion":9910,"start":9911,"enrollment":98,"conditions":9912,"interventions":9914},"NCT03678090","The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.",[87],"2020-02-28","2018-12-01",[6228,9913],"Cancer, Lung",[9898,9915],"tPA low dosage",{"trials":9917,"activeCount":98},[],{"trials":9919,"activeCount":98},[],{"trials":9921,"activeCount":98},[],{"intervention":9915,"totalTrials":109,"cells":9923},{"EARLY_PHASE1":9924,"PHASE1":9926,"PHASE2":9928,"PHASE3":9934,"PHASE4":9936,"NA":9938},{"trials":9925,"activeCount":98},[],{"trials":9927,"activeCount":98},[],{"trials":9929,"activeCount":98},[9930],{"nctId":9907,"briefTitle":9908,"status":1051,"phases":9931,"primaryCompletion":9910,"completion":9910,"start":9911,"enrollment":98,"conditions":9932,"interventions":9933},[87],[6228,9913],[9898,9915],{"trials":9935,"activeCount":98},[],{"trials":9937,"activeCount":98},[],{"trials":9939,"activeCount":98},[],{"intervention":9941,"totalTrials":109,"cells":9942},"Temozolomide + Olaparib",{"EARLY_PHASE1":9943,"PHASE1":9945,"PHASE2":9947,"PHASE3":9957,"PHASE4":9959,"NA":9961},{"trials":9944,"activeCount":98},[],{"trials":9946,"activeCount":98},[],{"trials":9948,"activeCount":98},[9949],{"nctId":9950,"briefTitle":9951,"status":152,"phases":9952,"primaryCompletion":9953,"completion":6509,"start":9954,"enrollment":6758,"conditions":9955,"interventions":9956},"NCT04166435","TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer",[87],"2022-01-06","2020-06-17",[8800],[9941],{"trials":9958,"activeCount":98},[],{"trials":9960,"activeCount":98},[],{"trials":9962,"activeCount":98},[],{"intervention":9964,"totalTrials":109,"cells":9965},"Pentostatin",{"EARLY_PHASE1":9966,"PHASE1":9968,"PHASE2":9970,"PHASE3":9979,"PHASE4":9981,"NA":9983},{"trials":9967,"activeCount":98},[],{"trials":9969,"activeCount":98},[],{"trials":9971,"activeCount":98},[9972],{"nctId":9973,"briefTitle":9974,"status":152,"phases":9975,"primaryCompletion":1858,"completion":1983,"start":726,"enrollment":1675,"conditions":9976,"interventions":9978},"NCT00402714","A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies",[87],[9977],"Hematologic Malignancies",[9964,9964],{"trials":9980,"activeCount":98},[],{"trials":9982,"activeCount":98},[],{"trials":9984,"activeCount":98},[],{"intervention":9986,"totalTrials":109,"cells":9987},"Tofacitinib 10 mg",{"EARLY_PHASE1":9988,"PHASE1":9990,"PHASE2":9992,"PHASE3":10003,"PHASE4":10005,"NA":10007},{"trials":9989,"activeCount":98},[],{"trials":9991,"activeCount":98},[],{"trials":9993,"activeCount":98},[9994],{"nctId":9995,"briefTitle":9996,"status":711,"phases":9997,"primaryCompletion":9998,"completion":9998,"start":9999,"enrollment":2659,"conditions":10000,"interventions":10002},"NCT04415151","Tofacitinib for Treatment of Moderate COVID-19",[87],"2021-02-28","2020-10-14",[10001],"COVID-19 Pneumonia",[9986],{"trials":10004,"activeCount":98},[],{"trials":10006,"activeCount":98},[],{"trials":10008,"activeCount":98},[],{"intervention":10010,"totalTrials":109,"cells":10011},"Pemoline",{"EARLY_PHASE1":10012,"PHASE1":10014,"PHASE2":10016,"PHASE3":10024,"PHASE4":10026,"NA":10028},{"trials":10013,"activeCount":98},[],{"trials":10015,"activeCount":98},[],{"trials":10017,"activeCount":98},[10018],{"nctId":10019,"briefTitle":10020,"status":152,"phases":10021,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":98,"conditions":10022,"interventions":10023},"NCT00000282","Pemoline for Cocaine Abuse - 7",[87],[210],[10010],{"trials":10025,"activeCount":98},[],{"trials":10027,"activeCount":98},[],{"trials":10029,"activeCount":98},[],{"intervention":10031,"totalTrials":109,"cells":10032},"Pembrolizumab and Ramucirumab",{"EARLY_PHASE1":10033,"PHASE1":10035,"PHASE2":10037,"PHASE3":10049,"PHASE4":10051,"NA":10053},{"trials":10034,"activeCount":98},[],{"trials":10036,"activeCount":98},[],{"trials":10038,"activeCount":98},[10039],{"nctId":10040,"briefTitle":10041,"status":1051,"phases":10042,"primaryCompletion":10043,"completion":10044,"start":10045,"enrollment":98,"conditions":10046,"interventions":10048},"NCT04179110","Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor",[87],"2022-12-15","2023-06-15","2020-09-18",[10047],"Transitional Cell Carcinoma",[10031],{"trials":10050,"activeCount":98},[],{"trials":10052,"activeCount":98},[],{"trials":10054,"activeCount":98},[],{"intervention":10056,"totalTrials":109,"cells":10057},"Taltz",{"EARLY_PHASE1":10058,"PHASE1":10060,"PHASE2":10062,"PHASE3":10073,"PHASE4":10075,"NA":10077},{"trials":10059,"activeCount":98},[],{"trials":10061,"activeCount":98},[],{"trials":10063,"activeCount":98},[10064],{"nctId":10065,"briefTitle":10066,"status":152,"phases":10067,"primaryCompletion":10068,"completion":10068,"start":10069,"enrollment":1315,"conditions":10070,"interventions":10072},"NCT05309616","Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis",[87],"2026-05-19","2025-02-20",[10071],"Idiopathic Subglottic Stenosis",[10056],{"trials":10074,"activeCount":98},[],{"trials":10076,"activeCount":98},[],{"trials":10078,"activeCount":98},[],{"intervention":7801,"totalTrials":109,"cells":10080},{"EARLY_PHASE1":10081,"PHASE1":10083,"PHASE2":10085,"PHASE3":10091,"PHASE4":10093,"NA":10095},{"trials":10082,"activeCount":98},[],{"trials":10084,"activeCount":98},[],{"trials":10086,"activeCount":98},[10087],{"nctId":7795,"briefTitle":7796,"status":152,"phases":10088,"primaryCompletion":7798,"completion":7798,"start":7786,"enrollment":7420,"conditions":10089,"interventions":10090},[87],[4403],[7755,7789,7801,7802,7792],{"trials":10092,"activeCount":98},[],{"trials":10094,"activeCount":98},[],{"trials":10096,"activeCount":98},[],{"intervention":1763,"totalTrials":109,"cells":10098},{"EARLY_PHASE1":10099,"PHASE1":10101,"PHASE2":10103,"PHASE3":10109,"PHASE4":10111,"NA":10113},{"trials":10100,"activeCount":98},[],{"trials":10102,"activeCount":98},[],{"trials":10104,"activeCount":98},[10105],{"nctId":1756,"briefTitle":1757,"status":1051,"phases":10106,"primaryCompletion":1759,"completion":1759,"start":1759,"enrollment":98,"conditions":10107,"interventions":10108},[87],[1761],[1608,1763],{"trials":10110,"activeCount":98},[],{"trials":10112,"activeCount":98},[],{"trials":10114,"activeCount":98},[],{"intervention":8013,"totalTrials":109,"cells":10116},{"EARLY_PHASE1":10117,"PHASE1":10119,"PHASE2":10121,"PHASE3":10127,"PHASE4":10129,"NA":10131},{"trials":10118,"activeCount":98},[],{"trials":10120,"activeCount":98},[],{"trials":10122,"activeCount":98},[10123],{"nctId":8000,"briefTitle":8001,"status":152,"phases":10124,"primaryCompletion":8003,"completion":8004,"start":8005,"enrollment":19,"conditions":10125,"interventions":10126},[87],[8007,8008,8009,8010,8011],[8013,8014,2260,8015],{"trials":10128,"activeCount":98},[],{"trials":10130,"activeCount":98},[],{"trials":10132,"activeCount":98},[],{"intervention":8014,"totalTrials":109,"cells":10134},{"EARLY_PHASE1":10135,"PHASE1":10137,"PHASE2":10139,"PHASE3":10145,"PHASE4":10147,"NA":10149},{"trials":10136,"activeCount":98},[],{"trials":10138,"activeCount":98},[],{"trials":10140,"activeCount":98},[10141],{"nctId":8000,"briefTitle":8001,"status":152,"phases":10142,"primaryCompletion":8003,"completion":8004,"start":8005,"enrollment":19,"conditions":10143,"interventions":10144},[87],[8007,8008,8009,8010,8011],[8013,8014,2260,8015],{"trials":10146,"activeCount":98},[],{"trials":10148,"activeCount":98},[],{"trials":10150,"activeCount":98},[],{"intervention":8015,"totalTrials":109,"cells":10152},{"EARLY_PHASE1":10153,"PHASE1":10155,"PHASE2":10157,"PHASE3":10163,"PHASE4":10165,"NA":10167},{"trials":10154,"activeCount":98},[],{"trials":10156,"activeCount":98},[],{"trials":10158,"activeCount":98},[10159],{"nctId":8000,"briefTitle":8001,"status":152,"phases":10160,"primaryCompletion":8003,"completion":8004,"start":8005,"enrollment":19,"conditions":10161,"interventions":10162},[87],[8007,8008,8009,8010,8011],[8013,8014,2260,8015],{"trials":10164,"activeCount":98},[],{"trials":10166,"activeCount":98},[],{"trials":10168,"activeCount":98},[],{"intervention":10170,"totalTrials":109,"cells":10171},"Propofol-Ketamine",{"EARLY_PHASE1":10172,"PHASE1":10174,"PHASE2":10176,"PHASE3":10186,"PHASE4":10188,"NA":10190},{"trials":10173,"activeCount":98},[],{"trials":10175,"activeCount":98},[],{"trials":10177,"activeCount":98},[10178],{"nctId":10179,"briefTitle":10180,"status":1051,"phases":10181,"primaryCompletion":4079,"completion":8199,"start":714,"enrollment":98,"conditions":10182,"interventions":10184},"NCT02282891","Compare the Effect of Propofol vs. \"Ketofol\" on Hemodynamic Stability During Induction of General Anesthesia",[87],[10183],"Patients With \"ASA 3\" Designation",[10185,10170],"Propofol",{"trials":10187,"activeCount":98},[],{"trials":10189,"activeCount":98},[],{"trials":10191,"activeCount":98},[],{"intervention":7671,"totalTrials":109,"cells":10193},{"EARLY_PHASE1":10194,"PHASE1":10196,"PHASE2":10198,"PHASE3":10204,"PHASE4":10206,"NA":10208},{"trials":10195,"activeCount":98},[],{"trials":10197,"activeCount":98},[],{"trials":10199,"activeCount":98},[10200],{"nctId":7664,"briefTitle":7665,"status":152,"phases":10201,"primaryCompletion":1031,"completion":1031,"start":164,"enrollment":1878,"conditions":10202,"interventions":10203},[87],[7668],[7670,7671,7672],{"trials":10205,"activeCount":98},[],{"trials":10207,"activeCount":98},[],{"trials":10209,"activeCount":98},[],{"intervention":7672,"totalTrials":109,"cells":10211},{"EARLY_PHASE1":10212,"PHASE1":10214,"PHASE2":10216,"PHASE3":10222,"PHASE4":10224,"NA":10226},{"trials":10213,"activeCount":98},[],{"trials":10215,"activeCount":98},[],{"trials":10217,"activeCount":98},[10218],{"nctId":7664,"briefTitle":7665,"status":152,"phases":10219,"primaryCompletion":1031,"completion":1031,"start":164,"enrollment":1878,"conditions":10220,"interventions":10221},[87],[7668],[7670,7671,7672],{"trials":10223,"activeCount":98},[],{"trials":10225,"activeCount":98},[],{"trials":10227,"activeCount":98},[],{"intervention":10229,"totalTrials":109,"cells":10230},"Intraoperative providone-iodine lavage",{"EARLY_PHASE1":10231,"PHASE1":10233,"PHASE2":10235,"PHASE3":10247,"PHASE4":10249,"NA":10251},{"trials":10232,"activeCount":98},[],{"trials":10234,"activeCount":98},[],{"trials":10236,"activeCount":98},[10237],{"nctId":10238,"briefTitle":10239,"status":1051,"phases":10240,"primaryCompletion":10241,"completion":10242,"start":10243,"enrollment":98,"conditions":10244,"interventions":10246},"NCT04371458","Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies",[86,87],"2025-07","2030-07","2020-07",[10245],"Stage IVA Thymoma",[10229],{"trials":10248,"activeCount":98},[],{"trials":10250,"activeCount":98},[],{"trials":10252,"activeCount":98},[],{"intervention":733,"totalTrials":109,"cells":10254},{"EARLY_PHASE1":10255,"PHASE1":10257,"PHASE2":10259,"PHASE3":10265,"PHASE4":10267,"NA":10269},{"trials":10256,"activeCount":98},[],{"trials":10258,"activeCount":98},[],{"trials":10260,"activeCount":98},[10261],{"nctId":723,"briefTitle":724,"status":152,"phases":10262,"completion":726,"start":727,"enrollment":728,"conditions":10263,"interventions":10264},[87],[730],[732,704,733],{"trials":10266,"activeCount":98},[],{"trials":10268,"activeCount":98},[],{"trials":10270,"activeCount":98},[],{"intervention":8409,"totalTrials":109,"cells":10272},{"EARLY_PHASE1":10273,"PHASE1":10275,"PHASE2":10277,"PHASE3":10283,"PHASE4":10285,"NA":10287},{"trials":10274,"activeCount":98},[],{"trials":10276,"activeCount":98},[],{"trials":10278,"activeCount":98},[10279],{"nctId":8402,"briefTitle":8403,"status":152,"phases":10280,"primaryCompletion":8405,"completion":8405,"start":8406,"enrollment":1512,"conditions":10281,"interventions":10282},[86,87],[2258],[8409,7769],{"trials":10284,"activeCount":98},[],{"trials":10286,"activeCount":98},[],{"trials":10288,"activeCount":98},[],{"intervention":10290,"totalTrials":109,"cells":10291},"combination nivolumab and ipilimumab",{"EARLY_PHASE1":10292,"PHASE1":10294,"PHASE2":10296,"PHASE3":10307,"PHASE4":10309,"NA":10311},{"trials":10293,"activeCount":98},[],{"trials":10295,"activeCount":98},[],{"trials":10297,"activeCount":98},[10298],{"nctId":10299,"briefTitle":10300,"status":152,"phases":10301,"primaryCompletion":10302,"completion":10302,"start":10303,"enrollment":118,"conditions":10304,"interventions":10306},"NCT03262779","Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.",[87],"2022-01-14","2017-07-20",[10305],"Carcinoma, Non-Small-Cell Lung",[10290],{"trials":10308,"activeCount":98},[],{"trials":10310,"activeCount":98},[],{"trials":10312,"activeCount":98},[],{"intervention":10314,"totalTrials":109,"cells":10315},"AbobotulinumtoxinA Treatment",{"EARLY_PHASE1":10316,"PHASE1":10318,"PHASE2":10320,"PHASE3":10330,"PHASE4":10332,"NA":10334},{"trials":10317,"activeCount":98},[],{"trials":10319,"activeCount":98},[],{"trials":10321,"activeCount":98},[10322],{"nctId":10323,"briefTitle":10324,"status":711,"phases":10325,"primaryCompletion":1973,"completion":1973,"start":1186,"enrollment":10326,"conditions":10327,"interventions":10329},"NCT02221648","Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain",[87],43,[10328],"Lower Back Pain",[10314],{"trials":10331,"activeCount":98},[],{"trials":10333,"activeCount":98},[],{"trials":10335,"activeCount":98},[],{"intervention":10337,"totalTrials":109,"cells":10338},"Tofacitinib ointment",{"EARLY_PHASE1":10339,"PHASE1":10341,"PHASE2":10343,"PHASE3":10354,"PHASE4":10356,"NA":10358},{"trials":10340,"activeCount":98},[],{"trials":10342,"activeCount":98},[],{"trials":10344,"activeCount":98},[10345],{"nctId":10346,"briefTitle":10347,"status":152,"phases":10348,"primaryCompletion":6163,"completion":9129,"start":1164,"enrollment":1315,"conditions":10349,"interventions":10353},"NCT02812342","Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants",[87],[10350,10351,10352],"Alopecia Areata","Alopecia Totalis","Alopecia Universalis",[10337],{"trials":10355,"activeCount":98},[],{"trials":10357,"activeCount":98},[],{"trials":10359,"activeCount":98},[],{"intervention":8494,"totalTrials":109,"cells":10361},{"EARLY_PHASE1":10362,"PHASE1":10364,"PHASE2":10366,"PHASE3":10372,"PHASE4":10374,"NA":10376},{"trials":10363,"activeCount":98},[],{"trials":10365,"activeCount":98},[],{"trials":10367,"activeCount":98},[10368],{"nctId":8488,"briefTitle":8489,"status":152,"phases":10369,"primaryCompletion":8491,"completion":8491,"start":1081,"enrollment":1512,"conditions":10370,"interventions":10371},[86,87],[2958],[7712,8494],{"trials":10373,"activeCount":98},[],{"trials":10375,"activeCount":98},[],{"trials":10377,"activeCount":98},[],{"intervention":10379,"totalTrials":109,"cells":10380},"Ropivacaine",{"EARLY_PHASE1":10381,"PHASE1":10383,"PHASE2":10385,"PHASE3":10398,"PHASE4":10400,"NA":10402},{"trials":10382,"activeCount":98},[],{"trials":10384,"activeCount":98},[],{"trials":10386,"activeCount":98},[10387],{"nctId":10388,"briefTitle":10389,"status":152,"phases":10390,"primaryCompletion":10391,"completion":10391,"start":10392,"enrollment":10393,"conditions":10394,"interventions":10396},"NCT03977454","Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty",[87],"2021-06-19","2019-11-11",192,[10395],"Hip Arthropathy",[10379,10397],"Dex",{"trials":10399,"activeCount":98},[],{"trials":10401,"activeCount":98},[],{"trials":10403,"activeCount":98},[],{"intervention":10397,"totalTrials":109,"cells":10405},{"EARLY_PHASE1":10406,"PHASE1":10408,"PHASE2":10410,"PHASE3":10416,"PHASE4":10418,"NA":10420},{"trials":10407,"activeCount":98},[],{"trials":10409,"activeCount":98},[],{"trials":10411,"activeCount":98},[10412],{"nctId":10388,"briefTitle":10389,"status":152,"phases":10413,"primaryCompletion":10391,"completion":10391,"start":10392,"enrollment":10393,"conditions":10414,"interventions":10415},[87],[10395],[10379,10397],{"trials":10417,"activeCount":98},[],{"trials":10419,"activeCount":98},[],{"trials":10421,"activeCount":98},[],{"intervention":10423,"totalTrials":109,"cells":10424},"Antioxidant Supplement",{"EARLY_PHASE1":10425,"PHASE1":10427,"PHASE2":10429,"PHASE3":10440,"PHASE4":10442,"NA":10444},{"trials":10426,"activeCount":98},[],{"trials":10428,"activeCount":98},[],{"trials":10430,"activeCount":98},[10431],{"nctId":10432,"briefTitle":10433,"status":152,"phases":10434,"primaryCompletion":10435,"completion":9129,"start":1742,"enrollment":10436,"conditions":10437,"interventions":10439},"NCT02421887","Males, Antioxidants, and Infertility Trial",[87],"2018-06-11",171,[10438],"Male Infertility",[10423],{"trials":10441,"activeCount":98},[],{"trials":10443,"activeCount":98},[],{"trials":10445,"activeCount":98},[],{"intervention":2044,"totalTrials":109,"cells":10447},{"EARLY_PHASE1":10448,"PHASE1":10450,"PHASE2":10452,"PHASE3":10458,"PHASE4":10460,"NA":10462},{"trials":10449,"activeCount":98},[],{"trials":10451,"activeCount":98},[],{"trials":10453,"activeCount":98},[10454],{"nctId":2034,"briefTitle":2035,"status":1051,"phases":10455,"primaryCompletion":2037,"completion":2038,"start":2039,"enrollment":98,"conditions":10456,"interventions":10457},[87],[2041,2042],[2044,1590],{"trials":10459,"activeCount":98},[],{"trials":10461,"activeCount":98},[],{"trials":10463,"activeCount":98},[],{"intervention":10465,"totalTrials":109,"cells":10466},"Intratumoral G100",{"EARLY_PHASE1":10467,"PHASE1":10469,"PHASE2":10471,"PHASE3":10482,"PHASE4":10484,"NA":10486},{"trials":10468,"activeCount":98},[],{"trials":10470,"activeCount":98},[],{"trials":10472,"activeCount":98},[10473],{"nctId":10474,"briefTitle":10475,"status":1051,"phases":10476,"primaryCompletion":2319,"completion":10477,"start":10478,"enrollment":98,"conditions":10479,"interventions":10481},"NCT03742804","Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma",[87],"2022-12","2019-06",[10480],"Lymphoma, T-Cell, Cutaneous",[10465],{"trials":10483,"activeCount":98},[],{"trials":10485,"activeCount":98},[],{"trials":10487,"activeCount":98},[],{"intervention":10489,"totalTrials":109,"cells":10490},"Gentamicin",{"EARLY_PHASE1":10491,"PHASE1":10493,"PHASE2":10495,"PHASE3":10507,"PHASE4":10509,"NA":10511},{"trials":10492,"activeCount":98},[],{"trials":10494,"activeCount":98},[],{"trials":10496,"activeCount":98},[10497],{"nctId":10498,"briefTitle":10499,"status":1051,"phases":10500,"primaryCompletion":10501,"completion":10501,"start":10502,"enrollment":98,"conditions":10503,"interventions":10506},"NCT06007352","Use of Antibiotic Based Irrigation for Ureteroscopic Treatment of Urolithiasis",[87],"2025-10","2024-10",[10504,10505],"Urinary Tract Infections","Sepsis",[10489],{"trials":10508,"activeCount":98},[],{"trials":10510,"activeCount":98},[],{"trials":10512,"activeCount":98},[],{"intervention":10514,"totalTrials":109,"cells":10515},"Tofacitinib Administration",{"EARLY_PHASE1":10516,"PHASE1":10518,"PHASE2":10520,"PHASE3":10531,"PHASE4":10533,"NA":10535},{"trials":10517,"activeCount":98},[],{"trials":10519,"activeCount":98},[],{"trials":10521,"activeCount":98},[10522],{"nctId":10523,"briefTitle":10524,"status":152,"phases":10525,"primaryCompletion":1148,"completion":1148,"start":1848,"enrollment":31,"conditions":10526,"interventions":10530},"NCT02197455","Tofacitnib for the Treatment of Alopecia Areata and Variants",[87],[10527,10528,10529],"Alopecia Areata (AA)","Alopecia Totalis (AT)","Alopecia Universalis (AU)",[10514],{"trials":10532,"activeCount":98},[],{"trials":10534,"activeCount":98},[],{"trials":10536,"activeCount":98},[],{"intervention":10538,"totalTrials":109,"cells":10539},"Nintedanib and AML induction",{"EARLY_PHASE1":10540,"PHASE1":10542,"PHASE2":10544,"PHASE3":10556,"PHASE4":10558,"NA":10560},{"trials":10541,"activeCount":98},[],{"trials":10543,"activeCount":98},[],{"trials":10545,"activeCount":98},[10546],{"nctId":10547,"briefTitle":10548,"status":152,"phases":10549,"primaryCompletion":10550,"completion":10551,"start":10552,"enrollment":1512,"conditions":10553,"interventions":10555},"NCT02665143","A Randomized Trial of a Combination of Nintedanib\u002FPlacebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia",[87],"2021-03-08","2021-03-30","2016-07-21",[10554],"Relapsed\u002FRefractory Acute Myeloid Leukemia",[10538],{"trials":10557,"activeCount":98},[],{"trials":10559,"activeCount":98},[],{"trials":10561,"activeCount":98},[],{"intervention":10563,"totalTrials":109,"cells":10564},"Camostat Mesilate",{"EARLY_PHASE1":10565,"PHASE1":10567,"PHASE2":10569,"PHASE3":10579,"PHASE4":10581,"NA":10583},{"trials":10566,"activeCount":98},[],{"trials":10568,"activeCount":98},[],{"trials":10570,"activeCount":98},[10571],{"nctId":10572,"briefTitle":10573,"status":152,"phases":10574,"primaryCompletion":10575,"completion":10576,"start":8999,"enrollment":3585,"conditions":10577,"interventions":10578},"NCT04353284","Camostat Mesylate in COVID-19 Outpatients",[87],"2021-03-03","2021-04-22",[7240],[10563],{"trials":10580,"activeCount":98},[],{"trials":10582,"activeCount":98},[],{"trials":10584,"activeCount":98},[],{"intervention":7887,"totalTrials":109,"cells":10586},{"EARLY_PHASE1":10587,"PHASE1":10589,"PHASE2":10591,"PHASE3":10597,"PHASE4":10599,"NA":10601},{"trials":10588,"activeCount":98},[],{"trials":10590,"activeCount":98},[],{"trials":10592,"activeCount":98},[10593],{"nctId":7881,"briefTitle":7882,"status":152,"phases":10594,"primaryCompletion":2194,"completion":2194,"start":5742,"enrollment":1305,"conditions":10595,"interventions":10596},[87],[7885],[7887,6761,7888,7889,7890,7891],{"trials":10598,"activeCount":98},[],{"trials":10600,"activeCount":98},[],{"trials":10602,"activeCount":98},[],{"intervention":7889,"totalTrials":109,"cells":10604},{"EARLY_PHASE1":10605,"PHASE1":10607,"PHASE2":10609,"PHASE3":10615,"PHASE4":10617,"NA":10619},{"trials":10606,"activeCount":98},[],{"trials":10608,"activeCount":98},[],{"trials":10610,"activeCount":98},[10611],{"nctId":7881,"briefTitle":7882,"status":152,"phases":10612,"primaryCompletion":2194,"completion":2194,"start":5742,"enrollment":1305,"conditions":10613,"interventions":10614},[87],[7885],[7887,6761,7888,7889,7890,7891],{"trials":10616,"activeCount":98},[],{"trials":10618,"activeCount":98},[],{"trials":10620,"activeCount":98},[],{"intervention":7890,"totalTrials":109,"cells":10622},{"EARLY_PHASE1":10623,"PHASE1":10625,"PHASE2":10627,"PHASE3":10633,"PHASE4":10635,"NA":10637},{"trials":10624,"activeCount":98},[],{"trials":10626,"activeCount":98},[],{"trials":10628,"activeCount":98},[10629],{"nctId":7881,"briefTitle":7882,"status":152,"phases":10630,"primaryCompletion":2194,"completion":2194,"start":5742,"enrollment":1305,"conditions":10631,"interventions":10632},[87],[7885],[7887,6761,7888,7889,7890,7891],{"trials":10634,"activeCount":98},[],{"trials":10636,"activeCount":98},[],{"trials":10638,"activeCount":98},[],{"intervention":10640,"totalTrials":109,"cells":10641},"Extended Varenicline Pretreatment",{"EARLY_PHASE1":10642,"PHASE1":10644,"PHASE2":10646,"PHASE3":10656,"PHASE4":10658,"NA":10660},{"trials":10643,"activeCount":98},[],{"trials":10645,"activeCount":98},[],{"trials":10647,"activeCount":98},[10648],{"nctId":10649,"briefTitle":10650,"status":152,"phases":10651,"primaryCompletion":6706,"completion":6706,"start":10652,"enrollment":31,"conditions":10653,"interventions":10654},"NCT00860028","Varenicline for Smoking Cessation in Heavy Drinking Smokers",[87],"2008-10",[24,33,1880],[10640,10655],"Short-term Varenicline Pretreatment",{"trials":10657,"activeCount":98},[],{"trials":10659,"activeCount":98},[],{"trials":10661,"activeCount":98},[],{"intervention":10655,"totalTrials":109,"cells":10663},{"EARLY_PHASE1":10664,"PHASE1":10666,"PHASE2":10668,"PHASE3":10674,"PHASE4":10676,"NA":10678},{"trials":10665,"activeCount":98},[],{"trials":10667,"activeCount":98},[],{"trials":10669,"activeCount":98},[10670],{"nctId":10649,"briefTitle":10650,"status":152,"phases":10671,"primaryCompletion":6706,"completion":6706,"start":10652,"enrollment":31,"conditions":10672,"interventions":10673},[87],[24,33,1880],[10640,10655],{"trials":10675,"activeCount":98},[],{"trials":10677,"activeCount":98},[],{"trials":10679,"activeCount":98},[],{"intervention":8381,"totalTrials":109,"cells":10681},{"EARLY_PHASE1":10682,"PHASE1":10684,"PHASE2":10686,"PHASE3":10692,"PHASE4":10694,"NA":10696},{"trials":10683,"activeCount":98},[],{"trials":10685,"activeCount":98},[],{"trials":10687,"activeCount":98},[10688],{"nctId":8373,"briefTitle":8374,"status":152,"phases":10689,"primaryCompletion":1186,"completion":1210,"start":6747,"enrollment":8376,"conditions":10690,"interventions":10691},[87],[8378],[8380,8381,8382],{"trials":10693,"activeCount":98},[],{"trials":10695,"activeCount":98},[],{"trials":10697,"activeCount":98},[],{"intervention":4084,"totalTrials":109,"cells":10699},{"EARLY_PHASE1":10700,"PHASE1":10702,"PHASE2":10704,"PHASE3":10710,"PHASE4":10712,"NA":10714},{"trials":10701,"activeCount":98},[],{"trials":10703,"activeCount":98},[],{"trials":10705,"activeCount":98},[10706],{"nctId":4076,"briefTitle":4077,"status":711,"phases":10707,"primaryCompletion":4079,"completion":4079,"start":4080,"enrollment":263,"conditions":10708,"interventions":10709},[87],[4082],[4059,4084,4085],{"trials":10711,"activeCount":98},[],{"trials":10713,"activeCount":98},[],{"trials":10715,"activeCount":98},[],{"intervention":4085,"totalTrials":109,"cells":10717},{"EARLY_PHASE1":10718,"PHASE1":10720,"PHASE2":10722,"PHASE3":10728,"PHASE4":10730,"NA":10732},{"trials":10719,"activeCount":98},[],{"trials":10721,"activeCount":98},[],{"trials":10723,"activeCount":98},[10724],{"nctId":4076,"briefTitle":4077,"status":711,"phases":10725,"primaryCompletion":4079,"completion":4079,"start":4080,"enrollment":263,"conditions":10726,"interventions":10727},[87],[4082],[4059,4084,4085],{"trials":10729,"activeCount":98},[],{"trials":10731,"activeCount":98},[],{"trials":10733,"activeCount":98},[],{"intervention":8341,"totalTrials":109,"cells":10735},{"EARLY_PHASE1":10736,"PHASE1":10738,"PHASE2":10740,"PHASE3":10746,"PHASE4":10748,"NA":10750},{"trials":10737,"activeCount":98},[],{"trials":10739,"activeCount":98},[],{"trials":10741,"activeCount":98},[10742],{"nctId":8335,"briefTitle":8336,"status":711,"phases":10743,"primaryCompletion":1164,"completion":1164,"start":6677,"enrollment":94,"conditions":10744,"interventions":10745},[87],[8339],[7738,8341],{"trials":10747,"activeCount":98},[],{"trials":10749,"activeCount":98},[],{"trials":10751,"activeCount":98},[],{"intervention":10753,"totalTrials":109,"cells":10754},"Pimozide",{"EARLY_PHASE1":10755,"PHASE1":10757,"PHASE2":10759,"PHASE3":10767,"PHASE4":10769,"NA":10771},{"trials":10756,"activeCount":98},[],{"trials":10758,"activeCount":98},[],{"trials":10760,"activeCount":98},[10761],{"nctId":10762,"briefTitle":10763,"status":152,"phases":10764,"primaryCompletion":7871,"completion":7871,"start":7765,"enrollment":1743,"conditions":10765,"interventions":10766},"NCT00374244","Efficacy of Pimozide Augmentation for Clozapine Partial Response",[87],[15],[10753],{"trials":10768,"activeCount":98},[],{"trials":10770,"activeCount":98},[],{"trials":10772,"activeCount":98},[],{"intervention":10774,"totalTrials":109,"cells":10775},"Gamma hydroxybutyric",{"EARLY_PHASE1":10776,"PHASE1":10778,"PHASE2":10780,"PHASE3":10788,"PHASE4":10790,"NA":10792},{"trials":10777,"activeCount":98},[],{"trials":10779,"activeCount":98},[],{"trials":10781,"activeCount":98},[10782],{"nctId":10783,"briefTitle":10784,"status":1051,"phases":10785,"primaryCompletion":1053,"completion":1053,"start":1054,"enrollment":98,"conditions":10786,"interventions":10787},"NCT00000193","Neurobiology of Opioid Dependence: 2 - 2",[87],[157],[10774],{"trials":10789,"activeCount":98},[],{"trials":10791,"activeCount":98},[],{"trials":10793,"activeCount":98},[],{"intervention":2592,"totalTrials":109,"cells":10795},{"EARLY_PHASE1":10796,"PHASE1":10798,"PHASE2":10800,"PHASE3":10806,"PHASE4":10808,"NA":10810},{"trials":10797,"activeCount":98},[],{"trials":10799,"activeCount":98},[],{"trials":10801,"activeCount":98},[10802],{"nctId":2574,"briefTitle":2575,"status":1051,"phases":10803,"primaryCompletion":2038,"completion":2577,"start":2578,"enrollment":98,"conditions":10804,"interventions":10805},[87],[2580,2581,2582,2583,2584,2585,2586,2587,2588],[2590,2591,2592],{"trials":10807,"activeCount":98},[],{"trials":10809,"activeCount":98},[],{"trials":10811,"activeCount":98},[],{"intervention":10813,"totalTrials":109,"cells":10814},"PF-03463275",{"EARLY_PHASE1":10815,"PHASE1":10817,"PHASE2":10819,"PHASE3":10828,"PHASE4":10830,"NA":10832},{"trials":10816,"activeCount":98},[],{"trials":10818,"activeCount":98},[],{"trials":10820,"activeCount":98},[10821],{"nctId":10822,"briefTitle":10823,"status":152,"phases":10824,"primaryCompletion":9129,"completion":9129,"start":6766,"enrollment":8746,"conditions":10825,"interventions":10827},"NCT01911676","Translational Neuroscience Optimization of GlyT1 Inhibitor",[87],[10826],"Cognitive Impairments Associated With Schizophrenia",[10813],{"trials":10829,"activeCount":98},[],{"trials":10831,"activeCount":98},[],{"trials":10833,"activeCount":98},[],{"intervention":10835,"totalTrials":109,"cells":10836},"Flucytosine and fluconazole",{"EARLY_PHASE1":10837,"PHASE1":10839,"PHASE2":10841,"PHASE3":10851,"PHASE4":10853,"NA":10855},{"trials":10838,"activeCount":98},[],{"trials":10840,"activeCount":98},[],{"trials":10842,"activeCount":98},[10843],{"nctId":10844,"briefTitle":10845,"status":711,"phases":10846,"primaryCompletion":1848,"completion":1848,"start":5742,"enrollment":1416,"conditions":10847,"interventions":10849},"NCT01562132","Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection",[87],[10848],"Cryptococcal Infection Disseminated",[10835,10850],"Fluconazole",{"trials":10852,"activeCount":98},[],{"trials":10854,"activeCount":98},[],{"trials":10856,"activeCount":98},[],{"intervention":10850,"totalTrials":109,"cells":10858},{"EARLY_PHASE1":10859,"PHASE1":10861,"PHASE2":10863,"PHASE3":10869,"PHASE4":10871,"NA":10873},{"trials":10860,"activeCount":98},[],{"trials":10862,"activeCount":98},[],{"trials":10864,"activeCount":98},[10865],{"nctId":10844,"briefTitle":10845,"status":711,"phases":10866,"primaryCompletion":1848,"completion":1848,"start":5742,"enrollment":1416,"conditions":10867,"interventions":10868},[87],[10848],[10835,10850],{"trials":10870,"activeCount":98},[],{"trials":10872,"activeCount":98},[],{"trials":10874,"activeCount":98},[],{"intervention":10876,"totalTrials":109,"cells":10877},"Extended-Release Naltrexone",{"EARLY_PHASE1":10878,"PHASE1":10880,"PHASE2":10882,"PHASE3":10893,"PHASE4":10895,"NA":10897},{"trials":10879,"activeCount":98},[],{"trials":10881,"activeCount":98},[],{"trials":10883,"activeCount":98},[10884],{"nctId":10885,"briefTitle":10886,"status":152,"phases":10887,"primaryCompletion":1781,"completion":7533,"start":10888,"enrollment":10889,"conditions":10890,"interventions":10892},"NCT01246401","Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations",[86,87],"2011-03",151,[35,10891,221,290],"AIDS",[10876],{"trials":10894,"activeCount":98},[],{"trials":10896,"activeCount":98},[],{"trials":10898,"activeCount":98},[],{"intervention":10900,"totalTrials":109,"cells":10901},"PF 04457845",{"EARLY_PHASE1":10902,"PHASE1":10904,"PHASE2":10906,"PHASE3":10917,"PHASE4":10919,"NA":10921},{"trials":10903,"activeCount":98},[],{"trials":10905,"activeCount":98},[],{"trials":10907,"activeCount":98},[10908],{"nctId":10909,"briefTitle":10910,"status":152,"phases":10911,"primaryCompletion":10912,"completion":10912,"start":10913,"enrollment":10914,"conditions":10915,"interventions":10916},"NCT03386487","Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)",[87],"2022-07-25","2019-01-14",228,[3972],[10900],{"trials":10918,"activeCount":98},[],{"trials":10920,"activeCount":98},[],{"trials":10922,"activeCount":98},[],{"intervention":10924,"totalTrials":109,"cells":10925},"Varenicline Tartrate",{"EARLY_PHASE1":10926,"PHASE1":10928,"PHASE2":10930,"PHASE3":10939,"PHASE4":10941,"NA":10943},{"trials":10927,"activeCount":98},[],{"trials":10929,"activeCount":98},[],{"trials":10931,"activeCount":98},[10932],{"nctId":10933,"briefTitle":10934,"status":152,"phases":10935,"primaryCompletion":7929,"completion":7929,"start":10936,"enrollment":1044,"conditions":10937,"interventions":10938},"NCT05541497","Varenicline for Treatment of E-cigarette Dependence",[87],"2022-11-04",[1860],[10924],{"trials":10940,"activeCount":98},[],{"trials":10942,"activeCount":98},[],{"trials":10944,"activeCount":98},[],{"intervention":10946,"totalTrials":109,"cells":10947},"Vemurafenib",{"EARLY_PHASE1":10948,"PHASE1":10950,"PHASE2":10952,"PHASE3":10961,"PHASE4":10963,"NA":10965},{"trials":10949,"activeCount":98},[],{"trials":10951,"activeCount":98},[],{"trials":10953,"activeCount":98},[10954],{"nctId":10955,"briefTitle":10956,"status":152,"phases":10957,"primaryCompletion":8457,"completion":8457,"start":10958,"enrollment":263,"conditions":10959,"interventions":10960},"NCT01781026","Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases",[87],"2013-04",[1491],[10946],{"trials":10962,"activeCount":98},[],{"trials":10964,"activeCount":98},[],{"trials":10966,"activeCount":98},[],{"intervention":10968,"totalTrials":109,"cells":10969},"Pembrolizumab plus Bevacizumab",{"EARLY_PHASE1":10970,"PHASE1":10972,"PHASE2":10974,"PHASE3":10986,"PHASE4":10988,"NA":10990},{"trials":10971,"activeCount":98},[],{"trials":10973,"activeCount":98},[],{"trials":10975,"activeCount":98},[10976],{"nctId":10977,"briefTitle":10978,"status":152,"phases":10979,"primaryCompletion":10980,"completion":10981,"start":10982,"enrollment":7849,"conditions":10983,"interventions":10985},"NCT02681549","Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)",[87],"2024-09-11","2025-03-31","2016-05-01",[1491,2024,10984],"Brain Metastasis",[10968],{"trials":10987,"activeCount":98},[],{"trials":10989,"activeCount":98},[],{"trials":10991,"activeCount":98},[],{"intervention":10993,"totalTrials":109,"cells":10994},"ziprasidone",{"EARLY_PHASE1":10995,"PHASE1":10997,"PHASE2":10999,"PHASE3":11009,"PHASE4":11011,"NA":11013},{"trials":10996,"activeCount":98},[],{"trials":10998,"activeCount":98},[],{"trials":11000,"activeCount":98},[11001],{"nctId":11002,"briefTitle":11003,"status":152,"phases":11004,"primaryCompletion":11005,"completion":11005,"start":8270,"enrollment":766,"conditions":11006,"interventions":11008},"NCT00635700","Ziprasidone in the Psychosis Prodrome",[87],"2012-11",[11007],"Psychosis Prodrome",[10993],{"trials":11010,"activeCount":98},[],{"trials":11012,"activeCount":98},[],{"trials":11014,"activeCount":98},[],{"intervention":11016,"totalTrials":109,"cells":11017},"oral azacitidine",{"EARLY_PHASE1":11018,"PHASE1":11020,"PHASE2":11022,"PHASE3":11032,"PHASE4":11034,"NA":11036},{"trials":11019,"activeCount":98},[],{"trials":11021,"activeCount":98},[],{"trials":11023,"activeCount":98},[11024],{"nctId":11025,"briefTitle":11026,"status":1051,"phases":11027,"primaryCompletion":408,"completion":11028,"start":11029,"enrollment":98,"conditions":11030,"interventions":11031},"NCT06180863","Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients",[87],"2029-04","2023-11",[2042],[11016],{"trials":11033,"activeCount":98},[],{"trials":11035,"activeCount":98},[],{"trials":11037,"activeCount":98},[],{"intervention":11039,"totalTrials":109,"cells":11040},"Maintenance lenalidomide",{"EARLY_PHASE1":11041,"PHASE1":11043,"PHASE2":11045,"PHASE3":11055,"PHASE4":11057,"NA":11059},{"trials":11042,"activeCount":98},[],{"trials":11044,"activeCount":98},[],{"trials":11046,"activeCount":98},[11047],{"nctId":11048,"briefTitle":11049,"status":711,"phases":11050,"primaryCompletion":1886,"completion":1886,"start":11051,"enrollment":263,"conditions":11052,"interventions":11054},"NCT01465230","Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia",[87],"2012-03",[11053],"Chronic Lymphocytic Leukemia",[11039],{"trials":11056,"activeCount":98},[],{"trials":11058,"activeCount":98},[],{"trials":11060,"activeCount":98},[],{"intervention":11062,"totalTrials":109,"cells":11063},"Intravenous digoxin",{"EARLY_PHASE1":11064,"PHASE1":11066,"PHASE2":11068,"PHASE3":11083,"PHASE4":11085,"NA":11087},{"trials":11065,"activeCount":98},[],{"trials":11067,"activeCount":98},[],{"trials":11069,"activeCount":98},[11070],{"nctId":11071,"briefTitle":11072,"status":711,"phases":11073,"primaryCompletion":11074,"completion":11075,"start":11076,"enrollment":1609,"conditions":11077,"interventions":11082},"NCT05014087","Digoxin In Treatment of Alcohol Associated Hepatitis",[87],"2025-06-22","2025-09-12","2021-10-08",[11078,11079,11080,11081],"Acute Alcoholic Hepatitis","Chemical and Drug Induced Liver Injury","Alcohol-Induced Disorders","Steatohepatitis Caused by Ingestible Alcohol",[11062],{"trials":11084,"activeCount":98},[],{"trials":11086,"activeCount":98},[],{"trials":11088,"activeCount":98},[],{"intervention":11090,"totalTrials":109,"cells":11091},"Naltrexone and memantine first",{"EARLY_PHASE1":11092,"PHASE1":11094,"PHASE2":11096,"PHASE3":11107,"PHASE4":11109,"NA":11111},{"trials":11093,"activeCount":98},[],{"trials":11095,"activeCount":98},[],{"trials":11097,"activeCount":98},[11098],{"nctId":11099,"briefTitle":11100,"status":152,"phases":11101,"primaryCompletion":11102,"completion":11103,"start":5722,"enrollment":4645,"conditions":11104,"interventions":11105},"NCT01519063","Naltrexone and Memantine Effects on Alcohol Drinking Behaviors",[87],"2017-03-29","2017-05-01",[1034],[11090,11106],"Naltrexone and Placebo first",{"trials":11108,"activeCount":98},[],{"trials":11110,"activeCount":98},[],{"trials":11112,"activeCount":98},[],{"intervention":11106,"totalTrials":109,"cells":11114},{"EARLY_PHASE1":11115,"PHASE1":11117,"PHASE2":11119,"PHASE3":11125,"PHASE4":11127,"NA":11129},{"trials":11116,"activeCount":98},[],{"trials":11118,"activeCount":98},[],{"trials":11120,"activeCount":98},[11121],{"nctId":11099,"briefTitle":11100,"status":152,"phases":11122,"primaryCompletion":11102,"completion":11103,"start":5722,"enrollment":4645,"conditions":11123,"interventions":11124},[87],[1034],[11090,11106],{"trials":11126,"activeCount":98},[],{"trials":11128,"activeCount":98},[],{"trials":11130,"activeCount":98},[],{"intervention":11132,"totalTrials":109,"cells":11133},"fibrinogen concentrate",{"EARLY_PHASE1":11134,"PHASE1":11136,"PHASE2":11138,"PHASE3":11149,"PHASE4":11151,"NA":11153},{"trials":11135,"activeCount":98},[],{"trials":11137,"activeCount":98},[],{"trials":11139,"activeCount":98},[11140],{"nctId":11141,"briefTitle":11142,"status":1051,"phases":11143,"primaryCompletion":11144,"completion":11144,"start":11145,"enrollment":98,"conditions":11146,"interventions":11148},"NCT02528708","A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)",[86,87],"2021-12","2021-01",[11147],"Postpartum Hemorrhage",[11132],{"trials":11150,"activeCount":98},[],{"trials":11152,"activeCount":98},[],{"trials":11154,"activeCount":98},[],{"intervention":11156,"totalTrials":109,"cells":11157},"PF-06650833",{"EARLY_PHASE1":11158,"PHASE1":11160,"PHASE2":11162,"PHASE3":11172,"PHASE4":11174,"NA":11176},{"trials":11159,"activeCount":98},[],{"trials":11161,"activeCount":98},[],{"trials":11163,"activeCount":98},[11164],{"nctId":11165,"briefTitle":11166,"status":711,"phases":11167,"primaryCompletion":11168,"completion":11168,"start":11169,"enrollment":1466,"conditions":11170,"interventions":11171},"NCT04575610","IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)",[87],"2021-10-06","2020-11-27",[7240],[11156],{"trials":11173,"activeCount":98},[],{"trials":11175,"activeCount":98},[],{"trials":11177,"activeCount":98},[],{"intervention":11179,"totalTrials":109,"cells":11180},"Lipiodol",{"EARLY_PHASE1":11181,"PHASE1":11183,"PHASE2":11185,"PHASE3":11193,"PHASE4":11195,"NA":11197},{"trials":11182,"activeCount":98},[],{"trials":11184,"activeCount":98},[],{"trials":11186,"activeCount":98},[11187],{"nctId":11188,"briefTitle":11189,"status":152,"phases":11190,"primaryCompletion":1501,"completion":1501,"start":10958,"enrollment":1257,"conditions":11191,"interventions":11192},"NCT01877187","Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer",[87],[7668],[11179],{"trials":11194,"activeCount":98},[],{"trials":11196,"activeCount":98},[],{"trials":11198,"activeCount":98},[],{"intervention":11200,"totalTrials":109,"cells":11201},"Mecamylamine hydrochloride",{"EARLY_PHASE1":11202,"PHASE1":11204,"PHASE2":11206,"PHASE3":11214,"PHASE4":11216,"NA":11218},{"trials":11203,"activeCount":98},[],{"trials":11205,"activeCount":98},[],{"trials":11207,"activeCount":98},[11208],{"nctId":11209,"briefTitle":11210,"status":152,"phases":11211,"completion":271,"start":1108,"enrollment":105,"conditions":11212,"interventions":11213},"NCT00319319","Nicotinic Receptor Augmentation of SSRI Antidepressants",[87],[1771],[11200],{"trials":11215,"activeCount":98},[],{"trials":11217,"activeCount":98},[],{"trials":11219,"activeCount":98},[],{"intervention":11221,"totalTrials":109,"cells":11222},"Etrasimod",{"EARLY_PHASE1":11223,"PHASE1":11225,"PHASE2":11227,"PHASE3":11237,"PHASE4":11239,"NA":11241},{"trials":11224,"activeCount":98},[],{"trials":11226,"activeCount":98},[],{"trials":11228,"activeCount":98},[11229],{"nctId":11230,"briefTitle":11231,"status":1051,"phases":11232,"primaryCompletion":2290,"completion":2290,"start":6068,"enrollment":98,"conditions":11233,"interventions":11235},"NCT06521762","Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis",[87],[11234],"Immune Checkpoint Inhibitor-Related Diarrhea and Colitis",[11221,11236],"Corticosteroids",{"trials":11238,"activeCount":98},[],{"trials":11240,"activeCount":98},[],{"trials":11242,"activeCount":98},[],{"intervention":11236,"totalTrials":109,"cells":11244},{"EARLY_PHASE1":11245,"PHASE1":11247,"PHASE2":11249,"PHASE3":11255,"PHASE4":11257,"NA":11259},{"trials":11246,"activeCount":98},[],{"trials":11248,"activeCount":98},[],{"trials":11250,"activeCount":98},[11251],{"nctId":11230,"briefTitle":11231,"status":1051,"phases":11252,"primaryCompletion":2290,"completion":2290,"start":6068,"enrollment":98,"conditions":11253,"interventions":11254},[87],[11234],[11221,11236],{"trials":11256,"activeCount":98},[],{"trials":11258,"activeCount":98},[],{"trials":11260,"activeCount":98},[],{"intervention":11262,"totalTrials":109,"cells":11263},"CAM2038",{"EARLY_PHASE1":11264,"PHASE1":11266,"PHASE2":11268,"PHASE3":11280,"PHASE4":11282,"NA":11284},{"trials":11265,"activeCount":98},[],{"trials":11267,"activeCount":98},[],{"trials":11269,"activeCount":98},[11270],{"nctId":11271,"briefTitle":11272,"status":152,"phases":11273,"primaryCompletion":239,"completion":239,"start":11274,"enrollment":11275,"conditions":11276,"interventions":11278},"NCT04225598","Emergency Department-Initiated Buprenorphine Validation Network Trial",[87],"2020-07-08",2000,[11277],"Opioid-use Disorder",[11262,11279],"Buprenorphine Sublingual Product",{"trials":11281,"activeCount":98},[],{"trials":11283,"activeCount":98},[],{"trials":11285,"activeCount":98},[],{"intervention":11279,"totalTrials":109,"cells":11287},{"EARLY_PHASE1":11288,"PHASE1":11290,"PHASE2":11292,"PHASE3":11298,"PHASE4":11300,"NA":11302},{"trials":11289,"activeCount":98},[],{"trials":11291,"activeCount":98},[],{"trials":11293,"activeCount":98},[11294],{"nctId":11271,"briefTitle":11272,"status":152,"phases":11295,"primaryCompletion":239,"completion":239,"start":11274,"enrollment":11275,"conditions":11296,"interventions":11297},[87],[11277],[11262,11279],{"trials":11299,"activeCount":98},[],{"trials":11301,"activeCount":98},[],{"trials":11303,"activeCount":98},[],{"intervention":11305,"totalTrials":109,"cells":11306},"Lofexidine",{"EARLY_PHASE1":11307,"PHASE1":11309,"PHASE2":11311,"PHASE3":11320,"PHASE4":11322,"NA":11324},{"trials":11308,"activeCount":98},[],{"trials":11310,"activeCount":98},[],{"trials":11312,"activeCount":98},[11313],{"nctId":11314,"briefTitle":11315,"status":152,"phases":11316,"primaryCompletion":2214,"completion":2214,"start":7034,"enrollment":11317,"conditions":11318,"interventions":11319},"NCT00142909","Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1",[87],86,[157],[11305],{"trials":11321,"activeCount":98},[],{"trials":11323,"activeCount":98},[],{"trials":11325,"activeCount":98},[],{"intervention":11327,"totalTrials":109,"cells":11328},"Divalproex sodium",{"EARLY_PHASE1":11329,"PHASE1":11331,"PHASE2":11333,"PHASE3":11343,"PHASE4":11345,"NA":11347},{"trials":11330,"activeCount":98},[],{"trials":11332,"activeCount":98},[],{"trials":11334,"activeCount":98},[11335],{"nctId":11336,"briefTitle":11337,"status":1051,"phases":11338,"primaryCompletion":7707,"completion":7707,"start":8457,"enrollment":98,"conditions":11339,"interventions":11342},"NCT02166229","Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma",[86,87],[11340,11341],"Scleroderma","Systemic Sclerosis",[11327],{"trials":11344,"activeCount":98},[],{"trials":11346,"activeCount":98},[],{"trials":11348,"activeCount":98},[],{"intervention":11350,"totalTrials":109,"cells":11351},"MEDI4736",{"EARLY_PHASE1":11352,"PHASE1":11354,"PHASE2":11356,"PHASE3":11367,"PHASE4":11369,"NA":11371},{"trials":11353,"activeCount":98},[],{"trials":11355,"activeCount":98},[],{"trials":11357,"activeCount":98},[11358],{"nctId":11359,"briefTitle":11360,"status":152,"phases":11361,"primaryCompletion":11362,"completion":11363,"start":6677,"enrollment":6900,"conditions":11364,"interventions":11366},"NCT02489448","Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer",[86,87],"2021-06-15","2021-08-02",[11365],"Breast Neoplasms",[11350],{"trials":11368,"activeCount":98},[],{"trials":11370,"activeCount":98},[],{"trials":11372,"activeCount":98},[],{"intervention":11374,"totalTrials":109,"cells":11375},"Nicotine 0 mg\u002FmL",{"EARLY_PHASE1":11376,"PHASE1":11378,"PHASE2":11380,"PHASE3":11394,"PHASE4":11396,"NA":11398},{"trials":11377,"activeCount":98},[],{"trials":11379,"activeCount":98},[],{"trials":11381,"activeCount":98},[11382],{"nctId":11383,"briefTitle":11384,"status":152,"phases":11385,"primaryCompletion":11386,"completion":11386,"start":11387,"enrollment":2133,"conditions":11388,"interventions":11390},"NCT04038515","Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes",[87],"2024-06-03","2022-10-27",[1658,11389],"E-liquid Flavors",[11374,11391,11392,11393],"Nicotine 6 mg\u002FmL","Nicotine 12 mg\u002FmL","Nicotine 24 mg\u002FmL",{"trials":11395,"activeCount":98},[],{"trials":11397,"activeCount":98},[],{"trials":11399,"activeCount":98},[],{"intervention":11391,"totalTrials":109,"cells":11401},{"EARLY_PHASE1":11402,"PHASE1":11404,"PHASE2":11406,"PHASE3":11412,"PHASE4":11414,"NA":11416},{"trials":11403,"activeCount":98},[],{"trials":11405,"activeCount":98},[],{"trials":11407,"activeCount":98},[11408],{"nctId":11383,"briefTitle":11384,"status":152,"phases":11409,"primaryCompletion":11386,"completion":11386,"start":11387,"enrollment":2133,"conditions":11410,"interventions":11411},[87],[1658,11389],[11374,11391,11392,11393],{"trials":11413,"activeCount":98},[],{"trials":11415,"activeCount":98},[],{"trials":11417,"activeCount":98},[],{"intervention":11392,"totalTrials":109,"cells":11419},{"EARLY_PHASE1":11420,"PHASE1":11422,"PHASE2":11424,"PHASE3":11430,"PHASE4":11432,"NA":11434},{"trials":11421,"activeCount":98},[],{"trials":11423,"activeCount":98},[],{"trials":11425,"activeCount":98},[11426],{"nctId":11383,"briefTitle":11384,"status":152,"phases":11427,"primaryCompletion":11386,"completion":11386,"start":11387,"enrollment":2133,"conditions":11428,"interventions":11429},[87],[1658,11389],[11374,11391,11392,11393],{"trials":11431,"activeCount":98},[],{"trials":11433,"activeCount":98},[],{"trials":11435,"activeCount":98},[],{"intervention":11393,"totalTrials":109,"cells":11437},{"EARLY_PHASE1":11438,"PHASE1":11440,"PHASE2":11442,"PHASE3":11448,"PHASE4":11450,"NA":11452},{"trials":11439,"activeCount":98},[],{"trials":11441,"activeCount":98},[],{"trials":11443,"activeCount":98},[11444],{"nctId":11383,"briefTitle":11384,"status":152,"phases":11445,"primaryCompletion":11386,"completion":11386,"start":11387,"enrollment":2133,"conditions":11446,"interventions":11447},[87],[1658,11389],[11374,11391,11392,11393],{"trials":11449,"activeCount":98},[],{"trials":11451,"activeCount":98},[],{"trials":11453,"activeCount":98},[],{"intervention":4051,"totalTrials":109,"cells":11455},{"EARLY_PHASE1":11456,"PHASE1":11458,"PHASE2":11460,"PHASE3":11466,"PHASE4":11468,"NA":11470},{"trials":11457,"activeCount":98},[],{"trials":11459,"activeCount":98},[],{"trials":11461,"activeCount":98},[11462],{"nctId":4041,"briefTitle":4042,"status":711,"phases":11463,"primaryCompletion":4044,"completion":4044,"start":4045,"enrollment":94,"conditions":11464,"interventions":11465},[87],[4047,4048],[4013,4050,4051],{"trials":11467,"activeCount":98},[],{"trials":11469,"activeCount":98},[],{"trials":11471,"activeCount":98},[],{"intervention":11473,"totalTrials":109,"cells":11474},"neoadjuvant mFOLFIRINOX",{"EARLY_PHASE1":11475,"PHASE1":11477,"PHASE2":11479,"PHASE3":11490,"PHASE4":11492,"NA":11494},{"trials":11476,"activeCount":98},[],{"trials":11478,"activeCount":98},[],{"trials":11480,"activeCount":98},[11481],{"nctId":11482,"briefTitle":11483,"status":711,"phases":11484,"primaryCompletion":11485,"completion":11485,"start":11486,"enrollment":219,"conditions":11487,"interventions":11488},"NCT03099265","Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma",[87],"2019-09-18","2017-06-26",[2958],[11473,11489],"Stereotactic body radiotherapy",{"trials":11491,"activeCount":98},[],{"trials":11493,"activeCount":98},[],{"trials":11495,"activeCount":98},[],{"intervention":11489,"totalTrials":109,"cells":11497},{"EARLY_PHASE1":11498,"PHASE1":11500,"PHASE2":11502,"PHASE3":11508,"PHASE4":11510,"NA":11512},{"trials":11499,"activeCount":98},[],{"trials":11501,"activeCount":98},[],{"trials":11503,"activeCount":98},[11504],{"nctId":11482,"briefTitle":11483,"status":711,"phases":11505,"primaryCompletion":11485,"completion":11485,"start":11486,"enrollment":219,"conditions":11506,"interventions":11507},[87],[2958],[11473,11489],{"trials":11509,"activeCount":98},[],{"trials":11511,"activeCount":98},[],{"trials":11513,"activeCount":98},[],{"intervention":11515,"totalTrials":109,"cells":11516},"Deucravacitinib",{"EARLY_PHASE1":11517,"PHASE1":11519,"PHASE2":11521,"PHASE3":11531,"PHASE4":11533,"NA":11535},{"trials":11518,"activeCount":98},[],{"trials":11520,"activeCount":98},[],{"trials":11522,"activeCount":98},[11523],{"nctId":11524,"briefTitle":11525,"status":1051,"phases":11526,"primaryCompletion":1439,"completion":1439,"start":5007,"enrollment":98,"conditions":11527,"interventions":11530},"NCT06725264","Tyrosine Kinase 2 (TYK2) for GA and CS",[87],[11528,11529],"Sarcoidosis","Granuloma Annulare",[11515],{"trials":11532,"activeCount":98},[],{"trials":11534,"activeCount":98},[],{"trials":11536,"activeCount":98},[],{"intervention":11538,"totalTrials":109,"cells":11539},"Doxazosin 4mg\u002Fday",{"EARLY_PHASE1":11540,"PHASE1":11542,"PHASE2":11544,"PHASE3":11554,"PHASE4":11556,"NA":11558},{"trials":11541,"activeCount":98},[],{"trials":11543,"activeCount":98},[],{"trials":11545,"activeCount":98},[11546],{"nctId":11547,"briefTitle":11548,"status":152,"phases":11549,"primaryCompletion":1137,"completion":1137,"start":11550,"enrollment":25,"conditions":11551,"interventions":11552},"NCT01730846","Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?",[87],"2013-02",[33],[11538,11553],"Doxazosin 8mg\u002Fday",{"trials":11555,"activeCount":98},[],{"trials":11557,"activeCount":98},[],{"trials":11559,"activeCount":98},[],{"intervention":11553,"totalTrials":109,"cells":11561},{"EARLY_PHASE1":11562,"PHASE1":11564,"PHASE2":11566,"PHASE3":11572,"PHASE4":11574,"NA":11576},{"trials":11563,"activeCount":98},[],{"trials":11565,"activeCount":98},[],{"trials":11567,"activeCount":98},[11568],{"nctId":11547,"briefTitle":11548,"status":152,"phases":11569,"primaryCompletion":1137,"completion":1137,"start":11550,"enrollment":25,"conditions":11570,"interventions":11571},[87],[33],[11538,11553],{"trials":11573,"activeCount":98},[],{"trials":11575,"activeCount":98},[],{"trials":11577,"activeCount":98},[],{"intervention":7689,"totalTrials":109,"cells":11579},{"EARLY_PHASE1":11580,"PHASE1":11582,"PHASE2":11584,"PHASE3":11590,"PHASE4":11592,"NA":11594},{"trials":11581,"activeCount":98},[],{"trials":11583,"activeCount":98},[],{"trials":11585,"activeCount":98},[11586],{"nctId":7682,"briefTitle":7683,"status":152,"phases":11587,"primaryCompletion":1210,"completion":1848,"start":327,"enrollment":1257,"conditions":11588,"interventions":11589},[87],[7686,7687],[7689,7670],{"trials":11591,"activeCount":98},[],{"trials":11593,"activeCount":98},[],{"trials":11595,"activeCount":98},[],{"intervention":11597,"totalTrials":109,"cells":11598},"anetumab ravtansine",{"EARLY_PHASE1":11599,"PHASE1":11601,"PHASE2":11603,"PHASE3":11614,"PHASE4":11616,"NA":11618},{"trials":11600,"activeCount":98},[],{"trials":11602,"activeCount":98},[],{"trials":11604,"activeCount":98},[11605],{"nctId":11606,"briefTitle":11607,"status":152,"phases":11608,"primaryCompletion":11609,"completion":11610,"start":11611,"enrollment":1367,"conditions":11612,"interventions":11613},"NCT03023722","Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer",[87],"2019-08-06","2019-12-11","2017-05-11",[2958],[11597],{"trials":11615,"activeCount":98},[],{"trials":11617,"activeCount":98},[],{"trials":11619,"activeCount":98},[],{"intervention":11621,"totalTrials":109,"cells":11622},"9-valent HPV vaccine",{"EARLY_PHASE1":11623,"PHASE1":11625,"PHASE2":11627,"PHASE3":11641,"PHASE4":11643,"NA":11645},{"trials":11624,"activeCount":98},[],{"trials":11626,"activeCount":98},[],{"trials":11628,"activeCount":98},[11629],{"nctId":11630,"briefTitle":11631,"status":152,"phases":11632,"primaryCompletion":11633,"completion":11634,"start":7533,"enrollment":11635,"conditions":11636,"interventions":11639},"NCT02864147","Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2\u002F3)",[87],"2022-05-24","2022-11-22",134,[11637,11638],"Cervical Intraepithelial Neoplasia","Cervical Dysplasia",[11621,11640],"Imiquimod",{"trials":11642,"activeCount":98},[],{"trials":11644,"activeCount":98},[],{"trials":11646,"activeCount":98},[],{"intervention":11640,"totalTrials":109,"cells":11648},{"EARLY_PHASE1":11649,"PHASE1":11651,"PHASE2":11653,"PHASE3":11659,"PHASE4":11661,"NA":11663},{"trials":11650,"activeCount":98},[],{"trials":11652,"activeCount":98},[],{"trials":11654,"activeCount":98},[11655],{"nctId":11630,"briefTitle":11631,"status":152,"phases":11656,"primaryCompletion":11633,"completion":11634,"start":7533,"enrollment":11635,"conditions":11657,"interventions":11658},[87],[11637,11638],[11621,11640],{"trials":11660,"activeCount":98},[],{"trials":11662,"activeCount":98},[],{"trials":11664,"activeCount":98},[],{"intervention":11666,"totalTrials":109,"cells":11667},"Camostat Mesylate",{"EARLY_PHASE1":11668,"PHASE1":11670,"PHASE2":11672,"PHASE3":11684,"PHASE4":11686,"NA":11688},{"trials":11669,"activeCount":98},[],{"trials":11671,"activeCount":98},[],{"trials":11673,"activeCount":98},[11674],{"nctId":11675,"briefTitle":11676,"status":1051,"phases":11677,"primaryCompletion":11678,"completion":11678,"start":5918,"enrollment":98,"conditions":11679,"interventions":11682},"NCT04435015","The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications",[86,87],"2021-12-31",[11680,11681,7240],"Coagulopathy","Cardiovascular Complication",[11666,11683],"Microcrystalline Cellulose, NF",{"trials":11685,"activeCount":98},[],{"trials":11687,"activeCount":98},[],{"trials":11689,"activeCount":98},[],{"intervention":11683,"totalTrials":109,"cells":11691},{"EARLY_PHASE1":11692,"PHASE1":11694,"PHASE2":11696,"PHASE3":11702,"PHASE4":11704,"NA":11706},{"trials":11693,"activeCount":98},[],{"trials":11695,"activeCount":98},[],{"trials":11697,"activeCount":98},[11698],{"nctId":11675,"briefTitle":11676,"status":1051,"phases":11699,"primaryCompletion":11678,"completion":11678,"start":5918,"enrollment":98,"conditions":11700,"interventions":11701},[86,87],[11680,11681,7240],[11666,11683],{"trials":11703,"activeCount":98},[],{"trials":11705,"activeCount":98},[],{"trials":11707,"activeCount":98},[],{"intervention":11709,"totalTrials":109,"cells":11710},"21mg transdermal nicotine patch",{"EARLY_PHASE1":11711,"PHASE1":11713,"PHASE2":11715,"PHASE3":11724,"PHASE4":11726,"NA":11728},{"trials":11712,"activeCount":98},[],{"trials":11714,"activeCount":98},[],{"trials":11716,"activeCount":98},[11717],{"nctId":11718,"briefTitle":11719,"status":152,"phases":11720,"primaryCompletion":1137,"completion":1137,"start":369,"enrollment":1289,"conditions":11721,"interventions":11722},"NCT00699556","Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy",[87],[1034],[11709,11723],"1mg nicotine nasal spray",{"trials":11725,"activeCount":98},[],{"trials":11727,"activeCount":98},[],{"trials":11729,"activeCount":98},[],{"intervention":11723,"totalTrials":109,"cells":11731},{"EARLY_PHASE1":11732,"PHASE1":11734,"PHASE2":11736,"PHASE3":11742,"PHASE4":11744,"NA":11746},{"trials":11733,"activeCount":98},[],{"trials":11735,"activeCount":98},[],{"trials":11737,"activeCount":98},[11738],{"nctId":11718,"briefTitle":11719,"status":152,"phases":11739,"primaryCompletion":1137,"completion":1137,"start":369,"enrollment":1289,"conditions":11740,"interventions":11741},[87],[1034],[11709,11723],{"trials":11743,"activeCount":98},[],{"trials":11745,"activeCount":98},[],{"trials":11747,"activeCount":98},[],{"intervention":11749,"totalTrials":109,"cells":11750},"Abrocitinib 200 mg",{"EARLY_PHASE1":11751,"PHASE1":11753,"PHASE2":11755,"PHASE3":11765,"PHASE4":11767,"NA":11769},{"trials":11752,"activeCount":98},[],{"trials":11754,"activeCount":98},[],{"trials":11756,"activeCount":98},[11757],{"nctId":11758,"briefTitle":11759,"status":152,"phases":11760,"primaryCompletion":11761,"completion":11761,"start":11762,"enrollment":1315,"conditions":11763,"interventions":11764},"NCT05696795","Janus Kinase Inhibition in Sarcoidosis",[87],"2025-04-23","2023-06-01",[11528],[11749],{"trials":11766,"activeCount":98},[],{"trials":11768,"activeCount":98},[],{"trials":11770,"activeCount":98},[],{"intervention":2324,"totalTrials":1246,"cells":11772},{"EARLY_PHASE1":11773,"PHASE1":11775,"PHASE2":11800,"PHASE3":11802,"PHASE4":11804,"NA":11806},{"trials":11774,"activeCount":98},[],{"trials":11776,"activeCount":98},[11777,11781,11788,11796],{"nctId":2316,"briefTitle":2317,"status":711,"phases":11778,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":1416,"conditions":11779,"interventions":11780},[86],[2322],[2324,2309],{"nctId":11782,"briefTitle":11783,"status":152,"phases":11784,"primaryCompletion":8457,"completion":8457,"start":5721,"enrollment":303,"conditions":11785,"interventions":11786},"NCT02018263","Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans",[86],[330],[11787,1658],"Cocaine hydrochloride",{"nctId":11789,"briefTitle":11790,"status":152,"phases":11791,"primaryCompletion":8160,"completion":8160,"start":11005,"enrollment":36,"conditions":11792,"interventions":11794},"NCT01978431","Impulsivity and Stimulant Administration",[86],[330,11793],"Impulsivity",[2324,11795],"methylphenidate",{"nctId":5727,"briefTitle":5728,"status":152,"phases":11797,"primaryCompletion":1876,"completion":1876,"start":5730,"enrollment":1685,"conditions":11798,"interventions":11799},[86],[330],[2324,5733],{"trials":11801,"activeCount":98},[],{"trials":11803,"activeCount":98},[],{"trials":11805,"activeCount":98},[],{"trials":11807,"activeCount":98},[],{"intervention":11809,"totalTrials":263,"cells":11810},"Abraxane",{"EARLY_PHASE1":11811,"PHASE1":11813,"PHASE2":11832,"PHASE3":11834,"PHASE4":11836,"NA":11838},{"trials":11812,"activeCount":98},[],{"trials":11814,"activeCount":98},[11815,11824],{"nctId":11816,"briefTitle":11817,"status":152,"phases":11818,"primaryCompletion":6725,"completion":6725,"start":11819,"enrollment":141,"conditions":11820,"interventions":11822},"NCT00473720","Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers",[86],"2007-05",[11821],"Advanced Cancers",[11823,11809],"Satraplatin",{"nctId":11825,"briefTitle":11826,"status":711,"phases":11827,"primaryCompletion":6777,"completion":6777,"start":6747,"enrollment":1609,"conditions":11828,"interventions":11830},"NCT00337376","A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers",[86],[11829],"Advanced Solid Cancers",[11831,11809],"Rapamune",{"trials":11833,"activeCount":98},[],{"trials":11835,"activeCount":98},[],{"trials":11837,"activeCount":98},[],{"trials":11839,"activeCount":98},[],{"intervention":11841,"totalTrials":263,"cells":11842},"lenalidomide",{"EARLY_PHASE1":11843,"PHASE1":11845,"PHASE2":11864,"PHASE3":11866,"PHASE4":11868,"NA":11870},{"trials":11844,"activeCount":98},[],{"trials":11846,"activeCount":98},[11847,11855],{"nctId":11848,"briefTitle":11849,"status":711,"phases":11850,"primaryCompletion":8199,"completion":8199,"start":2320,"enrollment":272,"conditions":11851,"interventions":11854},"NCT01742793","An Open Label, International, Multi-centre, Phase I\u002FIIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed \u002FRefractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)",[86],[11852,11853,3474],"Hodgkin's Lymphoma","Mature T-cell Lymphoma",[11841],{"nctId":11856,"briefTitle":11857,"status":152,"phases":11858,"primaryCompletion":8737,"completion":8737,"start":1071,"enrollment":1416,"conditions":11859,"interventions":11861},"NCT00698776","Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma",[86],[11860],"Myeloma",[11862,11863],"Lenalidomide","Monocyte derived DCs loaded with KRN7000",{"trials":11865,"activeCount":98},[],{"trials":11867,"activeCount":98},[],{"trials":11869,"activeCount":98},[],{"trials":11871,"activeCount":98},[],{"intervention":11873,"totalTrials":263,"cells":11874},"IV nicotine",{"EARLY_PHASE1":11875,"PHASE1":11889,"PHASE2":11900,"PHASE3":11902,"PHASE4":11904,"NA":11906},{"trials":11876,"activeCount":98},[11877],{"nctId":11878,"briefTitle":11879,"status":152,"phases":11880,"primaryCompletion":11881,"completion":11882,"start":11883,"enrollment":1878,"conditions":11884,"interventions":11885},"NCT03243630","Effects of Flavors on Nicotine Reinforcement in Smokers",[85],"2018-12-19","2019-01-31","2018-04-23",[24],[11873,11886,11887,11888],"Menthol flavor","green apple","green apple and menthol",{"trials":11890,"activeCount":98},[11891],{"nctId":11892,"briefTitle":11893,"status":152,"phases":11894,"primaryCompletion":10888,"completion":10888,"start":5754,"enrollment":272,"conditions":11895,"interventions":11897},"NCT01417429","Galantamine Effects on Nicotine Responses in Smokers",[86],[33,11896],"Tobacco Withdrawal",[11898,11899],"Galantamine","IV Nicotine",{"trials":11901,"activeCount":98},[],{"trials":11903,"activeCount":98},[],{"trials":11905,"activeCount":98},[],{"trials":11907,"activeCount":98},[],{"intervention":4131,"totalTrials":263,"cells":11909},{"EARLY_PHASE1":11910,"PHASE1":11912,"PHASE2":11922,"PHASE3":11924,"PHASE4":11926,"NA":11928},{"trials":11911,"activeCount":98},[],{"trials":11913,"activeCount":98},[11914,11918],{"nctId":4193,"briefTitle":4194,"status":152,"phases":11915,"primaryCompletion":4196,"completion":4196,"start":4197,"enrollment":1685,"conditions":11916,"interventions":11917},[86],[3590],[3933,4131],{"nctId":4125,"briefTitle":4126,"status":152,"phases":11919,"primaryCompletion":4128,"completion":4128,"start":1423,"enrollment":22,"conditions":11920,"interventions":11921},[86],[3590],[4102,4131],{"trials":11923,"activeCount":98},[],{"trials":11925,"activeCount":98},[],{"trials":11927,"activeCount":98},[],{"trials":11929,"activeCount":98},[],{"intervention":1346,"totalTrials":263,"cells":11931},{"EARLY_PHASE1":11932,"PHASE1":11934,"PHASE2":11944,"PHASE3":11946,"PHASE4":11948,"NA":11950},{"trials":11933,"activeCount":98},[],{"trials":11935,"activeCount":98},[11936,11940],{"nctId":2410,"briefTitle":2411,"status":1051,"phases":11937,"primaryCompletion":2413,"completion":2413,"start":2414,"enrollment":98,"conditions":11938,"interventions":11939},[86],[1688],[2403,1346],{"nctId":1339,"briefTitle":1340,"status":152,"phases":11941,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":28,"conditions":11942,"interventions":11943},[86],[1336],[1295,1346],{"trials":11945,"activeCount":98},[],{"trials":11947,"activeCount":98},[],{"trials":11949,"activeCount":98},[],{"trials":11951,"activeCount":98},[],{"intervention":11953,"totalTrials":263,"cells":11954},"Lipopolysaccharide",{"EARLY_PHASE1":11955,"PHASE1":11957,"PHASE2":11974,"PHASE3":11976,"PHASE4":11978,"NA":11980},{"trials":11956,"activeCount":98},[],{"trials":11958,"activeCount":98},[11959,11966],{"nctId":11960,"briefTitle":11961,"status":152,"phases":11962,"primaryCompletion":11963,"completion":11963,"start":8005,"enrollment":314,"conditions":11964,"interventions":11965},"NCT04233593","Neuroimmune Response to Lipopolysaccharide",[86],"2021-08-17",[3590],[11953],{"nctId":11967,"briefTitle":11968,"status":152,"phases":11969,"primaryCompletion":11970,"completion":11970,"start":11971,"enrollment":3897,"conditions":11972,"interventions":11973},"NCT04236986","Imaging the Neuroimmune System in PTSD",[86],"2023-05-30","2017-03-28",[1688],[11953],{"trials":11975,"activeCount":98},[],{"trials":11977,"activeCount":98},[],{"trials":11979,"activeCount":98},[],{"trials":11981,"activeCount":98},[],{"intervention":11983,"totalTrials":263,"cells":11984},"Low dose THC marijuana",{"EARLY_PHASE1":11985,"PHASE1":11997,"PHASE2":12006,"PHASE3":12008,"PHASE4":12010,"NA":12012},{"trials":11986,"activeCount":98},[11987],{"nctId":11988,"briefTitle":11989,"status":152,"phases":11990,"primaryCompletion":11991,"completion":11991,"start":4959,"enrollment":1878,"conditions":11992,"interventions":11994},"NCT03191084","Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations",[85],"2020-03-30",[11993],"Marijuana Impairment",[11995,11996],"Low Dose THC Marijuana","High Dose THC Marijuana",{"trials":11998,"activeCount":98},[11999],{"nctId":12000,"briefTitle":12001,"status":152,"phases":12002,"primaryCompletion":5919,"completion":5919,"start":1647,"enrollment":1935,"conditions":12003,"interventions":12004},"NCT02757313","Neuroscience of Marijuana Impaired Driving",[86],[11993],[11983,12005],"High dose THC marijuana",{"trials":12007,"activeCount":98},[],{"trials":12009,"activeCount":98},[],{"trials":12011,"activeCount":98},[],{"trials":12013,"activeCount":98},[],{"intervention":12005,"totalTrials":263,"cells":12015},{"EARLY_PHASE1":12016,"PHASE1":12022,"PHASE2":12028,"PHASE3":12030,"PHASE4":12032,"NA":12034},{"trials":12017,"activeCount":98},[12018],{"nctId":11988,"briefTitle":11989,"status":152,"phases":12019,"primaryCompletion":11991,"completion":11991,"start":4959,"enrollment":1878,"conditions":12020,"interventions":12021},[85],[11993],[11995,11996],{"trials":12023,"activeCount":98},[12024],{"nctId":12000,"briefTitle":12001,"status":152,"phases":12025,"primaryCompletion":5919,"completion":5919,"start":1647,"enrollment":1935,"conditions":12026,"interventions":12027},[86],[11993],[11983,12005],{"trials":12029,"activeCount":98},[],{"trials":12031,"activeCount":98},[],{"trials":12033,"activeCount":98},[],{"trials":12035,"activeCount":98},[],{"intervention":4165,"totalTrials":263,"cells":12037},{"EARLY_PHASE1":12038,"PHASE1":12040,"PHASE2":12050,"PHASE3":12052,"PHASE4":12054,"NA":12056},{"trials":12039,"activeCount":98},[],{"trials":12041,"activeCount":98},[12042,12046],{"nctId":4157,"briefTitle":4158,"status":152,"phases":12043,"primaryCompletion":4160,"completion":4161,"start":4162,"enrollment":1675,"conditions":12044,"interventions":12045},[86],[1369],[4165,47],{"nctId":4167,"briefTitle":4168,"status":711,"phases":12047,"primaryCompletion":4170,"completion":4170,"start":4171,"enrollment":272,"conditions":12048,"interventions":12049},[86],[4071],[47,4165],{"trials":12051,"activeCount":98},[],{"trials":12053,"activeCount":98},[],{"trials":12055,"activeCount":98},[],{"trials":12057,"activeCount":98},[],{"intervention":12059,"totalTrials":263,"cells":12060},"Ethanol",{"EARLY_PHASE1":12061,"PHASE1":12069,"PHASE2":12078,"PHASE3":12080,"PHASE4":12082,"NA":12084},{"trials":12062,"activeCount":98},[12063],{"nctId":12064,"briefTitle":12065,"status":152,"phases":12066,"primaryCompletion":6725,"completion":6725,"start":271,"enrollment":1367,"conditions":12067,"interventions":12068},"NCT00616746","Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans",[85],[1190,1961],[1658,12059],{"trials":12070,"activeCount":98},[12071],{"nctId":12072,"briefTitle":12073,"status":152,"phases":12074,"primaryCompletion":12075,"completion":12075,"start":1503,"enrollment":2167,"conditions":12076,"interventions":12077},"NCT03165942","Neuroendocrine Response to Oral Alcohol Administration",[86],"2018-06-30",[1911],[12059],{"trials":12079,"activeCount":98},[],{"trials":12081,"activeCount":98},[],{"trials":12083,"activeCount":98},[],{"trials":12085,"activeCount":98},[],{"intervention":12087,"totalTrials":263,"cells":12088},"Calcitriol",{"EARLY_PHASE1":12089,"PHASE1":12100,"PHASE2":12111,"PHASE3":12113,"PHASE4":12115,"NA":12117},{"trials":12090,"activeCount":98},[12091],{"nctId":12092,"briefTitle":12093,"status":711,"phases":12094,"primaryCompletion":12095,"completion":12095,"start":12096,"enrollment":1246,"conditions":12097,"interventions":12099},"NCT04826133","Vitamin D and Cocaine Administration",[85],"2020-01-17","2019-03-27",[12098],"Cocaine Use Disorder",[12087],{"trials":12101,"activeCount":98},[12102],{"nctId":12103,"briefTitle":12104,"status":711,"phases":12105,"primaryCompletion":12106,"completion":12106,"start":12107,"enrollment":94,"conditions":12108,"interventions":12110},"NCT04386811","Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning.",[86],"2020-09-29","2020-08-05",[12109],"ADHD",[12087],{"trials":12112,"activeCount":98},[],{"trials":12114,"activeCount":98},[],{"trials":12116,"activeCount":98},[],{"trials":12118,"activeCount":98},[],{"intervention":2238,"totalTrials":109,"cells":12120},{"EARLY_PHASE1":12121,"PHASE1":12123,"PHASE2":12129,"PHASE3":12131,"PHASE4":12133,"NA":12135},{"trials":12122,"activeCount":98},[],{"trials":12124,"activeCount":98},[12125],{"nctId":2230,"briefTitle":2231,"status":711,"phases":12126,"primaryCompletion":1983,"completion":1072,"start":164,"enrollment":28,"conditions":12127,"interventions":12128},[86],[2234,2235,2236],[2223,2238],{"trials":12130,"activeCount":98},[],{"trials":12132,"activeCount":98},[],{"trials":12134,"activeCount":98},[],{"trials":12136,"activeCount":98},[],{"intervention":11823,"totalTrials":109,"cells":12138},{"EARLY_PHASE1":12139,"PHASE1":12141,"PHASE2":12147,"PHASE3":12149,"PHASE4":12151,"NA":12153},{"trials":12140,"activeCount":98},[],{"trials":12142,"activeCount":98},[12143],{"nctId":11816,"briefTitle":11817,"status":152,"phases":12144,"primaryCompletion":6725,"completion":6725,"start":11819,"enrollment":141,"conditions":12145,"interventions":12146},[86],[11821],[11823,11809],{"trials":12148,"activeCount":98},[],{"trials":12150,"activeCount":98},[],{"trials":12152,"activeCount":98},[],{"trials":12154,"activeCount":98},[],{"intervention":12156,"totalTrials":109,"cells":12157},"Nalmefene",{"EARLY_PHASE1":12158,"PHASE1":12160,"PHASE2":12170,"PHASE3":12172,"PHASE4":12174,"NA":12176},{"trials":12159,"activeCount":98},[],{"trials":12161,"activeCount":98},[12162],{"nctId":12163,"briefTitle":12164,"status":152,"phases":12165,"primaryCompletion":9499,"completion":9499,"start":12166,"enrollment":1315,"conditions":12167,"interventions":12169},"NCT03279562","Patient Driven Recovery With Nalmefene and Coaching",[86],"2017-09-01",[11277,12168],"Harmful; Use, Alcohol",[12156],{"trials":12171,"activeCount":98},[],{"trials":12173,"activeCount":98},[],{"trials":12175,"activeCount":98},[],{"trials":12177,"activeCount":98},[],{"intervention":12179,"totalTrials":109,"cells":12180},"dialysate sodium individualization",{"EARLY_PHASE1":12181,"PHASE1":12183,"PHASE2":12194,"PHASE3":12196,"PHASE4":12198,"NA":12200},{"trials":12182,"activeCount":98},[],{"trials":12184,"activeCount":98},[12185],{"nctId":12186,"briefTitle":12187,"status":711,"phases":12188,"primaryCompletion":1256,"completion":1256,"start":6874,"enrollment":109,"conditions":12189,"interventions":12192},"NCT00259714","Dialysate Sodium Individualization in Hemodialysis",[86],[12190,12191],"Hypertension","Hemodialysis Patients",[12179,12193],"standard dialysate sodium",{"trials":12195,"activeCount":98},[],{"trials":12197,"activeCount":98},[],{"trials":12199,"activeCount":98},[],{"trials":12201,"activeCount":98},[],{"intervention":12193,"totalTrials":109,"cells":12203},{"EARLY_PHASE1":12204,"PHASE1":12206,"PHASE2":12212,"PHASE3":12214,"PHASE4":12216,"NA":12218},{"trials":12205,"activeCount":98},[],{"trials":12207,"activeCount":98},[12208],{"nctId":12186,"briefTitle":12187,"status":711,"phases":12209,"primaryCompletion":1256,"completion":1256,"start":6874,"enrollment":109,"conditions":12210,"interventions":12211},[86],[12190,12191],[12179,12193],{"trials":12213,"activeCount":98},[],{"trials":12215,"activeCount":98},[],{"trials":12217,"activeCount":98},[],{"trials":12219,"activeCount":98},[],{"intervention":12221,"totalTrials":109,"cells":12222},"Neosporin",{"EARLY_PHASE1":12223,"PHASE1":12225,"PHASE2":12237,"PHASE3":12239,"PHASE4":12241,"NA":12243},{"trials":12224,"activeCount":98},[],{"trials":12226,"activeCount":98},[12227],{"nctId":12228,"briefTitle":12229,"status":152,"phases":12230,"primaryCompletion":12231,"completion":12231,"start":12232,"enrollment":12233,"conditions":12234,"interventions":12236},"NCT05449392","Topical Antibacterial Agents for Prevention of COVID-19",[86],"2023-09-22","2022-09-01",67,[7240,12235],"SARS-CoV2 Infection",[12221],{"trials":12238,"activeCount":98},[],{"trials":12240,"activeCount":98},[],{"trials":12242,"activeCount":98},[],{"trials":12244,"activeCount":98},[],{"intervention":12246,"totalTrials":109,"cells":12247},"(18F)Flutemetamol",{"EARLY_PHASE1":12248,"PHASE1":12250,"PHASE2":12260,"PHASE3":12262,"PHASE4":12264,"NA":12266},{"trials":12249,"activeCount":98},[],{"trials":12251,"activeCount":98},[12252],{"nctId":12253,"briefTitle":12254,"status":152,"phases":12255,"primaryCompletion":12256,"completion":12256,"start":8003,"enrollment":272,"conditions":12257,"interventions":12259},"NCT05374564","Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy",[86],"2024-11-14",[12258],"Cardiomyopathies, Primary",[12246],{"trials":12261,"activeCount":98},[],{"trials":12263,"activeCount":98},[],{"trials":12265,"activeCount":98},[],{"trials":12267,"activeCount":98},[],{"intervention":12269,"totalTrials":109,"cells":12270},"dialysate sodium",{"EARLY_PHASE1":12271,"PHASE1":12273,"PHASE2":12284,"PHASE3":12286,"PHASE4":12288,"NA":12290},{"trials":12272,"activeCount":98},[],{"trials":12274,"activeCount":98},[12275],{"nctId":12276,"briefTitle":12277,"status":711,"phases":12278,"primaryCompletion":10652,"completion":10652,"start":727,"enrollment":1246,"conditions":12279,"interventions":12282},"NCT00237783","Safety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic Hypotension",[86],[12280,12281],"Hemodialysis","Hypotension",[12269,12283],"individualized dialysate sodium",{"trials":12285,"activeCount":98},[],{"trials":12287,"activeCount":98},[],{"trials":12289,"activeCount":98},[],{"trials":12291,"activeCount":98},[],{"intervention":12283,"totalTrials":109,"cells":12293},{"EARLY_PHASE1":12294,"PHASE1":12296,"PHASE2":12302,"PHASE3":12304,"PHASE4":12306,"NA":12308},{"trials":12295,"activeCount":98},[],{"trials":12297,"activeCount":98},[12298],{"nctId":12276,"briefTitle":12277,"status":711,"phases":12299,"primaryCompletion":10652,"completion":10652,"start":727,"enrollment":1246,"conditions":12300,"interventions":12301},[86],[12280,12281],[12269,12283],{"trials":12303,"activeCount":98},[],{"trials":12305,"activeCount":98},[],{"trials":12307,"activeCount":98},[],{"trials":12309,"activeCount":98},[],{"intervention":12311,"totalTrials":109,"cells":12312},"Disulfiram plus Contingency Management",{"EARLY_PHASE1":12313,"PHASE1":12315,"PHASE2":12327,"PHASE3":12329,"PHASE4":12331,"NA":12333},{"trials":12314,"activeCount":98},[],{"trials":12316,"activeCount":98},[12317],{"nctId":12318,"briefTitle":12319,"status":152,"phases":12320,"primaryCompletion":1673,"completion":1673,"start":12321,"enrollment":12322,"conditions":12323,"interventions":12325},"NCT00350870","CBT With Disulfiram and Contingency Management",[86],"2005-04",181,[12324],"Cocaine Abuse",[12326,12311],"disulfiram",{"trials":12328,"activeCount":98},[],{"trials":12330,"activeCount":98},[],{"trials":12332,"activeCount":98},[],{"trials":12334,"activeCount":98},[],{"intervention":12336,"totalTrials":109,"cells":12337},"Telmisartan",{"EARLY_PHASE1":12338,"PHASE1":12340,"PHASE2":12351,"PHASE3":12353,"PHASE4":12355,"NA":12357},{"trials":12339,"activeCount":98},[],{"trials":12341,"activeCount":98},[12342],{"nctId":12343,"briefTitle":12344,"status":152,"phases":12345,"primaryCompletion":12346,"completion":12346,"start":12347,"enrollment":5030,"conditions":12348,"interventions":12350},"NCT02170246","Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection",[86],"2018-06-13","2015-01-28",[12349,274],"Acute HIV Infection",[12336],{"trials":12352,"activeCount":98},[],{"trials":12354,"activeCount":98},[],{"trials":12356,"activeCount":98},[],{"trials":12358,"activeCount":98},[],{"intervention":1659,"totalTrials":109,"cells":12360},{"EARLY_PHASE1":12361,"PHASE1":12363,"PHASE2":12369,"PHASE3":12371,"PHASE4":12373,"NA":12375},{"trials":12362,"activeCount":98},[],{"trials":12364,"activeCount":98},[12365],{"nctId":1652,"briefTitle":1653,"status":152,"phases":12366,"primaryCompletion":1120,"completion":180,"start":1655,"enrollment":31,"conditions":12367,"interventions":12368},[86],[730],[1608,1658,1659],{"trials":12370,"activeCount":98},[],{"trials":12372,"activeCount":98},[],{"trials":12374,"activeCount":98},[],{"trials":12376,"activeCount":98},[],{"intervention":12378,"totalTrials":109,"cells":12379},"Afrezza low dose",{"EARLY_PHASE1":12380,"PHASE1":12382,"PHASE2":12395,"PHASE3":12397,"PHASE4":12399,"NA":12401},{"trials":12381,"activeCount":98},[],{"trials":12383,"activeCount":98},[12384],{"nctId":12385,"briefTitle":12386,"status":152,"phases":12387,"primaryCompletion":12388,"completion":12388,"start":12389,"enrollment":141,"conditions":12390,"interventions":12393},"NCT03234491","Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy",[86],"2019-07-22","2017-11-22",[12391,12392],"Post-Prandial Hyperglycemia","Post-Prandial Hypoglycemia",[12378,12394],"Afrezza high dose",{"trials":12396,"activeCount":98},[],{"trials":12398,"activeCount":98},[],{"trials":12400,"activeCount":98},[],{"trials":12402,"activeCount":98},[],{"intervention":12394,"totalTrials":109,"cells":12404},{"EARLY_PHASE1":12405,"PHASE1":12407,"PHASE2":12413,"PHASE3":12415,"PHASE4":12417,"NA":12419},{"trials":12406,"activeCount":98},[],{"trials":12408,"activeCount":98},[12409],{"nctId":12385,"briefTitle":12386,"status":152,"phases":12410,"primaryCompletion":12388,"completion":12388,"start":12389,"enrollment":141,"conditions":12411,"interventions":12412},[86],[12391,12392],[12378,12394],{"trials":12414,"activeCount":98},[],{"trials":12416,"activeCount":98},[],{"trials":12418,"activeCount":98},[],{"trials":12420,"activeCount":98},[],{"intervention":12422,"totalTrials":109,"cells":12423},"Olaparib",{"EARLY_PHASE1":12424,"PHASE1":12426,"PHASE2":12438,"PHASE3":12440,"PHASE4":12442,"NA":12444},{"trials":12425,"activeCount":98},[],{"trials":12427,"activeCount":98},[12428],{"nctId":12429,"briefTitle":12430,"status":1051,"phases":12431,"primaryCompletion":12432,"completion":12433,"start":12434,"enrollment":98,"conditions":12435,"interventions":12437},"NCT02686008","Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC",[86],"2019-01","2019-07","2018-01",[12436],"Squamous Cell Carcinoma of the Head and Neck",[12422],{"trials":12439,"activeCount":98},[],{"trials":12441,"activeCount":98},[],{"trials":12443,"activeCount":98},[],{"trials":12445,"activeCount":98},[],{"intervention":12447,"totalTrials":109,"cells":12448},"hydrocortisone",{"EARLY_PHASE1":12449,"PHASE1":12451,"PHASE2":12460,"PHASE3":12462,"PHASE4":12464,"NA":12466},{"trials":12450,"activeCount":98},[],{"trials":12452,"activeCount":98},[12453],{"nctId":12454,"briefTitle":12455,"status":152,"phases":12456,"primaryCompletion":12457,"completion":12457,"start":1907,"enrollment":1743,"conditions":12458,"interventions":12459},"NCT02722200","Investigating the Central and Peripheral Mechanisms by Which Glucocorticoids Affect Hunger",[86],"2017-07-19",[18],[12447],{"trials":12461,"activeCount":98},[],{"trials":12463,"activeCount":98},[],{"trials":12465,"activeCount":98},[],{"trials":12467,"activeCount":98},[],{"intervention":2026,"totalTrials":109,"cells":12469},{"EARLY_PHASE1":12470,"PHASE1":12472,"PHASE2":12478,"PHASE3":12480,"PHASE4":12482,"NA":12484},{"trials":12471,"activeCount":98},[],{"trials":12473,"activeCount":98},[12474],{"nctId":2017,"briefTitle":2018,"status":152,"phases":12475,"primaryCompletion":2020,"completion":2021,"start":2022,"enrollment":1397,"conditions":12476,"interventions":12477},[86],[2012,2024,1492],[2015,2026,1590],{"trials":12479,"activeCount":98},[],{"trials":12481,"activeCount":98},[],{"trials":12483,"activeCount":98},[],{"trials":12485,"activeCount":98},[],{"intervention":12487,"totalTrials":109,"cells":12488},"Fish Oil with ethanol and placebo ethanol infusions",{"EARLY_PHASE1":12489,"PHASE1":12491,"PHASE2":12502,"PHASE3":12504,"PHASE4":12506,"NA":12508},{"trials":12490,"activeCount":98},[],{"trials":12492,"activeCount":98},[12493],{"nctId":12494,"briefTitle":12495,"status":152,"phases":12496,"primaryCompletion":12497,"completion":12498,"start":12499,"enrollment":1815,"conditions":12500,"interventions":12501},"NCT03010917","Fish Oil vs. Placebo on Subjective Effects of Alcohol",[86],"2021-05-30","2021-09-08","2017-03-02",[1112],[12487],{"trials":12503,"activeCount":98},[],{"trials":12505,"activeCount":98},[],{"trials":12507,"activeCount":98},[],{"trials":12509,"activeCount":98},[],{"intervention":12511,"totalTrials":109,"cells":12512},"GLP-1 analogue - semaglutide",{"EARLY_PHASE1":12513,"PHASE1":12515,"PHASE2":12524,"PHASE3":12526,"PHASE4":12528,"NA":12530},{"trials":12514,"activeCount":98},[],{"trials":12516,"activeCount":98},[12517],{"nctId":12518,"briefTitle":12519,"status":152,"phases":12520,"primaryCompletion":4687,"completion":4687,"start":12521,"enrollment":728,"conditions":12522,"interventions":12523},"NCT04779697","GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight",[86],"2021-02-01",[18],[12511],{"trials":12525,"activeCount":98},[],{"trials":12527,"activeCount":98},[],{"trials":12529,"activeCount":98},[],{"trials":12531,"activeCount":98},[],{"intervention":12533,"totalTrials":109,"cells":12534},"Furosemide 20 MG",{"EARLY_PHASE1":12535,"PHASE1":12537,"PHASE2":12548,"PHASE3":12550,"PHASE4":12552,"NA":12554},{"trials":12536,"activeCount":98},[],{"trials":12538,"activeCount":98},[12539],{"nctId":12540,"briefTitle":12541,"status":1051,"phases":12542,"primaryCompletion":12543,"completion":12543,"start":12544,"enrollment":98,"conditions":12545,"interventions":12547},"NCT03093090","Evaluating Predictive Methods & Product Performance in Healthy Adults for Pediatric Patients, A Case Study: Furosemide",[86],"2019-06-01","2018-12-31",[12546],"Medication Absorption",[12533],{"trials":12549,"activeCount":98},[],{"trials":12551,"activeCount":98},[],{"trials":12553,"activeCount":98},[],{"trials":12555,"activeCount":98},[],{"intervention":12557,"totalTrials":109,"cells":12558},"Dronabinol 2.5 MG",{"EARLY_PHASE1":12559,"PHASE1":12561,"PHASE2":12572,"PHASE3":12574,"PHASE4":12576,"NA":12578},{"trials":12560,"activeCount":98},[],{"trials":12562,"activeCount":98},[12563],{"nctId":12564,"briefTitle":12565,"status":711,"phases":12566,"primaryCompletion":9868,"completion":9868,"start":12567,"enrollment":1416,"conditions":12568,"interventions":12570},"NCT03978156","Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease",[86],"2019-07-26",[12569],"Sickle Cell Disease",[12557,12571],"Microcrystalline cellulose",{"trials":12573,"activeCount":98},[],{"trials":12575,"activeCount":98},[],{"trials":12577,"activeCount":98},[],{"trials":12579,"activeCount":98},[],{"intervention":12571,"totalTrials":109,"cells":12581},{"EARLY_PHASE1":12582,"PHASE1":12584,"PHASE2":12590,"PHASE3":12592,"PHASE4":12594,"NA":12596},{"trials":12583,"activeCount":98},[],{"trials":12585,"activeCount":98},[12586],{"nctId":12564,"briefTitle":12565,"status":711,"phases":12587,"primaryCompletion":9868,"completion":9868,"start":12567,"enrollment":1416,"conditions":12588,"interventions":12589},[86],[12569],[12557,12571],{"trials":12591,"activeCount":98},[],{"trials":12593,"activeCount":98},[],{"trials":12595,"activeCount":98},[],{"trials":12597,"activeCount":98},[],{"intervention":12599,"totalTrials":109,"cells":12600},"125 mg AZD0530",{"EARLY_PHASE1":12601,"PHASE1":12603,"PHASE2":12614,"PHASE3":12616,"PHASE4":12618,"NA":12620},{"trials":12602,"activeCount":98},[],{"trials":12604,"activeCount":98},[12605],{"nctId":12606,"briefTitle":12607,"status":152,"phases":12608,"primaryCompletion":12609,"completion":12609,"start":12610,"enrollment":9130,"conditions":12611,"interventions":12612},"NCT02262026","The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism",[86],"2019-04-26","2014-11-01",[1111],[12599,12613],"50 mg AZD0530",{"trials":12615,"activeCount":98},[],{"trials":12617,"activeCount":98},[],{"trials":12619,"activeCount":98},[],{"trials":12621,"activeCount":98},[],{"intervention":12613,"totalTrials":109,"cells":12623},{"EARLY_PHASE1":12624,"PHASE1":12626,"PHASE2":12632,"PHASE3":12634,"PHASE4":12636,"NA":12638},{"trials":12625,"activeCount":98},[],{"trials":12627,"activeCount":98},[12628],{"nctId":12606,"briefTitle":12607,"status":152,"phases":12629,"primaryCompletion":12609,"completion":12609,"start":12610,"enrollment":9130,"conditions":12630,"interventions":12631},[86],[1111],[12599,12613],{"trials":12633,"activeCount":98},[],{"trials":12635,"activeCount":98},[],{"trials":12637,"activeCount":98},[],{"trials":12639,"activeCount":98},[],{"intervention":12641,"totalTrials":109,"cells":12642},"BMS-984923",{"EARLY_PHASE1":12643,"PHASE1":12645,"PHASE2":12656,"PHASE3":12658,"PHASE4":12660,"NA":12662},{"trials":12644,"activeCount":98},[],{"trials":12646,"activeCount":98},[12647],{"nctId":12648,"briefTitle":12649,"status":152,"phases":12650,"primaryCompletion":12651,"completion":12651,"start":12652,"enrollment":1619,"conditions":12653,"interventions":12655},"NCT04805983","Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923",[86],"2022-04-24","2021-03-25",[12654],"Alzheimer Disease",[12641],{"trials":12657,"activeCount":98},[],{"trials":12659,"activeCount":98},[],{"trials":12661,"activeCount":98},[],{"trials":12663,"activeCount":98},[],{"intervention":12665,"totalTrials":109,"cells":12666},"11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor",{"EARLY_PHASE1":12667,"PHASE1":12669,"PHASE2":12679,"PHASE3":12681,"PHASE4":12683,"NA":12685},{"trials":12668,"activeCount":98},[],{"trials":12670,"activeCount":98},[12671],{"nctId":12672,"briefTitle":12673,"status":152,"phases":12674,"primaryCompletion":12675,"completion":12675,"start":12676,"enrollment":1367,"conditions":12677,"interventions":12678},"NCT05105542","M1 Schizophrenia PET Study",[86],"2023-10-31","2021-04-20",[15,1213,3590],[12665],{"trials":12680,"activeCount":98},[],{"trials":12682,"activeCount":98},[],{"trials":12684,"activeCount":98},[],{"trials":12686,"activeCount":98},[],{"intervention":11863,"totalTrials":109,"cells":12688},{"EARLY_PHASE1":12689,"PHASE1":12691,"PHASE2":12697,"PHASE3":12699,"PHASE4":12701,"NA":12703},{"trials":12690,"activeCount":98},[],{"trials":12692,"activeCount":98},[12693],{"nctId":11856,"briefTitle":11857,"status":152,"phases":12694,"primaryCompletion":8737,"completion":8737,"start":1071,"enrollment":1416,"conditions":12695,"interventions":12696},[86],[11860],[11862,11863],{"trials":12698,"activeCount":98},[],{"trials":12700,"activeCount":98},[],{"trials":12702,"activeCount":98},[],{"trials":12704,"activeCount":98},[],{"intervention":12706,"totalTrials":109,"cells":12707},"Ferumoxytol Injectable Product",{"EARLY_PHASE1":12708,"PHASE1":12710,"PHASE2":12720,"PHASE3":12722,"PHASE4":12724,"NA":12726},{"trials":12709,"activeCount":98},[],{"trials":12711,"activeCount":98},[12712],{"nctId":12713,"briefTitle":12714,"status":152,"phases":12715,"primaryCompletion":11386,"completion":11386,"start":12716,"enrollment":31,"conditions":12717,"interventions":12719},"NCT03084523","Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI",[86],"2017-04-26",[7213,12718],"Intracranial Atherosclerosis",[12706],{"trials":12721,"activeCount":98},[],{"trials":12723,"activeCount":98},[],{"trials":12725,"activeCount":98},[],{"trials":12727,"activeCount":98},[],{"intervention":7924,"totalTrials":109,"cells":12729},{"EARLY_PHASE1":12730,"PHASE1":12732,"PHASE2":12738,"PHASE3":12740,"PHASE4":12742,"NA":12744},{"trials":12731,"activeCount":98},[],{"trials":12733,"activeCount":98},[12734],{"nctId":7917,"briefTitle":7918,"status":152,"phases":12735,"primaryCompletion":7920,"completion":7920,"start":7921,"enrollment":6758,"conditions":12736,"interventions":12737},[86],[15,1213],[7924,2543],{"trials":12739,"activeCount":98},[],{"trials":12741,"activeCount":98},[],{"trials":12743,"activeCount":98},[],{"trials":12745,"activeCount":98},[],{"intervention":12747,"totalTrials":109,"cells":12748},"Radiotracer",{"EARLY_PHASE1":12749,"PHASE1":12751,"PHASE2":12761,"PHASE3":12763,"PHASE4":12765,"NA":12767},{"trials":12750,"activeCount":98},[],{"trials":12752,"activeCount":98},[12753],{"nctId":12754,"briefTitle":12755,"status":152,"phases":12756,"primaryCompletion":1867,"completion":1867,"start":12757,"enrollment":118,"conditions":12758,"interventions":12760},"NCT05418608","Novel in Vivo Synaptic Imaging in Experienced Meditators",[86],"2022-04-21",[12759],"Behavior, Health",[12747],{"trials":12762,"activeCount":98},[],{"trials":12764,"activeCount":98},[],{"trials":12766,"activeCount":98},[],{"trials":12768,"activeCount":98},[],{"intervention":12770,"totalTrials":109,"cells":12771},"Chemo with concomitant Capecitabine and KD018",{"EARLY_PHASE1":12772,"PHASE1":12774,"PHASE2":12784,"PHASE3":12786,"PHASE4":12788,"NA":12790},{"trials":12773,"activeCount":98},[],{"trials":12775,"activeCount":98},[12776],{"nctId":12777,"briefTitle":12778,"status":152,"phases":12779,"primaryCompletion":12780,"completion":12780,"start":1848,"enrollment":36,"conditions":12781,"interventions":12783},"NCT02178644","Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer",[86],"2019-09-20",[12782],"Rectal Cancer",[12770],{"trials":12785,"activeCount":98},[],{"trials":12787,"activeCount":98},[],{"trials":12789,"activeCount":98},[],{"trials":12791,"activeCount":98},[],{"intervention":12793,"totalTrials":109,"cells":12794},"ABT-199",{"EARLY_PHASE1":12795,"PHASE1":12797,"PHASE2":12809,"PHASE3":12811,"PHASE4":12813,"NA":12815},{"trials":12796,"activeCount":98},[],{"trials":12798,"activeCount":98},[12799],{"nctId":12800,"briefTitle":12801,"status":152,"phases":12802,"primaryCompletion":12803,"completion":12804,"start":12805,"enrollment":1246,"conditions":12806,"interventions":12808},"NCT04171791","A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)",[86],"2021-02-10","2021-06-22","2020-01-15",[12807],"CTCL",[12793],{"trials":12810,"activeCount":98},[],{"trials":12812,"activeCount":98},[],{"trials":12814,"activeCount":98},[],{"trials":12816,"activeCount":98},[],{"intervention":4115,"totalTrials":109,"cells":12818},{"EARLY_PHASE1":12819,"PHASE1":12821,"PHASE2":12827,"PHASE3":12829,"PHASE4":12831,"NA":12833},{"trials":12820,"activeCount":98},[],{"trials":12822,"activeCount":98},[12823],{"nctId":4109,"briefTitle":4110,"status":152,"phases":12824,"primaryCompletion":4112,"completion":4112,"start":2956,"enrollment":1289,"conditions":12825,"interventions":12826},[86],[1399,1608],[4102,4115],{"trials":12828,"activeCount":98},[],{"trials":12830,"activeCount":98},[],{"trials":12832,"activeCount":98},[],{"trials":12834,"activeCount":98},[],{"intervention":12836,"totalTrials":109,"cells":12837},"Active CBD\u002FTHC Dose 1",{"EARLY_PHASE1":12838,"PHASE1":12840,"PHASE2":12851,"PHASE3":12853,"PHASE4":12855,"NA":12857},{"trials":12839,"activeCount":98},[],{"trials":12841,"activeCount":98},[12842],{"nctId":12843,"briefTitle":12844,"status":152,"phases":12845,"primaryCompletion":12846,"completion":12846,"start":12847,"enrollment":2659,"conditions":12848,"interventions":12849},"NCT04226690","Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products",[86],"2023-12-15","2022-11-15",[316],[12836,12850],"Active CBD\u002FTHC Dose 2",{"trials":12852,"activeCount":98},[],{"trials":12854,"activeCount":98},[],{"trials":12856,"activeCount":98},[],{"trials":12858,"activeCount":98},[],{"intervention":12850,"totalTrials":109,"cells":12860},{"EARLY_PHASE1":12861,"PHASE1":12863,"PHASE2":12869,"PHASE3":12871,"PHASE4":12873,"NA":12875},{"trials":12862,"activeCount":98},[],{"trials":12864,"activeCount":98},[12865],{"nctId":12843,"briefTitle":12844,"status":152,"phases":12866,"primaryCompletion":12846,"completion":12846,"start":12847,"enrollment":2659,"conditions":12867,"interventions":12868},[86],[316],[12836,12850],{"trials":12870,"activeCount":98},[],{"trials":12872,"activeCount":98},[],{"trials":12874,"activeCount":98},[],{"trials":12876,"activeCount":98},[],{"intervention":12878,"totalTrials":109,"cells":12879},"Oral all-trans retinoic acid",{"EARLY_PHASE1":12880,"PHASE1":12882,"PHASE2":12890,"PHASE3":12892,"PHASE4":12894,"NA":12896},{"trials":12881,"activeCount":98},[],{"trials":12883,"activeCount":98},[12884],{"nctId":12885,"briefTitle":12886,"status":152,"phases":12887,"primaryCompletion":8457,"completion":1742,"start":9373,"enrollment":1020,"conditions":12888,"interventions":12889},"NCT01456468","Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis",[86],[9871],[12878],{"trials":12891,"activeCount":98},[],{"trials":12893,"activeCount":98},[],{"trials":12895,"activeCount":98},[],{"trials":12897,"activeCount":98},[],{"intervention":12899,"totalTrials":109,"cells":12900},"cetuximab and savolitinib",{"EARLY_PHASE1":12901,"PHASE1":12903,"PHASE2":12911,"PHASE3":12913,"PHASE4":12915,"NA":12917},{"trials":12902,"activeCount":98},[],{"trials":12904,"activeCount":98},[12905],{"nctId":12906,"briefTitle":12907,"status":1051,"phases":12908,"primaryCompletion":12434,"completion":12434,"start":1091,"enrollment":98,"conditions":12909,"interventions":12910},"NCT02630420","Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer",[86],[8800],[12899],{"trials":12912,"activeCount":98},[],{"trials":12914,"activeCount":98},[],{"trials":12916,"activeCount":98},[],{"trials":12918,"activeCount":98},[],{"intervention":12920,"totalTrials":109,"cells":12921},"Nicotine form",{"EARLY_PHASE1":12922,"PHASE1":12924,"PHASE2":12933,"PHASE3":12935,"PHASE4":12937,"NA":12939},{"trials":12923,"activeCount":98},[],{"trials":12925,"activeCount":98},[12926],{"nctId":12927,"briefTitle":12928,"status":152,"phases":12929,"primaryCompletion":1010,"completion":12930,"start":1898,"enrollment":118,"conditions":12931,"interventions":12932},"NCT04262817","The Interaction of Flavor With Nicotine Form in Adult Smokers",[86],"2022-02-02",[24],[12920],{"trials":12934,"activeCount":98},[],{"trials":12936,"activeCount":98},[],{"trials":12938,"activeCount":98},[],{"trials":12940,"activeCount":98},[],{"intervention":12942,"totalTrials":109,"cells":12943},"Clofarabine",{"EARLY_PHASE1":12944,"PHASE1":12946,"PHASE2":12955,"PHASE3":12957,"PHASE4":12959,"NA":12961},{"trials":12945,"activeCount":98},[],{"trials":12947,"activeCount":98},[12948],{"nctId":12949,"briefTitle":12950,"status":152,"phases":12951,"primaryCompletion":5754,"completion":1176,"start":727,"enrollment":1648,"conditions":12952,"interventions":12954},"NCT00338494","Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma",[86],[12953],"B-Cell Lymphoma",[12942],{"trials":12956,"activeCount":98},[],{"trials":12958,"activeCount":98},[],{"trials":12960,"activeCount":98},[],{"trials":12962,"activeCount":98},[],{"intervention":12964,"totalTrials":109,"cells":12965},"[11C]-PHNO",{"EARLY_PHASE1":12966,"PHASE1":12968,"PHASE2":12978,"PHASE3":12980,"PHASE4":12982,"NA":12984},{"trials":12967,"activeCount":98},[],{"trials":12969,"activeCount":98},[12970],{"nctId":12971,"briefTitle":12972,"status":152,"phases":12973,"primaryCompletion":12974,"completion":12974,"start":12975,"enrollment":303,"conditions":12976,"interventions":12977},"NCT06261905","Vitamin D in OUD: Exploration of Alterations on the Dopamine D2\u002FD3 Receptor System",[86],"2025-02-18","2024-03-13",[30],[12964],{"trials":12979,"activeCount":98},[],{"trials":12981,"activeCount":98},[],{"trials":12983,"activeCount":98},[],{"trials":12985,"activeCount":98},[],{"intervention":12987,"totalTrials":109,"cells":12988},"Flavoring Agents",{"EARLY_PHASE1":12989,"PHASE1":12991,"PHASE2":13002,"PHASE3":13004,"PHASE4":13006,"NA":13008},{"trials":12990,"activeCount":98},[],{"trials":12992,"activeCount":98},[12993],{"nctId":12994,"briefTitle":12995,"status":152,"phases":12996,"primaryCompletion":12997,"completion":1334,"start":12998,"enrollment":1397,"conditions":12999,"interventions":13001},"NCT03634839","Effects of E-cigarette Flavors on Youth TCORS 2.0",[86],"2023-06-16","2022-11-07",[13000],"Nicotine Use Disorder",[12987,1658],{"trials":13003,"activeCount":98},[],{"trials":13005,"activeCount":98},[],{"trials":13007,"activeCount":98},[],{"trials":13009,"activeCount":98},[],{"intervention":13011,"totalTrials":109,"cells":13012},"NYX-783",{"EARLY_PHASE1":13013,"PHASE1":13015,"PHASE2":13026,"PHASE3":13028,"PHASE4":13030,"NA":13032},{"trials":13014,"activeCount":98},[],{"trials":13016,"activeCount":98},[13017],{"nctId":13018,"briefTitle":13019,"status":152,"phases":13020,"primaryCompletion":13021,"completion":13021,"start":13022,"enrollment":219,"conditions":13023,"interventions":13024},"NCT05447286","Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study",[86],"2024-12-30","2023-05-15",[30],[13011,13025],"Oxycodone",{"trials":13027,"activeCount":98},[],{"trials":13029,"activeCount":98},[],{"trials":13031,"activeCount":98},[],{"trials":13033,"activeCount":98},[],{"intervention":13025,"totalTrials":109,"cells":13035},{"EARLY_PHASE1":13036,"PHASE1":13038,"PHASE2":13044,"PHASE3":13046,"PHASE4":13048,"NA":13050},{"trials":13037,"activeCount":98},[],{"trials":13039,"activeCount":98},[13040],{"nctId":13018,"briefTitle":13019,"status":152,"phases":13041,"primaryCompletion":13021,"completion":13021,"start":13022,"enrollment":219,"conditions":13042,"interventions":13043},[86],[30],[13011,13025],{"trials":13045,"activeCount":98},[],{"trials":13047,"activeCount":98},[],{"trials":13049,"activeCount":98},[],{"trials":13051,"activeCount":98},[],{"intervention":13053,"totalTrials":109,"cells":13054},"Insulin analogs",{"EARLY_PHASE1":13055,"PHASE1":13057,"PHASE2":13066,"PHASE3":13068,"PHASE4":13070,"NA":13072},{"trials":13056,"activeCount":98},[],{"trials":13058,"activeCount":98},[13059],{"nctId":13060,"briefTitle":13061,"status":152,"phases":13062,"primaryCompletion":1166,"completion":1166,"start":1245,"enrollment":1619,"conditions":13063,"interventions":13065},"NCT00652288","Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs",[86],[13064],"Diabetes Mellitus, Type I",[13053,13053,13053,13053,13053],{"trials":13067,"activeCount":98},[],{"trials":13069,"activeCount":98},[],{"trials":13071,"activeCount":98},[],{"trials":13073,"activeCount":98},[],{"intervention":13075,"totalTrials":109,"cells":13076},"Ivabradine",{"EARLY_PHASE1":13077,"PHASE1":13079,"PHASE2":13090,"PHASE3":13092,"PHASE4":13094,"NA":13096},{"trials":13078,"activeCount":98},[],{"trials":13080,"activeCount":98},[13081],{"nctId":13082,"briefTitle":13083,"status":152,"phases":13084,"primaryCompletion":13085,"completion":13085,"start":13086,"enrollment":1246,"conditions":13087,"interventions":13089},"NCT03987204","Ivabradine for Rate Control in Permanent Atrial Fibrillation",[86],"2019-09-17","2019-06-15",[744,13088],"Atrial Fibrillation, Persistent",[13075],{"trials":13091,"activeCount":98},[],{"trials":13093,"activeCount":98},[],{"trials":13095,"activeCount":98},[],{"trials":13097,"activeCount":98},[],{"intervention":13099,"totalTrials":109,"cells":13100},"Medium THC",{"EARLY_PHASE1":13101,"PHASE1":13103,"PHASE2":13111,"PHASE3":13113,"PHASE4":13115,"NA":13117},{"trials":13102,"activeCount":98},[],{"trials":13104,"activeCount":98},[13105],{"nctId":13106,"briefTitle":13107,"status":152,"phases":13108,"primaryCompletion":1715,"completion":1715,"start":6654,"enrollment":7849,"conditions":13109,"interventions":13110},"NCT05115513","Standardized Field Test for Marijuana Impairment II",[86],[11993],[13099],{"trials":13112,"activeCount":98},[],{"trials":13114,"activeCount":98},[],{"trials":13116,"activeCount":98},[],{"trials":13118,"activeCount":98},[],{"intervention":13120,"totalTrials":109,"cells":13121},"PHNO",{"EARLY_PHASE1":13122,"PHASE1":13124,"PHASE2":13135,"PHASE3":13137,"PHASE4":13139,"NA":13141},{"trials":13123,"activeCount":98},[],{"trials":13125,"activeCount":98},[13126],{"nctId":13127,"briefTitle":13128,"status":152,"phases":13129,"primaryCompletion":13130,"completion":13130,"start":13131,"enrollment":2659,"conditions":13132,"interventions":13133},"NCT03103750","Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD",[86],"2023-01-17","2017-08-15",[12109],[13120,13134],"Dextro Amphetamine",{"trials":13136,"activeCount":98},[],{"trials":13138,"activeCount":98},[],{"trials":13140,"activeCount":98},[],{"trials":13142,"activeCount":98},[],{"intervention":13134,"totalTrials":109,"cells":13144},{"EARLY_PHASE1":13145,"PHASE1":13147,"PHASE2":13153,"PHASE3":13155,"PHASE4":13157,"NA":13159},{"trials":13146,"activeCount":98},[],{"trials":13148,"activeCount":98},[13149],{"nctId":13127,"briefTitle":13128,"status":152,"phases":13150,"primaryCompletion":13130,"completion":13130,"start":13131,"enrollment":2659,"conditions":13151,"interventions":13152},[86],[12109],[13120,13134],{"trials":13154,"activeCount":98},[],{"trials":13156,"activeCount":98},[],{"trials":13158,"activeCount":98},[],{"trials":13160,"activeCount":98},[],{"intervention":13162,"totalTrials":109,"cells":13163},"High Morphine Dose",{"EARLY_PHASE1":13164,"PHASE1":13166,"PHASE2":13177,"PHASE3":13179,"PHASE4":13181,"NA":13183},{"trials":13165,"activeCount":98},[],{"trials":13167,"activeCount":98},[13168],{"nctId":13169,"briefTitle":13170,"status":152,"phases":13171,"primaryCompletion":311,"completion":311,"start":13172,"enrollment":1315,"conditions":13173,"interventions":13175},"NCT03801629","Neuroimmune Effects of Opioid Administration",[86],"2019-09-12",[13174],"Drug Effect",[13162,13176],"Low Morphine Dose",{"trials":13178,"activeCount":98},[],{"trials":13180,"activeCount":98},[],{"trials":13182,"activeCount":98},[],{"trials":13184,"activeCount":98},[],{"intervention":13176,"totalTrials":109,"cells":13186},{"EARLY_PHASE1":13187,"PHASE1":13189,"PHASE2":13195,"PHASE3":13197,"PHASE4":13199,"NA":13201},{"trials":13188,"activeCount":98},[],{"trials":13190,"activeCount":98},[13191],{"nctId":13169,"briefTitle":13170,"status":152,"phases":13192,"primaryCompletion":311,"completion":311,"start":13172,"enrollment":1315,"conditions":13193,"interventions":13194},[86],[13174],[13162,13176],{"trials":13196,"activeCount":98},[],{"trials":13198,"activeCount":98},[],{"trials":13200,"activeCount":98},[],{"trials":13202,"activeCount":98},[],{"intervention":13204,"totalTrials":109,"cells":13205},"adnectin 18F-BMS-986192 Head and Neck Cancer",{"EARLY_PHASE1":13206,"PHASE1":13208,"PHASE2":13222,"PHASE3":13224,"PHASE4":13226,"NA":13228},{"trials":13207,"activeCount":98},[],{"trials":13209,"activeCount":98},[13210],{"nctId":13211,"briefTitle":13212,"status":711,"phases":13213,"primaryCompletion":13214,"completion":13214,"start":13215,"enrollment":1466,"conditions":13216,"interventions":13220},"NCT05408871","Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases",[86],"2024-01-31","2023-02-21",[13217,13218,13219],"Cancer Head Neck","Metastatic Cancer","Metastatic Lung Cancer",[13204,13221],"adnectin 18F-BMS-986192 Brain Metastases",{"trials":13223,"activeCount":98},[],{"trials":13225,"activeCount":98},[],{"trials":13227,"activeCount":98},[],{"trials":13229,"activeCount":98},[],{"intervention":13221,"totalTrials":109,"cells":13231},{"EARLY_PHASE1":13232,"PHASE1":13234,"PHASE2":13240,"PHASE3":13242,"PHASE4":13244,"NA":13246},{"trials":13233,"activeCount":98},[],{"trials":13235,"activeCount":98},[13236],{"nctId":13211,"briefTitle":13212,"status":711,"phases":13237,"primaryCompletion":13214,"completion":13214,"start":13215,"enrollment":1466,"conditions":13238,"interventions":13239},[86],[13217,13218,13219],[13204,13221],{"trials":13241,"activeCount":98},[],{"trials":13243,"activeCount":98},[],{"trials":13245,"activeCount":98},[],{"trials":13247,"activeCount":98},[],{"intervention":13249,"totalTrials":109,"cells":13250},"Glucagon",{"EARLY_PHASE1":13251,"PHASE1":13253,"PHASE2":13265,"PHASE3":13267,"PHASE4":13269,"NA":13271},{"trials":13252,"activeCount":98},[],{"trials":13254,"activeCount":98},[13255],{"nctId":13256,"briefTitle":13257,"status":152,"phases":13258,"primaryCompletion":13259,"completion":13260,"start":13261,"enrollment":1315,"conditions":13262,"interventions":13264},"NCT03965130","The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA",[86],"2022-07-07","2023-07-06","2019-06-05",[13263],"Healthy Participants",[13249],{"trials":13266,"activeCount":98},[],{"trials":13268,"activeCount":98},[],{"trials":13270,"activeCount":98},[],{"trials":13272,"activeCount":98},[],{"intervention":13274,"totalTrials":109,"cells":13275},"0.143 mg\u002Fkg Psilocybin or 10 mg Psilocybin",{"EARLY_PHASE1":13276,"PHASE1":13278,"PHASE2":13290,"PHASE3":13292,"PHASE4":13294,"NA":13296},{"trials":13277,"activeCount":98},[],{"trials":13279,"activeCount":98},[13280],{"nctId":13281,"briefTitle":13282,"status":152,"phases":13283,"primaryCompletion":7870,"completion":13284,"start":13285,"enrollment":1512,"conditions":13286,"interventions":13288},"NCT02981173","Psilocybin for the Treatment of Cluster Headache",[86],"2022-10-21","2016-12-05",[13287],"Cluster Headache",[13274,13289],"0.0143 mg\u002Fkg Psilocybin or 1 mg Psilocybin",{"trials":13291,"activeCount":98},[],{"trials":13293,"activeCount":98},[],{"trials":13295,"activeCount":98},[],{"trials":13297,"activeCount":98},[],{"intervention":13289,"totalTrials":109,"cells":13299},{"EARLY_PHASE1":13300,"PHASE1":13302,"PHASE2":13308,"PHASE3":13310,"PHASE4":13312,"NA":13314},{"trials":13301,"activeCount":98},[],{"trials":13303,"activeCount":98},[13304],{"nctId":13281,"briefTitle":13282,"status":152,"phases":13305,"primaryCompletion":7870,"completion":13284,"start":13285,"enrollment":1512,"conditions":13306,"interventions":13307},[86],[13287],[13274,13289],{"trials":13309,"activeCount":98},[],{"trials":13311,"activeCount":98},[],{"trials":13313,"activeCount":98},[],{"trials":13315,"activeCount":98},[],{"intervention":13317,"totalTrials":109,"cells":13318},"N-acetyl cysteine",{"EARLY_PHASE1":13319,"PHASE1":13321,"PHASE2":13330,"PHASE3":13332,"PHASE4":13334,"NA":13336},{"trials":13320,"activeCount":98},[],{"trials":13322,"activeCount":98},[13323],{"nctId":13324,"briefTitle":13325,"status":152,"phases":13326,"primaryCompletion":13327,"completion":13327,"start":8798,"enrollment":1416,"conditions":13328,"interventions":13329},"NCT02124941","Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS",[86],"2022-08-14",[330,3590],[13317],{"trials":13331,"activeCount":98},[],{"trials":13333,"activeCount":98},[],{"trials":13335,"activeCount":98},[],{"trials":13337,"activeCount":98},[],{"intervention":13339,"totalTrials":109,"cells":13340},"Cocaine Self-adminstration",{"EARLY_PHASE1":13341,"PHASE1":13343,"PHASE2":13353,"PHASE3":13355,"PHASE4":13357,"NA":13359},{"trials":13342,"activeCount":98},[],{"trials":13344,"activeCount":98},[13345],{"nctId":13346,"briefTitle":13347,"status":152,"phases":13348,"primaryCompletion":13349,"completion":13349,"start":13350,"enrollment":1523,"conditions":13351,"interventions":13352},"NCT03471182","Investigation of Cocaine Addiction Using mGluR5 PET and fMRI",[86],"2022-08-18","2018-02-26",[330],[13339],{"trials":13354,"activeCount":98},[],{"trials":13356,"activeCount":98},[],{"trials":13358,"activeCount":98},[],{"trials":13360,"activeCount":98},[],{"intervention":6751,"totalTrials":109,"cells":13362},{"EARLY_PHASE1":13363,"PHASE1":13365,"PHASE2":13371,"PHASE3":13373,"PHASE4":13375,"NA":13377},{"trials":13364,"activeCount":98},[],{"trials":13366,"activeCount":98},[13367],{"nctId":6743,"briefTitle":6744,"status":711,"phases":13368,"primaryCompletion":6746,"completion":6746,"start":6747,"enrollment":1367,"conditions":13369,"interventions":13370},[86],[6749],[6751,6736],{"trials":13372,"activeCount":98},[],{"trials":13374,"activeCount":98},[],{"trials":13376,"activeCount":98},[],{"trials":13378,"activeCount":98},[],{"intervention":13380,"totalTrials":109,"cells":13381},"Sunscreen",{"EARLY_PHASE1":13382,"PHASE1":13384,"PHASE2":13393,"PHASE3":13395,"PHASE4":13397,"NA":13399},{"trials":13383,"activeCount":98},[],{"trials":13385,"activeCount":98},[13386],{"nctId":13387,"briefTitle":13388,"status":152,"phases":13389,"primaryCompletion":7929,"completion":7929,"start":13022,"enrollment":31,"conditions":13390,"interventions":13392},"NCT05736224","Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen",[86],[13391],"Skin Cancer",[13380],{"trials":13394,"activeCount":98},[],{"trials":13396,"activeCount":98},[],{"trials":13398,"activeCount":98},[],{"trials":13400,"activeCount":98},[],{"intervention":13402,"totalTrials":109,"cells":13403},"Increased Intravenous Bolus Loop Diuretic Dose",{"EARLY_PHASE1":13404,"PHASE1":13406,"PHASE2":13418,"PHASE3":13420,"PHASE4":13422,"NA":13424},{"trials":13405,"activeCount":98},[],{"trials":13407,"activeCount":98},[13408],{"nctId":13409,"briefTitle":13410,"status":152,"phases":13411,"primaryCompletion":13412,"completion":13412,"start":13413,"enrollment":13414,"conditions":13415,"interventions":13416},"NCT02546583","Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure",[86],"2020-01-23","2015-08-31",458,[107],[13402,13417],"IV Chlorothiazide",{"trials":13419,"activeCount":98},[],{"trials":13421,"activeCount":98},[],{"trials":13423,"activeCount":98},[],{"trials":13425,"activeCount":98},[],{"intervention":13417,"totalTrials":109,"cells":13427},{"EARLY_PHASE1":13428,"PHASE1":13430,"PHASE2":13436,"PHASE3":13438,"PHASE4":13440,"NA":13442},{"trials":13429,"activeCount":98},[],{"trials":13431,"activeCount":98},[13432],{"nctId":13409,"briefTitle":13410,"status":152,"phases":13433,"primaryCompletion":13412,"completion":13412,"start":13413,"enrollment":13414,"conditions":13434,"interventions":13435},[86],[107],[13402,13417],{"trials":13437,"activeCount":98},[],{"trials":13439,"activeCount":98},[],{"trials":13441,"activeCount":98},[],{"trials":13443,"activeCount":98},[],{"intervention":13445,"totalTrials":109,"cells":13446},"Ketalar",{"EARLY_PHASE1":13447,"PHASE1":13449,"PHASE2":13457,"PHASE3":13459,"PHASE4":13461,"NA":13463},{"trials":13448,"activeCount":98},[],{"trials":13450,"activeCount":98},[13451],{"nctId":13452,"briefTitle":13453,"status":152,"phases":13454,"primaryCompletion":6677,"completion":6677,"start":11051,"enrollment":303,"conditions":13455,"interventions":13456},"NCT01551329","Ketamine for Depression and Alcohol Dependence",[86],[21,1112],[13445],{"trials":13458,"activeCount":98},[],{"trials":13460,"activeCount":98},[],{"trials":13462,"activeCount":98},[],{"trials":13464,"activeCount":98},[],{"intervention":13466,"totalTrials":109,"cells":13467},"Pregnenolone300",{"EARLY_PHASE1":13468,"PHASE1":13470,"PHASE2":13481,"PHASE3":13483,"PHASE4":13485,"NA":13487},{"trials":13469,"activeCount":98},[],{"trials":13471,"activeCount":98},[13472],{"nctId":13473,"briefTitle":13474,"status":152,"phases":13475,"primaryCompletion":13476,"completion":4668,"start":13477,"enrollment":328,"conditions":13478,"interventions":13479},"NCT03872128","The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders",[86],"2022-11-01","2018-09-27",[27],[13466,13480],"Pregnenolone500",{"trials":13482,"activeCount":98},[],{"trials":13484,"activeCount":98},[],{"trials":13486,"activeCount":98},[],{"trials":13488,"activeCount":98},[],{"intervention":13480,"totalTrials":109,"cells":13490},{"EARLY_PHASE1":13491,"PHASE1":13493,"PHASE2":13499,"PHASE3":13501,"PHASE4":13503,"NA":13505},{"trials":13492,"activeCount":98},[],{"trials":13494,"activeCount":98},[13495],{"nctId":13473,"briefTitle":13474,"status":152,"phases":13496,"primaryCompletion":13476,"completion":4668,"start":13477,"enrollment":328,"conditions":13497,"interventions":13498},[86],[27],[13466,13480],{"trials":13500,"activeCount":98},[],{"trials":13502,"activeCount":98},[],{"trials":13504,"activeCount":98},[],{"trials":13506,"activeCount":98},[],{"intervention":13508,"totalTrials":109,"cells":13509},"Beta-hydroxybutyrate",{"EARLY_PHASE1":13510,"PHASE1":13512,"PHASE2":13523,"PHASE3":13525,"PHASE4":13527,"NA":13529},{"trials":13511,"activeCount":98},[],{"trials":13513,"activeCount":98},[13514],{"nctId":13515,"briefTitle":13516,"status":152,"phases":13517,"primaryCompletion":13518,"completion":13518,"start":13519,"enrollment":1923,"conditions":13520,"interventions":13522},"NCT02471040","Brain Ketone Metabolism in Type 1 Diabetes",[86],"2022-04-04","2013-05-14",[5724,13521],"Hypoglycemia",[13508],{"trials":13524,"activeCount":98},[],{"trials":13526,"activeCount":98},[],{"trials":13528,"activeCount":98},[],{"trials":13530,"activeCount":98},[],{"intervention":13532,"totalTrials":109,"cells":13533},"Standard Sunscreen",{"EARLY_PHASE1":13534,"PHASE1":13536,"PHASE2":13547,"PHASE3":13549,"PHASE4":13551,"NA":13553},{"trials":13535,"activeCount":98},[],{"trials":13537,"activeCount":98},[13538],{"nctId":13539,"briefTitle":13540,"status":152,"phases":13541,"primaryCompletion":13542,"completion":13542,"start":13543,"enrollment":1685,"conditions":13544,"interventions":13546},"NCT02668536","A Sunscreen Based on Bioadhesive Nanoparticles",[86],"2017-08-18","2017-07-17",[1491,13545],"UV Ray Skin Damage",[13532],{"trials":13548,"activeCount":98},[],{"trials":13550,"activeCount":98},[],{"trials":13552,"activeCount":98},[],{"trials":13554,"activeCount":98},[],{"intervention":7932,"totalTrials":109,"cells":13556},{"EARLY_PHASE1":13557,"PHASE1":13559,"PHASE2":13565,"PHASE3":13567,"PHASE4":13569,"NA":13571},{"trials":13558,"activeCount":98},[],{"trials":13560,"activeCount":98},[13561],{"nctId":7926,"briefTitle":7927,"status":152,"phases":13562,"primaryCompletion":7929,"completion":7929,"start":313,"enrollment":1315,"conditions":13563,"interventions":13564},[86],[27],[7932,2543],{"trials":13566,"activeCount":98},[],{"trials":13568,"activeCount":98},[],{"trials":13570,"activeCount":98},[],{"trials":13572,"activeCount":98},[],{"intervention":13574,"totalTrials":109,"cells":13575},"iomazenil",{"EARLY_PHASE1":13576,"PHASE1":13578,"PHASE2":13587,"PHASE3":13589,"PHASE4":13591,"NA":13593},{"trials":13577,"activeCount":98},[],{"trials":13579,"activeCount":98},[13580],{"nctId":13581,"briefTitle":13582,"status":152,"phases":13583,"primaryCompletion":13584,"completion":13584,"start":271,"enrollment":1609,"conditions":13585,"interventions":13586},"NCT00611572","GABA-glutamate Interactions and Psychosis",[86],"2018-10-02",[8822],[13574,13574],{"trials":13588,"activeCount":98},[],{"trials":13590,"activeCount":98},[],{"trials":13592,"activeCount":98},[],{"trials":13594,"activeCount":98},[],{"intervention":13596,"totalTrials":109,"cells":13597},"nicotine replacement patches",{"EARLY_PHASE1":13598,"PHASE1":13600,"PHASE2":13610,"PHASE3":13612,"PHASE4":13614,"NA":13616},{"trials":13599,"activeCount":98},[],{"trials":13601,"activeCount":98},[13602],{"nctId":13603,"briefTitle":13604,"status":152,"phases":13605,"primaryCompletion":2213,"completion":2213,"start":8160,"enrollment":105,"conditions":13606,"interventions":13608},"NCT02081144","Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study",[86],[33,13607],"Tobacco Abstinence",[13596,13609],"Nicotine Replacement Gum",{"trials":13611,"activeCount":98},[],{"trials":13613,"activeCount":98},[],{"trials":13615,"activeCount":98},[],{"trials":13617,"activeCount":98},[],{"intervention":13609,"totalTrials":109,"cells":13619},{"EARLY_PHASE1":13620,"PHASE1":13622,"PHASE2":13628,"PHASE3":13630,"PHASE4":13632,"NA":13634},{"trials":13621,"activeCount":98},[],{"trials":13623,"activeCount":98},[13624],{"nctId":13603,"briefTitle":13604,"status":152,"phases":13625,"primaryCompletion":2213,"completion":2213,"start":8160,"enrollment":105,"conditions":13626,"interventions":13627},[86],[33,13607],[13596,13609],{"trials":13629,"activeCount":98},[],{"trials":13631,"activeCount":98},[],{"trials":13633,"activeCount":98},[],{"trials":13635,"activeCount":98},[],{"intervention":13637,"totalTrials":109,"cells":13638},"5-Azacitadine",{"EARLY_PHASE1":13639,"PHASE1":13641,"PHASE2":13651,"PHASE3":13653,"PHASE4":13655,"NA":13657},{"trials":13640,"activeCount":98},[],{"trials":13642,"activeCount":98},[13643],{"nctId":13644,"briefTitle":13645,"status":152,"phases":13646,"primaryCompletion":13647,"completion":13647,"start":13648,"enrollment":1367,"conditions":13649,"interventions":13650},"NCT02178072","Window Trial 5-aza in HNSCC, T-tare",[86],"2019-10-23","2015-02-19",[1505],[13637],{"trials":13652,"activeCount":98},[],{"trials":13654,"activeCount":98},[],{"trials":13656,"activeCount":98},[],{"trials":13658,"activeCount":98},[],{"intervention":8275,"totalTrials":109,"cells":13660},{"EARLY_PHASE1":13661,"PHASE1":13663,"PHASE2":13669,"PHASE3":13671,"PHASE4":13673,"NA":13675},{"trials":13662,"activeCount":98},[],{"trials":13664,"activeCount":98},[13665],{"nctId":8267,"briefTitle":8268,"status":152,"phases":13666,"primaryCompletion":8270,"completion":8270,"enrollment":1648,"conditions":13667,"interventions":13668},[86],[8272,8273],[1784,8275,8276,8277,8278,8279],{"trials":13670,"activeCount":98},[],{"trials":13672,"activeCount":98},[],{"trials":13674,"activeCount":98},[],{"trials":13676,"activeCount":98},[],{"intervention":8276,"totalTrials":109,"cells":13678},{"EARLY_PHASE1":13679,"PHASE1":13681,"PHASE2":13687,"PHASE3":13689,"PHASE4":13691,"NA":13693},{"trials":13680,"activeCount":98},[],{"trials":13682,"activeCount":98},[13683],{"nctId":8267,"briefTitle":8268,"status":152,"phases":13684,"primaryCompletion":8270,"completion":8270,"enrollment":1648,"conditions":13685,"interventions":13686},[86],[8272,8273],[1784,8275,8276,8277,8278,8279],{"trials":13688,"activeCount":98},[],{"trials":13690,"activeCount":98},[],{"trials":13692,"activeCount":98},[],{"trials":13694,"activeCount":98},[],{"intervention":8277,"totalTrials":109,"cells":13696},{"EARLY_PHASE1":13697,"PHASE1":13699,"PHASE2":13705,"PHASE3":13707,"PHASE4":13709,"NA":13711},{"trials":13698,"activeCount":98},[],{"trials":13700,"activeCount":98},[13701],{"nctId":8267,"briefTitle":8268,"status":152,"phases":13702,"primaryCompletion":8270,"completion":8270,"enrollment":1648,"conditions":13703,"interventions":13704},[86],[8272,8273],[1784,8275,8276,8277,8278,8279],{"trials":13706,"activeCount":98},[],{"trials":13708,"activeCount":98},[],{"trials":13710,"activeCount":98},[],{"trials":13712,"activeCount":98},[],{"intervention":8278,"totalTrials":109,"cells":13714},{"EARLY_PHASE1":13715,"PHASE1":13717,"PHASE2":13723,"PHASE3":13725,"PHASE4":13727,"NA":13729},{"trials":13716,"activeCount":98},[],{"trials":13718,"activeCount":98},[13719],{"nctId":8267,"briefTitle":8268,"status":152,"phases":13720,"primaryCompletion":8270,"completion":8270,"enrollment":1648,"conditions":13721,"interventions":13722},[86],[8272,8273],[1784,8275,8276,8277,8278,8279],{"trials":13724,"activeCount":98},[],{"trials":13726,"activeCount":98},[],{"trials":13728,"activeCount":98},[],{"trials":13730,"activeCount":98},[],{"intervention":8279,"totalTrials":109,"cells":13732},{"EARLY_PHASE1":13733,"PHASE1":13735,"PHASE2":13741,"PHASE3":13743,"PHASE4":13745,"NA":13747},{"trials":13734,"activeCount":98},[],{"trials":13736,"activeCount":98},[13737],{"nctId":8267,"briefTitle":8268,"status":152,"phases":13738,"primaryCompletion":8270,"completion":8270,"enrollment":1648,"conditions":13739,"interventions":13740},[86],[8272,8273],[1784,8275,8276,8277,8278,8279],{"trials":13742,"activeCount":98},[],{"trials":13744,"activeCount":98},[],{"trials":13746,"activeCount":98},[],{"trials":13748,"activeCount":98},[],{"intervention":13750,"totalTrials":109,"cells":13751},"Empagliflozin",{"EARLY_PHASE1":13752,"PHASE1":13754,"PHASE2":13765,"PHASE3":13767,"PHASE4":13769,"NA":13771},{"trials":13753,"activeCount":98},[],{"trials":13755,"activeCount":98},[13756],{"nctId":13757,"briefTitle":13758,"status":152,"phases":13759,"primaryCompletion":13760,"completion":12543,"start":13761,"enrollment":5030,"conditions":13762,"interventions":13764},"NCT03027960","Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects",[86],"2019-05-14","2017-06-27",[107,13763],"Type II; Diabetes",[13750],{"trials":13766,"activeCount":98},[],{"trials":13768,"activeCount":98},[],{"trials":13770,"activeCount":98},[],{"trials":13772,"activeCount":98},[],{"intervention":11831,"totalTrials":109,"cells":13774},{"EARLY_PHASE1":13775,"PHASE1":13777,"PHASE2":13783,"PHASE3":13785,"PHASE4":13787,"NA":13789},{"trials":13776,"activeCount":98},[],{"trials":13778,"activeCount":98},[13779],{"nctId":11825,"briefTitle":11826,"status":711,"phases":13780,"primaryCompletion":6777,"completion":6777,"start":6747,"enrollment":1609,"conditions":13781,"interventions":13782},[86],[11829],[11831,11809],{"trials":13784,"activeCount":98},[],{"trials":13786,"activeCount":98},[],{"trials":13788,"activeCount":98},[],{"trials":13790,"activeCount":98},[],{"intervention":13792,"totalTrials":109,"cells":13793},"Ketamine and Org 25935",{"EARLY_PHASE1":13794,"PHASE1":13796,"PHASE2":13806,"PHASE3":13808,"PHASE4":13810,"NA":13812},{"trials":13795,"activeCount":98},[],{"trials":13797,"activeCount":98},[13798],{"nctId":13799,"briefTitle":13800,"status":152,"phases":13801,"primaryCompletion":13802,"completion":13802,"start":13803,"enrollment":141,"conditions":13804,"interventions":13805},"NCT00700076","Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects",[86],"2009-03-09","2008-01-22",[3590],[13792],{"trials":13807,"activeCount":98},[],{"trials":13809,"activeCount":98},[],{"trials":13811,"activeCount":98},[],{"trials":13813,"activeCount":98},[],{"intervention":13815,"totalTrials":109,"cells":13816},"Omalizumab",{"EARLY_PHASE1":13817,"PHASE1":13819,"PHASE2":13828,"PHASE3":13830,"PHASE4":13832,"NA":13834},{"trials":13818,"activeCount":98},[],{"trials":13820,"activeCount":98},[13821],{"nctId":13822,"briefTitle":13823,"status":152,"phases":13824,"primaryCompletion":4152,"completion":4152,"start":5730,"enrollment":219,"conditions":13825,"interventions":13827},"NCT02266355","Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction",[86],[13826],"Colon Cancer",[13815],{"trials":13829,"activeCount":98},[],{"trials":13831,"activeCount":98},[],{"trials":13833,"activeCount":98},[],{"trials":13835,"activeCount":98},[],{"intervention":13837,"totalTrials":109,"cells":13838},"Flavor",{"EARLY_PHASE1":13839,"PHASE1":13841,"PHASE2":13850,"PHASE3":13852,"PHASE4":13854,"NA":13856},{"trials":13840,"activeCount":98},[],{"trials":13842,"activeCount":98},[13843],{"nctId":13844,"briefTitle":13845,"status":152,"phases":13846,"primaryCompletion":13847,"completion":13847,"start":13760,"enrollment":1827,"conditions":13848,"interventions":13849},"NCT03635333","Effects of E-Cigarette Flavors on Adults TCORS 2.0",[86],"2023-07-12",[13000],[1658,13837],{"trials":13851,"activeCount":98},[],{"trials":13853,"activeCount":98},[],{"trials":13855,"activeCount":98},[],{"trials":13857,"activeCount":98},[],{"intervention":13859,"totalTrials":109,"cells":13860},"EPI-743",{"EARLY_PHASE1":13861,"PHASE1":13863,"PHASE2":13871,"PHASE3":13873,"PHASE4":13875,"NA":13877},{"trials":13862,"activeCount":98},[],{"trials":13864,"activeCount":98},[13865],{"nctId":13866,"briefTitle":13867,"status":152,"phases":13868,"primaryCompletion":5721,"completion":5721,"start":2320,"enrollment":1315,"conditions":13869,"interventions":13870},"NCT01719523","Open-Trial of EPI-743 for Adults With Tourette Syndrome",[86],[5849],[13859],{"trials":13872,"activeCount":98},[],{"trials":13874,"activeCount":98},[],{"trials":13876,"activeCount":98},[],{"trials":13878,"activeCount":98},[],{"intervention":13880,"totalTrials":109,"cells":13881},"Tofacitinib 5 mg twice daily",{"EARLY_PHASE1":13882,"PHASE1":13884,"PHASE2":13895,"PHASE3":13897,"PHASE4":13899,"NA":13901},{"trials":13883,"activeCount":98},[],{"trials":13885,"activeCount":98},[13886],{"nctId":13887,"briefTitle":13888,"status":152,"phases":13889,"primaryCompletion":13890,"completion":13890,"start":13891,"enrollment":141,"conditions":13892,"interventions":13894},"NCT03910543","Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare",[86],"2021-06-01","2019-04-11",[13893,11529],"Cutaneous Sarcoidosis",[13880],{"trials":13896,"activeCount":98},[],{"trials":13898,"activeCount":98},[],{"trials":13900,"activeCount":98},[],{"trials":13902,"activeCount":98},[],{"intervention":13904,"totalTrials":109,"cells":13905},"Intralipid",{"EARLY_PHASE1":13906,"PHASE1":13908,"PHASE2":13918,"PHASE3":13920,"PHASE4":13922,"NA":13924},{"trials":13907,"activeCount":98},[],{"trials":13909,"activeCount":98},[13910],{"nctId":13911,"briefTitle":13912,"status":1051,"phases":13913,"primaryCompletion":13914,"completion":13914,"start":13915,"enrollment":98,"conditions":13916,"interventions":13917},"NCT05553405","Neuroimmune Mechanisms in Obesity",[86],"2033-01-01","2024-01-01",[18],[13904],{"trials":13919,"activeCount":98},[],{"trials":13921,"activeCount":98},[],{"trials":13923,"activeCount":98},[],{"trials":13925,"activeCount":98},[],{"intervention":13927,"totalTrials":109,"cells":13928},"volasertib",{"EARLY_PHASE1":13929,"PHASE1":13931,"PHASE2":13943,"PHASE3":13945,"PHASE4":13947,"NA":13949},{"trials":13930,"activeCount":98},[],{"trials":13932,"activeCount":98},[13933],{"nctId":13934,"briefTitle":13935,"status":1051,"phases":13936,"primaryCompletion":13937,"completion":13938,"start":1647,"enrollment":98,"conditions":13939,"interventions":13941},"NCT02875002","Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas",[86],"2018-03","2018-09",[13940,7779],"Relapsed and Refractory Aggressive B- and T-cell Lymphomas",[13927,13942],"belinostat",{"trials":13944,"activeCount":98},[],{"trials":13946,"activeCount":98},[],{"trials":13948,"activeCount":98},[],{"trials":13950,"activeCount":98},[],{"intervention":13942,"totalTrials":109,"cells":13952},{"EARLY_PHASE1":13953,"PHASE1":13955,"PHASE2":13961,"PHASE3":13963,"PHASE4":13965,"NA":13967},{"trials":13954,"activeCount":98},[],{"trials":13956,"activeCount":98},[13957],{"nctId":13934,"briefTitle":13935,"status":1051,"phases":13958,"primaryCompletion":13937,"completion":13938,"start":1647,"enrollment":98,"conditions":13959,"interventions":13960},[86],[13940,7779],[13927,13942],{"trials":13962,"activeCount":98},[],{"trials":13964,"activeCount":98},[],{"trials":13966,"activeCount":98},[],{"trials":13968,"activeCount":98},[],{"intervention":13970,"totalTrials":109,"cells":13971},"PrEP",{"EARLY_PHASE1":13972,"PHASE1":13974,"PHASE2":13984,"PHASE3":13986,"PHASE4":13988,"NA":13990},{"trials":13973,"activeCount":98},[],{"trials":13975,"activeCount":98},[13976],{"nctId":13977,"briefTitle":13978,"status":152,"phases":13979,"primaryCompletion":13980,"completion":13980,"start":13981,"enrollment":4877,"conditions":13982,"interventions":13983},"NCT03293290","Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks",[86],"2020-05-15","2017-12-11",[274],[13970],{"trials":13985,"activeCount":98},[],{"trials":13987,"activeCount":98},[],{"trials":13989,"activeCount":98},[],{"trials":13991,"activeCount":98},[],{"intervention":13993,"totalTrials":109,"cells":13994},"whole liver lobe cTACE doxorubicin",{"EARLY_PHASE1":13995,"PHASE1":13997,"PHASE2":14006,"PHASE3":14008,"PHASE4":14010,"NA":14012},{"trials":13996,"activeCount":98},[],{"trials":13998,"activeCount":98},[13999],{"nctId":14000,"briefTitle":14001,"status":152,"phases":14002,"primaryCompletion":2319,"completion":2319,"start":6677,"enrollment":31,"conditions":14003,"interventions":14004},"NCT02753881","Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer",[86],[7668],[13993,14005],"superselective cTACE doxorubicin",{"trials":14007,"activeCount":98},[],{"trials":14009,"activeCount":98},[],{"trials":14011,"activeCount":98},[],{"trials":14013,"activeCount":98},[],{"intervention":14005,"totalTrials":109,"cells":14015},{"EARLY_PHASE1":14016,"PHASE1":14018,"PHASE2":14024,"PHASE3":14026,"PHASE4":14028,"NA":14030},{"trials":14017,"activeCount":98},[],{"trials":14019,"activeCount":98},[14020],{"nctId":14000,"briefTitle":14001,"status":152,"phases":14021,"primaryCompletion":2319,"completion":2319,"start":6677,"enrollment":31,"conditions":14022,"interventions":14023},[86],[7668],[13993,14005],{"trials":14025,"activeCount":98},[],{"trials":14027,"activeCount":98},[],{"trials":14029,"activeCount":98},[],{"trials":14031,"activeCount":98},[],{"intervention":14033,"totalTrials":109,"cells":14034},"4 mg Delta-9-THC",{"EARLY_PHASE1":14035,"PHASE1":14037,"PHASE2":14049,"PHASE3":14051,"PHASE4":14053,"NA":14055},{"trials":14036,"activeCount":98},[],{"trials":14038,"activeCount":98},[14039],{"nctId":14040,"briefTitle":14041,"status":711,"phases":14042,"primaryCompletion":14043,"completion":14043,"start":9818,"enrollment":263,"conditions":14044,"interventions":14047},"NCT03206463","Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder",[86],"2017-09-29",[14045,1215,14046],"Delta-9-Tetrahydroncannabinol","Healthy Controls",[14033,14048],"2 mg Delta-9-THC",{"trials":14050,"activeCount":98},[],{"trials":14052,"activeCount":98},[],{"trials":14054,"activeCount":98},[],{"trials":14056,"activeCount":98},[],{"intervention":14048,"totalTrials":109,"cells":14058},{"EARLY_PHASE1":14059,"PHASE1":14061,"PHASE2":14067,"PHASE3":14069,"PHASE4":14071,"NA":14073},{"trials":14060,"activeCount":98},[],{"trials":14062,"activeCount":98},[14063],{"nctId":14040,"briefTitle":14041,"status":711,"phases":14064,"primaryCompletion":14043,"completion":14043,"start":9818,"enrollment":263,"conditions":14065,"interventions":14066},[86],[14045,1215,14046],[14033,14048],{"trials":14068,"activeCount":98},[],{"trials":14070,"activeCount":98},[],{"trials":14072,"activeCount":98},[],{"trials":14074,"activeCount":98},[],{"intervention":14076,"totalTrials":109,"cells":14077},"Transdermal nicotine",{"EARLY_PHASE1":14078,"PHASE1":14080,"PHASE2":14091,"PHASE3":14093,"PHASE4":14095,"NA":14097},{"trials":14079,"activeCount":98},[],{"trials":14081,"activeCount":98},[14082],{"nctId":14083,"briefTitle":14084,"status":152,"phases":14085,"primaryCompletion":14086,"completion":14086,"start":1973,"enrollment":1296,"conditions":14087,"interventions":14090},"NCT02552147","Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism",[86],"2017-11-17",[8210,14088,14089],"Aggression","Irritability",[14076],{"trials":14092,"activeCount":98},[],{"trials":14094,"activeCount":98},[],{"trials":14096,"activeCount":98},[],{"trials":14098,"activeCount":98},[],{"intervention":14100,"totalTrials":109,"cells":14101},"furosemide, Na supplements",{"EARLY_PHASE1":14102,"PHASE1":14104,"PHASE2":14112,"PHASE3":14114,"PHASE4":14116,"NA":14118},{"trials":14103,"activeCount":98},[],{"trials":14105,"activeCount":98},[14106],{"nctId":14107,"briefTitle":14108,"status":152,"phases":14109,"primaryCompletion":10888,"completion":11051,"start":1984,"enrollment":31,"conditions":14110,"interventions":14111},"NCT00611741","The Effect of Plasma Osmolality on Brain Glutamate",[86],[15],[14100],{"trials":14113,"activeCount":98},[],{"trials":14115,"activeCount":98},[],{"trials":14117,"activeCount":98},[],{"trials":14119,"activeCount":98},[],{"intervention":14121,"totalTrials":109,"cells":14122},"0.05, 0.025, and 0.0125 mg nicotine\u002Fpulse of nicotine",{"EARLY_PHASE1":14123,"PHASE1":14125,"PHASE2":14135,"PHASE3":14137,"PHASE4":14139,"NA":14141},{"trials":14124,"activeCount":98},[],{"trials":14126,"activeCount":98},[14127],{"nctId":14128,"briefTitle":14129,"status":152,"phases":14130,"primaryCompletion":14131,"completion":4668,"start":14132,"enrollment":6758,"conditions":14133,"interventions":14134},"NCT05159934","Nicotine Differences in Smokers",[86],"2023-07-19","2022-02-16",[24],[14121,8235],{"trials":14136,"activeCount":98},[],{"trials":14138,"activeCount":98},[],{"trials":14140,"activeCount":98},[],{"trials":14142,"activeCount":98},[],{"intervention":14144,"totalTrials":109,"cells":14145},"Topotecan",{"EARLY_PHASE1":14146,"PHASE1":14148,"PHASE2":14157,"PHASE3":14159,"PHASE4":14161,"NA":14163},{"trials":14147,"activeCount":98},[],{"trials":14149,"activeCount":98},[14150],{"nctId":14151,"briefTitle":14152,"status":152,"phases":14153,"primaryCompletion":6706,"completion":6706,"start":1082,"enrollment":1315,"conditions":14154,"interventions":14155},"NCT00703807","Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers",[86],[7873],[14144,14156],"RAD001",{"trials":14158,"activeCount":98},[],{"trials":14160,"activeCount":98},[],{"trials":14162,"activeCount":98},[],{"trials":14164,"activeCount":98},[],{"intervention":14156,"totalTrials":109,"cells":14166},{"EARLY_PHASE1":14167,"PHASE1":14169,"PHASE2":14175,"PHASE3":14177,"PHASE4":14179,"NA":14181},{"trials":14168,"activeCount":98},[],{"trials":14170,"activeCount":98},[14171],{"nctId":14151,"briefTitle":14152,"status":152,"phases":14172,"primaryCompletion":6706,"completion":6706,"start":1082,"enrollment":1315,"conditions":14173,"interventions":14174},[86],[7873],[14144,14156],{"trials":14176,"activeCount":98},[],{"trials":14178,"activeCount":98},[],{"trials":14180,"activeCount":98},[],{"trials":14182,"activeCount":98},[],{"intervention":8311,"totalTrials":109,"cells":14184},{"EARLY_PHASE1":14185,"PHASE1":14187,"PHASE2":14193,"PHASE3":14195,"PHASE4":14197,"NA":14199},{"trials":14186,"activeCount":98},[],{"trials":14188,"activeCount":98},[14189],{"nctId":8303,"briefTitle":8304,"status":152,"phases":14190,"primaryCompletion":327,"completion":327,"start":7034,"enrollment":118,"conditions":14191,"interventions":14192},[86],[8307,8308,7779,2041,8309],[8311,8312,8313,7791,6968,7793],{"trials":14194,"activeCount":98},[],{"trials":14196,"activeCount":98},[],{"trials":14198,"activeCount":98},[],{"trials":14200,"activeCount":98},[],{"intervention":8312,"totalTrials":109,"cells":14202},{"EARLY_PHASE1":14203,"PHASE1":14205,"PHASE2":14211,"PHASE3":14213,"PHASE4":14215,"NA":14217},{"trials":14204,"activeCount":98},[],{"trials":14206,"activeCount":98},[14207],{"nctId":8303,"briefTitle":8304,"status":152,"phases":14208,"primaryCompletion":327,"completion":327,"start":7034,"enrollment":118,"conditions":14209,"interventions":14210},[86],[8307,8308,7779,2041,8309],[8311,8312,8313,7791,6968,7793],{"trials":14212,"activeCount":98},[],{"trials":14214,"activeCount":98},[],{"trials":14216,"activeCount":98},[],{"trials":14218,"activeCount":98},[],{"intervention":8313,"totalTrials":109,"cells":14220},{"EARLY_PHASE1":14221,"PHASE1":14223,"PHASE2":14229,"PHASE3":14231,"PHASE4":14233,"NA":14235},{"trials":14222,"activeCount":98},[],{"trials":14224,"activeCount":98},[14225],{"nctId":8303,"briefTitle":8304,"status":152,"phases":14226,"primaryCompletion":327,"completion":327,"start":7034,"enrollment":118,"conditions":14227,"interventions":14228},[86],[8307,8308,7779,2041,8309],[8311,8312,8313,7791,6968,7793],{"trials":14230,"activeCount":98},[],{"trials":14232,"activeCount":98},[],{"trials":14234,"activeCount":98},[],{"trials":14236,"activeCount":98},[],{"intervention":7594,"totalTrials":94,"cells":14238},{"EARLY_PHASE1":14239,"PHASE1":14258,"PHASE2":14260,"PHASE3":14262,"PHASE4":14264,"NA":14266},{"trials":14240,"activeCount":98},[14241,14250,14254],{"nctId":14242,"briefTitle":14243,"status":152,"phases":14244,"primaryCompletion":14245,"completion":14245,"start":14246,"enrollment":1416,"conditions":14247,"interventions":14248},"NCT01591629","The Effects of ∆-9-THC and Naloxone in Humans",[85],"2012-06-01","2011-11-04",[3590],[14249,7594],"Naloxone",{"nctId":7587,"briefTitle":7588,"status":711,"phases":14251,"primaryCompletion":7590,"completion":7590,"start":7591,"enrollment":303,"conditions":14252,"interventions":14253},[85],[3590],[7594,7595],{"nctId":7825,"briefTitle":7826,"status":152,"phases":14255,"primaryCompletion":7828,"completion":7828,"start":7829,"enrollment":314,"conditions":14256,"interventions":14257},[85],[3590],[7810,7594],{"trials":14259,"activeCount":98},[],{"trials":14261,"activeCount":98},[],{"trials":14263,"activeCount":98},[],{"trials":14265,"activeCount":98},[],{"trials":14267,"activeCount":98},[],{"intervention":14269,"totalTrials":263,"cells":14270},"Lysine Chloride",{"EARLY_PHASE1":14271,"PHASE1":14290,"PHASE2":14292,"PHASE3":14294,"PHASE4":14296,"NA":14298},{"trials":14272,"activeCount":98},[14273,14281],{"nctId":14274,"briefTitle":14275,"status":152,"phases":14276,"primaryCompletion":14277,"completion":14277,"start":14278,"enrollment":1305,"conditions":14279,"interventions":14280},"NCT03446651","Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure",[85],"2022-09-07","2018-07-12",[107],[14269],{"nctId":14282,"briefTitle":14283,"status":152,"phases":14284,"primaryCompletion":14285,"completion":14285,"start":14286,"enrollment":118,"conditions":14287,"interventions":14289},"NCT03440970","Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure",[85],"2025-08-30","2019-01-15",[14288],"Decompensated Heart Failure",[14269],{"trials":14291,"activeCount":98},[],{"trials":14293,"activeCount":98},[],{"trials":14295,"activeCount":98},[],{"trials":14297,"activeCount":98},[],{"trials":14299,"activeCount":98},[],{"intervention":14301,"totalTrials":263,"cells":14302},"Insulin",{"EARLY_PHASE1":14303,"PHASE1":14323,"PHASE2":14325,"PHASE3":14327,"PHASE4":14329,"NA":14331},{"trials":14304,"activeCount":98},[14305,14313],{"nctId":14306,"briefTitle":14307,"status":152,"phases":14308,"primaryCompletion":14309,"completion":14309,"start":14310,"enrollment":1296,"conditions":14311,"interventions":14312},"NCT03469492","Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose",[85],"2020-03-20","2018-01-18",[5032],[14301],{"nctId":14314,"briefTitle":14315,"status":152,"phases":14316,"primaryCompletion":14317,"completion":14317,"start":14318,"enrollment":14319,"conditions":14320,"interventions":14322},"NCT03738852","Mechanisms for Restoration of Hypoglycemia Awareness",[85],"2023-08-14","2018-11-07",55,[14321],"Type1 Diabetes Mellitus",[14301],{"trials":14324,"activeCount":98},[],{"trials":14326,"activeCount":98},[],{"trials":14328,"activeCount":98},[],{"trials":14330,"activeCount":98},[],{"trials":14332,"activeCount":98},[],{"intervention":14334,"totalTrials":109,"cells":14335},"hyaluronidase",{"EARLY_PHASE1":14336,"PHASE1":14345,"PHASE2":14347,"PHASE3":14349,"PHASE4":14351,"NA":14353},{"trials":14337,"activeCount":98},[14338],{"nctId":14339,"briefTitle":14340,"status":152,"phases":14341,"primaryCompletion":1742,"completion":7533,"start":5742,"enrollment":1685,"conditions":14342,"interventions":14343},"NCT01945099","Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy",[85],[5724],[14334,14344],"Lispro-PH20",{"trials":14346,"activeCount":98},[],{"trials":14348,"activeCount":98},[],{"trials":14350,"activeCount":98},[],{"trials":14352,"activeCount":98},[],{"trials":14354,"activeCount":98},[],{"intervention":14344,"totalTrials":109,"cells":14356},{"EARLY_PHASE1":14357,"PHASE1":14363,"PHASE2":14365,"PHASE3":14367,"PHASE4":14369,"NA":14371},{"trials":14358,"activeCount":98},[14359],{"nctId":14339,"briefTitle":14340,"status":152,"phases":14360,"primaryCompletion":1742,"completion":7533,"start":5742,"enrollment":1685,"conditions":14361,"interventions":14362},[85],[5724],[14334,14344],{"trials":14364,"activeCount":98},[],{"trials":14366,"activeCount":98},[],{"trials":14368,"activeCount":98},[],{"trials":14370,"activeCount":98},[],{"trials":14372,"activeCount":98},[],{"intervention":8367,"totalTrials":109,"cells":14374},{"EARLY_PHASE1":14375,"PHASE1":14381,"PHASE2":14383,"PHASE3":14385,"PHASE4":14387,"NA":14389},{"trials":14376,"activeCount":98},[14377],{"nctId":8362,"briefTitle":8363,"status":152,"phases":14378,"primaryCompletion":5846,"completion":1186,"start":1187,"enrollment":1743,"conditions":14379,"interventions":14380},[85],[6718],[8357,8367],{"trials":14382,"activeCount":98},[],{"trials":14384,"activeCount":98},[],{"trials":14386,"activeCount":98},[],{"trials":14388,"activeCount":98},[],{"trials":14390,"activeCount":98},[],{"intervention":14392,"totalTrials":109,"cells":14393},"Intravenous ethanol placebo plus nicotine infusions",{"EARLY_PHASE1":14394,"PHASE1":14405,"PHASE2":14407,"PHASE3":14409,"PHASE4":14411,"NA":14413},{"trials":14395,"activeCount":98},[14396],{"nctId":14397,"briefTitle":14398,"status":152,"phases":14399,"primaryCompletion":8457,"completion":8457,"start":14400,"enrollment":303,"conditions":14401,"interventions":14402},"NCT01814410","Interactive Effects of IV Ethanol and IV Nicotine",[85],"2013-02-22",[3590],[14392,14403,14404],"intravenous ethanol 40mg% plus nicotine infusions","intravenous ethanol 100mg% plus nicotine infusions",{"trials":14406,"activeCount":98},[],{"trials":14408,"activeCount":98},[],{"trials":14410,"activeCount":98},[],{"trials":14412,"activeCount":98},[],{"trials":14414,"activeCount":98},[],{"intervention":14403,"totalTrials":109,"cells":14416},{"EARLY_PHASE1":14417,"PHASE1":14423,"PHASE2":14425,"PHASE3":14427,"PHASE4":14429,"NA":14431},{"trials":14418,"activeCount":98},[14419],{"nctId":14397,"briefTitle":14398,"status":152,"phases":14420,"primaryCompletion":8457,"completion":8457,"start":14400,"enrollment":303,"conditions":14421,"interventions":14422},[85],[3590],[14392,14403,14404],{"trials":14424,"activeCount":98},[],{"trials":14426,"activeCount":98},[],{"trials":14428,"activeCount":98},[],{"trials":14430,"activeCount":98},[],{"trials":14432,"activeCount":98},[],{"intervention":14404,"totalTrials":109,"cells":14434},{"EARLY_PHASE1":14435,"PHASE1":14441,"PHASE2":14443,"PHASE3":14445,"PHASE4":14447,"NA":14449},{"trials":14436,"activeCount":98},[14437],{"nctId":14397,"briefTitle":14398,"status":152,"phases":14438,"primaryCompletion":8457,"completion":8457,"start":14400,"enrollment":303,"conditions":14439,"interventions":14440},[85],[3590],[14392,14403,14404],{"trials":14442,"activeCount":98},[],{"trials":14444,"activeCount":98},[],{"trials":14446,"activeCount":98},[],{"trials":14448,"activeCount":98},[],{"trials":14450,"activeCount":98},[],{"intervention":14452,"totalTrials":109,"cells":14453},"Phenylephrine",{"EARLY_PHASE1":14454,"PHASE1":14466,"PHASE2":14468,"PHASE3":14470,"PHASE4":14472,"NA":14474},{"trials":14455,"activeCount":98},[14456],{"nctId":14457,"briefTitle":14458,"status":14459,"phases":14460,"primaryCompletion":2955,"completion":2955,"start":14461,"enrollment":1044,"conditions":14462,"interventions":14464},"NCT04218773","Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study","SUSPENDED",[85],"2020-09-11",[2892,14463],"Blood Pressure",[14452,14465],"Norepinephrine",{"trials":14467,"activeCount":98},[],{"trials":14469,"activeCount":98},[],{"trials":14471,"activeCount":98},[],{"trials":14473,"activeCount":98},[],{"trials":14475,"activeCount":98},[],{"intervention":14465,"totalTrials":109,"cells":14477},{"EARLY_PHASE1":14478,"PHASE1":14484,"PHASE2":14486,"PHASE3":14488,"PHASE4":14490,"NA":14492},{"trials":14479,"activeCount":98},[14480],{"nctId":14457,"briefTitle":14458,"status":14459,"phases":14481,"primaryCompletion":2955,"completion":2955,"start":14461,"enrollment":1044,"conditions":14482,"interventions":14483},[85],[2892,14463],[14452,14465],{"trials":14485,"activeCount":98},[],{"trials":14487,"activeCount":98},[],{"trials":14489,"activeCount":98},[],{"trials":14491,"activeCount":98},[],{"trials":14493,"activeCount":98},[],{"intervention":14495,"totalTrials":109,"cells":14496},"[11C]MK-3168",{"EARLY_PHASE1":14497,"PHASE1":14506,"PHASE2":14508,"PHASE3":14510,"PHASE4":14512,"NA":14514},{"trials":14498,"activeCount":98},[14499],{"nctId":14500,"briefTitle":14501,"status":711,"phases":14502,"primaryCompletion":1030,"completion":1030,"start":14503,"enrollment":1416,"conditions":14504,"interventions":14505},"NCT04404712","FAAH Availability in Psychiatric Disorders: A PET Study",[85],"2020-09-23",[1688,27,4998],[14495],{"trials":14507,"activeCount":98},[],{"trials":14509,"activeCount":98},[],{"trials":14511,"activeCount":98},[],{"trials":14513,"activeCount":98},[],{"trials":14515,"activeCount":98},[],{"intervention":14517,"totalTrials":109,"cells":14518},"cannabis",{"EARLY_PHASE1":14519,"PHASE1":14529,"PHASE2":14531,"PHASE3":14533,"PHASE4":14535,"NA":14537},{"trials":14520,"activeCount":98},[14521],{"nctId":14522,"briefTitle":14523,"status":152,"phases":14524,"primaryCompletion":6024,"completion":14525,"start":14526,"enrollment":1512,"conditions":14527,"interventions":14528},"NCT02817698","Imaging the Neurochemistry of Drug Addiction With PET",[85],"2024-06-14","2017-11-29",[33,1399],[14517],{"trials":14530,"activeCount":98},[],{"trials":14532,"activeCount":98},[],{"trials":14534,"activeCount":98},[],{"trials":14536,"activeCount":98},[],{"trials":14538,"activeCount":98},[],{"intervention":14540,"totalTrials":109,"cells":14541},"Oral Alcohol Challenge",{"EARLY_PHASE1":14542,"PHASE1":14552,"PHASE2":14554,"PHASE3":14556,"PHASE4":14558,"NA":14560},{"trials":14543,"activeCount":98},[14544],{"nctId":14545,"briefTitle":14546,"status":152,"phases":14547,"primaryCompletion":14548,"completion":14548,"start":14549,"enrollment":1675,"conditions":14550,"interventions":14551},"NCT04251221","Measuring the Neuroimmune Response to Alcohol",[85],"2021-11-20","2019-06-20",[1034],[14540],{"trials":14553,"activeCount":98},[],{"trials":14555,"activeCount":98},[],{"trials":14557,"activeCount":98},[],{"trials":14559,"activeCount":98},[],{"trials":14561,"activeCount":98},[],{"intervention":14563,"totalTrials":109,"cells":14564},"Salvinorin A",{"EARLY_PHASE1":14565,"PHASE1":14575,"PHASE2":14577,"PHASE3":14579,"PHASE4":14581,"NA":14583},{"trials":14566,"activeCount":98},[14567],{"nctId":14568,"briefTitle":14569,"status":152,"phases":14570,"primaryCompletion":14571,"completion":14571,"start":14572,"enrollment":4877,"conditions":14573,"interventions":14574},"NCT00700596","Effects of Salvinorin A in Healthy Controls",[85],"2014-08-22","2009-02-12",[3590],[14563],{"trials":14576,"activeCount":98},[],{"trials":14578,"activeCount":98},[],{"trials":14580,"activeCount":98},[],{"trials":14582,"activeCount":98},[],{"trials":14584,"activeCount":98},[],{"intervention":14586,"totalTrials":109,"cells":14587},"Eculizumab",{"EARLY_PHASE1":14588,"PHASE1":14600,"PHASE2":14602,"PHASE3":14604,"PHASE4":14606,"NA":14608},{"trials":14589,"activeCount":98},[14590],{"nctId":14591,"briefTitle":14592,"status":1051,"phases":14593,"primaryCompletion":14594,"completion":14595,"start":14596,"enrollment":98,"conditions":14597,"interventions":14599},"NCT03468140","Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation",[85],"2023-04-30","2023-12-31","2021-10-01",[14598],"End Stage Liver Disease",[14586],{"trials":14601,"activeCount":98},[],{"trials":14603,"activeCount":98},[],{"trials":14605,"activeCount":98},[],{"trials":14607,"activeCount":98},[],{"trials":14609,"activeCount":98},[],{"intervention":11886,"totalTrials":109,"cells":14611},{"EARLY_PHASE1":14612,"PHASE1":14618,"PHASE2":14620,"PHASE3":14622,"PHASE4":14624,"NA":14626},{"trials":14613,"activeCount":98},[14614],{"nctId":11878,"briefTitle":11879,"status":152,"phases":14615,"primaryCompletion":11881,"completion":11882,"start":11883,"enrollment":1878,"conditions":14616,"interventions":14617},[85],[24],[11873,11886,11887,11888],{"trials":14619,"activeCount":98},[],{"trials":14621,"activeCount":98},[],{"trials":14623,"activeCount":98},[],{"trials":14625,"activeCount":98},[],{"trials":14627,"activeCount":98},[],{"intervention":11887,"totalTrials":109,"cells":14629},{"EARLY_PHASE1":14630,"PHASE1":14636,"PHASE2":14638,"PHASE3":14640,"PHASE4":14642,"NA":14644},{"trials":14631,"activeCount":98},[14632],{"nctId":11878,"briefTitle":11879,"status":152,"phases":14633,"primaryCompletion":11881,"completion":11882,"start":11883,"enrollment":1878,"conditions":14634,"interventions":14635},[85],[24],[11873,11886,11887,11888],{"trials":14637,"activeCount":98},[],{"trials":14639,"activeCount":98},[],{"trials":14641,"activeCount":98},[],{"trials":14643,"activeCount":98},[],{"trials":14645,"activeCount":98},[],{"intervention":11888,"totalTrials":109,"cells":14647},{"EARLY_PHASE1":14648,"PHASE1":14654,"PHASE2":14656,"PHASE3":14658,"PHASE4":14660,"NA":14662},{"trials":14649,"activeCount":98},[14650],{"nctId":11878,"briefTitle":11879,"status":152,"phases":14651,"primaryCompletion":11881,"completion":11882,"start":11883,"enrollment":1878,"conditions":14652,"interventions":14653},[85],[24],[11873,11886,11887,11888],{"trials":14655,"activeCount":98},[],{"trials":14657,"activeCount":98},[],{"trials":14659,"activeCount":98},[],{"trials":14661,"activeCount":98},[],{"trials":14663,"activeCount":98},[],{"intervention":14665,"totalTrials":109,"cells":14666},"delta 9 tetrahydrocannabinol",{"EARLY_PHASE1":14667,"PHASE1":14678,"PHASE2":14680,"PHASE3":14682,"PHASE4":14684,"NA":14686},{"trials":14668,"activeCount":98},[14669],{"nctId":14670,"briefTitle":14671,"status":152,"phases":14672,"primaryCompletion":14673,"completion":14673,"start":14674,"enrollment":7035,"conditions":14675,"interventions":14677},"NCT00678730","Pharmacogenetics of Cannabinoid Response",[85],"2014-09-11","2007-08-23",[14676],"COMT Gene Polymorphism",[14665],{"trials":14679,"activeCount":98},[],{"trials":14681,"activeCount":98},[],{"trials":14683,"activeCount":98},[],{"trials":14685,"activeCount":98},[],{"trials":14687,"activeCount":98},[],{"intervention":14689,"totalTrials":109,"cells":14690},"Liraglutide",{"EARLY_PHASE1":14691,"PHASE1":14702,"PHASE2":14704,"PHASE3":14706,"PHASE4":14708,"NA":14710},{"trials":14692,"activeCount":98},[14693],{"nctId":14694,"briefTitle":14695,"status":711,"phases":14696,"primaryCompletion":14697,"completion":14697,"start":14698,"enrollment":1685,"conditions":14699,"interventions":14701},"NCT03500484","Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.",[85],"2020-06-25","2018-06-06",[2125,14700],"Neural Development",[14689],{"trials":14703,"activeCount":98},[],{"trials":14705,"activeCount":98},[],{"trials":14707,"activeCount":98},[],{"trials":14709,"activeCount":98},[],{"trials":14711,"activeCount":98},[],{"intervention":14713,"totalTrials":109,"cells":14714},"Two-hour dwell with 10% dextrose in sterile water",{"EARLY_PHASE1":14715,"PHASE1":14727,"PHASE2":14729,"PHASE3":14731,"PHASE4":14733,"NA":14735},{"trials":14716,"activeCount":98},[14717],{"nctId":14718,"briefTitle":14719,"status":152,"phases":14720,"primaryCompletion":14721,"completion":3840,"start":9911,"enrollment":272,"conditions":14722,"interventions":14725},"NCT03801226","Zero Sodium Peritoneal Dialysate Protocol Pilot Study",[85],"2019-05-01",[14723,14724],"Potential Applications for Heart Failure","Volume Overload",[14713,14726],"Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose",{"trials":14728,"activeCount":98},[],{"trials":14730,"activeCount":98},[],{"trials":14732,"activeCount":98},[],{"trials":14734,"activeCount":98},[],{"trials":14736,"activeCount":98},[],{"intervention":14726,"totalTrials":109,"cells":14738},{"EARLY_PHASE1":14739,"PHASE1":14745,"PHASE2":14747,"PHASE3":14749,"PHASE4":14751,"NA":14753},{"trials":14740,"activeCount":98},[14741],{"nctId":14718,"briefTitle":14719,"status":152,"phases":14742,"primaryCompletion":14721,"completion":3840,"start":9911,"enrollment":272,"conditions":14743,"interventions":14744},[85],[14723,14724],[14713,14726],{"trials":14746,"activeCount":98},[],{"trials":14748,"activeCount":98},[],{"trials":14750,"activeCount":98},[],{"trials":14752,"activeCount":98},[],{"trials":14754,"activeCount":98},[],{"intervention":14756,"totalTrials":109,"cells":14757},"Low-dose lipopolysaccharide",{"EARLY_PHASE1":14758,"PHASE1":14769,"PHASE2":14771,"PHASE3":14773,"PHASE4":14775,"NA":14777},{"trials":14759,"activeCount":98},[14760],{"nctId":14761,"briefTitle":14762,"status":152,"phases":14763,"primaryCompletion":14764,"completion":14764,"start":14765,"enrollment":1743,"conditions":14766,"interventions":14767},"NCT04398719","CBD-Microglia PET Study",[85],"2024-12-11","2021-05-07",[7821,3590],[14756,14768],"Intradermal Capsaicin",{"trials":14770,"activeCount":98},[],{"trials":14772,"activeCount":98},[],{"trials":14774,"activeCount":98},[],{"trials":14776,"activeCount":98},[],{"trials":14778,"activeCount":98},[],{"intervention":14768,"totalTrials":109,"cells":14780},{"EARLY_PHASE1":14781,"PHASE1":14787,"PHASE2":14789,"PHASE3":14791,"PHASE4":14793,"NA":14795},{"trials":14782,"activeCount":98},[14783],{"nctId":14761,"briefTitle":14762,"status":152,"phases":14784,"primaryCompletion":14764,"completion":14764,"start":14765,"enrollment":1743,"conditions":14785,"interventions":14786},[85],[7821,3590],[14756,14768],{"trials":14788,"activeCount":98},[],{"trials":14790,"activeCount":98},[],{"trials":14792,"activeCount":98},[],{"trials":14794,"activeCount":98},[],{"trials":14796,"activeCount":98},[],{"intervention":14249,"totalTrials":109,"cells":14798},{"EARLY_PHASE1":14799,"PHASE1":14805,"PHASE2":14807,"PHASE3":14809,"PHASE4":14811,"NA":14813},{"trials":14800,"activeCount":98},[14801],{"nctId":14242,"briefTitle":14243,"status":152,"phases":14802,"primaryCompletion":14245,"completion":14245,"start":14246,"enrollment":1416,"conditions":14803,"interventions":14804},[85],[3590],[14249,7594],{"trials":14806,"activeCount":98},[],{"trials":14808,"activeCount":98},[],{"trials":14810,"activeCount":98},[],{"trials":14812,"activeCount":98},[],{"trials":14814,"activeCount":98},[],{"intervention":14816,"totalTrials":109,"cells":14817},"Oxycodone Medication First",{"EARLY_PHASE1":14818,"PHASE1":14829,"PHASE2":14831,"PHASE3":14833,"PHASE4":14835,"NA":14837},{"trials":14819,"activeCount":98},[14820],{"nctId":14821,"briefTitle":14822,"status":152,"phases":14823,"primaryCompletion":14824,"completion":14824,"start":14825,"enrollment":118,"conditions":14826,"interventions":14828},"NCT03612713","Influence of Medication on Functional Connectivity",[85],"2022-06-02","2018-10-30",[14827],"Prescription Drug Abuse (Not Dependent)",[14816],{"trials":14830,"activeCount":98},[],{"trials":14832,"activeCount":98},[],{"trials":14834,"activeCount":98},[],{"trials":14836,"activeCount":98},[],{"trials":14838,"activeCount":98},[],{"intervention":14840,"totalTrials":109,"cells":14841},"drug condition",{"EARLY_PHASE1":14842,"PHASE1":14852,"PHASE2":14854,"PHASE3":14856,"PHASE4":14858,"NA":14860},{"trials":14843,"activeCount":98},[14844],{"nctId":14845,"briefTitle":14846,"status":152,"phases":14847,"primaryCompletion":1072,"completion":1072,"start":5870,"enrollment":14848,"conditions":14849,"interventions":14851},"NCT00842985","Dronabinol Interactions With Cognitive Enhancing Drug in Humans",[85],53,[1399,14850],"Marijuana Abuse",[14840],{"trials":14853,"activeCount":98},[],{"trials":14855,"activeCount":98},[],{"trials":14857,"activeCount":98},[],{"trials":14859,"activeCount":98},[],{"trials":14861,"activeCount":98},[],{"intervention":14863,"totalTrials":109,"cells":14864},"CBD Day 1",{"EARLY_PHASE1":14865,"PHASE1":14876,"PHASE2":14878,"PHASE3":14880,"PHASE4":14882,"NA":14884},{"trials":14866,"activeCount":98},[14867],{"nctId":14868,"briefTitle":14869,"status":152,"phases":14870,"primaryCompletion":14871,"completion":14871,"start":5123,"enrollment":1466,"conditions":14872,"interventions":14873},"NCT05076370","Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine",[85],"2024-06-28",[5707],[14863,14874,14875],"CBD Day 2","CBD Day 3",{"trials":14877,"activeCount":98},[],{"trials":14879,"activeCount":98},[],{"trials":14881,"activeCount":98},[],{"trials":14883,"activeCount":98},[],{"trials":14885,"activeCount":98},[],{"intervention":14874,"totalTrials":109,"cells":14887},{"EARLY_PHASE1":14888,"PHASE1":14894,"PHASE2":14896,"PHASE3":14898,"PHASE4":14900,"NA":14902},{"trials":14889,"activeCount":98},[14890],{"nctId":14868,"briefTitle":14869,"status":152,"phases":14891,"primaryCompletion":14871,"completion":14871,"start":5123,"enrollment":1466,"conditions":14892,"interventions":14893},[85],[5707],[14863,14874,14875],{"trials":14895,"activeCount":98},[],{"trials":14897,"activeCount":98},[],{"trials":14899,"activeCount":98},[],{"trials":14901,"activeCount":98},[],{"trials":14903,"activeCount":98},[],{"intervention":14875,"totalTrials":109,"cells":14905},{"EARLY_PHASE1":14906,"PHASE1":14912,"PHASE2":14914,"PHASE3":14916,"PHASE4":14918,"NA":14920},{"trials":14907,"activeCount":98},[14908],{"nctId":14868,"briefTitle":14869,"status":152,"phases":14909,"primaryCompletion":14871,"completion":14871,"start":5123,"enrollment":1466,"conditions":14910,"interventions":14911},[85],[5707],[14863,14874,14875],{"trials":14913,"activeCount":98},[],{"trials":14915,"activeCount":98},[],{"trials":14917,"activeCount":98},[],{"trials":14919,"activeCount":98},[],{"trials":14921,"activeCount":98},[],{"intervention":14923,"totalTrials":109,"cells":14924},"Nicotine saline infusion 0.00mcg\u002Fkg\u002Fs",{"EARLY_PHASE1":14925,"PHASE1":14939,"PHASE2":14941,"PHASE3":14943,"PHASE4":14945,"NA":14947},{"trials":14926,"activeCount":98},[14927],{"nctId":14928,"briefTitle":14929,"status":152,"phases":14930,"primaryCompletion":14931,"completion":14931,"start":14932,"enrollment":2659,"conditions":14933,"interventions":14934},"NCT03580525","Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol",[85],"2020-11-19","2019-02-14",[24],[14923,14935,14936,14937,14938],"Nicotine infusion 0.24mcg\u002Fkg\u002Fs","Nicotine infusion 0.096mcg\u002Fkg\u002Fs","Nicotine infusion 0.048 mcg\u002Fkg\u002Fs","Nicotine infusion 0.024mcg\u002Fkg\u002Fs",{"trials":14940,"activeCount":98},[],{"trials":14942,"activeCount":98},[],{"trials":14944,"activeCount":98},[],{"trials":14946,"activeCount":98},[],{"trials":14948,"activeCount":98},[],{"intervention":14935,"totalTrials":109,"cells":14950},{"EARLY_PHASE1":14951,"PHASE1":14957,"PHASE2":14959,"PHASE3":14961,"PHASE4":14963,"NA":14965},{"trials":14952,"activeCount":98},[14953],{"nctId":14928,"briefTitle":14929,"status":152,"phases":14954,"primaryCompletion":14931,"completion":14931,"start":14932,"enrollment":2659,"conditions":14955,"interventions":14956},[85],[24],[14923,14935,14936,14937,14938],{"trials":14958,"activeCount":98},[],{"trials":14960,"activeCount":98},[],{"trials":14962,"activeCount":98},[],{"trials":14964,"activeCount":98},[],{"trials":14966,"activeCount":98},[],{"intervention":14936,"totalTrials":109,"cells":14968},{"EARLY_PHASE1":14969,"PHASE1":14975,"PHASE2":14977,"PHASE3":14979,"PHASE4":14981,"NA":14983},{"trials":14970,"activeCount":98},[14971],{"nctId":14928,"briefTitle":14929,"status":152,"phases":14972,"primaryCompletion":14931,"completion":14931,"start":14932,"enrollment":2659,"conditions":14973,"interventions":14974},[85],[24],[14923,14935,14936,14937,14938],{"trials":14976,"activeCount":98},[],{"trials":14978,"activeCount":98},[],{"trials":14980,"activeCount":98},[],{"trials":14982,"activeCount":98},[],{"trials":14984,"activeCount":98},[],{"intervention":14937,"totalTrials":109,"cells":14986},{"EARLY_PHASE1":14987,"PHASE1":14993,"PHASE2":14995,"PHASE3":14997,"PHASE4":14999,"NA":15001},{"trials":14988,"activeCount":98},[14989],{"nctId":14928,"briefTitle":14929,"status":152,"phases":14990,"primaryCompletion":14931,"completion":14931,"start":14932,"enrollment":2659,"conditions":14991,"interventions":14992},[85],[24],[14923,14935,14936,14937,14938],{"trials":14994,"activeCount":98},[],{"trials":14996,"activeCount":98},[],{"trials":14998,"activeCount":98},[],{"trials":15000,"activeCount":98},[],{"trials":15002,"activeCount":98},[],{"intervention":14938,"totalTrials":109,"cells":15004},{"EARLY_PHASE1":15005,"PHASE1":15011,"PHASE2":15013,"PHASE3":15015,"PHASE4":15017,"NA":15019},{"trials":15006,"activeCount":98},[15007],{"nctId":14928,"briefTitle":14929,"status":152,"phases":15008,"primaryCompletion":14931,"completion":14931,"start":14932,"enrollment":2659,"conditions":15009,"interventions":15010},[85],[24],[14923,14935,14936,14937,14938],{"trials":15012,"activeCount":98},[],{"trials":15014,"activeCount":98},[],{"trials":15016,"activeCount":98},[],{"trials":15018,"activeCount":98},[],{"trials":15020,"activeCount":98},[],{"intervention":15022,"totalTrials":109,"cells":15023},"Tumor Infiltrating Lymphocytes",{"EARLY_PHASE1":15024,"PHASE1":15034,"PHASE2":15036,"PHASE3":15038,"PHASE4":15040,"NA":15042},{"trials":15025,"activeCount":98},[15026],{"nctId":15027,"briefTitle":15028,"status":711,"phases":15029,"primaryCompletion":9867,"completion":9867,"start":15030,"enrollment":1416,"conditions":15031,"interventions":15032},"NCT03526185","A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes",[85],"2018-02-06",[1495],[15022,15033],"Nivolumab and Ipilimumab",{"trials":15035,"activeCount":98},[],{"trials":15037,"activeCount":98},[],{"trials":15039,"activeCount":98},[],{"trials":15041,"activeCount":98},[],{"trials":15043,"activeCount":98},[],{"intervention":15033,"totalTrials":109,"cells":15045},{"EARLY_PHASE1":15046,"PHASE1":15052,"PHASE2":15054,"PHASE3":15056,"PHASE4":15058,"NA":15060},{"trials":15047,"activeCount":98},[15048],{"nctId":15027,"briefTitle":15028,"status":711,"phases":15049,"primaryCompletion":9867,"completion":9867,"start":15030,"enrollment":1416,"conditions":15050,"interventions":15051},[85],[1495],[15022,15033],{"trials":15053,"activeCount":98},[],{"trials":15055,"activeCount":98},[],{"trials":15057,"activeCount":98},[],{"trials":15059,"activeCount":98},[],{"trials":15061,"activeCount":98},[],{"intervention":15063,"totalTrials":109,"cells":15064},"tremelimumab\u002Fdurvalumab, ipilimumab\u002Fnivolumab and nivolumab monotherapy",{"EARLY_PHASE1":15065,"PHASE1":15077,"PHASE2":15079,"PHASE3":15081,"PHASE4":15083,"NA":15085},{"trials":15066,"activeCount":98},[15067],{"nctId":15068,"briefTitle":15069,"status":1051,"phases":15070,"primaryCompletion":15071,"completion":15072,"start":15073,"enrollment":98,"conditions":15074,"interventions":15076},"NCT04223648","Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma",[85],"2022-02","2025-02","2020-08-15",[15075],"Malignant Melanoma",[15063],{"trials":15078,"activeCount":98},[],{"trials":15080,"activeCount":98},[],{"trials":15082,"activeCount":98},[],{"trials":15084,"activeCount":98},[],{"trials":15086,"activeCount":98},[],{"intervention":15088,"totalTrials":109,"cells":15089},"Insulin Degludec",{"EARLY_PHASE1":15090,"PHASE1":15101,"PHASE2":15103,"PHASE3":15105,"PHASE4":15107,"NA":15109},{"trials":15091,"activeCount":98},[15092],{"nctId":15093,"briefTitle":15094,"status":152,"phases":15095,"primaryCompletion":15096,"completion":15096,"start":15097,"enrollment":1523,"conditions":15098,"interventions":15099},"NCT03400501","Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin",[85],"2021-06-07","2017-10-01",[9732],[15088,15100],"Insulin Glargine",{"trials":15102,"activeCount":98},[],{"trials":15104,"activeCount":98},[],{"trials":15106,"activeCount":98},[],{"trials":15108,"activeCount":98},[],{"trials":15110,"activeCount":98},[],{"intervention":15100,"totalTrials":109,"cells":15112},{"EARLY_PHASE1":15113,"PHASE1":15119,"PHASE2":15121,"PHASE3":15123,"PHASE4":15125,"NA":15127},{"trials":15114,"activeCount":98},[15115],{"nctId":15093,"briefTitle":15094,"status":152,"phases":15116,"primaryCompletion":15096,"completion":15096,"start":15097,"enrollment":1523,"conditions":15117,"interventions":15118},[85],[9732],[15088,15100],{"trials":15120,"activeCount":98},[],{"trials":15122,"activeCount":98},[],{"trials":15124,"activeCount":98},[],{"trials":15126,"activeCount":98},[],{"trials":15128,"activeCount":98},[],{"intervention":15130,"totalTrials":109,"cells":15131},"Dexmedetomidine",{"EARLY_PHASE1":15132,"PHASE1":15141,"PHASE2":15143,"PHASE3":15145,"PHASE4":15147,"NA":15149},{"trials":15133,"activeCount":98},[15134],{"nctId":15135,"briefTitle":15136,"status":1051,"phases":15137,"primaryCompletion":10477,"completion":10477,"start":11144,"enrollment":98,"conditions":15138,"interventions":15140},"NCT03757897","The Influence of Dexmedetomidine Hypnosis on Cerebrospinal Fluid (CSF) Volume, Brain Diffusion and 'Stiffness' Characteristics.",[85],[15139],"Cerebrospinal Fluid Pressure Increased",[15130],{"trials":15142,"activeCount":98},[],{"trials":15144,"activeCount":98},[],{"trials":15146,"activeCount":98},[],{"trials":15148,"activeCount":98},[],{"trials":15150,"activeCount":98},[],{"intervention":15152,"totalTrials":109,"cells":15153},"MAT taper with galantamine",{"EARLY_PHASE1":15154,"PHASE1":15166,"PHASE2":15168,"PHASE3":15170,"PHASE4":15172,"NA":15174},{"trials":15155,"activeCount":98},[15156],{"nctId":15157,"briefTitle":15158,"status":152,"phases":15159,"primaryCompletion":15160,"completion":15160,"start":15161,"enrollment":1416,"conditions":15162,"interventions":15164},"NCT03547622","Galantamine and CBT4CBT Pilot to Prevent Relapse.",[85],"2019-02-28","2018-05-01",[15163],"Methadone or Buprenorphine Detoxoxification",[15152,15165],"MAT taper with placebo",{"trials":15167,"activeCount":98},[],{"trials":15169,"activeCount":98},[],{"trials":15171,"activeCount":98},[],{"trials":15173,"activeCount":98},[],{"trials":15175,"activeCount":98},[],{"intervention":15165,"totalTrials":109,"cells":15177},{"EARLY_PHASE1":15178,"PHASE1":15184,"PHASE2":15186,"PHASE3":15188,"PHASE4":15190,"NA":15192},{"trials":15179,"activeCount":98},[15180],{"nctId":15157,"briefTitle":15158,"status":152,"phases":15181,"primaryCompletion":15160,"completion":15160,"start":15161,"enrollment":1416,"conditions":15182,"interventions":15183},[85],[15163],[15152,15165],{"trials":15185,"activeCount":98},[],{"trials":15187,"activeCount":98},[],{"trials":15189,"activeCount":98},[],{"trials":15191,"activeCount":98},[],{"trials":15193,"activeCount":98},[],{"intervention":15195,"totalTrials":109,"cells":15196},"Hydrocortisone 20 MG",{"EARLY_PHASE1":15197,"PHASE1":15209,"PHASE2":15211,"PHASE3":15213,"PHASE4":15215,"NA":15217},{"trials":15198,"activeCount":98},[15199],{"nctId":15200,"briefTitle":15201,"status":152,"phases":15202,"primaryCompletion":802,"completion":802,"start":15203,"enrollment":314,"conditions":15204,"interventions":15208},"NCT04896489","Neuroimaging Mechanisms by Which Memory and Glucocorticoids Promote Risky Drinking",[85],"2021-05-12",[1034,15205,15206,15207],"Drinking Behavior","Episodic Memory","Long-term Memory",[15195],{"trials":15210,"activeCount":98},[],{"trials":15212,"activeCount":98},[],{"trials":15214,"activeCount":98},[],{"trials":15216,"activeCount":98},[],{"trials":15218,"activeCount":98},[],{"intervention":15220,"totalTrials":109,"cells":15221},"Mifepristone",{"EARLY_PHASE1":15222,"PHASE1":15231,"PHASE2":15233,"PHASE3":15235,"PHASE4":15237,"NA":15239},{"trials":15223,"activeCount":98},[15224],{"nctId":15225,"briefTitle":15226,"status":711,"phases":15227,"primaryCompletion":15228,"completion":15228,"start":14526,"enrollment":1296,"conditions":15229,"interventions":15230},"NCT03248713","Glucocorticoid Antagonist Treatment for Tobacco Use Disorder",[85],"2019-05-20",[24],[15220],{"trials":15232,"activeCount":98},[],{"trials":15234,"activeCount":98},[],{"trials":15236,"activeCount":98},[],{"trials":15238,"activeCount":98},[],{"trials":15240,"activeCount":98},[],{"intervention":15242,"totalTrials":109,"cells":15243},"Goal-Standard Medication",{"EARLY_PHASE1":15244,"PHASE1":15253,"PHASE2":15255,"PHASE3":15257,"PHASE4":15259,"NA":15261},{"trials":15245,"activeCount":98},[15246],{"nctId":15247,"briefTitle":15248,"status":152,"phases":15249,"primaryCompletion":543,"completion":543,"start":12521,"enrollment":6900,"conditions":15250,"interventions":15252},"NCT04737512","Mindfulness-Based ADHD Treatment for Children: a Feasibility Study",[85],[15251],"Attention Deficit Hyperactivity Disorder",[15242],{"trials":15254,"activeCount":98},[],{"trials":15256,"activeCount":98},[],{"trials":15258,"activeCount":98},[],{"trials":15260,"activeCount":98},[],{"trials":15262,"activeCount":98},[],{"intervention":15264,"totalTrials":109,"cells":15265},"LPS",{"EARLY_PHASE1":15266,"PHASE1":15276,"PHASE2":15278,"PHASE3":15280,"PHASE4":15282,"NA":15284},{"trials":15267,"activeCount":98},[15268],{"nctId":15269,"briefTitle":15270,"status":152,"phases":15271,"primaryCompletion":15272,"completion":15272,"start":15273,"enrollment":1367,"conditions":15274,"interventions":15275},"NCT04057807","Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease",[85],"2022-07-27","2018-04-15",[12654],[15264],{"trials":15277,"activeCount":98},[],{"trials":15279,"activeCount":98},[],{"trials":15281,"activeCount":98},[],{"trials":15283,"activeCount":98},[],{"trials":15285,"activeCount":98},[],{"intervention":15287,"totalTrials":109,"cells":15288},"Fluorodeoxyglucose",{"EARLY_PHASE1":15289,"PHASE1":15299,"PHASE2":15301,"PHASE3":15303,"PHASE4":15305,"NA":15307},{"trials":15290,"activeCount":98},[15291],{"nctId":15292,"briefTitle":15293,"status":152,"phases":15294,"primaryCompletion":15295,"completion":15295,"start":9845,"enrollment":141,"conditions":15296,"interventions":15297},"NCT03048097","Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET\u002FCT With Rb-82",[85],"2018-07-02",[11528],[15287,15298],"Rubidium",{"trials":15300,"activeCount":98},[],{"trials":15302,"activeCount":98},[],{"trials":15304,"activeCount":98},[],{"trials":15306,"activeCount":98},[],{"trials":15308,"activeCount":98},[],{"intervention":15298,"totalTrials":109,"cells":15310},{"EARLY_PHASE1":15311,"PHASE1":15317,"PHASE2":15319,"PHASE3":15321,"PHASE4":15323,"NA":15325},{"trials":15312,"activeCount":98},[15313],{"nctId":15292,"briefTitle":15293,"status":152,"phases":15314,"primaryCompletion":15295,"completion":15295,"start":9845,"enrollment":141,"conditions":15315,"interventions":15316},[85],[11528],[15287,15298],{"trials":15318,"activeCount":98},[],{"trials":15320,"activeCount":98},[],{"trials":15322,"activeCount":98},[],{"trials":15324,"activeCount":98},[],{"trials":15326,"activeCount":98},[],{"intervention":15328,"totalTrials":109,"cells":15329},"Sodium Fluoride",{"EARLY_PHASE1":15330,"PHASE1":15341,"PHASE2":15343,"PHASE3":15345,"PHASE4":15347,"NA":15349},{"trials":15331,"activeCount":98},[15332],{"nctId":15333,"briefTitle":15334,"status":1051,"phases":15335,"primaryCompletion":15336,"completion":15336,"start":4032,"enrollment":98,"conditions":15337,"interventions":15339},"NCT03089567","Comparison of the Salivary Levels of Streptococcus Mutans in Pediatric Patients With Early Childhood Caries After the Application of Silver Diamine Fluoride or 5% Sodium Fluoride Varnish",[85],"2018-01-15",[15338],"Dental Caries",[15328,15340],"Silver diamine fluoride",{"trials":15342,"activeCount":98},[],{"trials":15344,"activeCount":98},[],{"trials":15346,"activeCount":98},[],{"trials":15348,"activeCount":98},[],{"trials":15350,"activeCount":98},[],{"intervention":15340,"totalTrials":109,"cells":15352},{"EARLY_PHASE1":15353,"PHASE1":15359,"PHASE2":15361,"PHASE3":15363,"PHASE4":15365,"NA":15367},{"trials":15354,"activeCount":98},[15355],{"nctId":15333,"briefTitle":15334,"status":1051,"phases":15356,"primaryCompletion":15336,"completion":15336,"start":4032,"enrollment":98,"conditions":15357,"interventions":15358},[85],[15338],[15328,15340],{"trials":15360,"activeCount":98},[],{"trials":15362,"activeCount":98},[],{"trials":15364,"activeCount":98},[],{"trials":15366,"activeCount":98},[],{"trials":15368,"activeCount":98},[],{"intervention":15370,"totalTrials":109,"cells":15371},"Alcohol",{"EARLY_PHASE1":15372,"PHASE1":15381,"PHASE2":15383,"PHASE3":15385,"PHASE4":15387,"NA":15389},{"trials":15373,"activeCount":98},[15374],{"nctId":15375,"briefTitle":15376,"status":152,"phases":15377,"primaryCompletion":7870,"completion":7870,"start":15378,"enrollment":1296,"conditions":15379,"interventions":15380},"NCT04159688","Imaging Glutamate Release From Alcohol",[85],"2020-03-01",[1034],[15370],{"trials":15382,"activeCount":98},[],{"trials":15384,"activeCount":98},[],{"trials":15386,"activeCount":98},[],{"trials":15388,"activeCount":98},[],{"trials":15390,"activeCount":98},[],{"intervention":15392,"totalTrials":109,"cells":15393},"Aspart insulin",{"EARLY_PHASE1":15394,"PHASE1":15404,"PHASE2":15406,"PHASE3":15408,"PHASE4":15410,"NA":15412},{"trials":15395,"activeCount":98},[15396],{"nctId":15397,"briefTitle":15398,"status":152,"phases":15399,"primaryCompletion":7375,"completion":7375,"start":15400,"enrollment":94,"conditions":15401,"interventions":15403},"NCT03666065","Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients",[85],"2020-01-01",[15402],"Type1diabetes",[15392],{"trials":15405,"activeCount":98},[],{"trials":15407,"activeCount":98},[],{"trials":15409,"activeCount":98},[],{"trials":15411,"activeCount":98},[],{"trials":15413,"activeCount":98},[],{"intervention":15415,"totalTrials":109,"cells":15416},"[18F]FPEB with PET",{"EARLY_PHASE1":15417,"PHASE1":15426,"PHASE2":15428,"PHASE3":15430,"PHASE4":15432,"NA":15434},{"trials":15418,"activeCount":98},[15419],{"nctId":15420,"briefTitle":15421,"status":711,"phases":15422,"primaryCompletion":15423,"completion":15423,"start":132,"enrollment":1416,"conditions":15424,"interventions":15425},"NCT05664763","Understanding Effects of Cannabis Use and Abstinence on Neural Glutamate Homeostasis",[85],"2024-07-03",[3972],[15415],{"trials":15427,"activeCount":98},[],{"trials":15429,"activeCount":98},[],{"trials":15431,"activeCount":98},[],{"trials":15433,"activeCount":98},[],{"trials":15435,"activeCount":98},[],{"intervention":15437,"totalTrials":109,"cells":15438},"Nicotine saline 0.00mcg\u002Fkg\u002Fs",{"EARLY_PHASE1":15439,"PHASE1":15452,"PHASE2":15454,"PHASE3":15456,"PHASE4":15458,"NA":15460},{"trials":15440,"activeCount":98},[15441],{"nctId":15442,"briefTitle":15443,"status":152,"phases":15444,"primaryCompletion":15445,"completion":15445,"start":15446,"enrollment":1367,"conditions":15447,"interventions":15448},"NCT03134339","The Effect of Nicotine Delivery Rate on Reinforcement",[85],"2018-01-29","2017-01-05",[1658],[15437,15449,15450,15451],"Nicotine 0.24 mcg\u002Fkg\u002Fs","Nicotine 0.048 mcg\u002Fkg\u002Fs","Nicotine 0.024 mcg\u002Fkg\u002Fs",{"trials":15453,"activeCount":98},[],{"trials":15455,"activeCount":98},[],{"trials":15457,"activeCount":98},[],{"trials":15459,"activeCount":98},[],{"trials":15461,"activeCount":98},[],{"intervention":15449,"totalTrials":109,"cells":15463},{"EARLY_PHASE1":15464,"PHASE1":15470,"PHASE2":15472,"PHASE3":15474,"PHASE4":15476,"NA":15478},{"trials":15465,"activeCount":98},[15466],{"nctId":15442,"briefTitle":15443,"status":152,"phases":15467,"primaryCompletion":15445,"completion":15445,"start":15446,"enrollment":1367,"conditions":15468,"interventions":15469},[85],[1658],[15437,15449,15450,15451],{"trials":15471,"activeCount":98},[],{"trials":15473,"activeCount":98},[],{"trials":15475,"activeCount":98},[],{"trials":15477,"activeCount":98},[],{"trials":15479,"activeCount":98},[],{"intervention":15450,"totalTrials":109,"cells":15481},{"EARLY_PHASE1":15482,"PHASE1":15488,"PHASE2":15490,"PHASE3":15492,"PHASE4":15494,"NA":15496},{"trials":15483,"activeCount":98},[15484],{"nctId":15442,"briefTitle":15443,"status":152,"phases":15485,"primaryCompletion":15445,"completion":15445,"start":15446,"enrollment":1367,"conditions":15486,"interventions":15487},[85],[1658],[15437,15449,15450,15451],{"trials":15489,"activeCount":98},[],{"trials":15491,"activeCount":98},[],{"trials":15493,"activeCount":98},[],{"trials":15495,"activeCount":98},[],{"trials":15497,"activeCount":98},[],{"intervention":15451,"totalTrials":109,"cells":15499},{"EARLY_PHASE1":15500,"PHASE1":15506,"PHASE2":15508,"PHASE3":15510,"PHASE4":15512,"NA":15514},{"trials":15501,"activeCount":98},[15502],{"nctId":15442,"briefTitle":15443,"status":152,"phases":15503,"primaryCompletion":15445,"completion":15445,"start":15446,"enrollment":1367,"conditions":15504,"interventions":15505},[85],[1658],[15437,15449,15450,15451],{"trials":15507,"activeCount":98},[],{"trials":15509,"activeCount":98},[],{"trials":15511,"activeCount":98},[],{"trials":15513,"activeCount":98},[],{"trials":15515,"activeCount":98},[],{"intervention":15517,"totalTrials":109,"cells":15518},"Tacrolimus, Extended Release,",{"EARLY_PHASE1":15519,"PHASE1":15529,"PHASE2":15531,"PHASE3":15533,"PHASE4":15535,"NA":15537},{"trials":15520,"activeCount":98},[15521],{"nctId":15522,"briefTitle":15523,"status":152,"phases":15524,"primaryCompletion":13915,"completion":3905,"start":15525,"enrollment":1743,"conditions":15526,"interventions":15528},"NCT03410654","Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.",[85],"2018-10-24",[15527],"Kidney Transplant; Complications",[15517],{"trials":15530,"activeCount":98},[],{"trials":15532,"activeCount":98},[],{"trials":15534,"activeCount":98},[],{"trials":15536,"activeCount":98},[],{"trials":15538,"activeCount":98},[],{"intervention":15540,"totalTrials":109,"cells":15541},"Nicotine 0.2mcg\u002Fkg\u002Fs and 1.0mcg\u002Fkg\u002Fs",{"EARLY_PHASE1":15542,"PHASE1":15551,"PHASE2":15553,"PHASE3":15555,"PHASE4":15557,"NA":15559},{"trials":15543,"activeCount":98},[15544],{"nctId":15545,"briefTitle":15546,"status":152,"phases":15547,"primaryCompletion":312,"completion":15548,"start":8099,"enrollment":1685,"conditions":15549,"interventions":15550},"NCT04488744","Smoking by IV Pulsed Nicotine",[85],"2021-05-31",[1860],[15540],{"trials":15552,"activeCount":98},[],{"trials":15554,"activeCount":98},[],{"trials":15556,"activeCount":98},[],{"trials":15558,"activeCount":98},[],{"trials":15560,"activeCount":98},[],{"intervention":15562,"totalTrials":109,"cells":15563},"GnRH antagonist",{"EARLY_PHASE1":15564,"PHASE1":15573,"PHASE2":15575,"PHASE3":15577,"PHASE4":15579,"NA":15581},{"trials":15565,"activeCount":98},[15566],{"nctId":15567,"briefTitle":15568,"status":711,"phases":15569,"primaryCompletion":7870,"completion":7870,"start":4959,"enrollment":1743,"conditions":15570,"interventions":15571},"NCT04327934","Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome",[85],[6718,12190],[15562,15572],"GnRH antagonist + MethylTESTOSTERone 5 MG",{"trials":15574,"activeCount":98},[],{"trials":15576,"activeCount":98},[],{"trials":15578,"activeCount":98},[],{"trials":15580,"activeCount":98},[],{"trials":15582,"activeCount":98},[],{"intervention":15572,"totalTrials":109,"cells":15584},{"EARLY_PHASE1":15585,"PHASE1":15591,"PHASE2":15593,"PHASE3":15595,"PHASE4":15597,"NA":15599},{"trials":15586,"activeCount":98},[15587],{"nctId":15567,"briefTitle":15568,"status":711,"phases":15588,"primaryCompletion":7870,"completion":7870,"start":4959,"enrollment":1743,"conditions":15589,"interventions":15590},[85],[6718,12190],[15562,15572],{"trials":15592,"activeCount":98},[],{"trials":15594,"activeCount":98},[],{"trials":15596,"activeCount":98},[],{"trials":15598,"activeCount":98},[],{"trials":15600,"activeCount":98},[],{"intervention":15602,"totalTrials":109,"cells":15603},"THC and Iomazenil",{"EARLY_PHASE1":15604,"PHASE1":15613,"PHASE2":15615,"PHASE3":15617,"PHASE4":15619,"NA":15621},{"trials":15605,"activeCount":98},[15606],{"nctId":15607,"briefTitle":15608,"status":152,"phases":15609,"primaryCompletion":14400,"completion":14400,"start":15610,"enrollment":1815,"conditions":15611,"interventions":15612},"NCT00982982","Effects of Delta-9-THC and Iomazenil in Healthy Humans",[85],"2009-02-11",[15,1704,1400],[15602],{"trials":15614,"activeCount":98},[],{"trials":15616,"activeCount":98},[],{"trials":15618,"activeCount":98},[],{"trials":15620,"activeCount":98},[],{"trials":15622,"activeCount":98},[],{"intervention":15624,"totalTrials":109,"cells":15625},"Low Marijuana, Hash, THC, or Grass",{"EARLY_PHASE1":15626,"PHASE1":15639,"PHASE2":15641,"PHASE3":15643,"PHASE4":15645,"NA":15647},{"trials":15627,"activeCount":98},[15628],{"nctId":15629,"briefTitle":15630,"status":152,"phases":15631,"primaryCompletion":15632,"completion":15632,"start":8207,"enrollment":7849,"conditions":15633,"interventions":15635},"NCT04856566","Examine the Feasibility of a Standardized Field Test for Marijuana and Alcohol Impairment: Laboratory Evaluations",[85],"2023-08-23",[11993,15634],"Alcohol Impairment",[15624,15636,15637,15638],"High Marijuana, Hash, THC, or Grass","0.05 BAC Alcohol","0.08 BAC Alcohol",{"trials":15640,"activeCount":98},[],{"trials":15642,"activeCount":98},[],{"trials":15644,"activeCount":98},[],{"trials":15646,"activeCount":98},[],{"trials":15648,"activeCount":98},[],{"intervention":15636,"totalTrials":109,"cells":15650},{"EARLY_PHASE1":15651,"PHASE1":15657,"PHASE2":15659,"PHASE3":15661,"PHASE4":15663,"NA":15665},{"trials":15652,"activeCount":98},[15653],{"nctId":15629,"briefTitle":15630,"status":152,"phases":15654,"primaryCompletion":15632,"completion":15632,"start":8207,"enrollment":7849,"conditions":15655,"interventions":15656},[85],[11993,15634],[15624,15636,15637,15638],{"trials":15658,"activeCount":98},[],{"trials":15660,"activeCount":98},[],{"trials":15662,"activeCount":98},[],{"trials":15664,"activeCount":98},[],{"trials":15666,"activeCount":98},[],{"intervention":15637,"totalTrials":109,"cells":15668},{"EARLY_PHASE1":15669,"PHASE1":15675,"PHASE2":15677,"PHASE3":15679,"PHASE4":15681,"NA":15683},{"trials":15670,"activeCount":98},[15671],{"nctId":15629,"briefTitle":15630,"status":152,"phases":15672,"primaryCompletion":15632,"completion":15632,"start":8207,"enrollment":7849,"conditions":15673,"interventions":15674},[85],[11993,15634],[15624,15636,15637,15638],{"trials":15676,"activeCount":98},[],{"trials":15678,"activeCount":98},[],{"trials":15680,"activeCount":98},[],{"trials":15682,"activeCount":98},[],{"trials":15684,"activeCount":98},[],{"intervention":15638,"totalTrials":109,"cells":15686},{"EARLY_PHASE1":15687,"PHASE1":15693,"PHASE2":15695,"PHASE3":15697,"PHASE4":15699,"NA":15701},{"trials":15688,"activeCount":98},[15689],{"nctId":15629,"briefTitle":15630,"status":152,"phases":15690,"primaryCompletion":15632,"completion":15632,"start":8207,"enrollment":7849,"conditions":15691,"interventions":15692},[85],[11993,15634],[15624,15636,15637,15638],{"trials":15694,"activeCount":98},[],{"trials":15696,"activeCount":98},[],{"trials":15698,"activeCount":98},[],{"trials":15700,"activeCount":98},[],{"trials":15702,"activeCount":98},[],{"intervention":1658,"totalTrials":1685,"cells":15704},{"EARLY_PHASE1":15705,"PHASE1":15736,"PHASE2":15790,"PHASE3":15792,"PHASE4":15794,"NA":15796},{"trials":15706,"activeCount":98},[15707,15715,15719,15727],{"nctId":15708,"briefTitle":15709,"status":152,"phases":15710,"primaryCompletion":15711,"completion":15711,"start":15712,"enrollment":1648,"conditions":15713,"interventions":15714},"NCT04535362","Nicotine's Potential Abuse With Menthol",[85],"2023-06-29","2021-06-28",[24],[1658],{"nctId":12064,"briefTitle":12065,"status":152,"phases":15716,"primaryCompletion":6725,"completion":6725,"start":271,"enrollment":1367,"conditions":15717,"interventions":15718},[85],[1190,1961],[1658,12059],{"nctId":15720,"briefTitle":15721,"status":152,"phases":15722,"primaryCompletion":11991,"completion":9157,"start":15723,"enrollment":3897,"conditions":15724,"interventions":15726},"NCT01495819","Nicotine Reinforcement and Aversion in Young Adult Light Smokers",[85],"2017-01-04",[15725],"Nicotine Addiction",[8235,1658],{"nctId":15728,"briefTitle":15729,"status":152,"phases":15730,"primaryCompletion":15731,"completion":15731,"start":15732,"enrollment":3897,"conditions":15733,"interventions":15735},"NCT06096714","Addictive Threshold of Nicotine",[85],"2026-03-27","2024-02-27",[15734],"Smoking Addiction",[1658],{"trials":15737,"activeCount":98},[15738,15748,15752,15756,15763,15772,15776,15780],{"nctId":15739,"briefTitle":15740,"status":152,"phases":15741,"primaryCompletion":15742,"completion":15742,"start":15743,"enrollment":15744,"conditions":15745,"interventions":15746},"NCT00969137","Sensitivity to Intravenous Nicotine: Genetic Moderators",[86],"2016-06-01","2009-06-02",213,[24],[15747,1658],"saline",{"nctId":1652,"briefTitle":1653,"status":152,"phases":15749,"primaryCompletion":1120,"completion":180,"start":1655,"enrollment":31,"conditions":15750,"interventions":15751},[86],[730],[1608,1658,1659],{"nctId":11782,"briefTitle":11783,"status":152,"phases":15753,"primaryCompletion":8457,"completion":8457,"start":5721,"enrollment":303,"conditions":15754,"interventions":15755},[86],[330],[11787,1658],{"nctId":15757,"briefTitle":15758,"status":152,"phases":15759,"primaryCompletion":615,"completion":615,"start":15760,"enrollment":1315,"conditions":15761,"interventions":15762},"NCT04521647","Effects of Menthol in E-cigarettes on Smoking Behaviors",[86],"2022-05-10",[24],[1658],{"nctId":15764,"briefTitle":15765,"status":152,"phases":15766,"primaryCompletion":15767,"completion":15768,"start":15769,"enrollment":4121,"conditions":15770,"interventions":15771},"NCT03168191","Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 2",[86],"2018-08-22","2019-02-25","2017-05-02",[24],[1658],{"nctId":12994,"briefTitle":12995,"status":152,"phases":15773,"primaryCompletion":12997,"completion":1334,"start":12998,"enrollment":1397,"conditions":15774,"interventions":15775},[86],[13000],[12987,1658],{"nctId":13844,"briefTitle":13845,"status":152,"phases":15777,"primaryCompletion":13847,"completion":13847,"start":13760,"enrollment":1827,"conditions":15778,"interventions":15779},[86],[13000],[1658,13837],{"nctId":15781,"briefTitle":15782,"status":152,"phases":15783,"primaryCompletion":15784,"completion":15785,"start":15786,"enrollment":1032,"conditions":15787,"interventions":15789},"NCT02179034","Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1",[86],"2016-07-18","2017-06-12","2014-10-23",[15788],"Nicotine Dependence, Other Tobacco Product",[1658],{"trials":15791,"activeCount":98},[],{"trials":15793,"activeCount":98},[],{"trials":15795,"activeCount":98},[],{"trials":15797,"activeCount":98},[15798],{"nctId":15799,"briefTitle":15800,"status":152,"phases":15801,"primaryCompletion":15802,"completion":15802,"start":15803,"enrollment":1407,"conditions":15804,"interventions":15805},"NCT02102100","The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users",[90],"2016-07-11","2014-03-26",[24],[15806,15807],"nicotine","menthol",{"intervention":1047,"totalTrials":1466,"cells":15809},{"EARLY_PHASE1":15810,"PHASE1":15812,"PHASE2":15820,"PHASE3":15834,"PHASE4":15842,"NA":15848},{"trials":15811,"activeCount":98},[],{"trials":15813,"activeCount":98},[15814],{"nctId":15815,"briefTitle":15816,"status":711,"phases":15817,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":98,"conditions":15818,"interventions":15819},"NCT00000276","Dopamine Reuptake Inhibitors of Cocaine Abuse - 1",[86],[210],[1047],{"trials":15821,"activeCount":98},[15822,15826,15830],{"nctId":1039,"briefTitle":1040,"status":152,"phases":15823,"completion":1042,"start":1043,"enrollment":1044,"conditions":15824,"interventions":15825},[86,87],[33,24],[890,1047],{"nctId":1125,"briefTitle":1126,"status":711,"phases":15827,"primaryCompletion":1128,"completion":1128,"start":1129,"enrollment":303,"conditions":15828,"interventions":15829},[87],[15,1131,18],[890,1047],{"nctId":1932,"briefTitle":1933,"status":152,"phases":15831,"primaryCompletion":1647,"completion":1647,"start":1245,"enrollment":1935,"conditions":15832,"interventions":15833},[87],[1937],[1141,1939],{"trials":15835,"activeCount":98},[15836],{"nctId":15837,"briefTitle":15838,"status":152,"phases":15839,"primaryCompletion":10888,"completion":10888,"start":1042,"enrollment":696,"conditions":15840,"interventions":15841},"NCT00414167","Craving, Binge Eating and Obesity",[87,88],[1291,18],[1939],{"trials":15843,"activeCount":98},[15844],{"nctId":1242,"briefTitle":1243,"status":711,"phases":15845,"primaryCompletion":1082,"completion":1082,"start":1245,"enrollment":1246,"conditions":15846,"interventions":15847},[89],[1248,24],[1219,1047],{"trials":15849,"activeCount":98},[15850],{"nctId":15851,"briefTitle":15852,"status":152,"phases":15853,"primaryCompletion":15854,"completion":1081,"start":15855,"enrollment":15856,"conditions":15857,"interventions":15858},"NCT00104598","Framing Messages for Smoking Cessation With Bupropion - 6",[90],"2004-09","2000-09",252,[1947],[1047],{"intervention":8382,"totalTrials":1466,"cells":15860},{"EARLY_PHASE1":15861,"PHASE1":15863,"PHASE2":15878,"PHASE3":15890,"PHASE4":15899,"NA":15909},{"trials":15862,"activeCount":98},[],{"trials":15864,"activeCount":98},[15865,15872],{"nctId":15866,"briefTitle":15867,"status":152,"phases":15868,"primaryCompletion":5870,"completion":5870,"start":15854,"enrollment":8628,"conditions":15869,"interventions":15870},"NCT00271206","Effect of Progesterone on Smoking Behavior in Male and Female Smokers",[86],[1947],[8382,15871],"sugar pill",{"nctId":15873,"briefTitle":15874,"status":152,"phases":15875,"primaryCompletion":5742,"completion":5742,"start":6276,"enrollment":105,"conditions":15876,"interventions":15877},"NCT00585520","Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues",[86],[330],[8382],{"trials":15879,"activeCount":98},[15880,15886],{"nctId":15881,"briefTitle":15882,"status":152,"phases":15883,"primaryCompletion":8199,"completion":1164,"start":1886,"enrollment":7849,"conditions":15884,"interventions":15885},"NCT01972464","Progesterone for Smoking Relapse Prevention Following Delivery",[87],[1947],[8382],{"nctId":8373,"briefTitle":8374,"status":152,"phases":15887,"primaryCompletion":1186,"completion":1210,"start":6747,"enrollment":8376,"conditions":15888,"interventions":15889},[87],[8378],[8380,8381,8382],{"trials":15891,"activeCount":98},[15892],{"nctId":15893,"briefTitle":15894,"status":152,"phases":15895,"primaryCompletion":12498,"completion":12498,"start":15896,"enrollment":1685,"conditions":15897,"interventions":15898},"NCT02187224","Progesterone Effect on Individuals Diagnoses With AD and PTSD.",[87,88],"2016-09-01",[1112,1838],[8382],{"trials":15900,"activeCount":98},[15901],{"nctId":15902,"briefTitle":15903,"status":152,"phases":15904,"primaryCompletion":15905,"completion":15906,"start":4197,"enrollment":2167,"conditions":15907,"interventions":15908},"NCT02685072","Progesterone Augmentation of Nicotine Replacement Therapy Study",[89],"2017-12-18","2018-03-12",[1860],[8382],{"trials":15910,"activeCount":98},[15911],{"nctId":15912,"briefTitle":15913,"status":152,"phases":15914,"primaryCompletion":1618,"completion":1618,"start":1031,"enrollment":1305,"conditions":15915,"interventions":15916},"NCT01249274","Progesterone for Postpartum Cocaine Relapse",[90],[12324,330],[8382],{"intervention":15918,"totalTrials":1466,"cells":15919},"Guanfacine",{"EARLY_PHASE1":15920,"PHASE1":15922,"PHASE2":15933,"PHASE3":15966,"PHASE4":15968,"NA":15970},{"trials":15921,"activeCount":98},[],{"trials":15923,"activeCount":98},[15924],{"nctId":15925,"briefTitle":15926,"status":152,"phases":15927,"primaryCompletion":3858,"completion":3858,"start":15928,"enrollment":4645,"conditions":15929,"interventions":15932},"NCT00585754","Guanfacine to Reduce Stress-Induced Cocaine\u002FAlcohol Craving and Relapse",[86],"2006-04",[15930,15931],"Cocaine Dependent","Alcohol Dependent",[15918],{"trials":15934,"activeCount":98},[15935,15943,15953,15960],{"nctId":15936,"briefTitle":15937,"status":152,"phases":15938,"primaryCompletion":15939,"completion":15939,"start":326,"enrollment":15940,"conditions":15941,"interventions":15942},"NCT02051309","Guanfacine Clinical Trial for Smoking Cessation",[87],"2020-11",121,[1860],[15918],{"nctId":15944,"briefTitle":15945,"status":152,"phases":15946,"primaryCompletion":15947,"completion":15947,"start":15948,"enrollment":15949,"conditions":15950,"interventions":15952},"NCT03980184","Guanfacine to Improve Substance Use Outcomes in Women",[87],"2022-11-30","2019-11-01",74,[15951],"Substance Use Disorders",[15918],{"nctId":15954,"briefTitle":15955,"status":152,"phases":15956,"primaryCompletion":8098,"completion":8098,"start":10652,"enrollment":1011,"conditions":15957,"interventions":15958},"NCT00773357","Modeling Stress-precipitated Smoking Behavior for Medication Development",[87],[33],[15959],"guanfacine",{"nctId":15961,"briefTitle":15962,"status":152,"phases":15963,"primaryCompletion":1972,"completion":1972,"start":1618,"enrollment":303,"conditions":15964,"interventions":15965},"NCT01904526","PK\u002FPD Comparison of Guanfacine ER and IR",[87],[33],[15918],{"trials":15967,"activeCount":98},[],{"trials":15969,"activeCount":98},[],{"trials":15971,"activeCount":98},[15972,15979],{"nctId":15973,"briefTitle":15974,"status":152,"phases":15975,"primaryCompletion":346,"completion":346,"start":270,"enrollment":1648,"conditions":15976,"interventions":15978},"NCT01600885","The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects",[90],[15977],"NMDA Receptor Function",[15918],{"nctId":15980,"briefTitle":15981,"status":152,"phases":15982,"primaryCompletion":7508,"completion":7508,"start":1120,"enrollment":15983,"conditions":15984,"interventions":15986},"NCT00935493","Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects",[90],154,[15985],"Cognitive Aging",[15918,15918],{"intervention":333,"totalTrials":1416,"cells":15988},{"EARLY_PHASE1":15989,"PHASE1":15991,"PHASE2":16008,"PHASE3":16014,"PHASE4":16016,"NA":16018},{"trials":15990,"activeCount":98},[],{"trials":15992,"activeCount":98},[15993,15997],{"nctId":15866,"briefTitle":15867,"status":152,"phases":15994,"primaryCompletion":5870,"completion":5870,"start":15854,"enrollment":8628,"conditions":15995,"interventions":15996},[86],[1947],[8382,15871],{"nctId":15998,"briefTitle":15999,"status":152,"phases":16000,"primaryCompletion":16001,"completion":16001,"start":16002,"enrollment":1315,"conditions":16003,"interventions":16005},"NCT02193269","The Effects of Minocycline in Humans",[86],"2015-11-05","2013-07-08",[16004],"Memory Impairment",[16006,16007],"Sugar pill","Minocycline",{"trials":16009,"activeCount":98},[16010],{"nctId":323,"briefTitle":324,"status":152,"phases":16011,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":16012,"interventions":16013},[86,87],[330],[332,333,262],{"trials":16015,"activeCount":98},[],{"trials":16017,"activeCount":98},[],{"trials":16019,"activeCount":98},[16020,16029,16038],{"nctId":16021,"briefTitle":16022,"status":152,"phases":16023,"primaryCompletion":16024,"completion":16024,"start":16025,"enrollment":1619,"conditions":16026,"interventions":16027},"NCT02448654","Treatment for Nicotine Addiction in Women",[90],"2019-06-30","2015-10-23",[24],[16028,333],"Tolcapone",{"nctId":16030,"briefTitle":16031,"status":152,"phases":16032,"primaryCompletion":1186,"completion":1759,"start":6276,"enrollment":16033,"conditions":16034,"interventions":16035},"NCT00566969","Cocaine Withdrawal and Pharmacotherapy Response",[90],106,[330,183],[15871,16036,16037],"Carvedilol 25 mg","Carvedilol 50 mg",{"nctId":16039,"briefTitle":16040,"status":152,"phases":16041,"primaryCompletion":1618,"completion":1618,"start":1664,"enrollment":25,"conditions":16042,"interventions":16043},"NCT01498549","Cognitive Effects of Atomoxetine in Humans: Genetic Moderators",[90],[5707],[16044,333],"Atomoxetine",{"intervention":16044,"totalTrials":1416,"cells":16046},{"EARLY_PHASE1":16047,"PHASE1":16049,"PHASE2":16051,"PHASE3":16088,"PHASE4":16090,"NA":16092},{"trials":16048,"activeCount":98},[],{"trials":16050,"activeCount":98},[],{"trials":16052,"activeCount":98},[16053,16060,16067,16074,16081],{"nctId":16054,"briefTitle":16055,"status":152,"phases":16056,"primaryCompletion":7707,"completion":7743,"start":1210,"enrollment":181,"conditions":16057,"interventions":16059},"NCT01863251","Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia",[87],[183,16058],"Stimulant Dependence",[16044],{"nctId":16061,"briefTitle":16062,"status":152,"phases":16063,"primaryCompletion":1061,"completion":180,"start":7604,"enrollment":1315,"conditions":16064,"interventions":16066},"NCT00611936","Effects of Atomoxetine Treatment in Humans",[86,87],[16065],"Stress",[16044],{"nctId":16068,"briefTitle":16069,"status":1051,"phases":16070,"primaryCompletion":16071,"completion":16071,"start":4080,"enrollment":98,"conditions":16072,"interventions":16073},"NCT02046551","Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers",[86,87],"2017-02",[24],[16044],{"nctId":16075,"briefTitle":16076,"status":152,"phases":16077,"completion":6276,"start":1106,"enrollment":272,"conditions":16078,"interventions":16080},"NCT00420498","Effects of Atomoxetine on Cognitive Function in Schizophrenia",[87],[15,16079,33],"Cognition",[16044],{"nctId":16082,"briefTitle":16083,"status":152,"phases":16084,"primaryCompletion":1061,"completion":180,"start":7604,"enrollment":1315,"conditions":16085,"interventions":16087},"NCT00607568","Atomoxetine Effects in Humans",[86,87],[16086],"Physiological Stress",[16044],{"trials":16089,"activeCount":98},[],{"trials":16091,"activeCount":98},[],{"trials":16093,"activeCount":98},[16094],{"nctId":16039,"briefTitle":16040,"status":152,"phases":16095,"primaryCompletion":1618,"completion":1618,"start":1664,"enrollment":25,"conditions":16096,"interventions":16097},[90],[5707],[16044,333],{"intervention":11898,"totalTrials":1416,"cells":16099},{"EARLY_PHASE1":16100,"PHASE1":16102,"PHASE2":16116,"PHASE3":16124,"PHASE4":16133,"NA":16135},{"trials":16101,"activeCount":98},[],{"trials":16103,"activeCount":98},[16104,16112],{"nctId":16105,"briefTitle":16106,"status":152,"phases":16107,"primaryCompletion":7871,"completion":16108,"start":1983,"enrollment":36,"conditions":16109,"interventions":16111},"NCT00969696","Galantamine Effects on Cognitive Function in Marijuana Users",[86],"2011-07",[16110],"Memory",[11898],{"nctId":11892,"briefTitle":11893,"status":152,"phases":16113,"primaryCompletion":10888,"completion":10888,"start":5754,"enrollment":272,"conditions":16114,"interventions":16115},[86],[33,11896],[11898,11899],{"trials":16117,"activeCount":98},[16118],{"nctId":16119,"briefTitle":16120,"status":152,"phases":16121,"primaryCompletion":714,"completion":714,"start":1665,"enrollment":3088,"conditions":16122,"interventions":16123},"NCT00809835","Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse",[87],[330],[11898],{"trials":16125,"activeCount":98},[16126],{"nctId":16127,"briefTitle":16128,"status":152,"phases":16129,"completion":6276,"start":16130,"enrollment":5030,"conditions":16131,"interventions":16132},"NCT00463879","Galantamine for Cognitive Deficits in Schizophrenia",[87,88],"2005-09",[15],[11898],{"trials":16134,"activeCount":98},[],{"trials":16136,"activeCount":98},[16137,16143],{"nctId":16138,"briefTitle":16139,"status":152,"phases":16140,"primaryCompletion":3858,"completion":3858,"start":1166,"enrollment":7263,"conditions":16141,"interventions":16142},"NCT01531153","Cognitive Enhancement as a Target for Cocaine Pharmacotherapy",[90],[5707],[11898],{"nctId":16144,"briefTitle":16145,"status":152,"phases":16146,"primaryCompletion":1092,"completion":1092,"start":16147,"enrollment":3897,"conditions":16148,"interventions":16149},"NCT00606801","Galantamine Effects on Cognitive Function in Abstinent Cocaine Users",[90],"2007-06",[12324],[11898],{"intervention":8235,"totalTrials":303,"cells":16151},{"EARLY_PHASE1":16152,"PHASE1":16158,"PHASE2":16168,"PHASE3":16174,"PHASE4":16176,"NA":16178},{"trials":16153,"activeCount":98},[16154],{"nctId":15720,"briefTitle":15721,"status":152,"phases":16155,"primaryCompletion":11991,"completion":9157,"start":15723,"enrollment":3897,"conditions":16156,"interventions":16157},[85],[15725],[8235,1658],{"trials":16159,"activeCount":98},[16160,16164],{"nctId":15739,"briefTitle":15740,"status":152,"phases":16161,"primaryCompletion":15742,"completion":15742,"start":15743,"enrollment":15744,"conditions":16162,"interventions":16163},[86],[24],[15747,1658],{"nctId":14128,"briefTitle":14129,"status":152,"phases":16165,"primaryCompletion":14131,"completion":4668,"start":14132,"enrollment":6758,"conditions":16166,"interventions":16167},[86],[24],[14121,8235],{"trials":16169,"activeCount":98},[16170],{"nctId":8228,"briefTitle":8229,"status":152,"phases":16171,"primaryCompletion":1973,"completion":1973,"start":7508,"enrollment":987,"conditions":16172,"interventions":16173},[87],[8232,8233],[8219,8235],{"trials":16175,"activeCount":98},[],{"trials":16177,"activeCount":98},[],{"trials":16179,"activeCount":98},[16180],{"nctId":16181,"briefTitle":16182,"status":1051,"phases":16183,"start":6276,"enrollment":98,"conditions":16184,"interventions":16186},"NCT00617864","The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome",[90],[16185],"Ovarian Hyperstimulation Syndrome",[16187,8235],"Human Albumin",{"intervention":16189,"totalTrials":303,"cells":16190},"Sertraline",{"EARLY_PHASE1":16191,"PHASE1":16193,"PHASE2":16195,"PHASE3":16215,"PHASE4":16217,"NA":16228},{"trials":16192,"activeCount":98},[],{"trials":16194,"activeCount":98},[],{"trials":16196,"activeCount":98},[16197,16201,16208],{"nctId":1103,"briefTitle":1104,"status":152,"phases":16198,"primaryCompletion":1106,"completion":1107,"start":1108,"enrollment":1109,"conditions":16199,"interventions":16200},[87],[1111,1112],[1114,1115],{"nctId":16202,"briefTitle":16203,"status":711,"phases":16204,"primaryCompletion":7743,"completion":7743,"start":5721,"enrollment":109,"conditions":16205,"interventions":16207},"NCT01977729","Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline",[87],[16206],"Anxiety Disorder of Adolescence",[16189],{"nctId":16209,"briefTitle":16210,"status":152,"phases":16211,"primaryCompletion":16147,"completion":1138,"start":7189,"enrollment":2076,"conditions":16212,"interventions":16214},"NCT00048854","Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder",[86,87],[16213],"Premenstrual Syndrome",[16189],{"trials":16216,"activeCount":98},[],{"trials":16218,"activeCount":98},[16219],{"nctId":16220,"briefTitle":16221,"status":152,"phases":16222,"primaryCompletion":16223,"completion":16223,"start":16224,"enrollment":15856,"conditions":16225,"interventions":16227},"NCT00536198","Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder",[89],"2012-02","2007-11-06",[16226],"Premenstrual Dysphoric Disorder",[16189],{"trials":16229,"activeCount":98},[16230],{"nctId":16231,"briefTitle":16232,"status":711,"phases":16233,"primaryCompletion":1858,"completion":1858,"start":369,"enrollment":1246,"conditions":16234,"interventions":16235},"NCT00585455","Vascular Effects of Sertraline in Heart Failure",[],[107,21],[1114],{"intervention":16237,"totalTrials":1246,"cells":16238},"levetiracetam",{"EARLY_PHASE1":16239,"PHASE1":16241,"PHASE2":16243,"PHASE3":16258,"PHASE4":16266,"NA":16268},{"trials":16240,"activeCount":98},[],{"trials":16242,"activeCount":98},[],{"trials":16244,"activeCount":98},[16245,16252],{"nctId":16246,"briefTitle":16247,"status":152,"phases":16248,"primaryCompletion":368,"completion":10652,"start":1121,"enrollment":1743,"conditions":16249,"interventions":16251},"NCT00577005","Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients",[87],[330,16250],"Opioid Dependency",[16237],{"nctId":16253,"briefTitle":16254,"status":152,"phases":16255,"primaryCompletion":1061,"completion":270,"start":271,"enrollment":141,"conditions":16256,"interventions":16257},"NCT00593125","Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.",[87],[330,221],[16237],{"trials":16259,"activeCount":98},[16260],{"nctId":16261,"briefTitle":16262,"status":152,"phases":16263,"primaryCompletion":15928,"enrollment":1305,"conditions":16264,"interventions":16265},"NCT00291213","Levetiracetam Treatment of Tardive Dyskinesia",[88],[2478],[16237],{"trials":16267,"activeCount":98},[],{"trials":16269,"activeCount":98},[16270],{"nctId":16271,"briefTitle":16272,"status":152,"phases":16273,"primaryCompletion":270,"completion":270,"start":727,"enrollment":25,"conditions":16274,"interventions":16275},"NCT00566150","Levetiracetam in the Management of Bipolar Depression",[90],[1761],[16276],"Levetiracetam",{"intervention":16278,"totalTrials":1246,"cells":16279},"Disulfiram",{"EARLY_PHASE1":16280,"PHASE1":16282,"PHASE2":16288,"PHASE3":16304,"PHASE4":16306,"NA":16308},{"trials":16281,"activeCount":98},[],{"trials":16283,"activeCount":98},[16284],{"nctId":12318,"briefTitle":12319,"status":152,"phases":16285,"primaryCompletion":1673,"completion":1673,"start":12321,"enrollment":12322,"conditions":16286,"interventions":16287},[86],[12324],[12326,12311],{"trials":16289,"activeCount":98},[16290,16296],{"nctId":16291,"briefTitle":16292,"status":152,"phases":16293,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":98,"conditions":16294,"interventions":16295},"NCT00000278","Disulfiram for Cocaine-Alcohol Abuse - 3",[87],[4560,210],[16278],{"nctId":16297,"briefTitle":16298,"status":152,"phases":16299,"primaryCompletion":197,"completion":197,"start":16300,"enrollment":16301,"conditions":16302,"interventions":16303},"NCT00913484","Disulfiram for Cocaine Abuse in Buprenorphine Treatment",[87],"2000-10",177,[330,16250],[16278],{"trials":16305,"activeCount":98},[],{"trials":16307,"activeCount":98},[],{"trials":16309,"activeCount":98},[16310],{"nctId":16311,"briefTitle":16312,"status":152,"phases":16313,"primaryCompletion":16314,"start":16315,"enrollment":16316,"conditions":16317,"interventions":16319},"NCT00580827","Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers",[90],"2004-03","2003-09",126,[16318,183],"Cocaine-Related Disorder",[16278,16278,16278],{"intervention":16321,"totalTrials":1246,"cells":16322},"Riluzole",{"EARLY_PHASE1":16323,"PHASE1":16325,"PHASE2":16333,"PHASE3":16349,"PHASE4":16351,"NA":16353},{"trials":16324,"activeCount":98},[],{"trials":16326,"activeCount":98},[16327],{"nctId":16328,"briefTitle":16329,"status":152,"phases":16330,"primaryCompletion":1780,"completion":1780,"start":5225,"enrollment":1367,"conditions":16331,"interventions":16332},"NCT02019940","A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)",[86],[1152],[16321],{"trials":16334,"activeCount":98},[16335,16343],{"nctId":16336,"briefTitle":16337,"status":152,"phases":16338,"primaryCompletion":179,"completion":179,"start":5871,"enrollment":1044,"conditions":16339,"interventions":16341},"NCT00523718","Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder",[87],[1726,16340],"Ocd",[16342],"riluzole",{"nctId":16344,"briefTitle":16345,"status":152,"phases":16346,"primaryCompletion":178,"completion":179,"start":7871,"enrollment":6277,"conditions":16347,"interventions":16348},"NCT01204918","Efficacy and Tolerability of Riluzole in Treatment Resistant Depression",[87],[21],[16321],{"trials":16350,"activeCount":98},[],{"trials":16352,"activeCount":98},[],{"trials":16354,"activeCount":98},[16355],{"nctId":16356,"briefTitle":16357,"status":152,"phases":16358,"primaryCompletion":16359,"completion":16359,"start":16360,"enrollment":3897,"conditions":16361,"interventions":16363},"NCT00375050","Treatment of Refractory Schizophrenia With Riluzole",[90],"2006-08-29","2002-05",[15,16362],"Schizoaffective",[16321],{"intervention":10185,"totalTrials":94,"cells":16365},{"EARLY_PHASE1":16366,"PHASE1":16368,"PHASE2":16370,"PHASE3":16376,"PHASE4":16378,"NA":16380},{"trials":16367,"activeCount":98},[],{"trials":16369,"activeCount":98},[],{"trials":16371,"activeCount":98},[16372],{"nctId":10179,"briefTitle":10180,"status":1051,"phases":16373,"primaryCompletion":4079,"completion":8199,"start":714,"enrollment":98,"conditions":16374,"interventions":16375},[87],[10183],[10185,10170],{"trials":16377,"activeCount":98},[],{"trials":16379,"activeCount":98},[],{"trials":16381,"activeCount":98},[16382,16391],{"nctId":16383,"briefTitle":16384,"status":152,"phases":16385,"primaryCompletion":1165,"completion":1165,"start":1907,"enrollment":16386,"conditions":16387,"interventions":16389},"NCT02786264","Association of Type of Anesthetic and Outcomes in Transfemoral Aortic Valve Replacement",[],186,[16388],"Aortic Stenosis",[16390,10185],"Dexmedetomidine with propofol",{"nctId":16392,"briefTitle":16393,"status":152,"phases":16394,"primaryCompletion":16395,"completion":16395,"start":16396,"enrollment":16397,"conditions":16398,"interventions":16400},"NCT03699696","A Pilot Analysis of the Association Between Anesthesia Induction Dosing and AKI in the Elderly Population",[],"2018-07-08","2014-12-01",541,[3634,12281,16399],"Anesthesia; Adverse Effect",[10185],{"intervention":332,"totalTrials":94,"cells":16402},{"EARLY_PHASE1":16403,"PHASE1":16405,"PHASE2":16407,"PHASE3":16419,"PHASE4":16421,"NA":16423},{"trials":16404,"activeCount":98},[],{"trials":16406,"activeCount":98},[],{"trials":16408,"activeCount":98},[16409,16415],{"nctId":16410,"briefTitle":16411,"status":152,"phases":16412,"primaryCompletion":1423,"completion":1423,"start":1674,"enrollment":1959,"conditions":16413,"interventions":16414},"NCT01137396","Modafinil, Sleep Architecture and Cocaine Relapse",[87],[330],[332],{"nctId":323,"briefTitle":324,"status":152,"phases":16416,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":16417,"interventions":16418},[86,87],[330],[332,333,262],{"trials":16420,"activeCount":98},[],{"trials":16422,"activeCount":98},[],{"trials":16424,"activeCount":98},[16425],{"nctId":16426,"briefTitle":16427,"status":152,"phases":16428,"primaryCompletion":1092,"completion":1092,"start":6137,"enrollment":1923,"conditions":16429,"interventions":16432},"NCT00582491","Modafinil, Sleep, and Cognition in Cocaine Dependence",[90],[330,16430,16431],"Substance-induced Sleep Disorder","Substance-induced Cognitive Disorder",[332],{"intervention":16007,"totalTrials":94,"cells":16434},{"EARLY_PHASE1":16435,"PHASE1":16437,"PHASE2":16451,"PHASE3":16453,"PHASE4":16455,"NA":16457},{"trials":16436,"activeCount":98},[],{"trials":16438,"activeCount":98},[16439,16447],{"nctId":16440,"briefTitle":16441,"status":152,"phases":16442,"primaryCompletion":16443,"completion":16443,"start":16444,"enrollment":2133,"conditions":16445,"interventions":16446},"NCT02187211","Minocycline's Effects on Alcohol Responses in Humans",[86],"2018-11-01","2015-07-01",[1112],[16007],{"nctId":15998,"briefTitle":15999,"status":152,"phases":16448,"primaryCompletion":16001,"completion":16001,"start":16002,"enrollment":1315,"conditions":16449,"interventions":16450},[86],[16004],[16006,16007],{"trials":16452,"activeCount":98},[],{"trials":16454,"activeCount":98},[],{"trials":16456,"activeCount":98},[],{"trials":16458,"activeCount":98},[16459],{"nctId":16460,"briefTitle":16461,"status":152,"phases":16462,"primaryCompletion":16463,"completion":16463,"start":16464,"enrollment":314,"conditions":16465,"interventions":16466},"NCT02359006","The Effects of Minocycline in Opioid-maintained Patients",[90],"2017-04-19","2015-03-12",[221,316],[16007],{"intervention":16468,"totalTrials":94,"cells":16469},"Nicotine patch",{"EARLY_PHASE1":16470,"PHASE1":16476,"PHASE2":16478,"PHASE3":16480,"PHASE4":16482,"NA":16484},{"trials":16471,"activeCount":98},[16472],{"nctId":1855,"briefTitle":1856,"status":711,"phases":16473,"primaryCompletion":1186,"completion":1186,"start":1858,"enrollment":1466,"conditions":16474,"interventions":16475},[85],[1860],[70,1862],{"trials":16477,"activeCount":98},[],{"trials":16479,"activeCount":98},[],{"trials":16481,"activeCount":98},[],{"trials":16483,"activeCount":98},[],{"trials":16485,"activeCount":98},[16486,16493],{"nctId":16487,"briefTitle":16488,"status":152,"phases":16489,"primaryCompletion":1886,"completion":1886,"start":6777,"enrollment":2133,"conditions":16490,"interventions":16492},"NCT01259466","Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers",[90],[1860,16491,18],"Overweight",[16468],{"nctId":16494,"briefTitle":16495,"status":152,"phases":16496,"primaryCompletion":1907,"completion":8199,"start":714,"enrollment":1044,"conditions":16497,"interventions":16498},"NCT02191033","Text Messaging for Smoking Cessation in College Health Clinics",[90],[1850],[16468],{"intervention":16500,"totalTrials":94,"cells":16501},"Metformin",{"EARLY_PHASE1":16502,"PHASE1":16504,"PHASE2":16506,"PHASE3":16508,"PHASE4":16510,"NA":16526},{"trials":16503,"activeCount":98},[],{"trials":16505,"activeCount":98},[],{"trials":16507,"activeCount":98},[],{"trials":16509,"activeCount":98},[],{"trials":16511,"activeCount":98},[16512,16519],{"nctId":16513,"briefTitle":16514,"status":711,"phases":16515,"primaryCompletion":6917,"completion":6917,"start":16516,"enrollment":1959,"conditions":16517,"interventions":16518},"NCT03258723","Diabetes Prevention With Lifestyle Intervention and Metformin Escalation",[89],"2018-07-30",[7215],[16500],{"nctId":16520,"briefTitle":16521,"status":152,"phases":16522,"primaryCompletion":1665,"completion":1665,"start":16314,"enrollment":1743,"conditions":16523,"interventions":16525},"NCT00667498","Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance",[89],[5873,5756,16524],"Hyperinsulinemia",[16500],{"trials":16527,"activeCount":98},[16528],{"nctId":16529,"briefTitle":16530,"status":152,"phases":16531,"primaryCompletion":1618,"completion":1618,"start":1120,"enrollment":1675,"conditions":16532,"interventions":16534},"NCT01070160","Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)",[],[16533],"Polycystic Ovarian Syndrome",[16535,16500],"Endometrin",{"intervention":16537,"totalTrials":263,"cells":16538},"Pregabalin",{"EARLY_PHASE1":16539,"PHASE1":16549,"PHASE2":16551,"PHASE3":16553,"PHASE4":16555,"NA":16557},{"trials":16540,"activeCount":98},[16541],{"nctId":16542,"briefTitle":16543,"status":152,"phases":16544,"primaryCompletion":16545,"completion":16545,"start":1061,"enrollment":2659,"conditions":16546,"interventions":16547},"NCT00644137","GABA (Gamma Amino Butyric Acid) Medication for Tobacco",[85],"2010-02",[24],[16548],"pregabalin",{"trials":16550,"activeCount":98},[],{"trials":16552,"activeCount":98},[],{"trials":16554,"activeCount":98},[],{"trials":16556,"activeCount":98},[],{"trials":16558,"activeCount":98},[16559],{"nctId":16560,"briefTitle":16561,"status":711,"phases":16562,"primaryCompletion":5871,"completion":5871,"start":15854,"enrollment":7035,"conditions":16563,"interventions":16564},"NCT00142883","The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3",[90],[12324,210],[16537],{"intervention":16566,"totalTrials":263,"cells":16567},"Cycloserine",{"EARLY_PHASE1":16568,"PHASE1":16570,"PHASE2":16572,"PHASE3":16580,"PHASE4":16582,"NA":16584},{"trials":16569,"activeCount":98},[],{"trials":16571,"activeCount":98},[],{"trials":16573,"activeCount":98},[16574],{"nctId":16575,"briefTitle":16576,"status":1051,"phases":16577,"primaryCompletion":1053,"completion":1053,"start":1054,"enrollment":98,"conditions":16578,"interventions":16579},"NCT00000194","Neurobiology of Opioid Dependence: 3 - 3",[87],[157],[16566],{"trials":16581,"activeCount":98},[],{"trials":16583,"activeCount":98},[],{"trials":16585,"activeCount":98},[16586],{"nctId":16587,"briefTitle":16588,"status":152,"phases":16589,"primaryCompletion":1187,"completion":1187,"start":1081,"enrollment":118,"conditions":16590,"interventions":16591},"NCT00633256","The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers",[90],[33],[16566],{"intervention":16593,"totalTrials":263,"cells":16594},"duloxetine",{"EARLY_PHASE1":16595,"PHASE1":16604,"PHASE2":16606,"PHASE3":16608,"PHASE4":16610,"NA":16612},{"trials":16596,"activeCount":98},[16597],{"nctId":16598,"briefTitle":16599,"status":152,"phases":16600,"primaryCompletion":1071,"completion":8491,"start":7330,"enrollment":1878,"conditions":16601,"interventions":16602},"NCT00763178","Effects of Duloxetine on Fear Conditioning in Posttraumatic Stress Disorder (PTSD)",[85],[1718],[16603],"Duloxetine",{"trials":16605,"activeCount":98},[],{"trials":16607,"activeCount":98},[],{"trials":16609,"activeCount":98},[],{"trials":16611,"activeCount":98},[],{"trials":16613,"activeCount":98},[16614],{"nctId":16615,"briefTitle":16616,"status":1051,"phases":16617,"primaryCompletion":1186,"completion":1210,"start":1121,"enrollment":98,"conditions":16618,"interventions":16620},"NCT00617045","Duloxetine for the Treatment of Postpartum Depression",[90],[16619,1772],"Postpartum Depression",[16593],{"intervention":16622,"totalTrials":263,"cells":16623},"Atorvastatin",{"EARLY_PHASE1":16624,"PHASE1":16626,"PHASE2":16637,"PHASE3":16639,"PHASE4":16641,"NA":16643},{"trials":16625,"activeCount":98},[],{"trials":16627,"activeCount":98},[16628],{"nctId":16629,"briefTitle":16630,"status":1051,"phases":16631,"primaryCompletion":16632,"completion":16632,"start":16633,"enrollment":98,"conditions":16634,"interventions":16636},"NCT04922424","Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men",[86],"2023-08-31","2022-09-30",[12190,16635],"Hyperlipidemias",[16622],{"trials":16638,"activeCount":98},[],{"trials":16640,"activeCount":98},[],{"trials":16642,"activeCount":98},[],{"trials":16644,"activeCount":98},[16645],{"nctId":16646,"briefTitle":16647,"status":152,"phases":16648,"primaryCompletion":1061,"completion":1061,"start":1107,"enrollment":36,"conditions":16649,"interventions":16651},"NCT00259662","High-dose Periop Statins for Prevention of DVT",[90],[16650],"Gynecologic Oncological Pelvic\u002FAbdominal Surgery",[16652],"atorvastatin",{"intervention":5818,"totalTrials":263,"cells":16654},{"EARLY_PHASE1":16655,"PHASE1":16657,"PHASE2":16659,"PHASE3":16661,"PHASE4":16663,"NA":16669},{"trials":16656,"activeCount":98},[],{"trials":16658,"activeCount":98},[],{"trials":16660,"activeCount":98},[],{"trials":16662,"activeCount":98},[],{"trials":16664,"activeCount":98},[16665],{"nctId":5813,"briefTitle":5814,"status":152,"phases":16666,"primaryCompletion":1655,"conditions":16667,"interventions":16668},[89],[15],[5818,5789,5819],{"trials":16670,"activeCount":98},[16671],{"nctId":16672,"briefTitle":16673,"status":152,"phases":16674,"primaryCompletion":6276,"completion":6276,"start":197,"enrollment":16675,"conditions":16676,"interventions":16678},"NCT00080145","RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders",[90],124,[16677],"Child Development Disorders, Pervasive",[16679],"Risperidone",{"intervention":16681,"totalTrials":263,"cells":16682},"Amphetamine",{"EARLY_PHASE1":16683,"PHASE1":16685,"PHASE2":16687,"PHASE3":16689,"PHASE4":16691,"NA":16693},{"trials":16684,"activeCount":98},[],{"trials":16686,"activeCount":98},[],{"trials":16688,"activeCount":98},[],{"trials":16690,"activeCount":98},[],{"trials":16692,"activeCount":98},[],{"trials":16694,"activeCount":98},[16695,16701],{"nctId":16696,"briefTitle":16697,"status":152,"phases":16698,"primaryCompletion":1618,"completion":1618,"start":1835,"enrollment":1315,"conditions":16699,"interventions":16700},"NCT01699607","Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm",[90],[24,3590],[16681],{"nctId":16702,"briefTitle":16703,"status":152,"phases":16704,"primaryCompletion":16705,"completion":16705,"start":1186,"enrollment":9130,"conditions":16706,"interventions":16707},"NCT02348385","Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers",[],"2017-12",[24],[16681],{"intervention":16709,"totalTrials":263,"cells":16710},"Domperidone",{"EARLY_PHASE1":16711,"PHASE1":16713,"PHASE2":16715,"PHASE3":16724,"PHASE4":16726,"NA":16728},{"trials":16712,"activeCount":98},[],{"trials":16714,"activeCount":98},[],{"trials":16716,"activeCount":98},[16717],{"nctId":16718,"briefTitle":16719,"status":711,"phases":16720,"primaryCompletion":16108,"completion":16108,"start":10652,"enrollment":1923,"conditions":16721,"interventions":16723},"NCT00760461","Domperidone in Refractory Gastroparesis",[87],[16722],"Gastroparesis",[16709],{"trials":16725,"activeCount":98},[],{"trials":16727,"activeCount":98},[],{"trials":16729,"activeCount":98},[16730],{"nctId":16731,"briefTitle":16732,"status":16733,"phases":16734,"conditions":16735,"interventions":16736},"NCT03810287","The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms","NO_LONGER_AVAILABLE",[],[16722],[16709],{"intervention":16738,"totalTrials":263,"cells":16739},"indomethacin",{"EARLY_PHASE1":16740,"PHASE1":16742,"PHASE2":16744,"PHASE3":16746,"PHASE4":16760,"NA":16762},{"trials":16741,"activeCount":98},[],{"trials":16743,"activeCount":98},[],{"trials":16745,"activeCount":98},[],{"trials":16747,"activeCount":98},[16748],{"nctId":16749,"briefTitle":16750,"status":152,"phases":16751,"primaryCompletion":11051,"completion":11051,"start":16752,"enrollment":16753,"conditions":16754,"interventions":16759},"NCT00033917","Indomethacin Germinal Matrix Hemorrhage\u002FIntraventricular Hemorrhage (GMH\u002FIVH) Prevention Trial",[88],"1989-09",630,[16755,16756,16757,16758],"Intraventricular Hemorrhage (IVH)","Bleeding in the Brain","Prematurity","Very Low Birth Weight Infants",[16738],{"trials":16761,"activeCount":98},[],{"trials":16763,"activeCount":98},[16764],{"nctId":16765,"briefTitle":16766,"status":152,"phases":16767,"primaryCompletion":7744,"completion":7508,"start":1106,"enrollment":16768,"conditions":16769,"interventions":16771},"NCT00727740","A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis",[90],117,[16770],"Pancreatitis",[16772],"Indomethacin",{"intervention":11795,"totalTrials":263,"cells":16774},{"EARLY_PHASE1":16775,"PHASE1":16777,"PHASE2":16783,"PHASE3":16785,"PHASE4":16787,"NA":16789},{"trials":16776,"activeCount":98},[],{"trials":16778,"activeCount":98},[16779],{"nctId":11789,"briefTitle":11790,"status":152,"phases":16780,"primaryCompletion":8160,"completion":8160,"start":11005,"enrollment":36,"conditions":16781,"interventions":16782},[86],[330,11793],[2324,11795],{"trials":16784,"activeCount":98},[],{"trials":16786,"activeCount":98},[],{"trials":16788,"activeCount":98},[],{"trials":16790,"activeCount":98},[16791],{"nctId":16792,"briefTitle":16793,"status":711,"phases":16794,"primaryCompletion":16795,"completion":16795,"start":8160,"enrollment":109,"conditions":16796,"interventions":16797},"NCT02152670","Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC\u002F[11C]PHNO PET",[90],"2014-06-09",[330],[16798,16799],"Methylphenidate","Alpha Methyl Para Tyrosine",{"intervention":16801,"totalTrials":263,"cells":16802},"Raltegravir",{"EARLY_PHASE1":16803,"PHASE1":16805,"PHASE2":16807,"PHASE3":16809,"PHASE4":16811,"NA":16813},{"trials":16804,"activeCount":98},[],{"trials":16806,"activeCount":98},[],{"trials":16808,"activeCount":98},[],{"trials":16810,"activeCount":98},[],{"trials":16812,"activeCount":98},[],{"trials":16814,"activeCount":98},[16815,16823],{"nctId":16816,"briefTitle":16817,"status":152,"phases":16818,"primaryCompletion":1210,"completion":1886,"start":8045,"enrollment":105,"conditions":16819,"interventions":16821},"NCT00814879","Pilot Study of a Raltegravir Based NRTI Sparing Regimen",[90],[16820,10891,287,274],"Acquired Immune Deficiency Syndrome",[16801,16822],"Atazanavir",{"nctId":16824,"briefTitle":16825,"status":152,"phases":16826,"primaryCompletion":8491,"completion":8491,"start":16827,"enrollment":272,"conditions":16828,"interventions":16830},"NCT00858962","Buprenorphine\u002FRaltegravir Pharmacokinetic Interaction Study",[90],"2009-03",[16829,274],"HIV Infection",[16801],{"intervention":16390,"totalTrials":109,"cells":16832},{"EARLY_PHASE1":16833,"PHASE1":16835,"PHASE2":16837,"PHASE3":16839,"PHASE4":16841,"NA":16843},{"trials":16834,"activeCount":98},[],{"trials":16836,"activeCount":98},[],{"trials":16838,"activeCount":98},[],{"trials":16840,"activeCount":98},[],{"trials":16842,"activeCount":98},[],{"trials":16844,"activeCount":98},[16845],{"nctId":16383,"briefTitle":16384,"status":152,"phases":16846,"primaryCompletion":1165,"completion":1165,"start":1907,"enrollment":16386,"conditions":16847,"interventions":16848},[],[16388],[16390,10185],{"intervention":16850,"totalTrials":109,"cells":16851},"Tecfidera",{"EARLY_PHASE1":16852,"PHASE1":16854,"PHASE2":16856,"PHASE3":16858,"PHASE4":16860,"NA":16862},{"trials":16853,"activeCount":98},[],{"trials":16855,"activeCount":98},[],{"trials":16857,"activeCount":98},[],{"trials":16859,"activeCount":98},[],{"trials":16861,"activeCount":98},[],{"trials":16863,"activeCount":98},[16864],{"nctId":16865,"briefTitle":16866,"status":711,"phases":16867,"primaryCompletion":1826,"completion":1826,"start":7707,"enrollment":1466,"conditions":16868,"interventions":16869},"NCT02218879","Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS",[],[6513],[16850],{"intervention":16871,"totalTrials":109,"cells":16872},"Sibutramine\u002FOrlistat",{"EARLY_PHASE1":16873,"PHASE1":16875,"PHASE2":16877,"PHASE3":16879,"PHASE4":16881,"NA":16883},{"trials":16874,"activeCount":98},[],{"trials":16876,"activeCount":98},[],{"trials":16878,"activeCount":98},[],{"trials":16880,"activeCount":98},[],{"trials":16882,"activeCount":98},[],{"trials":16884,"activeCount":98},[16885],{"nctId":16886,"briefTitle":16887,"status":152,"phases":16888,"primaryCompletion":1886,"completion":1886,"start":1992,"enrollment":16889,"conditions":16890,"interventions":16891},"NCT00829283","Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care",[90],191,[18,6255],[16871],{"intervention":16028,"totalTrials":109,"cells":16893},{"EARLY_PHASE1":16894,"PHASE1":16896,"PHASE2":16898,"PHASE3":16900,"PHASE4":16902,"NA":16904},{"trials":16895,"activeCount":98},[],{"trials":16897,"activeCount":98},[],{"trials":16899,"activeCount":98},[],{"trials":16901,"activeCount":98},[],{"trials":16903,"activeCount":98},[],{"trials":16905,"activeCount":98},[16906],{"nctId":16021,"briefTitle":16022,"status":152,"phases":16907,"primaryCompletion":16024,"completion":16024,"start":16025,"enrollment":1619,"conditions":16908,"interventions":16909},[90],[24],[16028,333],{"intervention":16911,"totalTrials":109,"cells":16912},"COVID19 vaccine",{"EARLY_PHASE1":16913,"PHASE1":16915,"PHASE2":16917,"PHASE3":16919,"PHASE4":16921,"NA":16923},{"trials":16914,"activeCount":98},[],{"trials":16916,"activeCount":98},[],{"trials":16918,"activeCount":98},[],{"trials":16920,"activeCount":98},[],{"trials":16922,"activeCount":98},[],{"trials":16924,"activeCount":98},[16925],{"nctId":16926,"briefTitle":16927,"status":152,"phases":16928,"primaryCompletion":16929,"completion":16929,"start":12803,"enrollment":16930,"conditions":16931,"interventions":16934},"NCT05286242","Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients",[],"2026-05-22",196,[6513,16932,16933],"Autoimmune Blistering Disease","B-Cell Deficiency",[16911],{"intervention":16936,"totalTrials":109,"cells":16937},"Buprenorphine Initiation",{"EARLY_PHASE1":16938,"PHASE1":16940,"PHASE2":16942,"PHASE3":16944,"PHASE4":16946,"NA":16948},{"trials":16939,"activeCount":98},[],{"trials":16941,"activeCount":98},[],{"trials":16943,"activeCount":98},[],{"trials":16945,"activeCount":98},[],{"trials":16947,"activeCount":98},[],{"trials":16949,"activeCount":98},[16950],{"nctId":16951,"briefTitle":16952,"status":152,"phases":16953,"primaryCompletion":6766,"completion":346,"start":5870,"enrollment":16954,"conditions":16955,"interventions":16956},"NCT00913770","Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department",[90],329,[289],[16936],{"intervention":16958,"totalTrials":109,"cells":16959},"Vivitrol- Intramuscular naltrexone",{"EARLY_PHASE1":16960,"PHASE1":16962,"PHASE2":16964,"PHASE3":16966,"PHASE4":16968,"NA":16970},{"trials":16961,"activeCount":98},[],{"trials":16963,"activeCount":98},[],{"trials":16965,"activeCount":98},[],{"trials":16967,"activeCount":98},[],{"trials":16969,"activeCount":98},[],{"trials":16971,"activeCount":98},[16972],{"nctId":16973,"briefTitle":16974,"status":152,"phases":16975,"primaryCompletion":179,"completion":179,"start":16976,"enrollment":1011,"conditions":16977,"interventions":16980},"NCT01077310","Alcohol Pharmacotherapy for HIV+ Prisoners",[90],"2010-08",[1112,16978,16979,287,10891],"Problem Drinking","Hazardous Drinking",[16958],{"intervention":16982,"totalTrials":109,"cells":16983},"Ketamine and Placebo",{"EARLY_PHASE1":16984,"PHASE1":16986,"PHASE2":16988,"PHASE3":16990,"PHASE4":16992,"NA":16994},{"trials":16985,"activeCount":98},[],{"trials":16987,"activeCount":98},[],{"trials":16989,"activeCount":98},[],{"trials":16991,"activeCount":98},[],{"trials":16993,"activeCount":98},[],{"trials":16995,"activeCount":98},[16996],{"nctId":16997,"briefTitle":16998,"status":152,"phases":16999,"primaryCompletion":1441,"completion":1441,"start":17000,"enrollment":17001,"conditions":17002,"interventions":17003},"NCT00588952","Ketamine\u002FPlacebo Family History Positive Study",[90],"2001-03",99,[1111],[16982],{"intervention":17005,"totalTrials":109,"cells":17006},"Thiopental",{"EARLY_PHASE1":17007,"PHASE1":17009,"PHASE2":17011,"PHASE3":17013,"PHASE4":17015,"NA":17017},{"trials":17008,"activeCount":98},[],{"trials":17010,"activeCount":98},[],{"trials":17012,"activeCount":98},[],{"trials":17014,"activeCount":98},[],{"trials":17016,"activeCount":98},[],{"trials":17018,"activeCount":98},[17019],{"nctId":17020,"briefTitle":17021,"status":152,"phases":17022,"primaryCompletion":5846,"completion":5846,"start":1107,"enrollment":17023,"conditions":17024,"interventions":17025},"NCT00611767","GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence",[90],73,[1111],[17005],{"intervention":17027,"totalTrials":109,"cells":17028},"Rosiglitazone",{"EARLY_PHASE1":17029,"PHASE1":17031,"PHASE2":17033,"PHASE3":17035,"PHASE4":17037,"NA":17039},{"trials":17030,"activeCount":98},[],{"trials":17032,"activeCount":98},[],{"trials":17034,"activeCount":98},[],{"trials":17036,"activeCount":98},[],{"trials":17038,"activeCount":98},[],{"trials":17040,"activeCount":98},[17041],{"nctId":17042,"briefTitle":17043,"status":152,"phases":17044,"primaryCompletion":5870,"completion":1082,"start":1107,"enrollment":5030,"conditions":17045,"interventions":17046},"NCT00413335","Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth",[90],[18,2123,2122],[17027],{"intervention":17048,"totalTrials":109,"cells":17049},"Palliative care",{"EARLY_PHASE1":17050,"PHASE1":17052,"PHASE2":17054,"PHASE3":17056,"PHASE4":17058,"NA":17060},{"trials":17051,"activeCount":98},[],{"trials":17053,"activeCount":98},[],{"trials":17055,"activeCount":98},[],{"trials":17057,"activeCount":98},[],{"trials":17059,"activeCount":98},[],{"trials":17061,"activeCount":98},[17062],{"nctId":17063,"briefTitle":17064,"status":152,"phases":17065,"primaryCompletion":17066,"completion":15073,"start":1875,"enrollment":17067,"conditions":17068,"interventions":17070},"NCT03712436","Examining Early Palliative Care in Newly Diagnosed Cancer Patients",[90],"2020-03-15",98,[17069],"Cancer",[17048,17071],"Standard oncological care",{"intervention":17071,"totalTrials":109,"cells":17073},{"EARLY_PHASE1":17074,"PHASE1":17076,"PHASE2":17078,"PHASE3":17080,"PHASE4":17082,"NA":17084},{"trials":17075,"activeCount":98},[],{"trials":17077,"activeCount":98},[],{"trials":17079,"activeCount":98},[],{"trials":17081,"activeCount":98},[],{"trials":17083,"activeCount":98},[],{"trials":17085,"activeCount":98},[17086],{"nctId":17063,"briefTitle":17064,"status":152,"phases":17087,"primaryCompletion":17066,"completion":15073,"start":1875,"enrollment":17067,"conditions":17088,"interventions":17089},[90],[17069],[17048,17071],{"intervention":17091,"totalTrials":109,"cells":17092},"[11-C]OMAR",{"EARLY_PHASE1":17093,"PHASE1":17095,"PHASE2":17097,"PHASE3":17099,"PHASE4":17101,"NA":17103},{"trials":17094,"activeCount":98},[],{"trials":17096,"activeCount":98},[],{"trials":17098,"activeCount":98},[],{"trials":17100,"activeCount":98},[],{"trials":17102,"activeCount":98},[],{"trials":17104,"activeCount":98},[17105],{"nctId":17106,"briefTitle":17107,"status":152,"phases":17108,"primaryCompletion":17109,"completion":17109,"start":1972,"enrollment":1716,"conditions":17110,"interventions":17111},"NCT03104257","The Neural Correlates of Cannabis Use",[],"2022-04-27",[8172,3590],[17091],{"intervention":1987,"totalTrials":109,"cells":17113},{"EARLY_PHASE1":17114,"PHASE1":17116,"PHASE2":17118,"PHASE3":17120,"PHASE4":17122,"NA":17124},{"trials":17115,"activeCount":98},[],{"trials":17117,"activeCount":98},[],{"trials":17119,"activeCount":98},[],{"trials":17121,"activeCount":98},[],{"trials":17123,"activeCount":98},[],{"trials":17125,"activeCount":98},[17126],{"nctId":1980,"briefTitle":1981,"status":152,"phases":17127,"primaryCompletion":1120,"completion":1983,"start":1984,"enrollment":28,"conditions":17128,"interventions":17129},[90],[330,24],[70,1987],{"intervention":17131,"totalTrials":109,"cells":17132},"Medroxyprogesterone",{"EARLY_PHASE1":17133,"PHASE1":17135,"PHASE2":17137,"PHASE3":17139,"PHASE4":17141,"NA":17143},{"trials":17134,"activeCount":98},[],{"trials":17136,"activeCount":98},[],{"trials":17138,"activeCount":98},[],{"trials":17140,"activeCount":98},[],{"trials":17142,"activeCount":98},[],{"trials":17144,"activeCount":98},[17145],{"nctId":17146,"briefTitle":17147,"status":152,"phases":17148,"primaryCompletion":11550,"completion":11550,"start":270,"enrollment":1619,"conditions":17149,"interventions":17150},"NCT00743574","Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)",[90],[16533,5497],[17131],{"intervention":17152,"totalTrials":109,"cells":17153},"(S,S)-[11C]MRB",{"EARLY_PHASE1":17154,"PHASE1":17156,"PHASE2":17158,"PHASE3":17160,"PHASE4":17162,"NA":17164},{"trials":17155,"activeCount":98},[],{"trials":17157,"activeCount":98},[],{"trials":17159,"activeCount":98},[],{"trials":17161,"activeCount":98},[],{"trials":17163,"activeCount":98},[],{"trials":17165,"activeCount":98},[17166],{"nctId":17167,"briefTitle":17168,"status":1051,"phases":17169,"primaryCompletion":7352,"completion":17170,"start":1121,"enrollment":98,"conditions":17171,"interventions":17172},"NCT01719458","Norepinephrine Transporter Imaging in Addiction Disorders",[],"2023-01-04",[18,1112],[17152],{"intervention":16036,"totalTrials":109,"cells":17174},{"EARLY_PHASE1":17175,"PHASE1":17177,"PHASE2":17179,"PHASE3":17181,"PHASE4":17183,"NA":17185},{"trials":17176,"activeCount":98},[],{"trials":17178,"activeCount":98},[],{"trials":17180,"activeCount":98},[],{"trials":17182,"activeCount":98},[],{"trials":17184,"activeCount":98},[],{"trials":17186,"activeCount":98},[17187],{"nctId":16030,"briefTitle":16031,"status":152,"phases":17188,"primaryCompletion":1186,"completion":1759,"start":6276,"enrollment":16033,"conditions":17189,"interventions":17190},[90],[330,183],[15871,16036,16037],{"intervention":16037,"totalTrials":109,"cells":17192},{"EARLY_PHASE1":17193,"PHASE1":17195,"PHASE2":17197,"PHASE3":17199,"PHASE4":17201,"NA":17203},{"trials":17194,"activeCount":98},[],{"trials":17196,"activeCount":98},[],{"trials":17198,"activeCount":98},[],{"trials":17200,"activeCount":98},[],{"trials":17202,"activeCount":98},[],{"trials":17204,"activeCount":98},[17205],{"nctId":16030,"briefTitle":16031,"status":152,"phases":17206,"primaryCompletion":1186,"completion":1759,"start":6276,"enrollment":16033,"conditions":17207,"interventions":17208},[90],[330,183],[15871,16036,16037],{"intervention":17210,"totalTrials":109,"cells":17211},"D-Cycloserine PO and Glycine IV",{"EARLY_PHASE1":17212,"PHASE1":17214,"PHASE2":17216,"PHASE3":17218,"PHASE4":17220,"NA":17222},{"trials":17213,"activeCount":98},[],{"trials":17215,"activeCount":98},[],{"trials":17217,"activeCount":98},[],{"trials":17219,"activeCount":98},[],{"trials":17221,"activeCount":98},[],{"trials":17223,"activeCount":98},[17224],{"nctId":17225,"briefTitle":17226,"status":152,"phases":17227,"primaryCompletion":1187,"completion":1187,"start":17228,"enrollment":1407,"conditions":17229,"interventions":17230},"NCT00635102","Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects",[90],"1997-10",[1112],[17210,17231],"D-Cycloserine PO and placebo Glycine IV",{"intervention":17231,"totalTrials":109,"cells":17233},{"EARLY_PHASE1":17234,"PHASE1":17236,"PHASE2":17238,"PHASE3":17240,"PHASE4":17242,"NA":17244},{"trials":17235,"activeCount":98},[],{"trials":17237,"activeCount":98},[],{"trials":17239,"activeCount":98},[],{"trials":17241,"activeCount":98},[],{"trials":17243,"activeCount":98},[],{"trials":17245,"activeCount":98},[17246],{"nctId":17225,"briefTitle":17226,"status":152,"phases":17247,"primaryCompletion":1187,"completion":1187,"start":17228,"enrollment":1407,"conditions":17248,"interventions":17249},[90],[1112],[17210,17231],{"intervention":17251,"totalTrials":109,"cells":17252},"18F-FP-DTBZ",{"EARLY_PHASE1":17253,"PHASE1":17255,"PHASE2":17257,"PHASE3":17259,"PHASE4":17261,"NA":17263},{"trials":17254,"activeCount":98},[],{"trials":17256,"activeCount":98},[],{"trials":17258,"activeCount":98},[],{"trials":17260,"activeCount":98},[],{"trials":17262,"activeCount":98},[],{"trials":17264,"activeCount":98},[17265],{"nctId":17266,"briefTitle":17267,"status":152,"phases":17268,"primaryCompletion":9373,"completion":8768,"start":1983,"enrollment":1648,"conditions":17269,"interventions":17270},"NCT00958997","Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients",[],[5040],[17251,17271],"Arginine-hydrochloride",{"intervention":17271,"totalTrials":109,"cells":17273},{"EARLY_PHASE1":17274,"PHASE1":17276,"PHASE2":17278,"PHASE3":17280,"PHASE4":17282,"NA":17284},{"trials":17275,"activeCount":98},[],{"trials":17277,"activeCount":98},[],{"trials":17279,"activeCount":98},[],{"trials":17281,"activeCount":98},[],{"trials":17283,"activeCount":98},[],{"trials":17285,"activeCount":98},[17286],{"nctId":17266,"briefTitle":17267,"status":152,"phases":17287,"primaryCompletion":9373,"completion":8768,"start":1983,"enrollment":1648,"conditions":17288,"interventions":17289},[],[5040],[17251,17271],{"intervention":17291,"totalTrials":109,"cells":17292},"PVA microporous hydrospheres\u002Fdoxorubicin hydrochloride",{"EARLY_PHASE1":17293,"PHASE1":17295,"PHASE2":17297,"PHASE3":17299,"PHASE4":17301,"NA":17303},{"trials":17294,"activeCount":98},[],{"trials":17296,"activeCount":98},[],{"trials":17298,"activeCount":98},[],{"trials":17300,"activeCount":98},[],{"trials":17302,"activeCount":98},[],{"trials":17304,"activeCount":98},[17305],{"nctId":17306,"briefTitle":17307,"status":711,"phases":17308,"primaryCompletion":8457,"completion":8457,"start":1092,"enrollment":1685,"conditions":17309,"interventions":17312},"NCT00730483","Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors",[90],[17310,17311,13218],"Gastrointestinal Carcinoid Tumor","Islet Cell Tumor",[17291],{"intervention":17314,"totalTrials":109,"cells":17315},"fluticasone nasal spray",{"EARLY_PHASE1":17316,"PHASE1":17318,"PHASE2":17320,"PHASE3":17322,"PHASE4":17324,"NA":17326},{"trials":17317,"activeCount":98},[],{"trials":17319,"activeCount":98},[],{"trials":17321,"activeCount":98},[],{"trials":17323,"activeCount":98},[],{"trials":17325,"activeCount":98},[],{"trials":17327,"activeCount":98},[17328],{"nctId":17329,"briefTitle":17330,"status":152,"phases":17331,"primaryCompletion":1148,"completion":179,"start":714,"enrollment":1523,"conditions":17332,"interventions":17335},"NCT02194062","Comparison of Nasal Steroids After FESS in CRSwNP",[90],[17333,17334],"Sinusitis","Nasal Polyps",[17314,17336,17337],"Budesonide head upright","Budesonide head forward",{"intervention":17336,"totalTrials":109,"cells":17339},{"EARLY_PHASE1":17340,"PHASE1":17342,"PHASE2":17344,"PHASE3":17346,"PHASE4":17348,"NA":17350},{"trials":17341,"activeCount":98},[],{"trials":17343,"activeCount":98},[],{"trials":17345,"activeCount":98},[],{"trials":17347,"activeCount":98},[],{"trials":17349,"activeCount":98},[],{"trials":17351,"activeCount":98},[17352],{"nctId":17329,"briefTitle":17330,"status":152,"phases":17353,"primaryCompletion":1148,"completion":179,"start":714,"enrollment":1523,"conditions":17354,"interventions":17355},[90],[17333,17334],[17314,17336,17337],{"intervention":17337,"totalTrials":109,"cells":17357},{"EARLY_PHASE1":17358,"PHASE1":17360,"PHASE2":17362,"PHASE3":17364,"PHASE4":17366,"NA":17368},{"trials":17359,"activeCount":98},[],{"trials":17361,"activeCount":98},[],{"trials":17363,"activeCount":98},[],{"trials":17365,"activeCount":98},[],{"trials":17367,"activeCount":98},[],{"trials":17369,"activeCount":98},[17370],{"nctId":17329,"briefTitle":17330,"status":152,"phases":17371,"primaryCompletion":1148,"completion":179,"start":714,"enrollment":1523,"conditions":17372,"interventions":17373},[90],[17333,17334],[17314,17336,17337],{"intervention":17375,"totalTrials":109,"cells":17376},"Formoterol",{"EARLY_PHASE1":17377,"PHASE1":17379,"PHASE2":17381,"PHASE3":17383,"PHASE4":17385,"NA":17387},{"trials":17378,"activeCount":98},[],{"trials":17380,"activeCount":98},[],{"trials":17382,"activeCount":98},[],{"trials":17384,"activeCount":98},[],{"trials":17386,"activeCount":98},[],{"trials":17388,"activeCount":98},[17389],{"nctId":17390,"briefTitle":17391,"status":152,"phases":17392,"primaryCompletion":7707,"completion":7707,"start":16976,"enrollment":1675,"conditions":17393,"interventions":17394},"NCT01194479","Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.",[90],[5724],[17375],{"intervention":276,"totalTrials":109,"cells":17396},{"EARLY_PHASE1":17397,"PHASE1":17399,"PHASE2":17401,"PHASE3":17403,"PHASE4":17405,"NA":17407},{"trials":17398,"activeCount":98},[],{"trials":17400,"activeCount":98},[],{"trials":17402,"activeCount":98},[],{"trials":17404,"activeCount":98},[],{"trials":17406,"activeCount":98},[],{"trials":17408,"activeCount":98},[17409],{"nctId":267,"briefTitle":268,"status":152,"phases":17410,"primaryCompletion":270,"completion":270,"start":271,"enrollment":272,"conditions":17411,"interventions":17412},[90],[274],[276,277],{"intervention":17414,"totalTrials":109,"cells":17415},"Atomoxetine, low dose",{"EARLY_PHASE1":17416,"PHASE1":17418,"PHASE2":17420,"PHASE3":17422,"PHASE4":17424,"NA":17426},{"trials":17417,"activeCount":98},[],{"trials":17419,"activeCount":98},[],{"trials":17421,"activeCount":98},[],{"trials":17423,"activeCount":98},[],{"trials":17425,"activeCount":98},[],{"trials":17427,"activeCount":98},[17428],{"nctId":17429,"briefTitle":17430,"status":711,"phases":17431,"primaryCompletion":326,"completion":326,"start":1186,"enrollment":1675,"conditions":17432,"interventions":17433},"NCT01802515","A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment",[90],[330,183],[17414,17434],"Atomoxetine, high dose",{"intervention":17434,"totalTrials":109,"cells":17436},{"EARLY_PHASE1":17437,"PHASE1":17439,"PHASE2":17441,"PHASE3":17443,"PHASE4":17445,"NA":17447},{"trials":17438,"activeCount":98},[],{"trials":17440,"activeCount":98},[],{"trials":17442,"activeCount":98},[],{"trials":17444,"activeCount":98},[],{"trials":17446,"activeCount":98},[],{"trials":17448,"activeCount":98},[17449],{"nctId":17429,"briefTitle":17430,"status":711,"phases":17450,"primaryCompletion":326,"completion":326,"start":1186,"enrollment":1675,"conditions":17451,"interventions":17452},[90],[330,183],[17414,17434],{"intervention":17454,"totalTrials":109,"cells":17455},"canagliflozin",{"EARLY_PHASE1":17456,"PHASE1":17458,"PHASE2":17460,"PHASE3":17462,"PHASE4":17464,"NA":17466},{"trials":17457,"activeCount":98},[],{"trials":17459,"activeCount":98},[],{"trials":17461,"activeCount":98},[],{"trials":17463,"activeCount":98},[],{"trials":17465,"activeCount":98},[],{"trials":17467,"activeCount":98},[17468],{"nctId":17469,"briefTitle":17470,"status":152,"phases":17471,"primaryCompletion":1091,"completion":6162,"start":4079,"enrollment":1315,"conditions":17472,"interventions":17473},"NCT02673138","Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion",[90],[5724],[17454],{"intervention":17475,"totalTrials":109,"cells":17476},"Once a day Trientine",{"EARLY_PHASE1":17477,"PHASE1":17479,"PHASE2":17481,"PHASE3":17483,"PHASE4":17485,"NA":17487},{"trials":17478,"activeCount":98},[],{"trials":17480,"activeCount":98},[],{"trials":17482,"activeCount":98},[],{"trials":17484,"activeCount":98},[],{"trials":17486,"activeCount":98},[],{"trials":17488,"activeCount":98},[17489],{"nctId":17490,"briefTitle":17491,"status":152,"phases":17492,"primaryCompletion":16108,"completion":16108,"start":347,"enrollment":1296,"conditions":17493,"interventions":17495},"NCT01472874","Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease",[90],[17494],"Wilson Disease",[17475],{"intervention":16535,"totalTrials":109,"cells":17497},{"EARLY_PHASE1":17498,"PHASE1":17500,"PHASE2":17502,"PHASE3":17504,"PHASE4":17506,"NA":17508},{"trials":17499,"activeCount":98},[],{"trials":17501,"activeCount":98},[],{"trials":17503,"activeCount":98},[],{"trials":17505,"activeCount":98},[],{"trials":17507,"activeCount":98},[],{"trials":17509,"activeCount":98},[17510],{"nctId":16529,"briefTitle":16530,"status":152,"phases":17511,"primaryCompletion":1618,"completion":1618,"start":1120,"enrollment":1675,"conditions":17512,"interventions":17513},[],[16533],[16535,16500],{"intervention":17515,"totalTrials":109,"cells":17516},"Low strength nicotine e-liquid",{"EARLY_PHASE1":17517,"PHASE1":17519,"PHASE2":17521,"PHASE3":17523,"PHASE4":17525,"NA":17527},{"trials":17518,"activeCount":98},[],{"trials":17520,"activeCount":98},[],{"trials":17522,"activeCount":98},[],{"trials":17524,"activeCount":98},[],{"trials":17526,"activeCount":98},[],{"trials":17528,"activeCount":98},[17529],{"nctId":17530,"briefTitle":17531,"status":1051,"phases":17532,"primaryCompletion":17533,"completion":17534,"start":17535,"enrollment":98,"conditions":17536,"interventions":17538},"NCT04258852","Understanding Factors That Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine Receptors",[90],"2024-02-01","2025-02-01","2022-12-30",[17537],"Electronic Cigarette Use",[17515,17539],"High strength nicotine e-liquid",{"intervention":17539,"totalTrials":109,"cells":17541},{"EARLY_PHASE1":17542,"PHASE1":17544,"PHASE2":17546,"PHASE3":17548,"PHASE4":17550,"NA":17552},{"trials":17543,"activeCount":98},[],{"trials":17545,"activeCount":98},[],{"trials":17547,"activeCount":98},[],{"trials":17549,"activeCount":98},[],{"trials":17551,"activeCount":98},[],{"trials":17553,"activeCount":98},[17554],{"nctId":17530,"briefTitle":17531,"status":1051,"phases":17555,"primaryCompletion":17533,"completion":17534,"start":17535,"enrollment":98,"conditions":17556,"interventions":17557},[90],[17537],[17515,17539],{"intervention":17559,"totalTrials":109,"cells":17560},"17 hydroxyprogesterone caproate intramuscular injections",{"EARLY_PHASE1":17561,"PHASE1":17563,"PHASE2":17565,"PHASE3":17567,"PHASE4":17569,"NA":17571},{"trials":17562,"activeCount":98},[],{"trials":17564,"activeCount":98},[],{"trials":17566,"activeCount":98},[],{"trials":17568,"activeCount":98},[],{"trials":17570,"activeCount":98},[],{"trials":17572,"activeCount":98},[17573],{"nctId":17574,"briefTitle":17575,"status":1051,"phases":17576,"start":17577,"enrollment":98,"conditions":17578,"interventions":17581},"NCT00120640","Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate",[90],"2005-07",[17579,17580],"Premature Birth","Premature Labor",[17559],{"intervention":15807,"totalTrials":109,"cells":17583},{"EARLY_PHASE1":17584,"PHASE1":17586,"PHASE2":17588,"PHASE3":17590,"PHASE4":17592,"NA":17594},{"trials":17585,"activeCount":98},[],{"trials":17587,"activeCount":98},[],{"trials":17589,"activeCount":98},[],{"trials":17591,"activeCount":98},[],{"trials":17593,"activeCount":98},[],{"trials":17595,"activeCount":98},[17596],{"nctId":15799,"briefTitle":15800,"status":152,"phases":17597,"primaryCompletion":15802,"completion":15802,"start":15803,"enrollment":1407,"conditions":17598,"interventions":17599},[90],[24],[15806,15807],{"intervention":17601,"totalTrials":109,"cells":17602},"HPV vaccine",{"EARLY_PHASE1":17603,"PHASE1":17605,"PHASE2":17607,"PHASE3":17609,"PHASE4":17611,"NA":17613},{"trials":17604,"activeCount":98},[],{"trials":17606,"activeCount":98},[],{"trials":17608,"activeCount":98},[],{"trials":17610,"activeCount":98},[],{"trials":17612,"activeCount":98},[],{"trials":17614,"activeCount":98},[17615],{"nctId":17616,"briefTitle":17617,"status":152,"phases":17618,"primaryCompletion":4161,"completion":4161,"start":1091,"enrollment":17619,"conditions":17620,"interventions":17622},"NCT02994290","Evaluation of the Implementation and Effectiveness of IPP-HPV",[90],817,[17621],"HPV Vaccination",[17601],{"intervention":17624,"totalTrials":109,"cells":17625},"Buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":17626,"PHASE1":17628,"PHASE2":17630,"PHASE3":17632,"PHASE4":17634,"NA":17636},{"trials":17627,"activeCount":98},[],{"trials":17629,"activeCount":98},[],{"trials":17631,"activeCount":98},[],{"trials":17633,"activeCount":98},[],{"trials":17635,"activeCount":98},[],{"trials":17637,"activeCount":98},[17638],{"nctId":17639,"briefTitle":17640,"status":152,"phases":17641,"primaryCompletion":17642,"completion":17643,"start":17644,"enrollment":1305,"conditions":17645,"interventions":17646},"NCT01550341","HIV, Buprenorphine, and the Criminal Justice System",[90],"2015-11-30","2016-11-30","2012-02-23",[287,288,289,290],[17624],{"intervention":17648,"totalTrials":109,"cells":17649},"HCV+PWID",{"EARLY_PHASE1":17650,"PHASE1":17652,"PHASE2":17654,"PHASE3":17656,"PHASE4":17658,"NA":17660},{"trials":17651,"activeCount":98},[],{"trials":17653,"activeCount":98},[],{"trials":17655,"activeCount":98},[],{"trials":17657,"activeCount":98},[],{"trials":17659,"activeCount":98},[],{"trials":17661,"activeCount":98},[17662],{"nctId":17663,"briefTitle":17664,"status":152,"phases":17665,"primaryCompletion":17666,"completion":17667,"start":8768,"enrollment":17668,"conditions":17669,"interventions":17671},"NCT01557998","Testing and Linkage to Care for Injecting Drug Users in Kenya",[90],"2016-04-30","2018-04-30",9449,[16829,17670],"HCV Coinfection",[17648],{"intervention":16822,"totalTrials":109,"cells":17673},{"EARLY_PHASE1":17674,"PHASE1":17676,"PHASE2":17678,"PHASE3":17680,"PHASE4":17682,"NA":17684},{"trials":17675,"activeCount":98},[],{"trials":17677,"activeCount":98},[],{"trials":17679,"activeCount":98},[],{"trials":17681,"activeCount":98},[],{"trials":17683,"activeCount":98},[],{"trials":17685,"activeCount":98},[17686],{"nctId":16816,"briefTitle":16817,"status":152,"phases":17687,"primaryCompletion":1210,"completion":1886,"start":8045,"enrollment":105,"conditions":17688,"interventions":17689},[90],[16820,10891,287,274],[16801,16822],{"intervention":17691,"totalTrials":109,"cells":17692},"Naltrexone 25mg",{"EARLY_PHASE1":17693,"PHASE1":17695,"PHASE2":17697,"PHASE3":17699,"PHASE4":17701,"NA":17703},{"trials":17694,"activeCount":98},[],{"trials":17696,"activeCount":98},[],{"trials":17698,"activeCount":98},[],{"trials":17700,"activeCount":98},[],{"trials":17702,"activeCount":98},[],{"trials":17704,"activeCount":98},[17705],{"nctId":17706,"briefTitle":17707,"status":152,"phases":17708,"primaryCompletion":7625,"completion":7625,"start":1082,"enrollment":2659,"conditions":17709,"interventions":17710},"NCT00793780","Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia",[90],[18,15,1213],[17691],{"intervention":16799,"totalTrials":109,"cells":17712},{"EARLY_PHASE1":17713,"PHASE1":17715,"PHASE2":17717,"PHASE3":17719,"PHASE4":17721,"NA":17723},{"trials":17714,"activeCount":98},[],{"trials":17716,"activeCount":98},[],{"trials":17718,"activeCount":98},[],{"trials":17720,"activeCount":98},[],{"trials":17722,"activeCount":98},[],{"trials":17724,"activeCount":98},[17725],{"nctId":16792,"briefTitle":16793,"status":711,"phases":17726,"primaryCompletion":16795,"completion":16795,"start":8160,"enrollment":109,"conditions":17727,"interventions":17728},[90],[330],[16798,16799],{"intervention":17730,"totalTrials":109,"cells":17731},"Naltrexone High Dose",{"EARLY_PHASE1":17732,"PHASE1":17734,"PHASE2":17736,"PHASE3":17738,"PHASE4":17740,"NA":17742},{"trials":17733,"activeCount":98},[],{"trials":17735,"activeCount":98},[],{"trials":17737,"activeCount":98},[],{"trials":17739,"activeCount":98},[],{"trials":17741,"activeCount":98},[],{"trials":17743,"activeCount":98},[17744],{"nctId":17745,"briefTitle":17746,"status":152,"phases":17747,"primaryCompletion":5721,"completion":5721,"start":7744,"enrollment":1815,"conditions":17748,"interventions":17749},"NCT01462227","Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia",[90],[13521],[17730,17750],"Naltrexone Low Dose",{"intervention":17750,"totalTrials":109,"cells":17752},{"EARLY_PHASE1":17753,"PHASE1":17755,"PHASE2":17757,"PHASE3":17759,"PHASE4":17761,"NA":17763},{"trials":17754,"activeCount":98},[],{"trials":17756,"activeCount":98},[],{"trials":17758,"activeCount":98},[],{"trials":17760,"activeCount":98},[],{"trials":17762,"activeCount":98},[],{"trials":17764,"activeCount":98},[17765],{"nctId":17745,"briefTitle":17746,"status":152,"phases":17766,"primaryCompletion":5721,"completion":5721,"start":7744,"enrollment":1815,"conditions":17767,"interventions":17768},[90],[13521],[17730,17750],{"intervention":17770,"totalTrials":109,"cells":17771},"[C-11]OMAR",{"EARLY_PHASE1":17772,"PHASE1":17774,"PHASE2":17776,"PHASE3":17778,"PHASE4":17780,"NA":17782},{"trials":17773,"activeCount":98},[],{"trials":17775,"activeCount":98},[],{"trials":17777,"activeCount":98},[],{"trials":17779,"activeCount":98},[],{"trials":17781,"activeCount":98},[],{"trials":17783,"activeCount":98},[17784],{"nctId":17785,"briefTitle":17786,"status":152,"phases":17787,"primaryCompletion":8160,"completion":8160,"start":1120,"enrollment":15949,"conditions":17788,"interventions":17790},"NCT01719497","Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET",[],[18,1112,17789],"High Stress",[17770],{"intervention":17792,"totalTrials":109,"cells":17793},"ceftriaxone",{"EARLY_PHASE1":17794,"PHASE1":17796,"PHASE2":17798,"PHASE3":17800,"PHASE4":17802,"NA":17804},{"trials":17795,"activeCount":98},[],{"trials":17797,"activeCount":98},[],{"trials":17799,"activeCount":98},[],{"trials":17801,"activeCount":98},[],{"trials":17803,"activeCount":98},[],{"trials":17805,"activeCount":98},[17806],{"nctId":17807,"briefTitle":17808,"status":711,"phases":17809,"primaryCompletion":8491,"completion":8491,"start":6276,"enrollment":303,"conditions":17810,"interventions":17811},"NCT00566111","Ceftriaxone in the Management of Bipolar Depression",[90],[1761],[17792,17812],"Saline solution",{"intervention":17812,"totalTrials":109,"cells":17814},{"EARLY_PHASE1":17815,"PHASE1":17817,"PHASE2":17819,"PHASE3":17821,"PHASE4":17823,"NA":17825},{"trials":17816,"activeCount":98},[],{"trials":17818,"activeCount":98},[],{"trials":17820,"activeCount":98},[],{"trials":17822,"activeCount":98},[],{"trials":17824,"activeCount":98},[],{"trials":17826,"activeCount":98},[17827],{"nctId":17807,"briefTitle":17808,"status":711,"phases":17828,"primaryCompletion":8491,"completion":8491,"start":6276,"enrollment":303,"conditions":17829,"interventions":17830},[90],[1761],[17792,17812],{"intervention":17832,"totalTrials":109,"cells":17833},"Acamprosate, naltrexone, or disulfiram",{"EARLY_PHASE1":17834,"PHASE1":17836,"PHASE2":17838,"PHASE3":17840,"PHASE4":17842,"NA":17844},{"trials":17835,"activeCount":98},[],{"trials":17837,"activeCount":98},[],{"trials":17839,"activeCount":98},[],{"trials":17841,"activeCount":98},[],{"trials":17843,"activeCount":98},[],{"trials":17845,"activeCount":98},[17846],{"nctId":17847,"briefTitle":17848,"status":711,"phases":17849,"primaryCompletion":9817,"completion":12521,"start":15400,"enrollment":12233,"conditions":17850,"interventions":17851},"NCT04287790","Promoting Medications for Alcohol Use Disorder on the General Medicine Service",[],[27],[17832],{"intervention":17853,"totalTrials":109,"cells":17854},"Galantamine 8mg",{"EARLY_PHASE1":17855,"PHASE1":17857,"PHASE2":17859,"PHASE3":17861,"PHASE4":17863,"NA":17865},{"trials":17856,"activeCount":98},[],{"trials":17858,"activeCount":98},[],{"trials":17860,"activeCount":98},[],{"trials":17862,"activeCount":98},[],{"trials":17864,"activeCount":98},[],{"trials":17866,"activeCount":98},[17867],{"nctId":17868,"briefTitle":17869,"status":152,"phases":17870,"primaryCompletion":1742,"completion":1742,"start":1887,"enrollment":105,"conditions":17871,"interventions":17872},"NCT01880099","A Study to Help People Quit Smoking.",[90],[24],[17853,17873],"Galantamine 16mg",{"intervention":17873,"totalTrials":109,"cells":17875},{"EARLY_PHASE1":17876,"PHASE1":17878,"PHASE2":17880,"PHASE3":17882,"PHASE4":17884,"NA":17886},{"trials":17877,"activeCount":98},[],{"trials":17879,"activeCount":98},[],{"trials":17881,"activeCount":98},[],{"trials":17883,"activeCount":98},[],{"trials":17885,"activeCount":98},[],{"trials":17887,"activeCount":98},[17888],{"nctId":17868,"briefTitle":17869,"status":152,"phases":17889,"primaryCompletion":1742,"completion":1742,"start":1887,"enrollment":105,"conditions":17890,"interventions":17891},[90],[24],[17853,17873],{"intervention":17893,"totalTrials":109,"cells":17894},"Nicotine pod",{"EARLY_PHASE1":17895,"PHASE1":17897,"PHASE2":17899,"PHASE3":17901,"PHASE4":17903,"NA":17905},{"trials":17896,"activeCount":98},[],{"trials":17898,"activeCount":98},[],{"trials":17900,"activeCount":98},[],{"trials":17902,"activeCount":98},[],{"trials":17904,"activeCount":98},[],{"trials":17906,"activeCount":98},[17907],{"nctId":17908,"briefTitle":17909,"status":152,"phases":17910,"primaryCompletion":17911,"completion":17911,"start":17912,"enrollment":1296,"conditions":17913,"interventions":17914},"NCT04901208","Acute Effects of Vaping Nicotine on Cognition in Young Adults",[90],"2022-08-17","2020-04-05",[15725,3288],[17893],{"intervention":17916,"totalTrials":109,"cells":17917},"Ethanol High Dose, Ethanol Low Dose, and Placebo",{"EARLY_PHASE1":17918,"PHASE1":17920,"PHASE2":17922,"PHASE3":17924,"PHASE4":17926,"NA":17928},{"trials":17919,"activeCount":98},[],{"trials":17921,"activeCount":98},[],{"trials":17923,"activeCount":98},[],{"trials":17925,"activeCount":98},[],{"trials":17927,"activeCount":98},[],{"trials":17929,"activeCount":98},[17930],{"nctId":17931,"briefTitle":17932,"status":152,"phases":17933,"primaryCompletion":1441,"completion":1441,"start":17000,"enrollment":1063,"conditions":17934,"interventions":17935},"NCT00612352","Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism",[90],[1111],[17916],{"intervention":1997,"totalTrials":109,"cells":17937},{"EARLY_PHASE1":17938,"PHASE1":17940,"PHASE2":17942,"PHASE3":17944,"PHASE4":17946,"NA":17948},{"trials":17939,"activeCount":98},[],{"trials":17941,"activeCount":98},[],{"trials":17943,"activeCount":98},[],{"trials":17945,"activeCount":98},[],{"trials":17947,"activeCount":98},[],{"trials":17949,"activeCount":98},[17950],{"nctId":1989,"briefTitle":1990,"status":152,"phases":17951,"primaryCompletion":1992,"completion":1993,"start":1061,"enrollment":1994,"conditions":17952,"interventions":17953},[90],[1860],[70,1997],{"intervention":17955,"totalTrials":109,"cells":17956},"Medications",{"EARLY_PHASE1":17957,"PHASE1":17959,"PHASE2":17961,"PHASE3":17963,"PHASE4":17965,"NA":17967},{"trials":17958,"activeCount":98},[],{"trials":17960,"activeCount":98},[],{"trials":17962,"activeCount":98},[],{"trials":17964,"activeCount":98},[],{"trials":17966,"activeCount":98},[],{"trials":17968,"activeCount":98},[17969],{"nctId":17970,"briefTitle":17971,"status":152,"phases":17972,"primaryCompletion":6766,"completion":6766,"start":6874,"enrollment":3088,"conditions":17973,"interventions":17975},"NCT00309452","Specialized Treatment Early in Psychosis (STEP)",[90],[17974],"Schizophrenia and Disorders With Psychotic Features",[17955],{"intervention":17977,"totalTrials":109,"cells":17978},"Buprenorphine, Tipranavir and ritonavir",{"EARLY_PHASE1":17979,"PHASE1":17981,"PHASE2":17983,"PHASE3":17985,"PHASE4":17987,"NA":17989},{"trials":17980,"activeCount":98},[],{"trials":17982,"activeCount":98},[],{"trials":17984,"activeCount":98},[],{"trials":17986,"activeCount":98},[],{"trials":17988,"activeCount":98},[],{"trials":17990,"activeCount":98},[17991],{"nctId":17992,"briefTitle":17993,"status":152,"phases":17994,"primaryCompletion":11819,"completion":11819,"start":164,"enrollment":272,"conditions":17995,"interventions":17996},"NCT00486330","Pharmacokinetic Interactions Between Buprenorphine and Tipranavir\u002FRitonavir",[90],[274],[17977],{"intervention":17998,"totalTrials":109,"cells":17999},"Isoniazid",{"EARLY_PHASE1":18000,"PHASE1":18002,"PHASE2":18004,"PHASE3":18006,"PHASE4":18008,"NA":18010},{"trials":18001,"activeCount":98},[],{"trials":18003,"activeCount":98},[],{"trials":18005,"activeCount":98},[],{"trials":18007,"activeCount":98},[],{"trials":18009,"activeCount":98},[],{"trials":18011,"activeCount":98},[18012],{"nctId":18013,"briefTitle":18014,"status":152,"phases":18015,"primaryCompletion":18016,"completion":18016,"start":18017,"enrollment":18018,"conditions":18019,"interventions":18022},"NCT03089983","Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings",[90],"2024-04-04","2017-08-21",316,[221,5707,18020,5921,18021],"HIV\u002FAIDS","Hepatitis",[17998,18023],"Rifapentine",{"intervention":18023,"totalTrials":109,"cells":18025},{"EARLY_PHASE1":18026,"PHASE1":18028,"PHASE2":18030,"PHASE3":18032,"PHASE4":18034,"NA":18036},{"trials":18027,"activeCount":98},[],{"trials":18029,"activeCount":98},[],{"trials":18031,"activeCount":98},[],{"trials":18033,"activeCount":98},[],{"trials":18035,"activeCount":98},[],{"trials":18037,"activeCount":98},[18038],{"nctId":18013,"briefTitle":18014,"status":152,"phases":18039,"primaryCompletion":18016,"completion":18016,"start":18017,"enrollment":18018,"conditions":18040,"interventions":18041},[90],[221,5707,18020,5921,18021],[17998,18023],{"intervention":18043,"totalTrials":109,"cells":18044},"Antibiotics",{"EARLY_PHASE1":18045,"PHASE1":18047,"PHASE2":18049,"PHASE3":18051,"PHASE4":18053,"NA":18055},{"trials":18046,"activeCount":98},[],{"trials":18048,"activeCount":98},[],{"trials":18050,"activeCount":98},[],{"trials":18052,"activeCount":98},[],{"trials":18054,"activeCount":98},[],{"trials":18056,"activeCount":98},[18057],{"nctId":18058,"briefTitle":18059,"status":1051,"phases":18060,"primaryCompletion":18061,"completion":18061,"start":12543,"enrollment":98,"conditions":18062,"interventions":18065},"NCT03982810","The Role of Guideline-adherent Perioperative Antibiotic Administration and the Risk of Surgical Site Infections After Non-cardiac Surgery.",[],"2024-03",[18063,18064],"Surgical Site Infection","Antibiotic Prophylaxis",[18043],{"intervention":16187,"totalTrials":109,"cells":18067},{"EARLY_PHASE1":18068,"PHASE1":18070,"PHASE2":18072,"PHASE3":18074,"PHASE4":18076,"NA":18078},{"trials":18069,"activeCount":98},[],{"trials":18071,"activeCount":98},[],{"trials":18073,"activeCount":98},[],{"trials":18075,"activeCount":98},[],{"trials":18077,"activeCount":98},[],{"trials":18079,"activeCount":98},[18080],{"nctId":16181,"briefTitle":16182,"status":1051,"phases":18081,"start":6276,"enrollment":98,"conditions":18082,"interventions":18083},[90],[16185],[16187,8235],{"intervention":18085,"totalTrials":109,"cells":18086},"nasal salmon calcitonin",{"EARLY_PHASE1":18087,"PHASE1":18089,"PHASE2":18091,"PHASE3":18093,"PHASE4":18095,"NA":18097},{"trials":18088,"activeCount":98},[],{"trials":18090,"activeCount":98},[],{"trials":18092,"activeCount":98},[],{"trials":18094,"activeCount":98},[],{"trials":18096,"activeCount":98},[],{"trials":18098,"activeCount":98},[18099],{"nctId":18100,"briefTitle":18101,"status":152,"phases":18102,"primaryCompletion":1973,"completion":1973,"start":10888,"enrollment":5030,"conditions":18103,"interventions":18105},"NCT01652573","Calcitonin for Treating X-linked Hypophosphatemia",[90],[18104],"Hypophosphatemic Rickets, X Linked Dominant",[18085,18106],"Saline Nasal Spray Placebo",{"intervention":18106,"totalTrials":109,"cells":18108},{"EARLY_PHASE1":18109,"PHASE1":18111,"PHASE2":18113,"PHASE3":18115,"PHASE4":18117,"NA":18119},{"trials":18110,"activeCount":98},[],{"trials":18112,"activeCount":98},[],{"trials":18114,"activeCount":98},[],{"trials":18116,"activeCount":98},[],{"trials":18118,"activeCount":98},[],{"trials":18120,"activeCount":98},[18121],{"nctId":18100,"briefTitle":18101,"status":152,"phases":18122,"primaryCompletion":1973,"completion":1973,"start":10888,"enrollment":5030,"conditions":18123,"interventions":18124},[90],[18104],[18085,18106],{"intervention":18126,"totalTrials":109,"cells":18127},"Physostigmine",{"EARLY_PHASE1":18128,"PHASE1":18130,"PHASE2":18132,"PHASE3":18134,"PHASE4":18136,"NA":18138},{"trials":18129,"activeCount":98},[],{"trials":18131,"activeCount":98},[],{"trials":18133,"activeCount":98},[],{"trials":18135,"activeCount":98},[],{"trials":18137,"activeCount":98},[],{"trials":18139,"activeCount":98},[18140],{"nctId":18141,"briefTitle":18142,"status":152,"phases":18143,"primaryCompletion":11144,"completion":11144,"start":5742,"enrollment":1424,"conditions":18144,"interventions":18145},"NCT02008292","Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors",[90],[33,15],[18126],{"intervention":18147,"totalTrials":109,"cells":18148},"Nicotine Transdermal Patch",{"EARLY_PHASE1":18149,"PHASE1":18151,"PHASE2":18153,"PHASE3":18155,"PHASE4":18157,"NA":18159},{"trials":18150,"activeCount":98},[],{"trials":18152,"activeCount":98},[],{"trials":18154,"activeCount":98},[],{"trials":18156,"activeCount":98},[],{"trials":18158,"activeCount":98},[],{"trials":18160,"activeCount":98},[18161],{"nctId":18162,"briefTitle":18163,"status":152,"phases":18164,"primaryCompletion":1848,"completion":714,"start":1993,"enrollment":15983,"conditions":18165,"interventions":18166},"NCT01145001","Enhancing a High School Based Smoking Cessation Program",[90],[24],[18147],{"intervention":18168,"totalTrials":109,"cells":18169},"Novel Oral Anti-Coagulants",{"EARLY_PHASE1":18170,"PHASE1":18172,"PHASE2":18174,"PHASE3":18176,"PHASE4":18178,"NA":18180},{"trials":18171,"activeCount":98},[],{"trials":18173,"activeCount":98},[],{"trials":18175,"activeCount":98},[],{"trials":18177,"activeCount":98},[],{"trials":18179,"activeCount":98},[],{"trials":18181,"activeCount":98},[18182],{"nctId":18183,"briefTitle":18184,"status":152,"phases":18185,"primaryCompletion":15400,"completion":15400,"start":18186,"enrollment":18187,"conditions":18188,"interventions":18190},"NCT03535883","The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants",[],"2017-10-30",590,[6228,18189],"Thoracic Effusion",[18168],{"intervention":18192,"totalTrials":109,"cells":18193},"percutaneous ethanol ablation",{"EARLY_PHASE1":18194,"PHASE1":18196,"PHASE2":18198,"PHASE3":18200,"PHASE4":18202,"NA":18204},{"trials":18195,"activeCount":98},[],{"trials":18197,"activeCount":98},[],{"trials":18199,"activeCount":98},[],{"trials":18201,"activeCount":98},[],{"trials":18203,"activeCount":98},[],{"trials":18205,"activeCount":98},[18206],{"nctId":18207,"briefTitle":18208,"status":711,"phases":18209,"primaryCompletion":12499,"completion":18210,"start":326,"enrollment":1466,"conditions":18211,"interventions":18213},"NCT01974284","Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma",[90],"2017-06-29",[18212],"Papillary Thyroid Cancer",[18192],{"intervention":18215,"totalTrials":109,"cells":18216},"Short-acting opioid prescription for acute pain",{"EARLY_PHASE1":18217,"PHASE1":18219,"PHASE2":18221,"PHASE3":18223,"PHASE4":18225,"NA":18227},{"trials":18218,"activeCount":98},[],{"trials":18220,"activeCount":98},[],{"trials":18222,"activeCount":98},[],{"trials":18224,"activeCount":98},[],{"trials":18226,"activeCount":98},[],{"trials":18228,"activeCount":98},[18229],{"nctId":18230,"briefTitle":18231,"status":152,"phases":18232,"primaryCompletion":18233,"completion":18233,"start":14461,"enrollment":18234,"conditions":18235,"interventions":18237},"NCT04509115","Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations",[],"2023-11-30",1709,[6301,18236],"Opioid Prescribing",[18215]]